alter table drugs.pbsconvert drop column route;
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Sachets 34 g, 30','t','oral powder','34g',30,'','');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Capsule 3 mg','t','capsule','3mg',1,'','');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Powder for injection 1200 IU with solvent','t','injection','1200iu',1,'','with solvent');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Powder for injection 600 IU with solvent','t','injection','600iu',1,'','with solvent');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Injection 200 mg (as sodium) in 1 mL','t','injection','200mg',1,'','as sodium');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Powder for injection 3 g-100 mg','t','injection','3g-100mg',1,'','');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Powder for oral suspension 125 mg (base) per 5 mL, 70 mL','t','oral solution','25mg/ml',1,'70ml','as powder');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Powder for injection 1 g (as hydrochloride)','t','injection','1g',1,'','as hydrochloride');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Powder for injection 2 g (as hydrochloride)','t','injection','2g',1,'','as hydrochloride');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values (' Lozenge 200 micrograms (as citrate)','t','lozenge','200mcg',1,'','as citrate');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,comment) values ('Lozenge 200 micrograms (as citrate)','t','lozenge','200mcg',1,'','as citrate');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Lozenge 400 micrograms (as citrate)','t','lozenge','400mcg',1,'','as citrate');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Lozenge 600 micrograms (as citrate)','t','lozenge','600mcg',1,'','as citrate');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Lozenge 800 micrograms (as citrate)','t','lozenge','800mcg',1,'','as citrate');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Lozenge 1200 micrograms (as citrate)','t','lozenge','1200mcg',1,'','as citrate');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Lozenge 1600 micrograms (as citrate)','t','lozenge','1600mcg',1,'','as citrate');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Dressings 4 cm, 10','t','dressing','',10,'','4cm');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Dressings 5.5 cm, 10','t','dressing','',10,'','5.5cm');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Tablet 1 mg (as mesilate)','t','tablet','1mg',1,'','as mesilate');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe','t','syringe','30mg',1,'3ml','as acetate, in single use pre-filled');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Tablet 90 mg','t','tablet','90mg',1,'','');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers','t','powder for inhalation','40mg',280,'','as capsules, with 2 inhalers');

insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Ear drops, ortho-dichlorobenzene 140 mg per mL, para-dichlorobenzene 20 mg per mL, chlorbutol 50 mg per mL, arachis oil 573 mg per mL, 10 mL','t','ear drops','140mg/ml-20mg/ml-50mg/ml-573mg/ml',1,'10ml','');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Eye gel 2 mg-10 mg per g (0.2%-1%), 10 g','t','eye gel','2mg/g-10mg/g',1,'10g','');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Eye gel 2 mg-10 mg per g (0.2%-1%), single dose units 0.6 g, 30','t','eye gel','2mg/g-10mg/g',30,'0.6g','single dose units');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Tablet 400 mg (as hydrochloride)','t','tablet','400mg',1,'','as hydrochloride');
insert into drugs.pbsconvert(fs,done,form,dose,packsize,amount,"comment") values ('Tablet 200 mg (as hydrochloride)','t','tablet','200mg',1,'','as hydrochloride');

insert into drugs.form (pk, form, volume_amount_required) values (75, 'eye gel', 't');


                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('65aad17c-c3fd-456e-9942-d19a725ae75c', 'MSUD MAXAMUM', 'SB', true, '328.54'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('af7d0d49-52f2-45c6-b0eb-85c61b23526d', 'CARDIPRIN 100', 'RC', true, '8.04'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('c9f0763e-2599-4093-9892-b657bcd71a15', 'CARTIA', 'GC', true, '6.34'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('c9f0763e-2599-4093-9892-b657bcd71a15', 'SPREN 100', 'QA', true, '1.18'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('49d7fad9-0728-4cc9-8e76-9e438e79280f', 'PANAMAX CO. 40', 'SW', true, '3.71'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('7085ece3-6aeb-408d-a668-433677dfc8e8', 'HOSPIRA PTY LIMITED HEPARIN', 'HH', true, '7.88'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('1c99dbbc-81fa-4a43-aed2-1bcf095118f0', 'MEDROXYPROGESTERONE SANDOZ', 'SZ', true, '6.87'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('21730542-432d-4af6-8f37-12c497d8b298', 'PENTASA', 'FP', true, '306.25'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('2c28b44d-69dc-4103-941a-edfa4ef0cd35', 'COLOXYL WITH SENNA', 'FM', true, '8.94'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('0b99ae95-6936-49db-a572-86568a3330b0', 'ZINCABAND 3604', 'SS', true, '9.90'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('0b99ae95-6936-49db-a572-86568a3330b0', 'FLEXIDRESS 650941', 'CC', true, 9.72::text::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('d366ef1c-7c96-4d35-9e7a-af30cfc3166d', 'TEGADERM TRANSPARENT 1628', 'MM', true, 3.51::text::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('0a50ce6d-039b-4012-acdb-907fcd698cea', 'TELFA 1970C', 'KE', true, 4.00::text::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('0a50ce6d-039b-4012-acdb-907fcd698cea', 'TELFA 7650C', 'KE', true, 4.87::text::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('0d64b0e4-1b9d-487d-ac3d-cfda76a83980', 'HYDROCOLL 900744', 'HR', true, 37.23::text::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('6e5c6692-87a0-4bba-b5a7-d61c273f0d6f', 'PROSCAR', 'MK', true, 95.70::text::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('409b4bde-e053-4de6-b2e0-e4efaa49adc4', 'ALLEVYN THIN 66047576', 'SN', true, 47.97::text::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('b5655072-bdaa-43ec-add8-7d07a79849ee', 'ACTISORB PLUS MAC031', 'JJ', true, '8.59'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('ffa3859b-c60a-4a5c-bcb8-95e277d0f3c3', 'ORION TEMOZOLOMIDE', 'ON', true, '151.17'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('7a9ec70e-0a40-4a31-b66c-98e0ee18d8da', 'ORION TEMOZOLOMIDE', 'ON', true, '625.63'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('bb2ef659-b270-46d7-abd5-a0b5ddcfc22d', 'ORION TEMOZOLOMIDE', 'ON', true, '853.96'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('baca06f3-ea80-44ac-b6e5-c2d5097d5e0d', 'CIALIS', 'LY', true, '69.85'::money)
                ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('0bbfc345-e862-46fb-95a5-eec6f306583e', 'AQUACEL 177903', 'CC', true, '92.14'::money)
                ;

              insert into drugs.product(pk,atccode,generic,fk_form,strength,free_comment,
              original_pbs_name,original_pbs_fs,units_per_pack,pack_size,amount,amount_unit) 
              values ('5ece9315-9060-4bf9-85ae-713c67980876','S02DC', 'ortho-dichlorobenzene;para-dichlorobenze;chlorbutol;arachnis oil',9,'140mg/ml-20mg/ml-50mg/ml-573mg/ml',NULL,$$dichlorobenzene with chlorbutol and arachis oil$$,$$Ear drops, ortho-dichlorobenzene 140 mg per mL, para-dichlorobenzene 20 mg per mL, chlorbutol 50 mg per mL, arachis oil 573 mg per mL, 10 mL$$,1,1,10.0,26)
              ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('5ece9315-9060-4bf9-85ae-713c67980876', 'CERUMOL', 'UN', true, '6.66'::money)
                ;

              insert into drugs.product(pk,atccode,generic,fk_form,strength,free_comment,
              original_pbs_name,original_pbs_fs,units_per_pack,pack_size,amount,amount_unit) 
              values ('fdcbf0b8-d2ae-4710-8441-1084eff850a7','S01XA20', 'carbomer;triglyceride lipids',75,'2mg/g-10mg/g',NULL,$$carbomer with triglyceride lipids$$,$$Eye gel 2 mg-10 mg per g (0.2%-1%), 10 g$$,1,1,10.0,35)
              ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('fdcbf0b8-d2ae-4710-8441-1084eff850a7', 'ARTELAC', 'BU', true, '3.35'::money)
                ;

              insert into drugs.product(pk,atccode,generic,fk_form,strength,free_comment,
              original_pbs_name,original_pbs_fs,units_per_pack,pack_size,amount,amount_unit) 
              values ('8cebb5b5-4a05-4d00-87de-26fda2a11c64','S01XA20', 'carbomer;triglyceride lipids',75,'2mg/g-10mg/g','single dose units',$$carbomer with triglyceride lipids$$,$$Eye gel 2 mg-10 mg per g (0.2%-1%), single dose units 0.6 g, 30$$,30,3,0.6,35) 
              ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('8cebb5b5-4a05-4d00-87de-26fda2a11c64', 'ARTELAC', 'BU', true, '8.60'::money)
                ;

              insert into drugs.product(pk,atccode,generic,fk_form,strength,free_comment,
              original_pbs_name,original_pbs_fs,units_per_pack,pack_size,amount,amount_unit) 
              values ('f1dfe027-5140-437a-9061-eb3ee3b362d2','L01XE11', 'pazopanib',59,'400mg','as hydrochloride',$$pazopanib$$,$$Tablet 400 mg (as hydrochloride)$$,1,60,NULL,NULL) 
              ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('f1dfe027-5140-437a-9061-eb3ee3b362d2', 'VOTRIENT', 'GK', true, '4597.22'::money)
                ;

              insert into drugs.product(pk,atccode,generic,fk_form,strength,free_comment,
              original_pbs_name,original_pbs_fs,units_per_pack,pack_size,amount,amount_unit) 
              values ('587735bd-c001-41a6-aed4-1ab7e5323a6c','L01XE11', 'pazopanib',59,'200mg','as hydrochloride',$$pazopanib$$,$$Tablet 200 mg (as hydrochloride)$$,1,90,NULL,NULL) returning (pk)
              ;

                insert into drugs.brand (fk_product, brand, fk_company, from_pbs, price)
                values ('587735bd-c001-41a6-aed4-1ab7e5323a6c', 'VOTRIENT', 'GK', true, '3465.40'::money)
                ;

alter table drugs.product add column old_original_pbs_name text;
update drugs.product set old_original_pbs_name=original_pbs_name;
update drugs.product set original_pbs_name=null;

alter table drugs.product add column sct text constraint sct_is_numeric check (sct ~ '^[0-9]+$');
alter table drugs.brand add column sct text constraint sct_is_numeric check (sct ~ '^[0-9]+$');
alter table drugs.brand add column "current" boolean not null default 't';

INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('b967fa00-b5df-4175-a4ee-323bfb77b947', 'V06DX', 'amino acid formula with vitamins and minerals without valine, leucine and isoleu', NULL, 35, '125ml', NULL, 'AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEUCINE Oral liquid 125 mL, 30, 1', 'Oral liquid 125 mL, 30', NULL, '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 30, 'amino acid formula with vitamins and minerals without valine, leucine and isoleu', '14981000144101');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('c79c4417-f2f3-444c-9dfe-f1339716deb4', 'V06DX', 'amino acid formula with vitamins and minerals without valine, leucine and isoleu', NULL, 36, '34g', NULL, 'AMINO ACID FORMULA with VITAMINS and MINERALS without VALINE, LEUCINE and ISOLEUCINE Sachets 34 g, 30, 1', 'Sachets 34 g, 30', NULL, '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 30, 'amino acid formula with vitamins and minerals without valine, leucine and isoleu', '15091000144104');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('8ace9530-f2b2-46cd-a0c3-2bd7f606e334', 'V06DX', 'amino acid formula with vitamins and minerals without methionine, threonine and', NULL, 35, '130ml', NULL, 'AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE, THREONINE and VALINE and low in ISOLEUCINE Oral liquid 130 mL, 30, 1', 'Oral liquid 130 mL, 30', NULL, '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 30, 'amino acid formula with vitamins and minerals without methionine, threonine and', '44851000144106');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('b334ae8b-387b-4911-bcb7-ffec7cdf1772', 'N03AA02', 'phenobarbitone', NULL, 22, '200mg', NULL, 'phenobarbitone sodium 219 mg/mL injection, 5 x 1 mL ampoules', 'Injection 200 mg (as sodium) in 1 mL', 'as sodium', '2012-12-13 20:50:03', NULL, true, 5, NULL, NULL, 1, 'phenobarbitone', '253021000144100');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('db3ce779-b4ba-4e29-bdde-b96b1ed0992f', 'N02AB03', 'fentanyl', NULL, 27, '1200mcg', NULL, 'FENTANYL Lozenge 1200 micrograms (as citrate), 30', 'Lozenge 1200 micrograms (as citrate)', 'as citrate', '2012-12-13 20:50:03', NULL, true, 30, NULL, NULL, 1, 'fentanyl', '49261000144107');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('226e935f-1d44-41ad-a966-20092a939b7d', 'N02AB03', 'fentanyl', NULL, 27, '1600mcg', NULL, 'FENTANYL Lozenge 1600 micrograms (as citrate), 30', 'Lozenge 1600 micrograms (as citrate)', 'as citrate', '2012-12-13 20:50:03', NULL, true, 30, NULL, NULL, 1, 'fentanyl', '49281000144103');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('de4543ce-7c38-46ba-95b6-8eee366ed7c1', 'G03GA02', 'human menopausal gonadotrophin', NULL, 22, '1200iu', NULL, 'gonadotrophin-menopausal human 1200 international units injection [1 x 1200 international units vial] (&) inert substance diluent [2 x 1 mL syringes], 1 pack', 'Powder for injection 1200 IU with solvent', 'with solvent', '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 1, 'human menopausal gonadotrophin', '71531000036100');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('3b5818a1-ee06-413a-a885-a7a5f9f2e112', 'R05CB16', 'mannitol', NULL, 46, '40mg', NULL, 'MANNITOL Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers, 1', 'Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers', 'as capsules, with 2 inhalers', '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 280, 'mannitol', '59761000144101');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('e81d820d-b344-4c51-9974-d035a9bb3a10', 'N02AB03', 'fentanyl', NULL, 27, '600mcg', NULL, 'FENTANYL Lozenge 600 micrograms (as citrate), 30', 'Lozenge 600 micrograms (as citrate)', 'as citrate', '2012-12-13 20:50:03', NULL, true, 30, NULL, NULL, 1, 'fentanyl', '49331000144108');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('ace13e67-d0bc-4205-b9d5-11bf71815398', 'V06DX', 'amino acid formula with vitamins and minerals without methionine', NULL, 35, '125ml', NULL, 'AMINO ACID FORMULA with VITAMINS and MINERALS without METHIONINE Oral liquid 125 mL, 30, 1', 'Oral liquid 125 mL, 30', NULL, '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 30, 'amino acid formula with vitamins and minerals without methionine', '14641000144104');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('30e73949-2c8f-4480-94d5-a238adc83e06', 'V04CA02', 'blood glucose indicator - bgstar', NULL, 73, NULL, NULL, 'glucose indicator blood strip: diagnostic, 100 diagnostic strips', 'Test strips, 100', 'Test strips, 100', '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 100, 'glucose indicator-blood', '51571011000036107');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('a4d958ff-0701-4a6f-91d9-b955a188071a', 'M01CB03', 'auranofin', NULL, 3, '3mg', NULL, 'AURANOFIN Capsule 3 mg, 60', 'Capsule 3 mg', NULL, '2012-12-13 20:50:03', NULL, true, 60, NULL, NULL, 1, 'auranofin', '15801000144102');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('133d9918-0c19-4999-95b0-ad7c63820708', 'N04BA02', 'levodopa;benserazide', NULL, 59, '100mg-25mg', NULL, 'levodopa 100 mg + benserazide 25 mg tablet, 100', 'Tablet 100 mg-25 mg', NULL, '2012-12-13 20:50:03', NULL, true, 100, NULL, NULL, 1, 'levodopa with benserazide', '27434011000036107');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('b49207d1-c119-456d-aff8-7c03ecf256f6', 'C04AX02', 'phenoxybenzamine hydrochloride', NULL, 3, '10mg', NULL, 'phenoxybenzamine hydrochloride 10 mg capsule, 100', 'Capsules 10 mg, 100', NULL, '2012-12-13 20:50:03', NULL, true, 100, NULL, NULL, 100, 'phenoxybenzamine hydrochloride', '26799011000036105');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('5e463026-8c63-4b7b-8fad-7cdb443324f2', 'J01DC02', 'cefuroxime axetil', NULL, 37, '25mg/ml', NULL, 'CEFUROXIME AXETIL Powder for oral suspension 125 mg (base) per 5 mL, 70 mL, 1', 'Powder for oral suspension 125 mg (base) per 5 mL, 70 mL', 'as powder', '2012-12-13 20:50:03', NULL, true, 1, 70, 26, 1, 'cefuroxime axetil', '49011000144103');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('14f8007f-bb28-400a-a399-4bb0bad1e066', 'S01XA20', 'paraffin', NULL, 1, '3.5g', NULL, 'paraffin 1 g/g eye ointment, 3.5 g', 'Compound eye ointment 3.5 g', NULL, '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 1, 'paraffin', '35762011000036104');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('314de5a4-34c4-4547-9895-4aed901d9ff1', 'N02AB03', 'fentanyl', NULL, 27, '400mcg', NULL, 'FENTANYL Lozenge 400 micrograms (as citrate), 30', 'Lozenge 400 micrograms (as citrate)', 'as citrate', '2012-12-13 20:50:03', NULL, true, 30, NULL, NULL, 1, 'fentanyl', '49311000144100');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('ffc02808-cafb-4ecd-a071-f589baee4121', 'N02AB03', 'fentanyl', NULL, 27, '800mcg', NULL, 'FENTANYL Lozenge 800 micrograms (as citrate), 30', 'Lozenge 800 micrograms (as citrate)', 'as citrate', '2012-12-13 20:50:03', NULL, true, 30, NULL, NULL, 1, 'fentanyl', '49351000144101');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('ec9c9461-b781-491c-8f6a-6680059ebce5', 'N02AB03', 'fentanyl', NULL, 27, '200mcg', NULL, 'FENTANYL Lozenge 200 micrograms (as citrate), 30', ' Lozenge 200 micrograms (as citrate)', 'as citrate', '2012-12-13 20:50:03', NULL, true, 30, NULL, NULL, 1, 'fentanyl', '49291000144101');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('92caee14-aca2-4bab-9a41-20c2135d059e', 'V07AY', 'dressing-hydroactive (debridement)', NULL, 8, NULL, NULL, 'DRESSING-HYDROACTIVE (DEBRIDEMENT) Dressings 7.5 cm x 7.5 cm, 10, 1', 'Dressings 4 cm, 10', '4cm', '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 10, 'dressing-hydroactive (debridement)', '54901000144104');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('004b261e-d99b-45d9-a22a-ef2f98911731', 'J05AR', 'lopinavir;ritonavir', NULL, 59, '100mg-25mg', NULL, 'lopinavir 100 mg + ritonavir 25 mg tablet, 60', 'Tablet 100 mg-25 mg', NULL, '2012-12-13 20:50:03', NULL, true, 60, NULL, NULL, 1, 'lopinavir with ritonavir', '51542011000036100');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('9fbd64da-ecd4-41f9-99ea-60a879d01be4', 'G03GA02', 'human menopausal gonadotrophin', NULL, 22, '600iu', NULL, 'gonadotrophin-menopausal human 600 international units injection [1 x 600 international units vial] (&) inert substance diluent [1 x 1 mL syringe], 1 pack', 'Powder for injection 600 IU with solvent', 'with solvent', '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 1, 'human menopausal gonadotrophin', '71511000036109');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('55a50505-0162-46ab-8c8d-1f1e30dfd4c6', 'N04BD02', 'rasagiline', NULL, 59, '1mg', NULL, 'RASAGILINE Tablet 1 mg (as mesilate), 30', 'Tablet 1 mg (as mesilate)', 'as mesilate', '2012-12-13 20:50:03', NULL, true, 30, NULL, NULL, 1, 'rasagiline', '59731000144106');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('d2110bc4-b2a0-48c7-b303-e3a62b893c3b', 'B01AC24', 'ticagrelor', NULL, 59, '90mg', NULL, 'TICAGRELOR Tablet 90 mg, 56', 'Tablet 90 mg', NULL, '2012-12-13 20:50:03', NULL, true, 56, NULL, NULL, 1, 'ticagrelor', '59751000144104');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('fa54ec17-7725-41c8-92e5-facf1e2b8377', 'V06DX', 'amino acid formula with vitamins and minerals without phenylalanine and tyrosine', NULL, 35, '125ml', NULL, 'AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE and TYROSINE Oral liquid 125 mL, 30, 1', 'Oral liquid 125 mL, 30', NULL, '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 30, 'amino acid formula with vitamins and minerals without phenylalanine and tyrosine', '36821000144105');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('159da67b-4d08-43ef-9dae-81b413075bf9', 'V06DX', 'amino acid formula with vitamins and minerals without phenylalanine', NULL, 36, '34g', NULL, 'AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE Sachets 34 g, 30, 1', 'Sachets 34 g, 30', NULL, '2012-12-13 20:50:03', NULL, true, 1, NULL, NULL, 30, 'amino acid formula with vitamins and minerals without phenylalanine', '14941000144109');
INSERT INTO product (pk, atccode, generic, salt, fk_form, strength, salt_strength, original_pbs_name, original_pbs_fs, free_comment, updated_at, fk_schedule, shared, pack_size, amount, amount_unit, units_per_pack, old_original_pbs_name, sct) VALUES ('efc457b7-7772-49a5-ae43-4a16bd2f1c9e', 'B06AC02', 'icatibant', NULL, 58, '30mg', NULL, 'ICATIBANT Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe, 1', 'Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe', 'as acetate, in single use pre-filled', '2012-12-13 20:50:03', NULL, true, 1, 3, 26, 1, 'icatibant', '59741000144102');


truncate table drugs.pbs cascade;

insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('575205a3-17f2-40a6-97b0-662882c3babc','1004W',100,3,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('449a5734-3f0d-462f-bba4-405bee522d37','1002R',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('449a5734-3f0d-462f-bba4-405bee522d37','5501M',1,0,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('11d5aea6-65bf-47f9-bea4-4df4a26fb283','8234J',120,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('11d5aea6-65bf-47f9-bea4-4df4a26fb283','1052J',35,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7c4da14a-3258-4759-9f40-289fdf9d3320','1007B',90,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce73aba5-099d-438e-97d4-8de678d4e77c','1003T',50,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce73aba5-099d-438e-97d4-8de678d4e77c','1555W',50,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed888815-ddf2-4bc2-b2f9-3bc9835f7de5','1016L',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5fc8754e-f3e0-4f1f-8472-a2eb2f91c6b1','3408J',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('739d72ba-0459-436c-b0db-5b512bf56899','3409K',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed888815-ddf2-4bc2-b2f9-3bc9835f7de5','3451P',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed888815-ddf2-4bc2-b2f9-3bc9835f7de5','5004J',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5fc8754e-f3e0-4f1f-8472-a2eb2f91c6b1','8697R',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('739d72ba-0459-436c-b0db-5b512bf56899','8698T',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6dec18b4-264b-4293-a47e-316da1edb752','2604C',60,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93c4018b-5720-4e5c-89ae-f91cc9b637cb','1557Y',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93c4018b-5720-4e5c-89ae-f91cc9b637cb','2600W',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('56bc7081-73cc-4186-bb5e-09080a05d961','2157M',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('27fe95eb-303e-42cc-a479-d62b3a67dc44','2159P',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c211d239-26e2-4ded-a9c2-8d1f8c35364e','3016R',100,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b0b790a7-bae2-4ea2-a5f7-ce44806c4cba','8328H',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b0b790a7-bae2-4ea2-a5f7-ce44806c4cba','8416Y',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8a79879a-dcb6-4fdc-89c1-3aaeaa8efe7e','8417B',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5f680ffb-bc52-4084-9b8f-282575be5f49','9133Q',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('539f73f4-b97b-492e-8e9f-d920703961f5','8677Q',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ace13e67-d0bc-4205-b9d5-11bf71815398','1548L',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9781150-b514-4ce5-bffa-d7021671d3a2','8744F',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3d1c7d29-cfa4-48ef-8322-6f53aedc7e14','1411G',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('751795fc-1916-45ed-accc-7db8a848a181','2382J',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8bb2ef59-d571-4d21-a0b4-ddc88eddea49','2474F',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5a960f0e-cec2-4d5d-95fa-968849232162','2738D',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5a960f0e-cec2-4d5d-95fa-968849232162','2739E',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('52c502db-224b-40d4-a498-a7c44d6f88c5','8545R',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9eb61de8-3c89-472e-9c13-ee926d536fc3','8613H',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e347d641-2930-4856-8a75-f4e5dfc23c4a','8727H',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5ea3addf-543e-47ef-be86-34cf04d0826e','8746H',90,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('188b2521-bca1-4410-8101-0b6186028eed','8804J',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5017c797-dd93-4323-89ac-b3633a109b16','8846N',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9b08cc95-ad06-4abe-b3ce-068f5f26e386','9021T',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4b3045ad-9420-429f-93cb-b3c6e5cefd47','9396M',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7fb9464a-c798-4445-aecc-1dd6cf05c501','9397N',2,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cdd213a7-fe51-4191-a959-a1c6813dcd18','8555G',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('00fc7498-36f0-4c72-b347-cdf47ef1685d','5483N',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('159da67b-4d08-43ef-9dae-81b413075bf9','1909L',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2c1319cc-ad3a-4e2f-a54e-600d2d297195','8591E',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42998cb5-3224-4d24-ab80-e5e755879968','2375B',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fc6b1e3c-1f18-4e4f-a141-55804a391ec4','2380G',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('65aad17c-c3fd-456e-9942-d19a725ae75c','8057C',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('65aad17c-c3fd-456e-9942-d19a725ae75c','8260R',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('65aad17c-c3fd-456e-9942-d19a725ae75c','8310J',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f0474a7a-3c61-4670-9f71-a790633e3d55','8745G',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('111d7f9b-18d8-439e-bd0d-909f5d6c1412','8592F',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b967fa00-b5df-4175-a4ee-323bfb77b947','1546J',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c79c4417-f2f3-444c-9dfe-f1339716deb4','1914R',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19e2b19e-ee31-4c58-adb9-4fbf38c8468c','8632H',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('88bee9bd-f25d-4a3a-9b9e-ad8a2c908dba','2347M',7,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8dbd70a6-1f66-48cb-b7a4-d4889e482df6','8554F',16,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('77158b79-cc1c-45ba-9131-0e9745e92743','8678R',24,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cb01a8be-71b0-400c-92a1-d6801b16a249','2344J',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('28023afe-9872-48cd-9ff9-d31ae62f76bc','2343H',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('32ac2472-8ffa-4a43-8fd1-965bed39b37c','2417F',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('061ec138-a8a2-4f8c-a593-69c465dc7c60','2418G',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8508251d-c8e6-44a1-952b-4ddd3042596d','2429W',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('46a1e479-671a-4da2-a4b3-97042822377f','1884E',20,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e87d8a22-d26c-45d7-bb83-22623f35a3f9','1886G',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('327bc726-c402-4266-9206-af49f5931370','1887H',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('02a6af1d-4085-42f7-a825-2ce27b6ddcfd','1888J',1,1,'SB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e457ac4f-15e8-4d0d-a983-c75b44523489','1889K',20,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e457ac4f-15e8-4d0d-a983-c75b44523489','3300Q',20,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('46a1e479-671a-4da2-a4b3-97042822377f','3301R',20,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e87d8a22-d26c-45d7-bb83-22623f35a3f9','3302T',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('327bc726-c402-4266-9206-af49f5931370','3393N',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b45a56c-ef0a-41d0-bc68-9100a62d856d','5225B',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('146a10c1-1c6c-4d53-82ad-f36513430262','8581P',14,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b45a56c-ef0a-41d0-bc68-9100a62d856d','8705E',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('02a6af1d-4085-42f7-a825-2ce27b6ddcfd','9714G',1,1,'SB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('02a6af1d-4085-42f7-a825-2ce27b6ddcfd','3310F',1,0,'DS','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a57a7af-6a6f-4571-bdf7-8a1d293ee062','1891M',10,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f24c70ad-12e3-49b8-b15f-245f007e0653','1892N',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2f979be2-9cdd-4d4a-a0e8-bc27cc617fda','5006L',10,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a57a7af-6a6f-4571-bdf7-8a1d293ee062','5008N',10,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f24c70ad-12e3-49b8-b15f-245f007e0653','5009P',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a226222a-d3b8-48b5-aa43-cc654373c240','5011R',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2f979be2-9cdd-4d4a-a0e8-bc27cc617fda','8254K',10,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a226222a-d3b8-48b5-aa43-cc654373c240','8319W',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0ef6b8e2-6291-4736-adc5-740d65b77031','2931G',20,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0ef6b8e2-6291-4736-adc5-740d65b77031','3306B',20,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ba7489d-6b8e-4101-880c-b50716448221','2390T',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b92b90b7-4f1f-4821-8f85-ec5016c97123','2977Q',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ba7489d-6b8e-4101-880c-b50716448221','3313J',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b92b90b7-4f1f-4821-8f85-ec5016c97123','3314K',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cc7ccaf1-ee83-4541-a704-0f257eeceaf8','1010E',96,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c9f0763e-2599-4093-9892-b657bcd71a15','4076M',90,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3757af7e-bed6-4fe9-bbfc-ad4ab0747f7e','4077N',84,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c9207d87-99d0-477c-b79d-2fd4eecc7d67','4078P',84,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cc7ccaf1-ee83-4541-a704-0f257eeceaf8','5018D',96,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3757af7e-bed6-4fe9-bbfc-ad4ab0747f7e','8202Q',112,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('08e4eb12-7fd4-4304-b44d-edd20eb9f670','1081X',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('397df2f2-2d6f-45be-b347-de4428fd2fcc','1089H',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('397df2f2-2d6f-45be-b347-de4428fd2fcc','5022H',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('397df2f2-2d6f-45be-b347-de4428fd2fcc','3453R',10,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a39589cd-b109-4148-a4c3-07f8b0547a47','1093M',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a83df8c2-0bfd-44b9-9139-000125cf2fc4','1095P',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a4d958ff-0701-4a6f-91d9-b955a188071a','2022K',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6bb5781b-0eda-4052-b77f-76ff4a923c54','2688L',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2cd92e7f-2938-4729-82bb-77c0d98b4148','2687K',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5d9fee99-735f-4ef5-9177-4ffab6cd3fcd','2729P',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4b1ed72b-ad79-4121-b914-e28db2093002','2730Q',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b173d7d-d312-4f0f-9aba-28ac94f20e5a','5617P',10,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b173d7d-d312-4f0f-9aba-28ac94f20e5a','6284R',10,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('51d3317e-076d-4491-b4d7-0249f1ff252e','8406K',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3c1e79ae-0c74-444e-9a17-a2d8648b24a3','8407L',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('51d3317e-076d-4491-b4d7-0249f1ff252e','8408M',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3c1e79ae-0c74-444e-9a17-a2d8648b24a3','8409N',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4ea85b15-a252-43ec-90a6-0cb1d603f40d','1109J',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('33f32f51-4f29-4a69-9ffa-ea3139811c79','1110K',200,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b563ad7-f4d9-42c3-9d38-a8314c3a83f4','2362H',60,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dad05e06-6b57-430d-b8a4-16c7d35df4e7','3038X',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dad05e06-6b57-430d-b8a4-16c7d35df4e7','3457Y',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dad05e06-6b57-430d-b8a4-16c7d35df4e7','5031T',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93166320-b7f1-429f-8625-fb2430afabd4','1775K',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a130ffc5-dac6-479d-a957-096c480a951c','2647H',10,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93166320-b7f1-429f-8625-fb2430afabd4','3398W',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a130ffc5-dac6-479d-a957-096c480a951c','3399X',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93166320-b7f1-429f-8625-fb2430afabd4','3486L',10,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a130ffc5-dac6-479d-a957-096c480a951c','3487M',1,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9159cf3b-68d1-4063-9297-7cf06c5cabf3','2694T',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9159cf3b-68d1-4063-9297-7cf06c5cabf3','5034Y',5,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('59d1151e-8d72-4d4a-a551-59a85af0c844','1115Q',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('23779cce-93c8-44c6-85dc-672b51829338','1119X',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e65094e1-96db-4309-ade1-2edb71d38c83','2812B',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('64edcabf-6895-405a-94d8-72a78497f2b6','2813C',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('43ec41a7-aa03-4e24-b4ff-2bbb85de2ae0','2815E',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cfb0e3be-9560-4c5e-a0cb-5910b3dcb033','2820K',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc22b5bb-0b36-4567-85dd-038f498e3b0d','4131K',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eb4f9148-5557-489e-ba21-0665ab55ecdd','4132L',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e84a034f-86fa-4fa2-b665-07a2c4604ec6','2811Y',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ea240e8c-fee5-4a89-a15f-c9cff69b66db','2825Q',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e84a034f-86fa-4fa2-b665-07a2c4604ec6','5543R',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ea240e8c-fee5-4a89-a15f-c9cff69b66db','5544T',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dd2ddc66-3054-42f3-862c-0dd5ccd6c702','1062X',100,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8059bc35-b229-4960-bf29-b88b8404fcfd','2544X',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c2a74c99-1d30-4680-805f-131db6dade9e','1258F',3,4,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2257f0e2-8573-4951-a755-879fce778ccd','1259G',200,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6a2238ac-a3f2-4786-95fa-f5d94545ce2f','1260H',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19509460-c962-4ea2-8c70-095dc7de54a5','1263L',1,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6a2238ac-a3f2-4786-95fa-f5d94545ce2f','3250C',9,0,'PQ','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19509460-c962-4ea2-8c70-095dc7de54a5','3263R',2,0,'PQ','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c2a74c99-1d30-4680-805f-131db6dade9e','3276K',8,0,'PQ','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2257f0e2-8573-4951-a755-879fce778ccd','5301B',200,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19509460-c962-4ea2-8c70-095dc7de54a5','5302C',1,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6a2238ac-a3f2-4786-95fa-f5d94545ce2f','5303D',3,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c2a74c99-1d30-4680-805f-131db6dade9e','5304E',3,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2257f0e2-8573-4951-a755-879fce778ccd','5305F',200,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19509460-c962-4ea2-8c70-095dc7de54a5','5306G',1,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6a2238ac-a3f2-4786-95fa-f5d94545ce2f','5307H',3,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c2a74c99-1d30-4680-805f-131db6dade9e','5308J',3,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2257f0e2-8573-4951-a755-879fce778ccd','3261P',400,0,'PQ','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('17064124-8b4c-468e-874b-e13c026b2d76','1444B',30,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5f42da42-56c4-4b51-8a34-9c477f8ff75f','1445C',100,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b8469e35-e6e1-4475-860b-8ab89759c756','1446D',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('77577819-f4a8-46bd-bbca-7c50b6bb8b17','1559C',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('77577819-f4a8-46bd-bbca-7c50b6bb8b17','1443Y',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8eda259f-41a6-4312-8051-f52193993c61','2065Q',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aca61760-e5dd-41d6-8b28-b78ff30a00a1','2066R',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8ad2bc57-2b11-4cd2-b2d9-1e40193b8521','2070Y',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('52d04ef1-18a0-4fbe-a1e8-bb96dc3e0f22','2071B',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cc58a05a-46fc-40e0-9d71-1ad064745803','2072C',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('77e77734-4abb-442c-aaa5-d911053c856e','4092J',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('388213ce-6078-4e57-8780-1d323129182c','4032F',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0c0e28d4-e787-4987-aa42-b8861b8b7ebd','1128J',100,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5aaedc5a-0e0a-4cdf-ad18-491d48b2351d','2502Q',100,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4be4905d-5c4d-40e1-b948-c5d724373747','3116B',240,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24b1660d-797c-4bf3-ab57-f2bbee7f3f33','3117C',240,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24b1660d-797c-4bf3-ab57-f2bbee7f3f33','4082W',120,1,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24b1660d-797c-4bf3-ab57-f2bbee7f3f33','4142B',240,1,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4be4905d-5c4d-40e1-b948-c5d724373747','4094L',240,1,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4be4905d-5c4d-40e1-b948-c5d724373747','4333C',120,1,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('492d941a-8937-416c-9d90-e22a816858c2','5870Y',4,1,'CT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('033eb54b-fb77-4020-a62c-f69614efd805','5904R',10,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d8179838-fd5a-4d8d-923c-084e6a52b749','8969C',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d8179838-fd5a-4d8d-923c-084e6a52b749','5863N',1,1,'CT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('033eb54b-fb77-4020-a62c-f69614efd805','2308L',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('492d941a-8937-416c-9d90-e22a816858c2','9041W',4,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('248623c8-0084-4f0b-aaef-151c4577cff0','8812T',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('248623c8-0084-4f0b-aaef-151c4577cff0','5886T',10,1,'CT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('248623c8-0084-4f0b-aaef-151c4577cff0','1704Q',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('248623c8-0084-4f0b-aaef-151c4577cff0','1904F',10,1,'CT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85bc1c18-d095-4241-9569-237abdd0b63c','8740B',10,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85bc1c18-d095-4241-9569-237abdd0b63c','1575X',10,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85bc1c18-d095-4241-9569-237abdd0b63c','1610R',10,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85bc1c18-d095-4241-9569-237abdd0b63c','5890B',10,2,'CT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85bc1c18-d095-4241-9569-237abdd0b63c','1894Q',10,2,'CT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85bc1c18-d095-4241-9569-237abdd0b63c','1899Y',10,2,'CT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85b23772-6e60-481a-929f-1ffbf099a6b3','8760C',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a816194-a1d2-43f3-ae5d-c906bc116512','1147J',90,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('16b92837-8000-4d42-afff-9fd283e82fce','1148K',90,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a6f187cb-b7e2-4d26-9c3e-154dade3c3af','1149L',90,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1ad42843-bb18-4468-b5f7-990935f73ea2','2426Q',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('759b8cb2-a577-4e8a-b30a-bcd608f7c497','2427R',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b730203-dd5d-4df6-a698-8a629f1eb646','2431Y',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b730203-dd5d-4df6-a698-8a629f1eb646','5037D',200,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1ad42843-bb18-4468-b5f7-990935f73ea2','5038E',200,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('759b8cb2-a577-4e8a-b30a-bcd608f7c497','5041H',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('74084d53-2f9b-4cb1-abb9-8fe7c759d2eb','2419H',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('47d73a1c-2218-4721-ac64-ad3d4e211f59','2422L',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('47d73a1c-2218-4721-ac64-ad3d4e211f59','5039F',200,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('74084d53-2f9b-4cb1-abb9-8fe7c759d2eb','5040G',200,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('74084d53-2f9b-4cb1-abb9-8fe7c759d2eb','1706T',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('47d73a1c-2218-4721-ac64-ad3d4e211f59','1708X',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('47d73a1c-2218-4721-ac64-ad3d4e211f59','1755J',200,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('74084d53-2f9b-4cb1-abb9-8fe7c759d2eb','1724R',200,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f8b2b095-4728-45e7-ac24-4ab2a607cac0','1153Q',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('76bf9059-2012-4dfc-bc3f-879d42cc01fc','4518T',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('58fe8aaa-ee67-4504-a9ee-fdfce48c88fc','1169M',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9380464f-29f3-4ee2-95e5-c4daa8fa74de','2460L',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7fdc7a5f-4f22-464f-94c6-e49b13157d9c','2461M',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('58fe8aaa-ee67-4504-a9ee-fdfce48c88fc','5045M',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9380464f-29f3-4ee2-95e5-c4daa8fa74de','5046N',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7fdc7a5f-4f22-464f-94c6-e49b13157d9c','5047P',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('56e7a10a-3955-4d32-af24-2dfe81a960f1','1085D',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0127b4ba-f052-460e-9286-31b445119f9b','1086E',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('56e7a10a-3955-4d32-af24-2dfe81a960f1','1758M',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0127b4ba-f052-460e-9286-31b445119f9b','1759N',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('56e7a10a-3955-4d32-af24-2dfe81a960f1','5048Q',10,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('56e7a10a-3955-4d32-af24-2dfe81a960f1','1768C',10,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0127b4ba-f052-460e-9286-31b445119f9b','5049R',10,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0127b4ba-f052-460e-9286-31b445119f9b','1769D',10,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce27c17e-8ac0-4765-846c-d22a06e2c1d1','1783W',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fa1bec6f-4200-47cd-857e-ba40bdabd792','1785Y',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce27c17e-8ac0-4765-846c-d22a06e2c1d1','9058R',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2cf6ae62-c125-4d0f-bf2d-85a28ee6aa12','1788D',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2cf6ae62-c125-4d0f-bf2d-85a28ee6aa12','1784X',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9437beb9-16c9-4266-93ce-039b9bef8e30','3058Y',20,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c4fb8e69-2fbc-4277-b854-d1d16b7b35c4','3094W',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0a7a5c50-903f-4eb3-a0e2-fe5956eb5dc4','3095X',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1508166c-6151-4cac-8972-b23d845dadaf','3119E',20,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9437beb9-16c9-4266-93ce-039b9bef8e30','3317N',20,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1508166c-6151-4cac-8972-b23d845dadaf','3318P',20,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c4fb8e69-2fbc-4277-b854-d1d16b7b35c4','3319Q',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0a7a5c50-903f-4eb3-a0e2-fe5956eb5dc4','3320R',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e625c922-63c5-416f-b632-40d96ec75d61','2964B',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e625c922-63c5-416f-b632-40d96ec75d61','3376Q',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fa19d30b-7d95-4b50-8ef0-7da45068d8f0','5477G',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fa19d30b-7d95-4b50-8ef0-7da45068d8f0','1256D',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8f3d3fee-82d0-43ea-9746-8c0aa3170f5f','5479J',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8f3d3fee-82d0-43ea-9746-8c0aa3170f5f','9326W',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e8b942a-dbe9-417a-90b6-8cca75eb64cc','1257E',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e8b942a-dbe9-417a-90b6-8cca75eb64cc','1797N',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e8b942a-dbe9-417a-90b6-8cca75eb64cc','5478H',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e8b942a-dbe9-417a-90b6-8cca75eb64cc','1799Q',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('477e7211-2f51-4e1d-a76b-a5e94c078546','1163F',100,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e13f8a8e-6412-4470-904e-0c339b3e3f7e','1171P',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3de5659f-4977-43da-bff9-71ab3131944d','1172Q',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bbbfa078-4a9a-43b5-a8c2-01b823ab1e15','2360F',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bbbfa078-4a9a-43b5-a8c2-01b823ab1e15','5055C',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e13f8a8e-6412-4470-904e-0c339b3e3f7e','5511C',1,0,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bbbfa078-4a9a-43b5-a8c2-01b823ab1e15','5512D',1,2,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6ffbffd1-833d-4a7d-9e49-c68f9ae3d861','4161B',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('57080a09-f700-4ea0-a64c-f571e883ff82','4204G',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('55a2a4fd-00c5-418d-8797-61f4bea8f36c','1195X',10,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cea26ed4-d95a-4851-8aba-ca5420b58ec8','1196Y',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b8a7ad6d-4e24-490e-899f-033d582fd899','1197B',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7f2c7918-97a8-4264-8946-71f1627cee38','1199D',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('873f4ceb-0bbe-4fee-a4a0-d3d87bab57f8','1201F',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('55a2a4fd-00c5-418d-8797-61f4bea8f36c','3455W',10,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('54dc21a8-573b-4812-887d-862e33286144','1585K',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('57814b6c-a697-492d-b505-5d91a7611377','2967E',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('57814b6c-a697-492d-b505-5d91a7611377','9249T',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d7b48311-a3bf-4850-bad7-51d0bfc9655b','1158Y',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e076a669-d7c2-4fc6-97fb-d2349af64a1e','1159B',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e70da9ee-fda8-4427-ab74-e39b9ebefe22','2480M',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('81beb9b2-0683-4198-a55c-7ecc73622926','1208N',14,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('16b1a125-4598-4af1-99ba-18824a9255b5','1209P',14,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('db100ffe-fbd3-4175-8a01-90f3afb8fe34','1210Q',14,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2830f236-a349-4882-98e9-435eebe596f1','1217C',2,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2830f236-a349-4882-98e9-435eebe596f1','5564W',2,0,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9f593c3b-c80c-417a-a79b-47912df0b7ff','3138E',24,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9f593c3b-c80c-417a-a79b-47912df0b7ff','5057E',24,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aea4e108-ca19-4bca-b38a-9b4e3c2da8c7','1561E',50,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('198e2e95-9dc4-4e2b-8a7e-dfcb0a2d6c53','1805B',200,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b62bd41c-2d9c-4c9b-bc33-a9877b0afe13','1806C',200,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e62babf5-6f71-4305-8a65-15b475b20e80','1807D',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a053ec48-6d18-46a7-8665-89ca3ad6f605','1808E',2,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a053ec48-6d18-46a7-8665-89ca3ad6f605','3478C',1,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('198e2e95-9dc4-4e2b-8a7e-dfcb0a2d6c53','5337X',100,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b62bd41c-2d9c-4c9b-bc33-a9877b0afe13','5338Y',100,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a053ec48-6d18-46a7-8665-89ca3ad6f605','5339B',2,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('198e2e95-9dc4-4e2b-8a7e-dfcb0a2d6c53','5340C',100,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b62bd41c-2d9c-4c9b-bc33-a9877b0afe13','5341D',100,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a053ec48-6d18-46a7-8665-89ca3ad6f605','5342E',2,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b16de30c-2ff3-4f29-87e9-827cdc2f7f98','3141H',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a0aaca20-63bf-46ee-ab5e-c4bf99cd45da','3145M',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('771f99a3-7ee0-4257-8d1c-6355af88c4b6','4016J',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('56477957-f4c6-426f-8ebc-b440549d57df','4017K',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('61d37b40-d3b7-4bbe-91a0-5107994fe237','4004R',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b313d63f-fddf-45cc-82ff-53134c969b36','5063L',20,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b313d63f-fddf-45cc-82ff-53134c969b36','1214X',20,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b8f68f4e-4826-45ec-985f-a071caaa9880','4286N',40,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ce9f2b7-1beb-4c3e-a2ec-f229e42bea66','1215Y',20,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ce9f2b7-1beb-4c3e-a2ec-f229e42bea66','3316M',20,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aa221ba0-45a8-4f6f-ab89-3bb4b2384aa4','4170L',20,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('49d7fad9-0728-4cc9-8e76-9e438e79280f','4171M',50,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ce9f2b7-1beb-4c3e-a2ec-f229e42bea66','8785J',60,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('49d7fad9-0728-4cc9-8e76-9e438e79280f','4275B',40,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('73ad80bd-431f-44d7-b1ed-fc537a579181','3410L',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c3c5d7e5-f92d-41d3-a315-f79b23cddb7c','1224K',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c3c5d7e5-f92d-41d3-a315-f79b23cddb7c','9250W',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a00f469-9c14-46cd-ae21-7ba867d2e59b','1246N',50,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10cfcbe3-dff2-4af0-b04f-a0b4ed6aa0d2','1247P',60,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0c338387-ddbc-4589-bfb2-e3a37c0fe486','1266P',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6a82f213-e7ed-4381-8844-7ad33bdf102d','1798P',100,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7387a078-935c-4324-bea0-2c4eaef14e58','1269T',20,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7387a078-935c-4324-bea0-2c4eaef14e58','1270W',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e028d880-b441-42ae-85a0-79de7f209052','8019C',50,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e86719f3-0572-49fa-b0f4-bfee3b96846d','1285P',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f16ba272-8b81-42ca-9640-7898d83309dc','1287R',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d46061fa-f4ae-4d83-b1a8-f30b7705a49b','1779P',100,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('21fc2201-4b85-4029-80b1-8c61a98f0ad3','1780Q',100,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2a69faa1-e345-4246-9c80-c3c4ab9a6bb8','9031H',1,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2a69faa1-e345-4246-9c80-c3c4ab9a6bb8','4341L',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9a368f33-23a0-4521-ae92-8f2205ced2e4','2129C',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('40bf123b-adc7-4474-a6d7-e03bcf4e3c21','8662X',90,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('40bf123b-adc7-4474-a6d7-e03bcf4e3c21','8663Y',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0af979da-a972-46a4-b9bc-69fc75475381','8711L',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0af979da-a972-46a4-b9bc-69fc75475381','8712M',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ca070268-22c9-4ab7-b4c8-e108f191213e','8975J',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b4b26690-8537-42ad-a26f-ac91d83b1ad6','9398P',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e7832af0-79c7-4495-a0d9-adae2402eeb8','1292B',30,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6803ff26-920e-45e1-ad91-60fcd7da5d35','2507Y',30,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('87a779fb-d4d9-4a23-bbe2-81b031310e56','5565X',1,0,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('87a779fb-d4d9-4a23-bbe2-81b031310e56','1288T',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('34696b50-a059-47ba-885d-a43e99c6f064','2781J',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c5089bb0-6a20-40ba-992e-4f258dd7c2bd','1165H',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('304f1bcb-baea-4fe2-90c6-0a2ed7b82fd7','2558P',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('304f1bcb-baea-4fe2-90c6-0a2ed7b82fd7','3458B',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e488bfd-7434-44b1-8f39-a71779229ed5','5071X',50,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ac62dd0a-406d-4cc2-8b22-ce3f5384ab67','5072Y',50,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('304f1bcb-baea-4fe2-90c6-0a2ed7b82fd7','5073B',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e488bfd-7434-44b1-8f39-a71779229ed5','5355W',50,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ac62dd0a-406d-4cc2-8b22-ce3f5384ab67','5356X',50,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e488bfd-7434-44b1-8f39-a71779229ed5','5357Y',50,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ac62dd0a-406d-4cc2-8b22-ce3f5384ab67','5358B',50,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e488bfd-7434-44b1-8f39-a71779229ed5','3161J',50,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ac62dd0a-406d-4cc2-8b22-ce3f5384ab67','3162K',50,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d092abc6-fcce-4245-8844-5f3c3139b929','1299J',100,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b20ed96-afba-455b-ab92-a35ba4719d83','1300K',50,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e28ec44e-9e77-4671-b1ea-a140be114ea2','1302M',40,3,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('335552b6-8b41-4aa5-a9fb-f4fff799318f','4046Y',1,3,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d092abc6-fcce-4245-8844-5f3c3139b929','5076E',100,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b20ed96-afba-455b-ab92-a35ba4719d83','5077F',50,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e28ec44e-9e77-4671-b1ea-a140be114ea2','5079H',40,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d092abc6-fcce-4245-8844-5f3c3139b929','5361E',100,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b20ed96-afba-455b-ab92-a35ba4719d83','5362F',50,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d092abc6-fcce-4245-8844-5f3c3139b929','5364H',100,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b20ed96-afba-455b-ab92-a35ba4719d83','5365J',50,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e28ec44e-9e77-4671-b1ea-a140be114ea2','5363G',40,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e28ec44e-9e77-4671-b1ea-a140be114ea2','5366K',40,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('462f76a7-8241-42e7-b5b5-a9ad83863163','1322N',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff4966df-3ba8-401c-b74c-01d3d8a6e81e','2605D',200,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('30e75a95-1866-43fe-8111-ace57087cbb1','3164M',2,3,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3d7ee4c-9ab3-4685-af2b-4ee9b540e003','1312C',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef36cf65-0057-4dc9-8ad9-75b9fcd1917e','1313D',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5c85b5b2-d2c8-4fb1-af47-e198e534c37b','1335G',90,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dd279a08-c0bf-4df5-abd4-b36cd9bc86ea','8480H',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4e25de44-9587-4ac5-ac0d-588af3abf7bc','2501P',20,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0f971efa-ece1-4555-ad71-8d076f17ad1a','3463G',20,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0f971efa-ece1-4555-ad71-8d076f17ad1a','8783G',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('06eeeb0c-86b1-4005-920e-68875d09bfc2','2923W',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('532fc00e-9360-4c3a-9580-380f7dd636b4','2924X',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4ec3fe71-2b00-4b8f-b9f3-0a237885455b','1347X',25,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('925f9238-fd83-444f-90ac-239d337230dd','1357K',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3205a504-92d4-4179-b2aa-bfc7451d2109','1358L',30,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3553ff28-454c-4ec7-8162-f0ac2d5506fa','1011F',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('beb54b08-e4c2-4e70-85b9-e0765f590dc0','1012G',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8733acc5-2217-4349-b058-672c3f7f8859','1013H',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f59fb2d-b5c1-41e4-a36b-133b0e96deb5','2703G',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e68e791c-23fb-425b-bb95-fd297b8f3c48','2707L',25,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f59fb2d-b5c1-41e4-a36b-133b0e96deb5','2708M',7,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f59fb2d-b5c1-41e4-a36b-133b0e96deb5','2715X',21,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f59fb2d-b5c1-41e4-a36b-133b0e96deb5','3322W',7,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09afc621-708c-40c5-9d0a-57d9ceeb4fb0','2702F',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09afc621-708c-40c5-9d0a-57d9ceeb4fb0','2709N',7,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09afc621-708c-40c5-9d0a-57d9ceeb4fb0','2714W',21,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09afc621-708c-40c5-9d0a-57d9ceeb4fb0','3321T',7,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09afc621-708c-40c5-9d0a-57d9ceeb4fb0','5082L',7,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09afc621-708c-40c5-9d0a-57d9ceeb4fb0','9105F',7,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09afc621-708c-40c5-9d0a-57d9ceeb4fb0','9107H',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b5fbaa6-7666-48b9-9f96-85c62623db9b','2711Q',25,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b5fbaa6-7666-48b9-9f96-85c62623db9b','9106G',25,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09afc621-708c-40c5-9d0a-57d9ceeb4fb0','1800R',21,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09afc621-708c-40c5-9d0a-57d9ceeb4fb0','9108J',21,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('16134cba-ddbe-4e94-81d6-32ddf91bc3e5','3199J',2,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0009e2f8-7786-455d-9264-e888de84e9ed','1368B',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b7418e0e-63fe-4286-863d-7904013f1183','1369C',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0225ff8f-36d1-4a60-99f7-ee1279f97497','1370D',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ccd888e5-c122-436c-a9ff-6113cca3acd7','1404X',25,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ccd888e5-c122-436c-a9ff-6113cca3acd7','3325B',25,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba8aea33-cb0e-454e-bdc3-6e5919894685','2424N',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7efc8068-c59c-459b-9709-b8d647915cb4','2428T',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('610f4302-eba4-4d9b-8442-fa2df4382beb','2750R',25,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba8aea33-cb0e-454e-bdc3-6e5919894685','3334L',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('610f4302-eba4-4d9b-8442-fa2df4382beb','3336N',25,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7efc8068-c59c-459b-9709-b8d647915cb4','3337P',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3e20bcb5-1c63-4c44-829b-0573c3348c5c','1397M',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3e20bcb5-1c63-4c44-829b-0573c3348c5c','5088T',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('671a0472-64d7-464e-9eb3-9c5f1ab9441c','8748K',200,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f71093de-14ef-49ec-b1aa-64b2538b14ac','1413J',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('860035a6-0212-45cc-840b-bfea346d7a06','1414K',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('80fecdd4-4110-407d-84e7-744f12612e52','1389D',10,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9359b51b-7b7b-4355-9f8b-0e13af1a665a','1396L',20,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('95cef274-c5a0-4438-bc7c-f1c819042b61','2488Y',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('476dd389-c931-47b9-a0bf-668d7c7236d6','2487X',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('948c5e0c-8977-4d83-a750-7242c4a7c87f','2367N',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6013953b-1efe-4aa5-ad38-285c841920cf','2361G',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fec1ae8e-6da8-4e0c-9201-05cc01c5e88b','2366M',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10d604e9-e027-46ff-96c0-44f6d3638082','1088G',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('72f9cc68-5826-4d81-9cfc-7bd37ede4bfb','1090J',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('55d31079-a423-48d8-bd87-7954d71ba502','1524F',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4489cede-26d1-407a-b921-2452a09ba333','1525G',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b4a1df8-0c36-4369-b7fa-a79aa3d9a2b6','1526H',24,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24436ba8-5cab-4b85-9032-855d971f755d','1527J',24,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b4a1df8-0c36-4369-b7fa-a79aa3d9a2b6','5090X',24,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24436ba8-5cab-4b85-9032-855d971f755d','5091Y',24,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('55d31079-a423-48d8-bd87-7954d71ba502','5094D',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4489cede-26d1-407a-b921-2452a09ba333','5095E',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('280f07fe-8d45-4ae7-af6b-a047f2eb3ae2','5257Q',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('59bc8a09-b60e-480a-a8d3-eaa11e7e191d','5258R',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('280f07fe-8d45-4ae7-af6b-a047f2eb3ae2','9149M',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('59bc8a09-b60e-480a-a8d3-eaa11e7e191d','9150N',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2b984dd-7ec1-40c9-8a7c-7fc900d3e001','1433K',200,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5b94afb5-04d4-4270-bca6-9572b3f7401e','1204J',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5b94afb5-04d4-4270-bca6-9572b3f7401e','5513E',1,0,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3fc7ef18-cc90-490e-86df-e21b0ab359aa','1438Q',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3fc7ef18-cc90-490e-86df-e21b0ab359aa','5533F',1,0,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0138a598-93ad-498b-b9e9-7967f1eedc14','4222F',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('243049f9-b9fd-49b1-bc4c-05f6cf63f1c1','1434L',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4f2ddff0-8ef5-460f-a74c-1ac11bb3d20d','8270G',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f0e6639-1406-4bcc-a4e6-3eeb989f428c','1001Q',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fe1a6f7f-ba3a-4551-9e02-223a67d3d5b1','1046C',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e2442530-9ef6-4d1c-959e-94b33cbe2322','3098C',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3aea6c1-66a2-40e5-9b90-ed0718b4538c','1437P',200,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c325b2f1-c76d-4841-952d-a041906709db','2958Q',200,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e7a71cb3-2ee6-41bd-992a-1497a0b9a245','1440T',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e7a71cb3-2ee6-41bd-992a-1497a0b9a245','5557L',1,2,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('79037283-1606-44da-9a4c-5f9d7ee8595c','2411X',1,3,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a882523-68cc-43af-978e-5ecb8d147f62','2412Y',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6f155126-5189-4703-81c7-4946a668e627','2413B',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e9394245-4c3d-4ae8-9adc-e05503c8de49','2415D',50,3,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6f155126-5189-4703-81c7-4946a668e627','3466K',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b12f561-96c9-4000-a829-d39a5c9abe11','1810G',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b12f561-96c9-4000-a829-d39a5c9abe11','2414C',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5f988e23-529e-47f4-ac72-85b728c2f893','2312Q',36,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0625e846-04fe-47f5-8f5a-cfce8efffd36','1453L',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0625e846-04fe-47f5-8f5a-cfce8efffd36','9248R',60,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8be1116b-05cb-49cf-be24-3eeb5e4d12d8','2824P',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b91161c6-4f0c-47fe-a3f3-2da61570c62b','5566Y',1,2,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b91161c6-4f0c-47fe-a3f3-2da61570c62b','1441W',1,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('80b372be-4bd3-4c83-bbb6-66f1cac52d9b','2939Q',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7036cc1a-5262-436f-951d-c84c8aab30cd','2449X',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('20923444-4ad4-4cda-ad8e-f66303b9044b','8535F',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c3e0797d-7362-4466-b893-2f3ad1308f0d','9302N',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4fa4910b-dc2b-400a-9c3c-801897cc8870','2440K',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3ece3ae0-f63c-4102-a8e5-8133287e807e','1449G',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3ece3ae0-f63c-4102-a8e5-8133287e807e','3467L',1,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3ece3ae0-f63c-4102-a8e5-8133287e807e','5105Q',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5c189287-a861-4f92-b7fd-d445c8d909be','2245E',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ab2712d5-1b9b-4df4-a0c9-3eb6d9db7d60','5005K',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5c189287-a861-4f92-b7fd-d445c8d909be','5106R',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ab2712d5-1b9b-4df4-a0c9-3eb6d9db7d60','9444C',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('26dbff21-23a0-44b7-972c-a5dce255cf77','9445D',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c139716d-1363-4def-90fd-b6ac2d4a5ef6','9474P',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('57a68f20-277a-40cd-8c93-7636f1ec87e7','2263D',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6dfdf016-cd80-4680-abbd-708e24f2ef40','2860M',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('17ec6cc3-e6ad-446b-93e7-a4310f50759a','2890D',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0aca3892-c56b-4e4a-b3a2-a453b49552c7','2914J',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c870effc-6513-4f22-9244-3b1dfa53d81c','2979T',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('adb27acd-3987-4bfe-903e-c9bbb43af486','3406G',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('adb27acd-3987-4bfe-903e-c9bbb43af486','3407H',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c80a7f2a-3866-47cb-bd6c-27a73ddca890','3411M',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c80a7f2a-3866-47cb-bd6c-27a73ddca890','3412N',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6904dec1-3255-4bb5-92ee-abae805b51b0','3441D',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6904dec1-3255-4bb5-92ee-abae805b51b0','3442E',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4da993d4-562a-48d6-8ebc-19f0c9df7dc9','8190C',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b212e1f6-684d-4f53-9e8e-fd2279598694','8522M',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('feffc77f-359c-417d-a5e2-62603ea5154f','8723D',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4c34cf89-2d34-48eb-9af3-74eaabc3a21d','8739Y',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0e4e31dd-abac-412f-abc8-338b5d00f2fa','8749L',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('226174cc-923b-449a-89c2-ba71e44b0b4f','8759B',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c21c86d7-d1ba-4dfd-af89-5bfb176576ee','8795X',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('941c0f64-ff93-4dd7-b188-9a8f84fc974d','8806L',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cfac4586-30cb-4631-a694-e87b2897dd0a','8825L',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a0e5de7-8a63-4d34-a5b1-ac0d2cc8c3c9','9013J',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d697e1a2-1d02-414f-8669-f8edc8c6df80','9154T',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c870effc-6513-4f22-9244-3b1dfa53d81c','9257F',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a0e5de7-8a63-4d34-a5b1-ac0d2cc8c3c9','9261K',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0e4e31dd-abac-412f-abc8-338b5d00f2fa','9263M',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('feffc77f-359c-417d-a5e2-62603ea5154f','9265P',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('57a68f20-277a-40cd-8c93-7636f1ec87e7','9267R',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cfac4586-30cb-4631-a694-e87b2897dd0a','9268T',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d697e1a2-1d02-414f-8669-f8edc8c6df80','9269W',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b212e1f6-684d-4f53-9e8e-fd2279598694','9270X',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4da993d4-562a-48d6-8ebc-19f0c9df7dc9','9273C',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4c34cf89-2d34-48eb-9af3-74eaabc3a21d','9274D',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('941c0f64-ff93-4dd7-b188-9a8f84fc974d','9275E',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('17ec6cc3-e6ad-446b-93e7-a4310f50759a','9276F',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6dfdf016-cd80-4680-abbd-708e24f2ef40','9277G',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('226174cc-923b-449a-89c2-ba71e44b0b4f','9278H',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0aca3892-c56b-4e4a-b3a2-a453b49552c7','9279J',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c21c86d7-d1ba-4dfd-af89-5bfb176576ee','9281L',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c5fd4948-564f-4479-b50c-b0598ca21c00','9297H',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c5fd4948-564f-4479-b50c-b0598ca21c00','9298J',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19d7cf6e-c338-4a83-9c2e-ad48f4a87c6b','9471L',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19d7cf6e-c338-4a83-9c2e-ad48f4a87c6b','9472M',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1b50858f-77e8-45e8-971c-74a0826021bf','9485F',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1b50858f-77e8-45e8-971c-74a0826021bf','9486G',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b8ff298-735c-4b99-9a4a-140a5b0c7a65','9300L',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b8ff298-735c-4b99-9a4a-140a5b0c7a65','9301M',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ebaa5c89-6057-456b-8738-b20d17bd38c4','5267F',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2be96cd4-62fb-42e8-9813-0a8c48aef700','5268G',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ebaa5c89-6057-456b-8738-b20d17bd38c4','5269H',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2be96cd4-62fb-42e8-9813-0a8c48aef700','5266E',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('86ec88d0-406b-41a1-b7c2-f35db619b1fd','5053Y',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('86ec88d0-406b-41a1-b7c2-f35db619b1fd','5043K',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1a964083-7602-4746-b402-713052ec0cdc','1518X',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1a964083-7602-4746-b402-713052ec0cdc','1503D',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('30e73949-2c8f-4480-94d5-a238adc83e06','1520B',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('30e73949-2c8f-4480-94d5-a238adc83e06','1519Y',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8f7d38ac-c4da-416f-b9f0-efcc3df18233','3104J',2,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8f7d38ac-c4da-416f-b9f0-efcc3df18233','9253B',2,4,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('960271e9-19e7-4586-b428-c84cbd6d9e86','3106L',2,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('960271e9-19e7-4586-b428-c84cbd6d9e86','3107M',2,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('960271e9-19e7-4586-b428-c84cbd6d9e86','9254C',2,4,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('960271e9-19e7-4586-b428-c84cbd6d9e86','9255D',2,4,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d4f431ca-b090-405a-80ab-d561966a08ca','2555L',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffd5b9cf-6ac6-4d78-bce6-9c9be290f083','2556M',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af1e42f1-5645-4d3a-80af-10c0b650d534','2557N',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d4f431ca-b090-405a-80ab-d561966a08ca','3265W',8,0,'PQ','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffd5b9cf-6ac6-4d78-bce6-9c9be290f083','3266X',8,0,'PQ','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af1e42f1-5645-4d3a-80af-10c0b650d534','3267Y',8,0,'PQ','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d4f431ca-b090-405a-80ab-d561966a08ca','5311M',3,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffd5b9cf-6ac6-4d78-bce6-9c9be290f083','5312N',3,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af1e42f1-5645-4d3a-80af-10c0b650d534','5313P',3,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d4f431ca-b090-405a-80ab-d561966a08ca','5314Q',3,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffd5b9cf-6ac6-4d78-bce6-9c9be290f083','5315R',3,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af1e42f1-5645-4d3a-80af-10c0b650d534','5316T',3,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af1e42f1-5645-4d3a-80af-10c0b650d534','4246L',3,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d2bea379-6fb3-40e0-9cea-ef9529f351a5','1459T',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('efc6c12d-0d3c-4975-8b75-640a4fe16f42','1515R',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('38451fe4-3748-4549-9945-16628a20bfc1','1516T',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bc8dffd0-655e-4366-aa6e-aa87fbf5024f','3475X',1,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d2bea379-6fb3-40e0-9cea-ef9529f351a5','5108W',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('efc6c12d-0d3c-4975-8b75-640a4fe16f42','8010N',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('38451fe4-3748-4549-9945-16628a20bfc1','8011P',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24bc0557-c3c2-4ec0-a288-3b5f4ef54973','8026K',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('efc6c12d-0d3c-4975-8b75-640a4fe16f42','8027L',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('38451fe4-3748-4549-9945-16628a20bfc1','8028M',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24bc0557-c3c2-4ec0-a288-3b5f4ef54973','8119H',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bc8dffd0-655e-4366-aa6e-aa87fbf5024f','8171C',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('65a93fbf-1884-4dc9-8fda-440766b6111b','1454M',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0f1ee7f7-b43d-4c44-977e-6b42ff81c61f','8093Y',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5470a01c-f8cd-445c-ba7e-12444be7d64a','1460W',100,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f62d2a2a-a2fd-4ad1-98cf-20d3b234c7b0','2982Y',28,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('acf25c1e-6bca-4b9b-833a-7b8276855801','2761H',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4e0bef10-a479-4a00-9a9d-f9a65669bba9','2763K',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6efcaf06-676a-4899-9ffe-4fd4bc2c0d9c','2767P',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d9f79db-8665-46bb-a3c2-70a6195d4c06','2768Q',10,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44b26046-f300-4206-aa25-5ed3a8c98318','2770T',50,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d9f79db-8665-46bb-a3c2-70a6195d4c06','3456X',10,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('27b8a220-69e2-40aa-926d-f57a93f84db3','2765M',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('20a1ed1b-8c4a-4b2a-a852-4ffeb4f5652e','2766N',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0257a436-5487-478c-97be-64b68d939c57','1076P',12,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7085ece3-6aeb-408d-a668-433677dfc8e8','1463B',50,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7085ece3-6aeb-408d-a668-433677dfc8e8','1466E',5,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5eff00c4-b271-4dd8-8738-a835c52a1682','3124K',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dec463a9-f176-4a25-9156-ae0f286f5ede','2541R',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('710dc06b-6db7-4f68-b24d-7cf52f2a8197','1581F',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('710dc06b-6db7-4f68-b24d-7cf52f2a8197','6178E',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('00efe2b5-54f1-4d90-9ef1-aca8021dff96','6181H',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('de4543ce-7c38-46ba-95b6-8eee366ed7c1','2038G',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9fbd64da-ecd4-41f9-99ea-60a879d01be4','2036E',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('12dc8b4c-3c97-460d-8475-2cff9b6cdadd','1639G',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('156f9639-d27c-4688-b4eb-92a969bfc4f1','1640H',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('72068ef9-665d-4a60-9902-050957d66689','1484D',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('73be6361-003d-474e-8e89-975d0ea5a877','1486F',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('76c93e96-fbc3-4da8-a6eb-11c1ba25de7c','1280J',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('474c618c-a5cd-4f4f-82d9-40e77ea07a52','1499X',50,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e8a39c31-e4d2-469c-8845-963e5f68d879','1500Y',60,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('07096497-d5c4-4cb0-9579-c8dad193ad20','1502C',2,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03c0f8b9-61ed-48b3-a072-46a8a42e9895','2441L',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e7607982-4a86-4c13-8d9e-1f54db063745','2881P',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a5ec86a3-ff4f-48c8-9600-c80032430b62','2882Q',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('90eecbc6-2168-4b7f-90e6-5e379c56c845','2887Y',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('21056d0c-8dcd-4263-8479-bd54ba5af9a1','2888B',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('90eecbc6-2168-4b7f-90e6-5e379c56c845','5111B',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('21056d0c-8dcd-4263-8479-bd54ba5af9a1','5112C',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e7607982-4a86-4c13-8d9e-1f54db063745','5113D',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a5ec86a3-ff4f-48c8-9600-c80032430b62','5114E',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03c0f8b9-61ed-48b3-a072-46a8a42e9895','5516H',1,0,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1059ccda-ac81-42fe-b62e-277cd7f94c08','1501B',2,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1059ccda-ac81-42fe-b62e-277cd7f94c08','1510L',6,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9b51d78-9c89-4dec-8882-03b11cceb82e','1511M',6,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9b51d78-9c89-4dec-8882-03b11cceb82e','3096Y',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1059ccda-ac81-42fe-b62e-277cd7f94c08','3470P',2,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9b51d78-9c89-4dec-8882-03b11cceb82e','3471Q',1,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1059ccda-ac81-42fe-b62e-277cd7f94c08','5118J',6,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9b51d78-9c89-4dec-8882-03b11cceb82e','5119K',6,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('072defaf-6aa0-4045-ad71-c73a70b521a6','9048F',3,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e9e45206-5631-46f0-b7aa-3126138ce5a0','3093T',100,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6848041e-9e61-493d-9855-8ce8b562f8a6','2956N',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6848041e-9e61-493d-9855-8ce8b562f8a6','5517J',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('33411eb1-96c5-43da-b897-db381ff6f3ba','5518K',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('33411eb1-96c5-43da-b897-db381ff6f3ba','8287E',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('33411eb1-96c5-43da-b897-db381ff6f3ba','9213X',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6848041e-9e61-493d-9855-8ce8b562f8a6','9214Y',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0c0a03f8-1014-45d7-94c7-a3d6414e5d79','5421H',1,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0c0a03f8-1014-45d7-94c7-a3d6414e5d79','5422J',1,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b65a0ec7-0356-40e2-8432-a7037b8a9b95','1509K',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b65a0ec7-0356-40e2-8432-a7037b8a9b95','5520M',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('639ec5a7-75d2-470d-9e4d-02c81ce5e6c0','5521N',3,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('639ec5a7-75d2-470d-9e4d-02c81ce5e6c0','8299T',3,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b65a0ec7-0356-40e2-8432-a7037b8a9b95','9216C',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9397ad7-bbc8-4298-ac65-130b41d71011','3190X',90,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e862a38-224d-465c-9a1a-9515eb736e18','3192B',30,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9397ad7-bbc8-4298-ac65-130b41d71011','5123P',90,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e862a38-224d-465c-9a1a-9515eb736e18','5124Q',30,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9397ad7-bbc8-4298-ac65-130b41d71011','5368M',90,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e862a38-224d-465c-9a1a-9515eb736e18','5370P',90,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('00e63d6b-c5d7-494c-bd35-c05b9b89cc1a','2420J',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2d70a79-c79b-42ef-8f1c-b50e85d8ba80','2421K',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('41743a2e-f21d-4f32-85cd-a93d3fccfa58','2436F',90,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f4520016-13b8-4fd2-a0f3-18f9e690f783','8532C',90,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7fa5f64e-3cb4-44bc-a316-0478aab1b24c','2454E',100,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a4747b5-2cf9-4145-acb3-99e3126f1db0','2757D',40,3,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7fa5f64e-3cb4-44bc-a316-0478aab1b24c','5126T',100,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a4747b5-2cf9-4145-acb3-99e3126f1db0','5128X',40,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7fa5f64e-3cb4-44bc-a316-0478aab1b24c','5377B',100,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7fa5f64e-3cb4-44bc-a316-0478aab1b24c','5379D',100,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a4747b5-2cf9-4145-acb3-99e3126f1db0','5378C',40,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a4747b5-2cf9-4145-acb3-99e3126f1db0','5380E',40,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d293473c-37c4-42cd-9242-d876e50c9bfb','2886X',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cfab8040-e3af-4bb5-b02b-ae5e8ea37eaa','2918N',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('337cad24-ab67-49b5-b376-48ad74ed5575','1533Q',5,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('14c052dd-d152-4e06-b246-a4311517173e','1711C',5,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('db72f87b-e7f2-4263-8e39-3aa4fa61f919','1761Q',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a1017f2f-4ddb-4968-ac7f-0a7c97973619','1531N',5,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4d24012a-dbbb-4ac0-9877-81a195c142d9','1713E',5,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('969819c8-da9a-410c-8862-a8dc35bb9411','1762R',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('83224c6b-1de2-4974-84c8-c38fef71cdd7','1211R',10,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('69536e4c-12c7-41dc-82ee-03ec3d264b70','1426C',5,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2a362908-5164-4ad2-bf65-fe86cfdcbe22','1763T',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad7a95b6-2044-426f-87c5-efbd56531936','2062M',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7663b156-ce2c-4046-8a8c-23b840da6582','1542E',2,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('359e7836-93e4-4a17-a71e-c58bdd7ee211','4089F',1,5,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4ad3ac16-f013-4b8e-a8d2-a32889f3427d','4090G',1,5,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('41afe0da-6899-4758-b669-6b2157178977','8238N',2,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('89512081-e0ab-46b3-8b27-3870c50939d9','8671J',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('247fbc6f-7434-4440-9897-3a90563009fb','2593L',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1c0a476f-ca85-488c-b3ac-ec9fe7b843de','1554T',100,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('04f2d376-a385-4ccf-adeb-9ab2a8b1a698','2588F',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4815f51f-30ec-4011-8d36-29e0e976ef5e','2549E',30,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed925f72-2f30-4855-b0f8-b3b3e00d8d08','2591J',60,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff40cc74-cc4e-45f9-83bd-0d5aa355f610','2592K',60,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9101f0b2-81fe-4289-8397-7a62a6996fec','1574W',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1c263433-5949-4a27-b79e-a344eec94696','4007X',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('291df2b0-d22a-4a4b-be1d-91481f6fa39d','9024Y',1,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9d84df62-4b10-4bd4-89d1-9a1984c15ce9','9025B',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('78281c8f-1d19-4615-889c-8019a84a749c','1572R',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ae7d835-bdd6-477e-8932-fa77f5272677','1573T',10,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9101f0b2-81fe-4289-8397-7a62a6996fec','4008Y',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('465eaed0-f85e-41b3-8f2e-77c718a3fd25','1588N',40,3,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ddc1e94c-d5cf-4683-b489-88bf9b5e8f84','1590Q',28,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ddc1e94c-d5cf-4683-b489-88bf9b5e8f84','5136H',28,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('465eaed0-f85e-41b3-8f2e-77c718a3fd25','5139L',40,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('89c816fc-6182-4f7a-b448-df181fdf2080','1566K',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8c9d1028-6ff4-49b7-8c50-9193aa02f073','1567L',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f64e4db0-715f-4b63-97f1-8e25ddf5626b','3064G',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f769211a-a092-4ea1-a64f-6f948b058ad0','5387M',3,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f769211a-a092-4ea1-a64f-6f948b058ad0','5388N',3,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('00cb91c2-9460-4e74-b5e7-28be752eb00e','8707G',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae9a2f3b-bcae-4fd8-89b8-041fc457e684','8708H',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bb10e6e9-7879-4629-bb2b-5d81cd852a6a','8709J',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4f28a1ac-c57d-4373-872c-b31c1c3e66d8','8859G',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('00cb91c2-9460-4e74-b5e7-28be752eb00e','8875D',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae9a2f3b-bcae-4fd8-89b8-041fc457e684','8876E',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bb10e6e9-7879-4629-bb2b-5d81cd852a6a','8877F',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('14e98313-9a5c-4293-a038-de352d40ffcd','2225D',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1210aadb-6161-4315-a51f-a2130f64bd4c','2226E',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b49e9c7b-d0b9-481b-89ef-395a339df0de','2227F',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('01de8a3d-0b31-4744-ad0c-d638eb43c983','2228G',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('133d9918-0c19-4999-95b0-ad7c63820708','2229H',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('79cb1913-b9ba-4ba7-9beb-e82a6e5ebc43','2231K',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7c1bdcc6-0f74-431c-82c4-169fea2869e3','8218M',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('36221be3-92a4-426f-831f-0f367aff340e','8219N',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9bda8ebe-17c1-457d-a9f5-bf0952b7c5e2','1242J',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba3f9016-acce-4ce1-8cf0-2d141dd25b96','1245M',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0dd2ae85-966f-4654-a7f4-b7e11f50fc73','1255C',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9161e22-8494-4536-80ac-8248baa692d5','8970D',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9161e22-8494-4536-80ac-8248baa692d5','9743T',56,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9161e22-8494-4536-80ac-8248baa692d5','9744W',56,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c6fd5b83-fa51-4996-b96e-74edd65d0cfe','2913H',4,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c7c7b64c-a542-4663-a04c-5c98073f01a0','8633J',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce1cb9ba-445b-4379-afe5-d1e2251189d8','1392G',4,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0f1720fd-231b-4833-a004-4a633d2fe5ed','1394J',4,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('54857133-3a78-4b2b-986a-b99a75ba1673','1456P',4,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b94a25c8-441f-45e8-8832-1ab4a286f6a5','2875H',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b94a25c8-441f-45e8-8832-1ab4a286f6a5','2876J',10,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b94a25c8-441f-45e8-8832-1ab4a286f6a5','3474W',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b94a25c8-441f-45e8-8832-1ab4a286f6a5','5142P',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('25863a1d-501c-4fc1-9047-08d82cb4afed','2530E',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('25863a1d-501c-4fc1-9047-08d82cb4afed','5144R',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a1a7d7ce-4027-428b-850b-a8ff9e2cf45e','2318B',100,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3e3f20cf-4a2a-41e9-8529-e00b6bec9054','3059B',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fa60dd1c-33c9-458c-8ac7-52dff15a7ec6','8290H',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9341e1eb-80d2-4efa-b250-35f4e6a2c8f8','1571Q',12,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef415145-7a5f-49ed-b00e-b95f2b7b35bd','2316X',60,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1c99dbbc-81fa-4a43-aed2-1bcf095118f0','2321E',30,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f6705091-da13-4197-a0a9-177b7e7b1272','2323G',56,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1c99dbbc-81fa-4a43-aed2-1bcf095118f0','2722G',100,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f3ddbef-3cff-4a34-8a19-b89092001ed2','2725K',100,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b76aad8d-4d81-42de-bb36-80797bcf437d','2727M',60,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6dddb1f5-6b37-4eb2-87de-e93942ee0640','2728N',30,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('90e566e2-1def-4524-a02e-0f61f10ada5f','3118D',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0e721eec-c012-48c9-909b-90f1c51f076d','1824B',50,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8723dece-310c-444f-87f0-1b3b72a3fffd','2734X',30,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('964751b8-c576-49ac-9f80-70b49d6beaf8','2547C',25,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c9f8d212-a60c-4e7a-a5f3-804779693f7b','1598D',100,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2861a90f-6162-492e-b52d-77889fb3e8c9','1611T',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c76d5e6b-096a-48a2-a0ec-34a1b75d350b','2214M',200,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e4595577-73f9-44c6-9c67-a2a41e262eac','2287J',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('84702967-f715-4a19-8f65-f8629f1e3f71','3413P',120,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3cdd5d36-560a-46ee-b13c-114506c7c0df','8731M',200,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('023e8f72-2e5c-4cdc-9012-219fd0371ee1','8616L',4,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f048fce9-7908-41d4-b0b9-6b7f1f6220d6','8617M',4,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5ac3bc9d-1195-4f19-bfbd-3a0324e04cad','8753Q',4,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a7398cbb-037b-40c5-9751-49e660ac1751','8768L',4,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c9d51ae0-4756-4c9f-9446-5159542791f2','8598M',200,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('755daebb-7a0d-4dfd-882c-4d13d9c60b86','8599N',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('57bcdcfc-6438-4b9c-8a29-353a7324ee90','9206M',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('da9050c8-2a54-4b63-af42-00147d3820f3','9353G',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2171c8ab-2175-44bd-9e31-bbeda2ab065a','5461K',30,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('755daebb-7a0d-4dfd-882c-4d13d9c60b86','2234N',120,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2171c8ab-2175-44bd-9e31-bbeda2ab065a','8752P',30,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5fdaab3b-bf6c-408e-baa6-faf029e784b9','1801T',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2d0dbc70-46d1-4b68-a030-fec41efafc46','2430X',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fa131941-03f0-4471-a7f0-0b02def4691f','3439B',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('db257e01-3afb-4f2a-bdcd-1e7547676c43','8607B',90,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('60d20be8-9cf9-4d0d-ac11-3d941ee63caf','9435N',120,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dbbeec68-cc1c-41a3-b968-5e121595c50b','6171T',1,0,'MD','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('156e0ce4-95be-48a3-b7a1-782eb4fd345f','6172W',1,0,'MD','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dbbeec68-cc1c-41a3-b968-5e121595c50b','5399E',1,2,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dbbeec68-cc1c-41a3-b968-5e121595c50b','5400F',1,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('86a56191-ddf9-4342-901a-44c7ed88e114','1606M',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e6f42017-13cf-4955-ac2d-8cc82aa6eb01','1609Q',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('455866e6-7817-4446-91ae-ad34a5b89f92','1622J',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('877e46e3-6eba-496c-b5ba-4fc15625d717','1623K',50,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('877e46e3-6eba-496c-b5ba-4fc15625d717','2272N',15,3,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('38424327-f5f4-42fc-94c8-a4a765f2bcaf','2396D',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24b4c655-d7f4-4169-8def-a06e815cba74','1818Q',5,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24b4c655-d7f4-4169-8def-a06e815cba74','2395C',5,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('70e09b75-2e26-4fb1-afa7-f16a4b5f251e','1629R',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('335ff15a-a437-4aa4-a90a-e576b1a1b645','1928L',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('335ff15a-a437-4aa4-a90a-e576b1a1b645','5148Y',5,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3310192b-03b8-4dc1-ab8d-4f0054822757','2981X',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9a71f47e-04dc-481e-89d9-c2c78208f56c','8834Y',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3310192b-03b8-4dc1-ab8d-4f0054822757','5263B',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9a71f47e-04dc-481e-89d9-c2c78208f56c','5264C',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1c89bc7b-ac41-4944-b015-34d3bc5a8f69','4022Q',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2fe2f873-6eb5-4427-af76-ccc8cb503b02','4023R',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f1aa520d-23c0-4560-812d-ac7f81bbcec8','4026X',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad1b552e-720d-4ff2-8c60-74e1b044e08a','2826R',100,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef803155-d42d-4826-90cb-f9c274ae6942','1206L',10,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2f8f40d2-6833-48a3-9f08-e762772027d8','1207M',25,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef803155-d42d-4826-90cb-f9c274ae6942','3476Y',10,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2f8f40d2-6833-48a3-9f08-e762772027d8','5151D',25,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef803155-d42d-4826-90cb-f9c274ae6942','5153F',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b1dda1a7-d6be-45ff-a615-1853e4843ee5','1324Q',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('229e2e00-0e0a-4506-87e1-364b21fa8df2','1325R',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('309aeb24-c10f-4038-b4ae-0ce700c3bc58','1621H',21,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ca323295-23c1-43f6-b18e-b2a37983fd3a','1636D',21,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5cfe923e-5723-4aa7-b10f-bb65862a66d8','1642K',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ca323295-23c1-43f6-b18e-b2a37983fd3a','3339R',21,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('309aeb24-c10f-4038-b4ae-0ce700c3bc58','5155H',21,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5cfe923e-5723-4aa7-b10f-bb65862a66d8','5157K',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc2aaaf1-b406-44fd-b2e4-7caba211cf2d','1638F',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc2aaaf1-b406-44fd-b2e4-7caba211cf2d','1821W',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc2aaaf1-b406-44fd-b2e4-7caba211cf2d','5154G',10,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc2aaaf1-b406-44fd-b2e4-7caba211cf2d','1832K',10,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f89734b-01e0-4ba8-a68c-2cdb28f5c13a','1630T',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f89734b-01e0-4ba8-a68c-2cdb28f5c13a','3341W',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bcd13256-04d5-41c5-b285-a5bef11a7316','1627P',50,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bb599242-a289-4595-b2f8-64081fad0dab','1628Q',50,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aa6548ec-38cb-4ec4-8f5c-90e491382e41','9026C',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('43fb86e0-0969-4ea5-835b-3aa8e816926a','9027D',1,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('312d7058-9c04-4d35-bfc0-76f05f227867','9028E',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('73c79285-0805-4923-97c3-64a2683f6736','9029F',1,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2478c845-5e2f-4b8c-8394-b9a3a4353012','9030G',1,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('43fb86e0-0969-4ea5-835b-3aa8e816926a','4454K',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('20eb7c1f-08b3-4c9b-86f0-d7df6b2c47b9','3400Y',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('34ef185c-879f-4088-bfe5-eb5dd050dfd4','2357C',3,10,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('34ef185c-879f-4088-bfe5-eb5dd050dfd4','2358D',3,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a0bccf0a-b941-4a87-ac5b-3608053cfbd4','1616C',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('173098d0-41bf-4d78-83e5-3f11c188c666','2313R',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e1d66d54-140d-4dae-a55e-670851b674b8','1648R',120,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44d93e69-7afb-431e-a6cf-24c6eca64626','1644M',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('92123297-a4ec-444c-b291-5299c556b8c6','1645N',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('04267387-6b29-47c9-950b-10d4d0ea7a1e','1647Q',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('92123297-a4ec-444c-b291-5299c556b8c6','3479D',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('04267387-6b29-47c9-950b-10d4d0ea7a1e','3480E',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6cfb8c32-b37e-4874-a910-9faed2ffd9c0','5163R',20,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44d93e69-7afb-431e-a6cf-24c6eca64626','5168B',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('92123297-a4ec-444c-b291-5299c556b8c6','5169C',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('04267387-6b29-47c9-950b-10d4d0ea7a1e','5170D',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6e7ff4f8-b79e-4a6a-828b-d7574b05f4b6','8669G',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f3871fd-0692-4d00-a97e-5e36a3e62509','8670H',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6e7ff4f8-b79e-4a6a-828b-d7574b05f4b6','5393W',20,2,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f3871fd-0692-4d00-a97e-5e36a3e62509','5394X',20,2,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6e7ff4f8-b79e-4a6a-828b-d7574b05f4b6','5395Y',20,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f3871fd-0692-4d00-a97e-5e36a3e62509','5396B',20,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6cfb8c32-b37e-4874-a910-9faed2ffd9c0','1646P',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8eef436a-33f9-4fad-b2ea-476a1860acfe','8453X',28,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8eef436a-33f9-4fad-b2ea-476a1860acfe','5391R',28,2,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8eef436a-33f9-4fad-b2ea-476a1860acfe','5392T',28,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6f2c0004-2298-40bd-9447-429994a11e26','8454Y',28,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bea3812d-4f39-4ba3-8b51-6dd1d06b1154','8494C',14,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dd00a43a-1320-4c4b-9ba0-bd0f5bd36316','8491X',14,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5ae96a96-ce24-4825-9235-8c0f754976ea','8492Y',14,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1fd7505c-e6ff-406e-aa67-75f39d1fd174','8493B',14,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bdd3798f-082a-40d9-a41d-832e4973b9f7','8306E',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19962104-70dc-432b-9362-ec6f4d836b95','8490W',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1652ff43-39df-4162-a12a-1f43de320c9b','8146R',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4ff1d700-c724-4c24-a68b-a67e7aaea059','8305D',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d5ed0b67-ef39-4571-805f-1e7c408782d7','8489T',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('04fec2a2-c82d-4004-879c-c842c0baf9d9','8035X',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c87f43bc-7a4f-4bab-ace0-bf5d8ff7927b','1653B',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b177e6d7-c9fe-472d-a991-09e7b145e9d1','1656E',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d07ba4f6-0219-485a-89b0-a2b1e2629410','1654C',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b0b874c9-3c10-4757-a76f-384a4b17d41d','1655D',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8eef436a-33f9-4fad-b2ea-476a1860acfe','4349X',28,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5cb8da54-b67b-409a-a358-5e76858e2a69','8349K',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e1b529f2-cd46-4601-8bc8-3937e1ea7e83','2839K',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('72fb149c-958c-4b19-be3b-121033b9d8f6','2840L',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fb3ca272-3ac4-439c-900d-8eb82c2d4f49','2841M',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0213e934-52bc-4d96-90d9-9a50082ca342','1607N',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b20563d-4cff-4076-955f-4278ad19c0f4','1753G',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b20563d-4cff-4076-955f-4278ad19c0f4','3482G',2,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b20563d-4cff-4076-955f-4278ad19c0f4','5175J',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2e93ac6f-d050-441a-ba52-c73779d8dd8b','1671Y',1,7,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ebf2027a-1f05-438f-94f1-4df7c2e97ecf','4035J',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9f7e618-c6d7-454a-85c5-d6c5b850700c','1614Y',28,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('02dc806e-1619-442e-82dd-e12d6b665828','1615B',28,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7194ac42-f863-4424-9880-67e12d45dd47','1659H',50,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b920e4b-d31a-4475-b32f-7efb7bf65613','1674D',100,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b920e4b-d31a-4475-b32f-7efb7bf65613','5176K',100,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7194ac42-f863-4424-9880-67e12d45dd47','5177L',50,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9f7e618-c6d7-454a-85c5-d6c5b850700c','5178M',28,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('02dc806e-1619-442e-82dd-e12d6b665828','5179N',28,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b920e4b-d31a-4475-b32f-7efb7bf65613','5345H',100,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7194ac42-f863-4424-9880-67e12d45dd47','5346J',50,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9f7e618-c6d7-454a-85c5-d6c5b850700c','5347K',28,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('02dc806e-1619-442e-82dd-e12d6b665828','5348L',28,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b920e4b-d31a-4475-b32f-7efb7bf65613','5349M',100,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7194ac42-f863-4424-9880-67e12d45dd47','5350N',50,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9f7e618-c6d7-454a-85c5-d6c5b850700c','5351P',28,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('02dc806e-1619-442e-82dd-e12d6b665828','5352Q',28,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('911d23ee-debd-44de-aa7f-1aec4fba517a','2296W',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('26dc2bf8-67df-4668-8616-abf3b20af620','1694E',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2251ab8c-d155-4721-877f-d5a9a5a212b7','1695F',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c597d876-5cfe-4569-a228-aa7153709ad5','8610E',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4c4e7780-ec51-4e04-b6a6-1a6a6aec7964','1906H',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('80b9ffec-8366-4b9d-ac8d-b9924fd340a9','1907J',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c681db1c-89db-4da7-a0a1-ab18ac15e92c','2723H',25,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c681db1c-89db-4da7-a0a1-ab18ac15e92c','2732T',50,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c681db1c-89db-4da7-a0a1-ab18ac15e92c','5189D',25,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c681db1c-89db-4da7-a0a1-ab18ac15e92c','5359C',50,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c681db1c-89db-4da7-a0a1-ab18ac15e92c','5360D',50,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c5463cb5-f5ce-49a0-935e-fc5e1f8c9150','1692C',30,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('40dc70ea-d87a-4948-83e2-9dc891a781f2','1693D',30,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('40d9b8ac-3ab2-4453-b406-37c8e72ff2ac','2993M',30,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24425ab2-2782-42c4-beea-ce053ac88eb6','1967M',4,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b983d85f-42b0-4f36-aae5-c8c0a4665e84','2774B',4,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('750d9273-3835-46c6-bdb5-5f8a6cbb5752','2775C',4,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2250b778-8379-4bec-be0e-5fac27b0d155','2776D',4,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4f1a1184-0df9-4d0a-92a2-bbc1cb5ef570','3179H',4,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('682470bb-1e91-4e88-84ce-ed54b426cc5c','3010K',14,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce891923-a709-4485-8b34-10f1bc48da95','2522R',50,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d6b0491e-eb9d-4b2f-8390-fcc9d4680310','2523T',50,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('91402d18-f4b1-4d4f-8caf-617119cadfe7','1696G',50,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('df13491c-af3f-438c-9193-030f9bdbf9c6','1698J',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9b976eb3-73a6-467c-9baf-8d44654b5e7a','1699K',50,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d2f8c3fb-16ad-4869-af61-122fb85d3d6e','3033P',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('91402d18-f4b1-4d4f-8caf-617119cadfe7','3342X',50,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d2f8c3fb-16ad-4869-af61-122fb85d3d6e','3343Y',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9b976eb3-73a6-467c-9baf-8d44654b5e7a','3345C',50,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('df13491c-af3f-438c-9193-030f9bdbf9c6','4001N',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cba32dde-a3f8-4ea4-9a81-99ed6c12af3f','4013F',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7767a0a3-7d04-4157-8c5f-748c3ff260df','1663M',56,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44f2deef-57ba-456b-bb55-6d3119715387','1664N',56,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a4fc560-c97e-4393-b0a8-970e949b9afc','1771F',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9205062a-dfe7-467b-b3a9-f9aaa4ff0336','1781R',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5fd640ba-730e-43db-a7ee-916673ac7a0c','1728Y',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('295cc4be-7018-4cb4-bd5a-030c4368456d','8086N',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e7578075-5642-4c4c-add8-27e9bd6af15b','1326T',30,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e7578075-5642-4c4c-add8-27e9bd6af15b','1327W',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('423b553e-b340-4a9d-b52f-dfe73c3182ad','8332M',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7543a142-4714-4904-a0b4-8bf86cccdae0','8331L',30,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7543a142-4714-4904-a0b4-8bf86cccdae0','8333N',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7543a142-4714-4904-a0b4-8bf86cccdae0','9109K',30,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7543a142-4714-4904-a0b4-8bf86cccdae0','9110L',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2d6f650e-b40b-4cec-9bc9-7140578cb30b','3132W',25,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e317ae2-3a26-4d31-8095-dcdb42494cd9','3133X',25,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2d6f650e-b40b-4cec-9bc9-7140578cb30b','3134Y',50,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e317ae2-3a26-4d31-8095-dcdb42494cd9','3135B',50,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2d6f650e-b40b-4cec-9bc9-7140578cb30b','5192G',25,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e317ae2-3a26-4d31-8095-dcdb42494cd9','5193H',25,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2d6f650e-b40b-4cec-9bc9-7140578cb30b','5371Q',50,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e317ae2-3a26-4d31-8095-dcdb42494cd9','5372R',50,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2d6f650e-b40b-4cec-9bc9-7140578cb30b','5373T',50,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e317ae2-3a26-4d31-8095-dcdb42494cd9','5374W',50,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9a9fe663-2f06-418d-8043-dfedc13693ed','2942W',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('650bbe57-8506-4e2f-8c00-74a8c4d9ddf2','2961W',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d05b9c6e-b82b-4dca-8a25-a784fa3367d2','5194J',12,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d05b9c6e-b82b-4dca-8a25-a784fa3367d2','2481N',12,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6a3114c3-a44b-4e0e-b726-f7965fdc7052','5190E',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a92bcf19-bf73-4a1e-803f-13636f4d16cf','5191F',20,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7bd316fe-3e66-49ac-89c7-a438f7b92106','5195K',20,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9846e8b3-f7ca-4c26-8d01-3b319e6d07d3','5197M',20,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7bd316fe-3e66-49ac-89c7-a438f7b92106','2622B',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a92bcf19-bf73-4a1e-803f-13636f4d16cf','8464L',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9846e8b3-f7ca-4c26-8d01-3b319e6d07d3','8501K',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6a3114c3-a44b-4e0e-b726-f7965fdc7052','8644Y',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b75f6371-046e-40a3-b0eb-237610a17797','8502L',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ecc1bcf9-c47a-4c7b-a1e0-904d356050ad','8385H',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ab54dccb-c88c-4fae-b2be-6689af8989fa','9399Q',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5c35d065-ef59-4025-8d2b-a06e8c51194e','8386J',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f78e2b6c-57df-4b3c-b251-42744f863417','9400R',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5b62d575-445d-4d9c-9f2e-ef6c65962711','8387K',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('61403930-4e7b-4955-90b2-96d9455fe7c8','8681X',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('806dffef-f4d3-4ac4-b194-201834ff98c4','8388L',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('714949de-ffb1-44fe-b091-60eafa56a1b8','8366H',200,10,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('714949de-ffb1-44fe-b091-60eafa56a1b8','9229R',200,21,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b771cc7f-d21b-4b46-ae04-a31289619861','1746X',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aec991ed-dd29-45b6-8e02-18c911beccb3','1747Y',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('483040f5-fa89-4aa8-82d5-30fdfe7e9722','1770E',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aec991ed-dd29-45b6-8e02-18c911beccb3','3348F',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('483040f5-fa89-4aa8-82d5-30fdfe7e9722','3349G',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b771cc7f-d21b-4b46-ae04-a31289619861','5196L',100,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b771cc7f-d21b-4b46-ae04-a31289619861','5224Y',300,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b771cc7f-d21b-4b46-ae04-a31289619861','8784H',300,4,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2764bcb8-0d54-4e2f-b3d1-ff2b1966153b','8814X',192,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('794dac5b-5f9a-47f1-9d7b-405b143b6b53','5319Y',4,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('794dac5b-5f9a-47f1-9d7b-405b143b6b53','5320B',4,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2764bcb8-0d54-4e2f-b3d1-ff2b1966153b','5343F',192,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2764bcb8-0d54-4e2f-b3d1-ff2b1966153b','5344G',192,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a75b1f8-42bb-48c5-867c-95b8cb191950','1750D',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('14f8007f-bb28-400a-a399-4bb0bad1e066','1754H',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a75b1f8-42bb-48c5-867c-95b8cb191950','5522P',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('14f8007f-bb28-400a-a399-4bb0bad1e066','5523Q',2,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('14f8007f-bb28-400a-a399-4bb0bad1e066','9217D',2,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a75b1f8-42bb-48c5-867c-95b8cb191950','9218E',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a49e3bb5-a3a6-4a69-86c7-bfe1933b2b79','2721F',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b85fb597-2ff1-4e15-bf7f-447510a12fb2','2838J',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ecd72291-bcab-4918-9ae9-ba324d1d3b86','1822X',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('adc06301-6205-4b13-86ba-6bed7584fee1','3052P',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d492b527-dc74-4b01-bc00-abec6217bb07','3053Q',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d978d5ab-b69a-4844-b240-731edd202b69','2856H',100,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('46ba1330-2239-4d4a-9813-1ef72ef63ac3','1850J',200,4,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b334ae8b-387b-4911-bcb7-ffec7cdf1772','2138M',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ec4c465b-674c-40ec-8972-240bfca26731','1166J',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b6e5797c-2eb0-4cc8-b0d5-4f402842d2f4','1862B',100,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b49207d1-c119-456d-aff8-7c03ecf256f6','9286R',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a996565-4f94-4357-a898-9579d9a94226','1703P',50,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f0b4ff11-27dd-4f1f-8c10-2dd29803c1f7','1705R',50,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a996565-4f94-4357-a898-9579d9a94226','1787C',50,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f0b4ff11-27dd-4f1f-8c10-2dd29803c1f7','1789E',50,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d0f1a8a2-378a-470e-956a-7af8272d3015','2965C',50,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9b2cbe30-fa56-440d-9493-9b13cf3441a8','3028J',50,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a996565-4f94-4357-a898-9579d9a94226','3360W',50,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9b2cbe30-fa56-440d-9493-9b13cf3441a8','3361X',50,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f0b4ff11-27dd-4f1f-8c10-2dd29803c1f7','3363B',50,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d0f1a8a2-378a-470e-956a-7af8272d3015','3364C',50,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9107e9ce-b3bc-4242-9216-2ba2336ae662','5012T',2,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9107e9ce-b3bc-4242-9216-2ba2336ae662','9143F',2,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c9ee3c7d-ba49-405a-bacd-cd92bee4975b','8977L',2,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('954cf3b6-c511-463a-88e0-d45ee2f17e0e','5024K',2,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c9ee3c7d-ba49-405a-bacd-cd92bee4975b','5029Q',2,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('954cf3b6-c511-463a-88e0-d45ee2f17e0e','8976K',2,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5a91ec26-17e6-4d98-876d-09a2d40bb282','1249R',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('11a8f7ea-d84a-4f26-9dbc-1f7844670742','2692Q',1,3,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8fd5cf06-f15c-4989-94b8-a096bba966e0','1873N',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a5ef1a2-f03d-4faf-9341-37fbc8c84ba6','1874P',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('57f39b2e-bdae-49e7-94a0-345eb52e0337','2595N',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('99e5fc46-21ed-4869-95c9-2a50fd4f0fc2','2596P',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('64bebfb2-8f5b-4444-973d-05ad90ea5a7a','2598R',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('57f39b2e-bdae-49e7-94a0-345eb52e0337','5536J',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('99e5fc46-21ed-4869-95c9-2a50fd4f0fc2','5537K',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('64bebfb2-8f5b-4444-973d-05ad90ea5a7a','5538L',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e0a2df1-ca89-457a-9362-06f34840d261','3062E',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b203c314-0164-40ba-bfd0-f7156337ee6f','3065H',50,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93ed3e48-9806-418d-83ff-d8dd1793edab','1895R',50,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('43c247eb-f27a-4c2c-ba7c-b43058327a63','1896T',25,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3621b87-836b-4984-a2e0-d4f91cd1feb7','1897W',50,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d1396ada-408e-46f6-96a5-2dea8a6f7cf0','1898X',25,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93ed3e48-9806-418d-83ff-d8dd1793edab','5201R',50,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('43c247eb-f27a-4c2c-ba7c-b43058327a63','5202T',25,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3621b87-836b-4984-a2e0-d4f91cd1feb7','5203W',50,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d1396ada-408e-46f6-96a5-2dea8a6f7cf0','5204X',25,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3d8c494e-8b0a-453b-b9a4-2da6b334e622','3074T',100,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4675012f-8580-4086-be10-dd1d229cdd67','1903E',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fe59f21d-da06-4a4d-9b50-131226ce7940','1512N',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19883d7e-577f-4073-b81f-0569dcae54d5','2681D',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('878aa018-d68c-45a6-ad53-44079a236abd','2682E',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19883d7e-577f-4073-b81f-0569dcae54d5','5525T',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('878aa018-d68c-45a6-ad53-44079a236abd','5526W',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('878aa018-d68c-45a6-ad53-44079a236abd','5527X',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19883d7e-577f-4073-b81f-0569dcae54d5','5528Y',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('878aa018-d68c-45a6-ad53-44079a236abd','8831T',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19883d7e-577f-4073-b81f-0569dcae54d5','8832W',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('878aa018-d68c-45a6-ad53-44079a236abd','9220G',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('878aa018-d68c-45a6-ad53-44079a236abd','9221H',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19883d7e-577f-4073-b81f-0569dcae54d5','9222J',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19883d7e-577f-4073-b81f-0569dcae54d5','9223K',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('363c403c-43d3-46be-bb5d-081edebced3f','2642C',200,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('363c403c-43d3-46be-bb5d-081edebced3f','1841X',200,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('88029096-f399-4da2-909c-ade501580769','1479W',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a10fa4d9-cad9-4245-8c11-5f557e18a3bd','1480X',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8cf71eef-026d-4718-9c0c-38e7278843b0','1478T',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71e9f411-7a03-4a1d-9a3b-1095165c1e70','1916W',30,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9d317370-59a5-4a31-9931-9b3c96eb35a9','1917X',60,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae56d0c3-cf8e-4603-9340-615c8afc46f9','3152X',100,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31c504ca-633b-423c-9c8b-cc89a4d68ea7','5568C',1,0,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31c504ca-633b-423c-9c8b-cc89a4d68ea7','3112T',1,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a79f171a-5d2e-4827-86b0-1750c8af3a62','1920C',28,3,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8900353b-e1f0-4a98-8698-6e99fe79c1aa','2554K',3,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8440d008-a3ed-4eb8-a6b6-befacc65cf49','8285C',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bcc051e5-3f0a-4ad7-ae32-fe3dcecd76d9','1934T',100,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('38f4cc87-182d-49fe-a649-fdac4dc56254','1935W',60,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('39345148-2d88-4ed0-a7cb-cff43dd41708','1936X',30,4,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9b31fef9-6645-4dd9-b2a1-6232fad033d5','1939C',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8e3e1603-e1c9-4a28-bad7-674caf3d4723','1940D',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad4fbecf-e284-44de-8f9a-23f75e70bfa5','1794K',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad4fbecf-e284-44de-8f9a-23f75e70bfa5','3371K',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad4fbecf-e284-44de-8f9a-23f75e70bfa5','3485K',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('08e64d10-4e2d-4ee0-b7f1-68931da23e35','2369Q',10,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('103c182a-befd-4bb6-bbc5-2aac7e391451','2893G',25,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('36edb11d-e3b9-48d3-9425-942d7e69c968','2895J',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('08e64d10-4e2d-4ee0-b7f1-68931da23e35','3477B',10,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('103c182a-befd-4bb6-bbc5-2aac7e391451','5205Y',25,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('08e64d10-4e2d-4ee0-b7f1-68931da23e35','5206B',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('36edb11d-e3b9-48d3-9425-942d7e69c968','5208D',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('79d4150f-f2e5-42ba-a103-4f07f0b769df','1948M',10,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('79d4150f-f2e5-42ba-a103-4f07f0b769df','3374N',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('79d4150f-f2e5-42ba-a103-4f07f0b769df','3488N',10,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('648d45ee-5ebf-4af9-a597-cf186d99ba05','1953T',200,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2f7ab7c4-d25d-4445-b414-50caffe8575b','2565B',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9891f904-64dc-4348-89c1-7d3344cf02d4','2566C',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc75bd4d-aa0b-420e-b70b-b4009d61a0ee','2899N',50,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8fc4c1d0-7c1c-45ca-befd-fa035204e724','1955X',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ccdf75c7-a907-4482-a501-c3ae9b2e9f12','3047J',6,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c75e0fc5-9277-4575-82ac-d6aba6244ff0','3048K',6,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae48f3bc-c78a-4fab-aa4d-2bed9a51f35a','1959D',150,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ca2b8e29-714d-4c7b-82d3-0a18ac4e79a5','2608G',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('23f45baa-a4e3-427e-9f85-df3ac3af1d6d','2724J',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a02589aa-2323-415e-b549-10bbb45e8fa2','1966L',50,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('70b0f337-0c72-4877-a584-5892b146c33d','1975Y',50,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a82e6169-3d8b-4c30-ba65-47d91652b11e','1937Y',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b37dc3f-724a-4bb0-bfcc-cdf2c6cc70fc','1977C',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8af9aee6-d664-411d-abc4-2c2edf43fe01','1978D',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ce587b3-94c6-42ad-9ebc-042951e14c44','8162N',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a82e6169-3d8b-4c30-ba65-47d91652b11e','8903N',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ce587b3-94c6-42ad-9ebc-042951e14c44','8905Q',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bf2df588-d9e6-4eaf-872c-99f6612d28b6','1981G',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bf2df588-d9e6-4eaf-872c-99f6612d28b6','1982H',100,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c0914cd5-3b4f-45ed-a4a1-4cda3eeac858','1983J',100,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c0914cd5-3b4f-45ed-a4a1-4cda3eeac858','1984K',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('34704733-ce41-4625-8a95-986c0f3332f8','8025J',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c42e19b9-c5d1-4a5c-9972-589480c3b3eb','1099W',200,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e407a768-f574-44fc-80e3-f4d3e0a3ed0f','1103C',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('612ee2a7-2d41-4ff5-bdb9-6f12ec7139f7','2000G',2,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f36499f0-0a9c-41c0-ad65-beabf0d517d8','2001H',2,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('90535263-b080-46c9-9134-3b2a2b8414df','2003K',2,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4081e0e2-5379-4298-a628-bdff9eb1d348','3495Y',1,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('612ee2a7-2d41-4ff5-bdb9-6f12ec7139f7','3496B',1,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f36499f0-0a9c-41c0-ad65-beabf0d517d8','3497C',1,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4081e0e2-5379-4298-a628-bdff9eb1d348','8288F',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4081e0e2-5379-4298-a628-bdff9eb1d348','8354Q',2,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9cd07f50-bf07-4ac4-bf92-fe695de94cd7','2011W',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9cd07f50-bf07-4ac4-bf92-fe695de94cd7','9242K',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8d7b0fa6-588f-46e7-9377-b91ce7971216','2012X',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8d7b0fa6-588f-46e7-9377-b91ce7971216','9243L',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('947aaafa-446d-48b5-b823-aa0a7371b3a1','8173E',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('947aaafa-446d-48b5-b823-aa0a7371b3a1','9244M',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9108b610-07b9-4c18-95f5-f97e3b21f29f','2013Y',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9108b610-07b9-4c18-95f5-f97e3b21f29f','9241J',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1fb6c50d-daf6-433b-a9e7-f1767f4f2864','8313M',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1fb6c50d-daf6-433b-a9e7-f1767f4f2864','9245N',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6ca2dfa3-8a18-4cac-ae17-0fd13ce6898c','2946C',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fc0620ce-56d3-4855-b2f3-934e0341bbb3','2016D',10,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a5fb75b1-b392-4b48-be42-9538ac6ad6c8','2017E',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31ce9e67-7553-4fc7-a4f6-7ffae8e7d849','2018F',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bbc3352a-813c-4d9b-b458-04df59b11dbf','9470K',100,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4f00946e-750f-4358-8667-e93327df94dc','2260Y',2,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b17ea17-adbe-4b37-a3f2-c3ae8bcabd31','2264E',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('060fa161-5c1a-46ca-9db1-17bf395f04d7','4460R',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2712d0ea-acc6-4cf6-80c5-ab9450f2863e','4461T',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f69d71a6-f3c9-47d0-8504-b1ee0e0bd537','5021G',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b17ea17-adbe-4b37-a3f2-c3ae8bcabd31','5212H',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4f00946e-750f-4358-8667-e93327df94dc','5213J',2,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f69d71a6-f3c9-47d0-8504-b1ee0e0bd537','9392H',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('00732aae-f99e-4f5d-98c9-e48e2cc86709','9473N',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae6f6ccd-847a-4bb5-87cb-5cd0520d3497','2278X',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b7677f5-887b-4894-b394-f3c4947d4bdd','2279Y',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7b2775ce-1207-42e8-a83c-f52f7efce0d9','2281C',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7b2775ce-1207-42e8-a83c-f52f7efce0d9','5214K',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b7677f5-887b-4894-b394-f3c4947d4bdd','5215L',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae6f6ccd-847a-4bb5-87cb-5cd0520d3497','5216M',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('394a4501-5e50-48c7-93c1-93701db76d90','2266G',4,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('61c5e4cf-603f-4cda-9e65-09386b70aa2e','4049D',1,4,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('13296e4d-f13e-4df7-8203-937f2f1194ec','1127H',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('310eb5ee-41e9-4034-a71c-2d078ee5bd60','2878L',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('37bb36c1-7ad6-4fb5-a096-2a1442ac1120','4468E',1,5,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('13296e4d-f13e-4df7-8203-937f2f1194ec','5529B',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0152e7ed-f832-42ac-9607-40feda7a04d2','8334P',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('844ff7d1-b27f-4610-8a55-9a3914d8d23d','8767K',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4647f597-88a4-4f41-8f2a-9a2577d18459','2286H',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2c494bc0-3b44-4d96-be5c-8576e3e15594','9416N',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c6354bd7-da3d-433e-86ab-4ec78f5bc473','2289L',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a0cdaf5-48b9-4658-814f-56eefb2305e1','2290M',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9e105c77-8853-4bc6-93b8-a4f014777d86','2293Q',2,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5644065b-aa70-41ea-b53b-c524952273fc','2294R',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9e105c77-8853-4bc6-93b8-a4f014777d86','2295T',2,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cf28611f-de72-4491-b580-bcd202371270','2043M',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c949e9d6-5e0d-455a-b0e4-f8031b1e30a6','8398B',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c37eabc5-bd5e-4105-b802-d718d6986057','2339D',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85f6f8ae-75e8-4c6b-a859-829737804a7b','2340E',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b6565a65-3da4-4fe0-a592-31bd97d244e6','1104D',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b6565a65-3da4-4fe0-a592-31bd97d244e6','3275J',2,0,'PQ','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b6565a65-3da4-4fe0-a592-31bd97d244e6','5322D',1,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b6565a65-3da4-4fe0-a592-31bd97d244e6','5324F',1,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b6565a65-3da4-4fe0-a592-31bd97d244e6','4558X',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bb2bab57-b116-4abb-9e68-be4800cc7149','2055E',120,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6812260e-c377-4378-84d3-8f1880191ec6','2093E',200,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6812260e-c377-4378-84d3-8f1880191ec6','2096H',200,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6812260e-c377-4378-84d3-8f1880191ec6','9208P',200,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6812260e-c377-4378-84d3-8f1880191ec6','9209Q',200,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9ece260b-8cb2-4c69-a93d-e41214f42b76','2099L',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5bba8058-4b81-48be-9526-7e111c6f323b','2100M',200,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('462ecd5f-6ab2-4a5c-8b98-42476e71dd10','2109B',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b2acd33a-11a5-4ca4-9d22-0fde89f54c01','1880Y',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b2acd33a-11a5-4ca4-9d22-0fde89f54c01','2110C',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('741ec909-9afc-4123-a27f-8d1c8e5a52d8','2088X',50,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('741ec909-9afc-4123-a27f-8d1c8e5a52d8','2089Y',25,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('741ec909-9afc-4123-a27f-8d1c8e5a52d8','5221T',25,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('741ec909-9afc-4123-a27f-8d1c8e5a52d8','5375X',50,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('741ec909-9afc-4123-a27f-8d1c8e5a52d8','5376Y',50,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e5bbbfe-a3c3-4f8c-97c1-7810ae336001','1034K',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('87b9264e-1d33-4129-8cf2-992c6407f673','1252X',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e5bbbfe-a3c3-4f8c-97c1-7810ae336001','3491R',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af52bcc3-9612-4dd6-98a2-91f9fd8b9afa','2114G',3,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('37c46252-0252-4f59-a44a-29bbe938cce0','2115H',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('17843162-6fa6-4eaa-9784-612786044419','9004X',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a3140dfd-5f9b-4aed-8230-fd8e7e1d9323','1330B',112,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ee790301-f0e5-4c3b-baee-34c332e35d8c','2832C',5,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1a7e6ab3-fc47-48de-99e4-1f9c35b376c4','2614N',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93ee40aa-e755-4fc8-809a-b2418b4b13ae','2634P',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('18917386-0a41-4e0a-a074-cdbb1756c4db','8230E',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0524872e-2272-4a14-9ff2-9dc2eb88d8f8','8231F',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('78c24286-c927-444b-a369-ead578dcfead','1070H',100,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('78c24286-c927-444b-a369-ead578dcfead','4043T',100,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('60b597dc-8ba8-4cd1-84bb-5ee5a8b9df94','1233X',25,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1ab5b355-e960-4e91-abd4-d4c7e0c4adb3','2173J',200,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5d5f5180-b4e0-4baa-aaa8-9dfb96f17907','2174K',200,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4ff60b01-8101-4b01-bb8c-2e5cffe54de2','2175L',200,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bce0bc22-824f-4b53-9a4d-b3500fc142b9','9287T',200,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a657442-f18d-433f-9718-216960a295f7','2103Q',60,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b47d7b4a-044b-4695-8f7c-e3ada056ca0f','2179Q',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b47d7b4a-044b-4695-8f7c-e3ada056ca0f','5230G',10,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ddf51b13-64f3-4320-9add-a7c1ab5259c0','1278G',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('038ee55c-80c7-4c07-b047-cd378e245ed2','1279H',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('736bc2a0-5ecd-499e-b945-98a6303d0428','1925H',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bbbd9f1b-54a2-40df-b180-e1a7af52b901','1926J',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9c44996c-a819-4989-9ce1-151958292182','5546X',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ddf51b13-64f3-4320-9add-a7c1ab5259c0','5547Y',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('038ee55c-80c7-4c07-b047-cd378e245ed2','5548B',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('736bc2a0-5ecd-499e-b945-98a6303d0428','5549C',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bbbd9f1b-54a2-40df-b180-e1a7af52b901','5550D',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9c44996c-a819-4989-9ce1-151958292182','8803H',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a8b6abb5-30e0-47fa-a6bd-2be03c74acba','1465D',4,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('59ad9d97-36c6-430d-881f-49ceebc94617','5569D',1,2,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('59ad9d97-36c6-430d-881f-49ceebc94617','2328M',1,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('66b1229f-9b54-4c15-80a0-312287a95f1a','5570E',1,0,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('66b1229f-9b54-4c15-80a0-312287a95f1a','2329N',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2a2078f5-cb4a-4db7-b638-95826587e2a3','5442K',56,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('826c1953-74d0-4894-b3ee-b4226f4f8496','1356J',10,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4013ff10-d921-42de-8117-e62d29d92021','8872Y',10,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fec287df-1621-461d-a5c2-3b40b38e7a1b','9480Y',10,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4f2838e5-854f-42e7-90a0-53e906ce19aa','2180R',100,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24c5e950-b69f-457b-b66e-d24b78345706','2444P',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('62838754-0626-429a-a763-f831ec2844cc','2117K',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('94c01457-ff48-4e4c-b3f7-7e8fad69895a','2118L',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad155e29-7dda-4535-80f6-78e35fc4634b','2990J',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad155e29-7dda-4535-80f6-78e35fc4634b','5233K',5,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('861c8914-1b3d-41a8-aba7-080fc1688def','2971J',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ecfa1a0c-68e3-499f-a143-45072e22b132','2974M',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9c5de-31c2-437a-b774-61e883e62a03','4482X',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5c972949-90c2-41b6-82d4-05c2cfe1c05f','2185B',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ccdedaad-c6e7-40fa-9d91-93f7640255bf','2186C',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d07e606a-ff49-431d-9bba-aafd745caf1f','2386N',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f6aa81ed-56d5-488a-ae2d-7f48e24aca32','3128P',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c43bdccc-6593-4558-96d4-90d6dfb8c8b3','9327X',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('713eb834-e1d3-45a6-a4c7-e0b617c965c5','2922T',7,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba1d81b3-62f0-4f45-af33-c7560a3067de','2951H',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cceb3c53-ad50-459c-8aaf-57fd90d95e11','3103H',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba1d81b3-62f0-4f45-af33-c7560a3067de','3390K',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cceb3c53-ad50-459c-8aaf-57fd90d95e11','3391L',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('91182397-3c6d-4ac5-8233-ac0c7b8b856c','4042R',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aabb3b99-539b-44a3-ae5b-d40375c594e9','3113W',40,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9594d47f-a9a4-4164-8e7b-918b93a1e871','3114X',40,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('151c812a-b995-40f3-8334-afafc4c983f0','3131T',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0852b804-0736-4f9c-9aa5-37129f229039','2270L',3,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('151c812a-b995-40f3-8334-afafc4c983f0','3130R',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0852b804-0736-4f9c-9aa5-37129f229039','2269K',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('151c812a-b995-40f3-8334-afafc4c983f0','3323X',2,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0852b804-0736-4f9c-9aa5-37129f229039','5083M',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e4e258e2-e3a5-4d81-9dc3-a60680f549fb','1241H',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a908d381-c077-4d61-a8eb-3fd4b9259dec','1248Q',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0230f624-138d-4395-af83-9f113dab1e80','1250T',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a5038eb5-3eb6-416c-abe4-876328d0d906','1254B',100,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af6ecb7e-42f6-4137-8579-c5173dcd3e55','2206D',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cfee682c-2b34-4fd4-af3f-b2928a6fc242','2207E',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bda3501b-e723-4aad-88c8-c126c79fc1ab','2208F',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('74643457-67e0-452b-82bc-ee254350091c','2209G',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0f973f6e-7e88-43d5-aff5-b05d0627a821','2211J',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dfe27723-d90c-4bb5-b49b-d286880c70c9','2843P',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8986fd46-f48a-489e-ae0b-0a76ccc684fe','2844Q',50,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('522e8ec3-b0ca-43c3-9388-a0dfd2395dde','4041Q',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('94e3c5c8-0c05-4496-9ac9-3cdc863dae22','4039N',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5aaf62f3-4bc6-4c75-9622-3de05a433334','4040P',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('94ec7fee-6122-48cb-a4e5-9e15764de7e8','4280G',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5463bf83-6e8f-42dd-b919-90d25cb4165e','4281H',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('38968c64-7fab-45d5-bfc0-5131dd999800','4505D',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c3cd2db5-9149-49ee-a959-0c1e340ce5eb','4118R',2,5,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b103bdd4-233a-4e7d-8e2d-94ccb681d152','4453J',200,5,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c405b849-3280-4a0e-8104-6e00479eb639','4107E',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c405b849-3280-4a0e-8104-6e00479eb639','4122Y',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('629a644c-b48e-44fa-9ddc-9a0b308b3163','1121B',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('629a644c-b48e-44fa-9ddc-9a0b308b3163','5032W',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('629a644c-b48e-44fa-9ddc-9a0b308b3163','5385K',1,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('629a644c-b48e-44fa-9ddc-9a0b308b3163','5386L',1,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('22de70e9-8b4e-4c1b-a516-49163f42524e','4150K',60,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3d00e4d8-41fb-4ab9-8d9d-146a150e5fcd','4151L',60,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('81153e36-ca24-4c34-b41c-cabe0a176ff2','4055K',200,5,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('739f90d4-3e09-41f0-8eac-6e0a2108833d','4551M',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bfce8447-d283-4ed1-9965-01f5554e3cec','4556T',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('59db4765-b455-4f41-a095-c11d84a28111','4191N',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7f3eb5f4-102f-487a-b30f-4fae2c758448','4199B',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('74527384-8874-4e6f-ac26-4bd9b559c098','4200C',100,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2c28b44d-69dc-4103-941a-edfa4ef0cd35','4028B',100,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2c28b44d-69dc-4103-941a-edfa4ef0cd35','4198Y',90,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a975adbc-20ba-4749-b067-041e2f0610ab','4216X',30,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('508502b4-89c7-402e-81a4-e066e9aa1ff9','4036K',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42c47733-a7b5-45b3-a46a-f5a9e34460c8','4038M',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4320f71d-7841-475c-a4d0-8ea8ebee0989','3473T',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4320f71d-7841-475c-a4d0-8ea8ebee0989','5317W',30,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4320f71d-7841-475c-a4d0-8ea8ebee0989','5318X',30,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4320f71d-7841-475c-a4d0-8ea8ebee0989','4279F',5,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('613cf26c-9e49-49b5-bc76-6500dbc9142f','4285M',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2c9acf1f-5c9b-433c-97e3-aa1a33b11e73','4308R',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0ebaf791-9940-4aa8-83f2-9b1a2dcbf0c6','5146W',50,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0ebaf791-9940-4aa8-83f2-9b1a2dcbf0c6','4321K',50,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3346a7b-b7ae-4e62-812c-248a68d5aef2','4325P',6,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('07d561ff-78d1-47c1-b003-d57c5c088248','4328T',90,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8317a101-f80d-4703-a263-e51632bd7b1c','4378K',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9f9871ac-b0c8-4016-9ac5-0ec71736feab','4379L',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d027b6b7-af59-4db8-aa78-1f8aeb018ee4','4071G',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('89102b31-3bd7-4687-85e1-6a31d50225c5','4405W',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4ef23d29-04a2-4e10-9db1-fc62249efdbc','4408B',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a204f0cd-a4f3-4c80-834c-cd2949f9ccfa','4411E',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b8ad06f4-37e6-47db-b3e0-f7351d009e69','4029C',12,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b6102a09-3b6d-4ca0-a0af-3e7dbf6c6e7a','4419N',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eae0b3f7-b4fe-4ebf-8b30-93cdb77b571f','4422R',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0879fb52-d7d7-4d33-84c3-216147c464d2','4434J',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba8e89ed-8a2d-4c2f-8a81-0e38ab95eb52','4560B',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b5fafe4e-fb31-4f05-9054-4bfe29d99238','4447C',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10522888-e78e-4f39-9cbf-d3807979cfdb','4452H',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5f1c259b-d475-458c-94fe-a3cf859a00fa','4074K',1,4,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('97350103-2e37-43a7-8a08-5c7c61d7abdb','4455L',100,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c603283e-2e11-489d-8fa0-3f12f6c3c992','4549K',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c65e8c1e-9dd4-4c73-ac24-6fea851ececc','2091C',2,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c65e8c1e-9dd4-4c73-ac24-6fea851ececc','3274H',4,0,'PQ','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8a290594-eddd-47fa-b8c3-2448c50520d2','4462W',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c65e8c1e-9dd4-4c73-ac24-6fea851ececc','5331N',2,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c65e8c1e-9dd4-4c73-ac24-6fea851ececc','5332P',2,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e027688a-a756-4568-b43b-7bc55e173616','4470G',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('174160c8-356b-4e13-971f-d0810a4a20a0','4543D',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fd752453-60b9-4282-a918-52515c3c6319','4544E',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('20ecf8f8-ebec-4746-b8db-98d1925d625c','4546G',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ddcf557c-15c5-4479-9639-87f44e387b5f','4307Q',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('768b43d9-4b23-44e6-bebb-9c0d851afe2b','4481W',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('682c06a0-10d5-4a17-8160-4431db80a1cd','4493L',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('01337c1a-1e84-487f-ab41-64142aee27e0','4497Q',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('20cb1e9a-2ad2-4355-8cb1-5e8c7a21a07c','4701K',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9d25a02a-3398-4a9d-9be9-21bb6f9a7057','4707R',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b54267d8-2fe9-4d84-b488-bceba001193d','4708T',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bb4b18f2-20a1-4853-b44a-607b2d265ebd','4717G',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('70817d45-3e9c-49b5-a835-7bd24d7fa6e8','4727T',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('70817d45-3e9c-49b5-a835-7bd24d7fa6e8','4728W',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('70817d45-3e9c-49b5-a835-7bd24d7fa6e8','4729X',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3bbd799-feeb-43a3-8804-3713d5db04ee','4660G',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3bbd799-feeb-43a3-8804-3713d5db04ee','4811F',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3bbd799-feeb-43a3-8804-3713d5db04ee','4812G',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3bbd799-feeb-43a3-8804-3713d5db04ee','4813H',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3bbd799-feeb-43a3-8804-3713d5db04ee','4814J',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b99ae95-6936-49db-a572-86568a3330b0','4668Q',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b99ae95-6936-49db-a572-86568a3330b0','4669R',2,3,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b99ae95-6936-49db-a572-86568a3330b0','4670T',2,3,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b99ae95-6936-49db-a572-86568a3330b0','4750B',2,3,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b99ae95-6936-49db-a572-86568a3330b0','4760M',1,3,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d366ef1c-7c96-4d35-9e7a-af30cfc3166d','4686P',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d366ef1c-7c96-4d35-9e7a-af30cfc3166d','4687Q',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d366ef1c-7c96-4d35-9e7a-af30cfc3166d','4688R',6,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d366ef1c-7c96-4d35-9e7a-af30cfc3166d','4893M',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b678db6f-6c46-40b2-962c-f73f5b3336b2','4243H',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('69dcf7e9-acf6-4186-8136-36a7ffe02761','4244J',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0a50ce6d-039b-4012-acdb-907fcd698cea','4755G',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0a50ce6d-039b-4012-acdb-907fcd698cea','4758K',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0a50ce6d-039b-4012-acdb-907fcd698cea','4844Y',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('69dcf7e9-acf6-4186-8136-36a7ffe02761','4944F',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0a50ce6d-039b-4012-acdb-907fcd698cea','4861W',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0a50ce6d-039b-4012-acdb-907fcd698cea','4862X',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0a50ce6d-039b-4012-acdb-907fcd698cea','4819P',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0a50ce6d-039b-4012-acdb-907fcd698cea','4860T',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d09db30e-2283-4a00-a82e-1280e0a23119','4759L',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9917e614-ce71-4f5f-86c6-903f6f9a12e5','4845B',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31effd12-67d5-4c1c-a670-27082cd9c50b','4761N',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8e2ef3c9-be53-488e-b844-cb9b2c24137e','4767X',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('66dabcad-bb10-4c2a-831d-094ab8ffd7c2','4768Y',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eb572acb-0562-4a38-8de1-f4f2ba865e48','4780N',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('de089953-dc5a-4444-b168-433183e5f88f','4781P',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2974ed31-33df-4f48-82a4-06a9f53181c2','4782Q',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('90933f8c-0c0e-4f89-8121-e009a5fc059c','4783R',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('90933f8c-0c0e-4f89-8121-e009a5fc059c','4785W',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('07f8dea3-4987-430d-b167-7d40d95cf9b0','4787Y',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('61ce64c4-ee3e-43e2-835b-9ed0c970817f','4788B',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d43db9fd-81a0-42fb-a7ab-8404057c697e','4789C',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d43db9fd-81a0-42fb-a7ab-8404057c697e','4790D',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('07f8dea3-4987-430d-b167-7d40d95cf9b0','4794H',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10fae152-ffd9-4ce6-a17f-176d2a5ee2ed','4848E',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8c0d3c32-4d80-451c-84a7-4e366d24111e','4849F',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff5826b9-b4d1-4acf-9b8e-a77325b1ace5','4663K',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff5826b9-b4d1-4acf-9b8e-a77325b1ace5','4664L',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff5826b9-b4d1-4acf-9b8e-a77325b1ace5','4665M',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff5826b9-b4d1-4acf-9b8e-a77325b1ace5','4855M',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff5826b9-b4d1-4acf-9b8e-a77325b1ace5','4856N',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff5826b9-b4d1-4acf-9b8e-a77325b1ace5','4857P',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff5826b9-b4d1-4acf-9b8e-a77325b1ace5','4858Q',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff5826b9-b4d1-4acf-9b8e-a77325b1ace5','4859R',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5795f2de-6f80-4a79-b379-8ebd7c794f94','4726R',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5795f2de-6f80-4a79-b379-8ebd7c794f94','4798M',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2080242e-3d10-48a9-a963-ff6e2318912a','3078B',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aabffda0-62db-4ea0-b349-022435f157d7','8445L',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2080242e-3d10-48a9-a963-ff6e2318912a','8446M',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2172cfb2-e423-492b-baf0-e83470012c8a','9132P',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6d02c05c-4078-4828-a286-3e88e9e2b26b','9395L',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c97dd36f-0881-4738-9a14-60c1b4b94c62','8631G',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fa54ec17-7725-41c8-92e5-facf1e2b8377','1547K',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f760eef3-a6b3-4a4b-ad1a-9e89e0328495','8667E',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cce0e3a2-8638-4c95-9a89-213e60550c50','2324H',3,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6de663fd-58df-4aad-8737-8a3b0fa283fa','2338C',3,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cce0e3a2-8638-4c95-9a89-213e60550c50','5505R',3,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6de663fd-58df-4aad-8737-8a3b0fa283fa','5506T',3,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e8b05322-0d06-4918-8295-8973f453c5d5','5507W',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4370d4e3-f8e4-46fb-957f-5f0b813f1939','5508X',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6c6231aa-8d7f-42a2-bd75-c1dbeff4241b','5509Y',4,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af132ec0-fa28-44da-aab5-dc5dd532eaae','5510B',3,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e8b05322-0d06-4918-8295-8973f453c5d5','8548X',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4370d4e3-f8e4-46fb-957f-5f0b813f1939','8593G',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6c6231aa-8d7f-42a2-bd75-c1dbeff4241b','8823J',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af132ec0-fa28-44da-aab5-dc5dd532eaae','8824K',3,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e8b05322-0d06-4918-8295-8973f453c5d5','9211T',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4370d4e3-f8e4-46fb-957f-5f0b813f1939','9212W',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dd8d3fd4-a394-462a-b85e-2af65993c13e','5333Q',1,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('83c0b828-b237-4e06-a90c-a1eeb81e14a6','5334R',1,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dd8d3fd4-a394-462a-b85e-2af65993c13e','5335T',1,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('83c0b828-b237-4e06-a90c-a1eeb81e14a6','5336W',1,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('83c0b828-b237-4e06-a90c-a1eeb81e14a6','4569L',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dd8d3fd4-a394-462a-b85e-2af65993c13e','4568K',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('33feffd5-2076-4690-a0ab-eee04bd4f8ec','1417N',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44ff81bc-af5c-49cc-ae76-38503289ecf9','1594X',10,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aa3231ef-3bbb-4a82-8ac2-6f6f6dd440cf','1596B',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('29ed7dd7-f227-4dde-9e5f-f2be1145c6d4','1597C',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8d45f93a-d7db-48b8-aa4d-24b3cbd99ff3','8233H',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aa3231ef-3bbb-4a82-8ac2-6f6f6dd440cf','8226Y',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('29ed7dd7-f227-4dde-9e5f-f2be1145c6d4','8227B',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8d45f93a-d7db-48b8-aa4d-24b3cbd99ff3','9441X',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aa3231ef-3bbb-4a82-8ac2-6f6f6dd440cf','5971G',1,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('29ed7dd7-f227-4dde-9e5f-f2be1145c6d4','5972H',1,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8d45f93a-d7db-48b8-aa4d-24b3cbd99ff3','5848T',1,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('88e9f5de-8391-4b32-aa21-5fafb8557e8d','1595Y',10,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44ff81bc-af5c-49cc-ae76-38503289ecf9','8224W',4,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('88e9f5de-8391-4b32-aa21-5fafb8557e8d','8225X',4,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44ff81bc-af5c-49cc-ae76-38503289ecf9','5967C',4,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('88e9f5de-8391-4b32-aa21-5fafb8557e8d','5968D',4,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4c008947-4db0-4739-bbb1-4b60a601321b','5471Y',4,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9fefa43f-40cd-4d90-8f0f-d8ed9cbf5e15','8411Q',4,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4c008947-4db0-4739-bbb1-4b60a601321b','5473C',10,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9fefa43f-40cd-4d90-8f0f-d8ed9cbf5e15','8413T',10,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4c008947-4db0-4739-bbb1-4b60a601321b','5858H',4,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9fefa43f-40cd-4d90-8f0f-d8ed9cbf5e15','5970F',4,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f7250234-db97-4401-8419-7a706c8cc7d4','5470X',4,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a1e8cb30-146f-4b5b-806b-efed4df55f42','8410P',4,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a1e8cb30-146f-4b5b-806b-efed4df55f42','8412R',10,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a1e8cb30-146f-4b5b-806b-efed4df55f42','5969E',4,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f7250234-db97-4401-8419-7a706c8cc7d4','5472B',10,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f7250234-db97-4401-8419-7a706c8cc7d4','5857G',4,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a53991f6-3892-4716-9673-c247b91158b9','2446R',3,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a5c8e6f8-629e-4e0f-928e-7ecb2c8afa5b','2448W',3,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3c5cdc39-0b6e-4b19-b100-66a981450c7e','1900B',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5f9d3d73-eebb-4a58-9095-8a1a5bef8ff5','8003F',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e0a27a72-15fa-48fc-84b8-60ca980393d3','1742Q',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b4c6dcd4-55d2-4207-a3cc-725e001b6cdf','8125P',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2166823c-b485-414e-989e-3ac499415d1d','8126Q',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3259d70a-f756-4cb0-9f64-2ae5ba507fe3','8140K',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c4288ff8-6c29-4135-931d-22013fc070af','8274L',56,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('80b60345-3af3-420e-bf03-93e86903e6d1','8286D',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('35750296-8d2f-4b78-bafd-35868cfc73f2','8311K',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0cb8df04-ba5d-4480-9c12-7720a578af95','8312L',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fba00821-f956-410a-8907-1bbb00d2a35a','8485N',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('22b75ceb-58c1-4b8e-a102-ecc39817bedf','8486P',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5a0646dd-0604-41f8-be49-738b64f0a8eb','8761D',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('de9c06af-17a5-4ca0-a476-f5d546eced6d','8762E',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8a3b46b5-0d60-4cc6-8c27-1293fc913d15','8763F',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8ad6e58b-0c19-4ba0-8210-6ffc7620b2ad','8764G',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fda4e340-5ff3-4e3e-8793-9774b44dc49e','8765H',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('84c89cdf-280f-46e3-9d6c-25bc9361a514','3196F',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5cace235-d815-4b52-b084-3d28e2456613','1182F',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ecb6229-b797-4160-909b-47997ab9b6e8','1183G',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93002d71-a78c-4019-b227-de86ae75091f','1558B',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10f18e33-1bd8-427d-a7c4-7f4b5b9962aa','8273K',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c58737bf-7886-4300-bcd3-14e210d95d0b','2457H',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f8ecba9e-0303-4cd0-a0c3-e263e0475915','2458J',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7f16e2d7-003b-4ad1-96a6-ab597ba00b01','2456G',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d5afbfde-72a3-429b-9802-da2de1166739','9120B',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eb2e1110-05f8-4133-bf74-cd764b344eea','8470T',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1eb2f15a-709b-4059-aca4-a9722e9d729f','9121C',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('941683e4-6b0e-4a65-8779-40f2d1928dd4','9122D',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('36c9cbcb-83f7-4a84-b6ac-70e7ca2943b4','8668F',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b8f2638d-3e68-4f2b-98f9-5f9a81ac8fe5','1944H',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('601646ca-0204-4958-8b7d-44abdc09f1c9','1316G',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('41b7ea2f-7dd6-4847-87dd-cb419d2cd637','1945J',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6402c7b6-7afa-413c-8019-83bdd6db666d','1946K',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('75c37280-7800-4a01-a76e-d5f48e057cab','2883R',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('65848e66-a6bf-4715-be26-488d2d18c305','2014B',2,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5c2ae164-4c06-43b4-bdf3-2da26724499b','1471K',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0eff0a5b-0c65-4bdd-bd56-f999327a84a1','1472L',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('373d9469-85ce-4361-94d6-d7434f8e0768','1473M',7,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('96f7d40f-5e94-46a7-a0fa-10c0d28af09a','1474N',7,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6524500a-8549-4e1e-a7c6-1cbfa49242ff','1475P',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('318d76ad-61df-4ded-8bb1-9d25db23616a','1757L',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1a670d7c-e6d3-4a16-b8fc-9799ea92402d','5446P',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('84a90c5c-5361-42e4-a20f-2f4dd869e7b1','1760P',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f83e9b98-bb50-4ad4-8ad4-f2b4a8c7c8e7','5259T',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('84a90c5c-5361-42e4-a20f-2f4dd869e7b1','5260W',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7b5f8aff-112a-4aa1-8974-0ad9210c244c','5261X',5,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7b5f8aff-112a-4aa1-8974-0ad9210c244c','8016X',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f83e9b98-bb50-4ad4-8ad4-f2b4a8c7c8e7','8129W',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5aa98955-9454-44e4-9a6c-851f93322abf','4656C',5,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5aa98955-9454-44e4-9a6c-851f93322abf','4657D',5,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5aa98955-9454-44e4-9a6c-851f93322abf','4736G',5,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5aa98955-9454-44e4-9a6c-851f93322abf','4748X',5,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5aa98955-9454-44e4-9a6c-851f93322abf','4658E',5,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5aa98955-9454-44e4-9a6c-851f93322abf','4598B',5,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6b1a5b23-01d1-4781-a383-cf2c5a6ab9c8','4938X',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('67544b3b-efe3-4d9a-a4c4-5e2175ee5c9f','4939Y',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c16c9103-89f1-4144-83b5-d520c63dacd0','4940B',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6b1a5b23-01d1-4781-a383-cf2c5a6ab9c8','4941C',4,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('67544b3b-efe3-4d9a-a4c4-5e2175ee5c9f','4942D',4,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c16c9103-89f1-4144-83b5-d520c63dacd0','4943E',4,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5aa98955-9454-44e4-9a6c-851f93322abf','4654Y',5,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5aa98955-9454-44e4-9a6c-851f93322abf','4050E',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4c36d06b-1209-4696-b206-a8f22b25ebf7','4683L',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('67103f1b-43c8-4b03-9b1f-9ce630ba26f0','4684M',10,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('67103f1b-43c8-4b03-9b1f-9ce630ba26f0','4831G',10,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('67103f1b-43c8-4b03-9b1f-9ce630ba26f0','4700J',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('67103f1b-43c8-4b03-9b1f-9ce630ba26f0','4691X',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('67103f1b-43c8-4b03-9b1f-9ce630ba26f0','4699H',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('adced5a9-1747-452c-aa33-b3d10bffc023','4886E',2,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('adced5a9-1747-452c-aa33-b3d10bffc023','4885D',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('40272c4d-ea89-4220-95c9-e7327a5f6882','4888G',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('40272c4d-ea89-4220-95c9-e7327a5f6882','4889H',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('40272c4d-ea89-4220-95c9-e7327a5f6882','4907G',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('40272c4d-ea89-4220-95c9-e7327a5f6882','4924E',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('40272c4d-ea89-4220-95c9-e7327a5f6882','4947J',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a15ceb8-700e-4e80-ad02-87166dff18ea','4892L',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('397ac5a9-55c5-473e-a233-21c523c8c6cf','4912M',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('afdea006-d2bc-4615-a89a-fe44e9bed6ce','4913N',3,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b3fc478-448b-417f-a821-10855df24fc7','4914P',3,3,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('032feb2c-a966-4dd6-9450-4aab8510890d','4894N',4,3,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b3fc478-448b-417f-a821-10855df24fc7','4599C',3,3,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2fcfe5b2-dd13-4d7d-af7f-390ca4ab7f1a','4895P',2,3,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3b9ad68-47da-4f64-b2f6-99984ea223bb','4896Q',10,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fcaf96ae-0419-4124-88c1-a3bac7020738','8180M',15,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fcaf96ae-0419-4124-88c1-a3bac7020738','8181N',15,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ca138db-9a6b-4fd8-8d90-87f4214fbca4','8182P',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2826e8e3-da21-46c6-9a07-19f2cd17315f','8183Q',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3bff6d0a-35c2-4aaf-8c44-0e7f3c8ed23b','8184R',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ca138db-9a6b-4fd8-8d90-87f4214fbca4','8551C',5,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2826e8e3-da21-46c6-9a07-19f2cd17315f','8552D',5,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3bff6d0a-35c2-4aaf-8c44-0e7f3c8ed23b','8553E',5,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fcaf96ae-0419-4124-88c1-a3bac7020738','5945X',15,4,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ca138db-9a6b-4fd8-8d90-87f4214fbca4','5996N',5,4,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2826e8e3-da21-46c6-9a07-19f2cd17315f','5997P',5,4,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3bff6d0a-35c2-4aaf-8c44-0e7f3c8ed23b','5998Q',5,4,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fcaf96ae-0419-4124-88c1-a3bac7020738','5946Y',15,5,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ca138db-9a6b-4fd8-8d90-87f4214fbca4','5947B',5,5,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2826e8e3-da21-46c6-9a07-19f2cd17315f','5948C',5,5,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3bff6d0a-35c2-4aaf-8c44-0e7f3c8ed23b','5949D',5,5,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fcaf96ae-0419-4124-88c1-a3bac7020738','6210W',30,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ca138db-9a6b-4fd8-8d90-87f4214fbca4','6211X',30,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2826e8e3-da21-46c6-9a07-19f2cd17315f','6212Y',30,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3bff6d0a-35c2-4aaf-8c44-0e7f3c8ed23b','6213B',30,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fcaf96ae-0419-4124-88c1-a3bac7020738','5759D',30,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ca138db-9a6b-4fd8-8d90-87f4214fbca4','5760E',30,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2826e8e3-da21-46c6-9a07-19f2cd17315f','5761F',30,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3bff6d0a-35c2-4aaf-8c44-0e7f3c8ed23b','5762G',30,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10e577f0-b71d-467e-9830-069c997da8fc','8348J',3,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('05dd5a6c-eae8-415c-a1c7-64ea800ff8cc','8476D',3,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10e577f0-b71d-467e-9830-069c997da8fc','8572E',3,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10e577f0-b71d-467e-9830-069c997da8fc','5893E',3,4,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10e577f0-b71d-467e-9830-069c997da8fc','5953H',3,5,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('05dd5a6c-eae8-415c-a1c7-64ea800ff8cc','5956L',3,5,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5a6f3d40-0b82-4d0a-a4d2-1de5591c67f0','6218G',15,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('859c572c-f1f6-4b82-8fcb-0f4c4978b7a6','6219H',15,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b46dc722-89fa-452c-8040-8c6d9eee0de8','6246R',15,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10e577f0-b71d-467e-9830-069c997da8fc','6253D',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('05dd5a6c-eae8-415c-a1c7-64ea800ff8cc','6254E',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3aefb717-5ef0-438b-8aec-bff34e0dcfda','6255F',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10e577f0-b71d-467e-9830-069c997da8fc','5763H',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('05dd5a6c-eae8-415c-a1c7-64ea800ff8cc','5764J',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3aefb717-5ef0-438b-8aec-bff34e0dcfda','5765K',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5a6f3d40-0b82-4d0a-a4d2-1de5591c67f0','5766L',15,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('859c572c-f1f6-4b82-8fcb-0f4c4978b7a6','5767M',15,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b46dc722-89fa-452c-8040-8c6d9eee0de8','5768N',15,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2900cf99-1acf-439e-a5ec-f29c046947da','1973W',100,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3506a9e7-3bf3-4e0b-ac5c-65a7baee28a2','8425K',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3506a9e7-3bf3-4e0b-ac5c-65a7baee28a2','8426L',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bc9b13a6-71af-457b-8336-db29b8e63411','1969P',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0e20589f-7fca-4cea-a011-82b9c1cd301d','1970Q',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3dfa999c-a66e-4ac2-94c1-6125f5d19575','1968N',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3d6cad79-cf61-49d7-8264-f2d143f031e9','1504E',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f2b5738b-b871-43fe-b5e5-976a4f9ce9e9','1505F',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('817bde64-6fc6-40ad-88dd-aaa6db3f2c7c','2095G',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('186962c0-fd61-42ce-bcd8-da3c0fba95df','2833D',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('186962c0-fd61-42ce-bcd8-da3c0fba95df','9237E',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c2cc476e-c596-408d-9fff-28b7e8d2aeca','9238F',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('349cc24d-140d-46a3-9bf7-d29a0b7c1b03','8197K',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d555be49-1138-48d4-af20-dca21a1005c3','8829Q',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('349cc24d-140d-46a3-9bf7-d29a0b7c1b03','9239G',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d555be49-1138-48d4-af20-dca21a1005c3','9240H',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c2cc476e-c596-408d-9fff-28b7e8d2aeca','2834E',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae0bb020-27bb-4507-8b27-3bf3a9858074','2752W',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae0bb020-27bb-4507-8b27-3bf3a9858074','1345T',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c96c8ddb-8919-446b-ac2b-75875f1880cb','2751T',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c96c8ddb-8919-446b-ac2b-75875f1880cb','1343Q',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('353bdc27-1d70-4126-a6bf-22678a2fabb8','4313B',30,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('409ac505-3a82-4e9c-9984-bb7f88527549','4390C',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('34704cea-b0cd-405e-acf3-be9c3e4cbc1d','4566H',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7318c9ac-51c8-4bc0-8044-c7abbf4c35b6','4689T',10,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7318c9ac-51c8-4bc0-8044-c7abbf4c35b6','4690W',10,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7318c9ac-51c8-4bc0-8044-c7abbf4c35b6','4898T',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7318c9ac-51c8-4bc0-8044-c7abbf4c35b6','4899W',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c1c53f29-dd69-401f-8aee-3e00ec265bcf','2667J',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44439168-0225-4835-9345-09b7207a9e9a','2668K',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b780ad5-b27a-4561-aac6-c0ba68578aae','5626D',100,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('82cb45ff-041a-4e35-94a0-86de3021b78d','5627E',100,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef634024-ffbc-4d44-ac0c-46f97de3734a','5628F',100,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dd8f13e7-5453-4d5e-890d-8372aab58181','5629G',100,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('829d7cd5-4202-46bd-9559-2d930cd5f508','5630H',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef634024-ffbc-4d44-ac0c-46f97de3734a','6101D',100,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dd8f13e7-5453-4d5e-890d-8372aab58181','6102E',100,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b780ad5-b27a-4561-aac6-c0ba68578aae','6417R',100,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('82cb45ff-041a-4e35-94a0-86de3021b78d','6418T',100,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('829d7cd5-4202-46bd-9559-2d930cd5f508','9632Y',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3ca2a269-2431-4fb6-8768-ae56b137cf11','5631J',10,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('625539bf-518e-45c4-8b83-ee749a0b13f2','5632K',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('be5fa59a-68db-45cb-9c31-a8f86115b245','5633L',4,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b94fc3f8-4951-41c6-ab6d-9f2ed0f51a97','5634M',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4d2c1075-121c-43ce-a45a-388e16fac94e','5635N',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('68fcb85c-a5e6-4946-a2c8-1ab7fe5a7aca','5636P',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3ca2a269-2431-4fb6-8768-ae56b137cf11','6109M',10,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b121cac0-585e-4553-9137-96fd76d0f819','6125J',4,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('625539bf-518e-45c4-8b83-ee749a0b13f2','6232B',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b94fc3f8-4951-41c6-ab6d-9f2ed0f51a97','6352H',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4d2c1075-121c-43ce-a45a-388e16fac94e','6353J',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('68fcb85c-a5e6-4946-a2c8-1ab7fe5a7aca','6354K',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('625539bf-518e-45c4-8b83-ee749a0b13f2','8657P',120,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b94fc3f8-4951-41c6-ab6d-9f2ed0f51a97','8658Q',60,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4d2c1075-121c-43ce-a45a-388e16fac94e','8659R',60,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('68fcb85c-a5e6-4946-a2c8-1ab7fe5a7aca','8660T',60,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b121cac0-585e-4553-9137-96fd76d0f819','8661W',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2138ce59-ee93-4f59-82ef-066534731d15','5661Y',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a8353d41-8ee8-40e1-a31c-078821e449cc','5662B',400,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a8353d41-8ee8-40e1-a31c-078821e449cc','6113R',400,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2138ce59-ee93-4f59-82ef-066534731d15','6270B',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6083c1d0-7af8-4647-be6c-30e225e773bb','6298L',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed09b1c8-b44b-40e2-8c8a-7d2aa7335cd5','6299M',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('48548c98-1159-42b5-8803-09d936c254ee','6300N',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b3788117-d7d8-48d9-8e05-0eca00921e42','6301P',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6083c1d0-7af8-4647-be6c-30e225e773bb','5663C',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed09b1c8-b44b-40e2-8c8a-7d2aa7335cd5','5664D',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('48548c98-1159-42b5-8803-09d936c254ee','5665E',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b3788117-d7d8-48d9-8e05-0eca00921e42','5666F',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b00920fc-98ff-4c0a-b5c4-daec0b95e18d','5713Q',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0293333b-d115-4606-96a2-9d7676569b78','5714R',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6b8cd691-9640-42f4-87de-60cf3d703391','5715T',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('64ece5b4-269a-465a-8e42-0a4ee1eba4c5','5716W',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('712abbbd-06c2-40e8-b76d-6d75e78b05c3','5717X',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1111cc93-8290-4e90-8f54-501d2636af16','5718Y',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5df753d3-7cf8-48e3-8b2d-82b3ed1f2fa9','5719B',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b75d7861-f00b-4612-91a0-57da192562e0','5720C',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2267066e-65c7-4bed-b4e6-b1bd0b1c2014','5721D',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b31397bd-b9dd-4758-9ae1-5fd59f681bac','5722E',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5df753d3-7cf8-48e3-8b2d-82b3ed1f2fa9','6204M',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b75d7861-f00b-4612-91a0-57da192562e0','6205N',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2267066e-65c7-4bed-b4e6-b1bd0b1c2014','6206P',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b31397bd-b9dd-4758-9ae1-5fd59f681bac','6207Q',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0293333b-d115-4606-96a2-9d7676569b78','6251B',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6b8cd691-9640-42f4-87de-60cf3d703391','6302Q',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('64ece5b4-269a-465a-8e42-0a4ee1eba4c5','6303R',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('712abbbd-06c2-40e8-b76d-6d75e78b05c3','6305W',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1111cc93-8290-4e90-8f54-501d2636af16','6339P',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b00920fc-98ff-4c0a-b5c4-daec0b95e18d','6434P',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eedaf0e9-6988-462f-b183-eecb2c30ec64','6126K',20,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6015c6f2-d243-4faf-8517-da8b759f02be','6127L',20,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8c290114-d883-4b27-978b-f2470313cdba','6291D',20,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8c290114-d883-4b27-978b-f2470313cdba','9693E',20,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b69f38b-370e-4914-bcb5-cd8d7cbb20f1','9695G',20,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b69f38b-370e-4914-bcb5-cd8d7cbb20f1','6292E',20,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6c900668-34eb-430f-ab9b-9f52f414bd21','5830W',20,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eedaf0e9-6988-462f-b183-eecb2c30ec64','5741E',20,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6015c6f2-d243-4faf-8517-da8b759f02be','5743G',20,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8c290114-d883-4b27-978b-f2470313cdba','9692D',20,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8c290114-d883-4b27-978b-f2470313cdba','5742F',20,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b69f38b-370e-4914-bcb5-cd8d7cbb20f1','9694F',20,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b69f38b-370e-4914-bcb5-cd8d7cbb20f1','5744H',20,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6c900668-34eb-430f-ab9b-9f52f414bd21','5829T',20,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8c290114-d883-4b27-978b-f2470313cdba','1082Y',20,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('874d3883-f5a1-420a-ad82-8657cd9fe4c1','1113N',20,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8c290114-d883-4b27-978b-f2470313cdba','1123D',20,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('874d3883-f5a1-420a-ad82-8657cd9fe4c1','1126G',20,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('920e0615-1b46-4f97-ac70-8ecb9835ff85','6153W',400,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3c84cdce-f394-49cb-94d4-ff080e38a184','6154X',240,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('662b8514-198c-4575-acd2-d7f1501a5483','6155Y',15,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('662b8514-198c-4575-acd2-d7f1501a5483','9570Q',15,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('920e0615-1b46-4f97-ac70-8ecb9835ff85','9651Y',400,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3c84cdce-f394-49cb-94d4-ff080e38a184','9652B',240,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('58a8c850-f053-4b9b-ac97-815be5d41f57','6169Q',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('99e96099-9559-4089-b378-f6aec5ce5152','6170R',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba9e9dd6-4c45-4552-8c91-71b8540cbc5d','6295H',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f013e59c-8cc6-40ae-b6e2-c41b13e0ac01','6296J',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b348038b-47ba-4591-8f93-cebed2dd0ad3','6297K',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('60e6d48d-3319-4aa1-ac4b-5ab98fae1a58','6312F',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('995edc15-2fc4-4196-96f3-8915140d7607','6313G',7,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8f41c87c-2471-4eb0-ac07-6fd930f7621c','6314H',7,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b1f09e7-c5c0-4bc0-823a-cefdeb534c55','6315J',7,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('62e50633-2eea-4d26-bc3f-eae633a88a2d','6316K',7,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a230011e-620f-4993-9284-43c0b9558a00','6317L',7,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bed16245-927d-403f-b594-3e904be609b4','6318M',7,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1dd0802f-3a5f-4985-8221-c45bf66d559b','6319N',7,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('18599d3d-959c-46cd-a238-87d338453a07','6329D',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9705956-4b86-4718-9e5a-3f8afb911f28','6330E',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b632f12b-4c17-453b-9947-a795093b9644','6345Y',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba9e9dd6-4c45-4552-8c91-71b8540cbc5d','6476W',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dec7618a-6b85-40ae-9084-fc31565d6a58','9585L',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('32a7d9bd-6142-4d1b-bdff-3819044d2120','9586M',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba017b44-f43e-484c-8321-3b42c94b597d','9604L',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1102fbac-ce53-4b74-bea3-f626a9c00d41','9628R',7,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f013e59c-8cc6-40ae-b6e2-c41b13e0ac01','6311E',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e0be1de1-3ae6-4c19-815a-3fc5f46185f0','6310D',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d01ab886-6eb7-42cf-80cb-09a0e1edd962','6266T',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2a71f91d-1884-4525-bb9e-47c206056278','5822K',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3db03651-38ca-4bc1-af07-5ed5aa3dcf99','5824M',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('94585f61-4b8c-404d-9993-3d7ce6af1388','3388H',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba9e9dd6-4c45-4552-8c91-71b8540cbc5d','5818F',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f013e59c-8cc6-40ae-b6e2-c41b13e0ac01','5819G',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b348038b-47ba-4591-8f93-cebed2dd0ad3','5820H',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba9e9dd6-4c45-4552-8c91-71b8540cbc5d','6465G',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f013e59c-8cc6-40ae-b6e2-c41b13e0ac01','6466H',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b348038b-47ba-4591-8f93-cebed2dd0ad3','6467J',1,0,'GH','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b68928e9-d96d-422e-b297-5569c66b8764','4674B',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b68928e9-d96d-422e-b297-5569c66b8764','4675C',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b68928e9-d96d-422e-b297-5569c66b8764','4797L',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b68928e9-d96d-422e-b297-5569c66b8764','4799N',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bf247d73-96cc-4c43-bd92-2388178b64d9','4661H',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bf247d73-96cc-4c43-bd92-2388178b64d9','4815K',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bf247d73-96cc-4c43-bd92-2388178b64d9','4816L',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0671eca5-5069-491e-b687-ec0b33479ffc','2130D',50,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('20e7ea30-2f3c-467c-a38f-dd1fd4d2bb0b','2131E',50,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6a2b6432-3be3-4109-a67e-a78423aff885','2132F',50,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3adbec6-ab8f-4616-9e51-0c14f9492352','8118G',50,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f3cfc26-1757-48de-aaa2-a10c852017ba','5747L',6,1,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f3cfc26-1757-48de-aaa2-a10c852017ba','6134W',6,1,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e93a0289-4887-4951-982c-4fed0cc804fc','8262W',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6e5ac1d5-5a18-4c06-8051-85e365ddecf5','8510X',20,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c9781813-1794-4d26-b34b-b5b2dc014a38','8558K',20,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6e5ac1d5-5a18-4c06-8051-85e365ddecf5','8639Q',20,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e93a0289-4887-4951-982c-4fed0cc804fc','8640R',20,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c9781813-1794-4d26-b34b-b5b2dc014a38','8716R',20,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9aec99f6-653b-4c09-aaf3-42389d538f7e','9195Y',20,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9aec99f6-653b-4c09-aaf3-42389d538f7e','9196B',20,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93298dea-069e-433f-b502-83962bc1852d','5434B',20,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93298dea-069e-433f-b502-83962bc1852d','8263X',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cbb33544-d25d-4c7c-bc81-f5df6d5bab12','5435C',20,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cbb33544-d25d-4c7c-bc81-f5df6d5bab12','8264Y',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('37b9b4ee-6654-4150-a7a8-36a32568bea6','3092R',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ead8a6ab-15a0-4067-8bfc-bb54ceaaf27e','3136C',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8f6f7d93-9262-4cc6-8dda-02b96cbfa568','4175R',30,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f625d269-fe5f-491f-8477-3594220eb7d9','2250K',12,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f625d269-fe5f-491f-8477-3594220eb7d9','8574G',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f625d269-fe5f-491f-8477-3594220eb7d9','8754R',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f625d269-fe5f-491f-8477-3594220eb7d9','8575H',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f625d269-fe5f-491f-8477-3594220eb7d9','8755T',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f625d269-fe5f-491f-8477-3594220eb7d9','1521C',12,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f625d269-fe5f-491f-8477-3594220eb7d9','1180D',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f625d269-fe5f-491f-8477-3594220eb7d9','1192R',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('23b37c6c-924b-4e29-8c42-45fb02b9ed61','1795L',50,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('23b37c6c-924b-4e29-8c42-45fb02b9ed61','5186Y',50,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('23b37c6c-924b-4e29-8c42-45fb02b9ed61','5353R',50,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('23b37c6c-924b-4e29-8c42-45fb02b9ed61','5354T',50,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('66ffb05b-bd10-4bc6-9169-921c9eaf30ea','2808T',100,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('04143df0-de59-424c-b950-bbdd31a0f78f','2809W',100,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e2c53a31-3f54-41f9-8e68-215bce83ceaf','2810X',100,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f261ca6e-e660-4515-8f88-efab721d46c4','5237P',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1c5b512a-e50d-436a-a688-d4ef312350e3','5238Q',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2fc126ee-8011-4a43-a948-e27ebeaa6764','5239R',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f261ca6e-e660-4515-8f88-efab721d46c4','2122Q',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1c5b512a-e50d-436a-a688-d4ef312350e3','2123R',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2fc126ee-8011-4a43-a948-e27ebeaa6764','2124T',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b4d1ddb2-55d9-4c23-a1a9-318abc947a26','4510J',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5547c16c-0b8d-4904-b313-3e78f4f2a075','1140B',3,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5547c16c-0b8d-4904-b313-3e78f4f2a075','5901N',3,1,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ab129ab7-bf74-4c1a-9578-2cc82065592b','2257T',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7e78f8e5-687c-4095-8b6e-6ef5b044ae47','2255Q',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dbbe86ac-78cb-4d0a-9ce6-0921aeabcb03','2242B',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dbbe86ac-78cb-4d0a-9ce6-0921aeabcb03','9197C',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('73e5f7b4-cdde-4004-8d0c-8e760dfffdd9','2236Q',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('30b47abd-23b2-4707-b423-666ab2bdaa3b','2237R',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('73e5f7b4-cdde-4004-8d0c-8e760dfffdd9','8836C',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('30b47abd-23b2-4707-b423-666ab2bdaa3b','8837D',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9e46cd1f-9533-437a-b269-5debe0fb0d80','8198L',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eec6fba4-e8db-4431-ad62-9e821c67e314','2240X',28,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eec6fba4-e8db-4431-ad62-9e821c67e314','2241Y',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce2c6cd2-9f9e-4a9b-a8c9-0dd43e36a053','9331D',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0bb560a6-0a59-4ede-82f2-8c9e93b93ac5','9477T',28,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0bb560a6-0a59-4ede-82f2-8c9e93b93ac5','9478W',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a58d78a2-a7f3-42c4-b277-9997bdd2f0c4','5787N',20,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9b348f4-84e2-43db-a08c-aaf261198d9d','5788P',20,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a58d78a2-a7f3-42c4-b277-9997bdd2f0c4','6337M',20,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9b348f4-84e2-43db-a08c-aaf261198d9d','6338N',20,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bd4926fc-c0fd-436c-b8ff-55b1bd3ff3ee','9198D',28,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('49d6f778-cf2a-4618-9781-a3d6f05e7d31','4571N',2,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('27a33c67-1006-41ae-b95c-72752fefea70','4572P',2,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ca98e73d-33f9-447e-b9c6-f86190c198d3','4573Q',2,2,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('097e8458-d9e8-4dd5-b07c-1a8116d6971c','4576W',2,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9a220b75-0c2f-4dac-8fc7-4ce73ebf2408','4577X',2,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('276e6b96-5afa-456a-b844-582995bbdc40','4578Y',2,2,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aa15c241-00e1-4ac8-abc4-112fea60f7a1','5573H',28,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('23aa34c9-549d-433e-82c0-139f128b9e11','5572G',28,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6f93910b-75bf-403c-9102-445a05f77338','5465P',28,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6f93910b-75bf-403c-9102-445a05f77338','3414Q',28,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6f93910b-75bf-403c-9102-445a05f77338','5571F',28,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d7caa873-dc4f-4faa-9050-ff6cb1a12cce','5815C',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d7caa873-dc4f-4faa-9050-ff6cb1a12cce','2962X',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e51b9ae8-4362-4523-8c0b-d49b44d8fdc4','6103F',1,0,'MF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e2096ea5-2b3a-4044-8e18-7a8c4e1b23cf','1131M',3,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e2096ea5-2b3a-4044-8e18-7a8c4e1b23cf','5902P',3,1,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1b30ba17-20e7-4b3e-8588-ea04fc756030','8641T',20,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fcb4da70-2934-468b-8590-928053ba3dc1','8642W',20,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8262ecba-8133-4e99-8e18-1766af1f1967','8956J',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d5a289a1-6532-482f-9a56-478380401613','8271H',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d5a289a1-6532-482f-9a56-478380401613','8643X',20,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('db6697ac-d121-4aa5-88d6-2b4ed6407458','8959M',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7e76a440-bd83-4b79-8920-d96ded5966d6','8960N',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1b30ba17-20e7-4b3e-8588-ea04fc756030','8603T',20,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fcb4da70-2934-468b-8590-928053ba3dc1','2816F',20,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('80c81a11-ab1d-45aa-a11f-e30e35483021','1229Q',20,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('80c81a11-ab1d-45aa-a11f-e30e35483021','8269F',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9979ead9-c5ea-4a83-8426-29f16a29b4ca','1296F',20,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9979ead9-c5ea-4a83-8426-29f16a29b4ca','5445N',10,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('80c81a11-ab1d-45aa-a11f-e30e35483021','8957K',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9979ead9-c5ea-4a83-8426-29f16a29b4ca','8958L',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('75f1a00d-f8f4-4579-8c51-1f82da1953ae','1834M',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c564ae70-4363-406b-9c6d-10adda8cb821','1835N',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('175059b4-66ff-45ff-b4ff-f8c0c2361b9a','4591P',100,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('75f1a00d-f8f4-4579-8c51-1f82da1953ae','4592Q',100,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c564ae70-4363-406b-9c6d-10adda8cb821','4593R',100,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a22facb7-61a9-4f0d-b5b6-23020d62d189','4594T',100,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b4f745b7-4d12-44de-abd9-03d86246e87f','4595W',100,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b4f745b7-4d12-44de-abd9-03d86246e87f','8389M',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('175059b4-66ff-45ff-b4ff-f8c0c2361b9a','8505P',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a22facb7-61a9-4f0d-b5b6-23020d62d189','8559L',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7475bc1d-4793-4414-90ad-795a0f13f884','2848X',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e91d6df1-b06a-48c0-9490-165089abc14c','2849Y',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f376da31-46d5-4067-acdb-dc620002cdaa','2850B',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e46b979c-115d-48e7-b1a1-7ddd09c1e52a','2851C',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('56153a6e-4a61-48e3-92c7-0a058048d146','8063J',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f599ed2b-5d0d-4317-a9c5-7561c8da21f8','2745L',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('926cbcbb-f0d3-443c-af76-047563d2ffaf','2746M',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f599ed2b-5d0d-4317-a9c5-7561c8da21f8','5986C',2,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('926cbcbb-f0d3-443c-af76-047563d2ffaf','5987D',1,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('636ee2a5-3e41-40a9-9e6a-1359d2d5c30d','3169T',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('06cd9469-21df-4a7f-90ae-1f3c8154266e','3170W',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dcf311d5-05b6-4dfe-867a-5ea194cbebd5','3171X',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b400bee2-f4b9-4ee4-ac98-2a7404dc7ec4','3172Y',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9c186ed-7c9e-4694-804a-2983b4404c60','8100H',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7236d29b-97d8-4652-b3aa-103fcecd8897','8788M',56,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('636ee2a5-3e41-40a9-9e6a-1359d2d5c30d','8789N',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9e8357fc-3d7a-4e89-b6b6-d9b0fbc205c6','8790P',56,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9e8357fc-3d7a-4e89-b6b6-d9b0fbc205c6','8792R',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71636773-db44-4aee-b2af-2e8378b75580','8794W',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7236d29b-97d8-4652-b3aa-103fcecd8897','8870W',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e32904ae-c12c-46ef-aded-d50ede17abd1','9075P',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('55f501fd-8585-4260-ac85-f4ffaeae3d7b','9076Q',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('06cd9469-21df-4a7f-90ae-1f3c8154266e','9079W',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71636773-db44-4aee-b2af-2e8378b75580','9080X',56,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9c186ed-7c9e-4694-804a-2983b4404c60','9293D',1,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f6a4b609-f25a-4594-873a-c0973d2f0472','8780D',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2758b11b-a51e-4d0a-92a8-9f39228ff6b1','8781E',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('221927c0-7872-4230-a272-7bf143d68128','8782F',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31806a1e-c64b-445d-8e67-fcd387b8cfba','8787L',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31806a1e-c64b-445d-8e67-fcd387b8cfba','1842Y',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31806a1e-c64b-445d-8e67-fcd387b8cfba','8869T',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31806a1e-c64b-445d-8e67-fcd387b8cfba','1846E',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b18560e5-914e-4f8e-a101-095db3203d52','8141L',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7640d75a-cfdb-42e7-8632-21361371a225','5769P',12,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7640d75a-cfdb-42e7-8632-21361371a225','6148N',12,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cbc261f6-11b7-44ed-a221-33fe8d5b1427','6195C',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cbc261f6-11b7-44ed-a221-33fe8d5b1427','9541E',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('954ffec7-b6e3-4f5c-b944-7a2fa3f1d505','8365G',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e6adcd3a-aa12-4509-be21-6e6636089291','3054R',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24361c7d-4094-4b38-b473-f01545496ec1','2792Y',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('370bc26f-5a89-48a7-b0d9-6612421e8f81','2793B',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4003d379-777a-4ea9-9866-37e2839e1210','8758Y',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4acd1308-0963-4e92-9706-cc9d0c16f78e','2791X',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('12644e59-c19f-49f0-b624-a31a39bfc6a8','5567B',2,0,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('12644e59-c19f-49f0-b624-a31a39bfc6a8','8383F',2,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f8666aba-04dc-4f42-b398-a16146d1dbb3','8336R',2,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2ed9a9f9-a517-4de5-b6dc-94dcd0f87950','8201P',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('de4dd39c-2f82-4a38-b7c4-cc59f7db1ed0','6221K',16,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('de4dd39c-2f82-4a38-b7c4-cc59f7db1ed0','5616N',16,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f8666aba-04dc-4f42-b398-a16146d1dbb3','8200N',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f8666aba-04dc-4f42-b398-a16146d1dbb3','4115N',3,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5b7377d5-fd7b-49d0-9602-2e3971366621','1913Q',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4e34ea05-9bf4-4158-a005-05115c8e658b','1915T',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7782f62c-47d0-4f6f-b45f-c25e7a0a8995','8043H',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b80c59a9-33c4-497a-9efe-381e31e31774','4342M',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5003c206-2d8e-4769-b3fc-90346f2b81bf','4343N',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4e3d3208-1251-4edc-bcee-68d0776cd043','2019G',100,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85aebe25-c32f-4478-b09c-51e7bf69fdd3','2020H',100,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d4a465e4-0de8-472b-958a-3aa6cd1c1963','8147T',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3fcfb8f8-2e69-4bd8-8942-08864dcd95fa','8148W',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09ee96ab-4e30-4476-a0e6-8d6e0be0ac4c','8149X',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('445971f7-406c-44e1-b786-280301788889','8345F',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e58a8fee-6575-4ed7-bd4c-a0cbce56c6e9','8346G',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('525aa1b9-ce46-4b84-8745-0fd656890e2a','8516F',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c489649c-29bf-412f-ab29-485ccf3b910c','2027Q',5,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('176a4926-de48-4a35-a2c4-5145647f73fa','8002E',21,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('176a4926-de48-4a35-a2c4-5145647f73fa','8217L',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fb6ccc4f-8d45-46fd-9ab9-ccf6bcac8b4f','8092X',40,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('176a4926-de48-4a35-a2c4-5145647f73fa','2274Q',20,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('505cbd0a-0a19-4221-a74f-2f7609200a7c','8897G',30,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('505cbd0a-0a19-4221-a74f-2f7609200a7c','8896F',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bb9758eb-35b0-405d-8637-98c321912e60','9423Y',30,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bb9758eb-35b0-405d-8637-98c321912e60','9424B',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a361a0fa-12ef-469a-bc9b-7350b5b01689','8399C',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4895009f-14f5-447f-9245-93409b11a154','8007K',30,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4895009f-14f5-447f-9245-93409b11a154','8008L',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('092ccc9b-4d55-4e49-ab5f-e991f2c24ae5','4919X',2,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('092ccc9b-4d55-4e49-ab5f-e991f2c24ae5','4918W',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('33730d7a-ca07-4ac2-9dc6-1d7882b801fc','4678F',5,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b6455463-a7b7-4140-9a7e-ead920b7754d','4679G',5,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d64b0e4-1b9d-487d-ac3d-cfda76a83980','4897R',2,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d64b0e4-1b9d-487d-ac3d-cfda76a83980','4920Y',2,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d64b0e4-1b9d-487d-ac3d-cfda76a83980','4923D',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d64b0e4-1b9d-487d-ac3d-cfda76a83980','4945G',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8cabe374-f1f6-48bb-b77c-4a05abed65d2','4946H',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d64b0e4-1b9d-487d-ac3d-cfda76a83980','4921B',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('675048e3-1d92-4734-8711-733090d36527','8300W',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f165c377-0b31-494d-a4f6-a2adad28fa7f','5514F',1,0,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f165c377-0b31-494d-a4f6-a2adad28fa7f','8699W',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d635bba5-a0e8-4486-a108-098390d04d45','4579B',6,3,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('01ef1cd3-12a2-4f1a-8b3b-6c1849dc0067','4580C',6,3,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6e5c6692-87a0-4bba-b5a7-d61c273f0d6f','4233T',30,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6e5c6692-87a0-4bba-b5a7-d61c273f0d6f','4303L',28,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('52dbdea5-c86c-4559-9afc-4c0d7209469b','8015W',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1c619b87-1b0e-43b1-bd16-489c2d4f1ee1','6120D',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1c619b87-1b0e-43b1-bd16-489c2d4f1ee1','5704F',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9fcdfa93-15ed-4659-8b35-c9e2ee415f70','8020D',500,10,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc959849-94bd-4604-9231-d84f5d1a12a9','8021E',200,10,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9fcdfa93-15ed-4659-8b35-c9e2ee415f70','9226N',500,21,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc959849-94bd-4604-9231-d84f5d1a12a9','9227P',200,21,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('25bfa7f9-66df-412b-b83e-6fd7513fdd24','9412J',200,10,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('25bfa7f9-66df-412b-b83e-6fd7513fdd24','9413K',200,21,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6bc0615c-1c59-4263-ad58-cca50f79a645','5454C',3,21,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6bc0615c-1c59-4263-ad58-cca50f79a645','5453B',3,10,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8ff35fe4-817f-4390-970e-d1cf33599ab5','2863Q',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2414847f-f17f-4ec0-b5bc-474fc95760b3','8023G',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2791de4a-a48c-4cf7-a5e6-ce6c7875d3d3','8024H',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2414847f-f17f-4ec0-b5bc-474fc95760b3','9234B',28,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2791de4a-a48c-4cf7-a5e6-ce6c7875d3d3','9235C',28,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8ff35fe4-817f-4390-970e-d1cf33599ab5','9236D',28,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('109210bb-5c9d-4de1-a271-d354576b4e58','5609F',5,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8fe83682-fc4a-46e6-a7c5-1df5b1c5f0a4','5610G',5,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a69d751-eaff-45b5-b3bf-dc8631365690','5611H',5,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('109210bb-5c9d-4de1-a271-d354576b4e58','9607P',5,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8fe83682-fc4a-46e6-a7c5-1df5b1c5f0a4','9640J',5,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a69d751-eaff-45b5-b3bf-dc8631365690','9647R',5,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e0ab71ba-8a83-452a-93c6-69362a71cf28','8039D',100,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0cd0d757-abba-4e77-9095-844851f9b2d2','5624B',100,2,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('51d03cc9-c5ab-4d8f-aa7f-f9ef17d9eef1','5625C',100,2,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('51d03cc9-c5ab-4d8f-aa7f-f9ef17d9eef1','6151R',100,2,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0cd0d757-abba-4e77-9095-844851f9b2d2','6152T',100,2,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('51d03cc9-c5ab-4d8f-aa7f-f9ef17d9eef1','8318T',14,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e03a1f26-fcca-4317-a3ab-38588ab22c86','9192T',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8939bcd4-d554-436e-9081-0fffb5aec215','8048N',3,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2385fe5e-865c-4884-a553-9b66ac3b0993','4310W',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f59bc230-d111-4c90-9e44-7dd9e14e5da4','4311X',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2281613-e59a-45bd-8bf5-4426a3f42818','4010C',1,1,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a51be6c3-0bcb-4829-9c30-5f4be944f5cf','8054X',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ec342dc-99d6-466b-9483-aca98bd4f4a3','8055Y',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ec342dc-99d6-466b-9483-aca98bd4f4a3','8128T',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('83614c11-b714-478d-a3cb-508202a8346b','8618N',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('64549dc6-1ebc-4f55-b019-091b73524450','8058D',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c94af356-c179-4584-8d3a-67344b22eb26','8059E',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c94af356-c179-4584-8d3a-67344b22eb26','8061G',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cbfeb91c-044a-4299-bec8-f6edf35e26e4','3444G',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8ace9530-f2b2-46cd-a0c3-2bd7f606e334','1923F',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2aa39877-bc9e-40e0-8816-c7ce240e9e78','3443F',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d885f1fa-4cb7-434a-b4ad-e6a02e403488','5748M',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7883af5f-0c3f-4aa8-b8fa-94f0d5b503ee','5749N',10,1,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7883af5f-0c3f-4aa8-b8fa-94f0d5b503ee','6136Y',10,1,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d885f1fa-4cb7-434a-b4ad-e6a02e403488','6256G',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ee0d9794-61c3-40aa-8343-1dfa1672356c','6186N',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7e6dff84-0c50-4d55-a712-723ee4b3d54c','6189R',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a54d641-b012-4890-b3d1-061851b9e138','6190T',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ee0d9794-61c3-40aa-8343-1dfa1672356c','9553T',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7e6dff84-0c50-4d55-a712-723ee4b3d54c','9554W',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a54d641-b012-4890-b3d1-061851b9e138','9556Y',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef466415-93f1-4dae-955f-d3a30cd0568f','6193Y',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71a9abe3-43ef-4182-92da-399e35cd19bd','6194B',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cf3d7d79-7a90-41cb-8f40-5435285dd127','6435Q',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef466415-93f1-4dae-955f-d3a30cd0568f','5772T',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71a9abe3-43ef-4182-92da-399e35cd19bd','5773W',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cf3d7d79-7a90-41cb-8f40-5435285dd127','5774X',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bf4ed648-2f32-4e6b-b06f-031f91b0a5a9','6257H',56,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2cb1d981-aa05-49ec-9b18-e9816bbbe02c','6271C',5,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bf4ed648-2f32-4e6b-b06f-031f91b0a5a9','5770Q',56,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2cb1d981-aa05-49ec-9b18-e9816bbbe02c','5771R',5,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cd5f2daa-b19e-4e8a-a930-9c2388023a6f','8134D',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cd5f2daa-b19e-4e8a-a930-9c2388023a6f','5480K',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cd5f2daa-b19e-4e8a-a930-9c2388023a6f','8133C',20,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cd5f2daa-b19e-4e8a-a930-9c2388023a6f','8064K',42,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cd5f2daa-b19e-4e8a-a930-9c2388023a6f','9568N',500,2,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cd5f2daa-b19e-4e8a-a930-9c2388023a6f','6280M',500,2,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('211d672a-ccc3-4354-bf6c-15999ae0c092','8301X',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ada790d3-7d08-4c0d-9dda-1380c1d6cf1e','8302Y',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1aaf6538-08a2-4b9b-a28d-c941ac255bd5','8868R',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d51b4956-c200-492b-a8d0-2b0358d9e3ed','5960Q',15,5,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03a4e956-e035-4164-92ef-e853561431a2','5961R',15,5,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d51b4956-c200-492b-a8d0-2b0358d9e3ed','8078E',15,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03a4e956-e035-4164-92ef-e853561431a2','8079F',15,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8d028695-2e3e-4592-ad46-87458f6c87ee','8427M',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1423fde1-8340-4978-9cf4-71373a4638d8','8428N',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('487612e8-a3f4-4ec5-b018-5890eefaf41b','8083K',1,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d55bdf4d-7514-4571-a4e8-fb2db553cb14','8084L',5,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('49a26c63-5964-4e14-af1a-8fb575bbabb2','8212F',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('440a2a50-3c70-4042-b0a7-6491b78d9029','8090T',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0edebffb-c950-4863-b18b-af050195eff6','8511Y',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('53410e5c-7c75-41d6-b6d0-616804b80754','8094B',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('22fc0c2a-a4bb-4a26-af7e-adf5a7c1d2e9','8098F',6,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1f1fe364-269b-41ef-92b3-663d8851b655','8099G',3,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6267a78d-cdb1-4572-87c2-ae5a7ff850f7','8460G',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9803b3e5-5bdf-435c-930c-a43971799fc9','8619P',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c8f4e582-edc9-4712-9d83-363cff34cc26','8830R',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('23085399-79bd-424b-83b4-3ec5ceafeac5','8097E',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2baee101-47aa-4bca-8b60-6a5a0870081c','8101J',15,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('823ba0de-504d-4af0-a96d-bb19608c6b19','6202K',360,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('823ba0de-504d-4af0-a96d-bb19608c6b19','5752R',360,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d64500eb-ab90-4078-b841-16090c0c3e39','8114C',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d64500eb-ab90-4078-b841-16090c0c3e39','8115D',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('794229fc-652b-4c73-9079-c4ed9d053b02','8393R',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2699fe08-498a-4503-a4c5-347f012e5e62','8394T',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('68740d19-c60d-4f6c-b329-56833494b109','5096F',24,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef2a025c-9a47-4757-b47f-30c72c7602e2','5097G',24,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('68740d19-c60d-4f6c-b329-56833494b109','8121K',24,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef2a025c-9a47-4757-b47f-30c72c7602e2','8122L',24,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a75909d6-0ef2-4e6c-8da7-6c1f90b234d9','6494T',10,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2ae8dc64-fd42-449f-9388-e5e25f91d82e','9677H',720,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a75909d6-0ef2-4e6c-8da7-6c1f90b234d9','9542F',10,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2ae8dc64-fd42-449f-9388-e5e25f91d82e','9660K',720,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3ff39ec0-a1ce-4f62-a144-8605f49d5177','5541P',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3ff39ec0-a1ce-4f62-a144-8605f49d5177','8488R',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('986df15f-fcbd-4fe3-b226-7471f97edf6c','4915Q',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0ea81b7f-8f7c-44b9-8b0f-1c2d8e7b5a7d','4917T',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3ebe42c4-4d6b-453c-9ba5-b668a27ac0d8','4396J',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('72da7678-d632-4c11-9f9c-bf29334803c9','4397K',28,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3bd23d6b-d042-4fae-b3f6-19c3a20bbdde','4398L',28,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4daa8c17-8133-4a4b-9850-6b7d8309d0a0','4399M',28,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71c525da-2ece-4b98-8f12-597e6f3f687c','8136F',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4cb679fb-e76e-45a8-b3a7-5db70241d43d','8239P',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3442565f-759f-4a65-b6ee-23898e563330','8240Q',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44d65b89-b298-46f7-807c-098f4da4ba5e','8131Y',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b676f4ff-70d3-4ae5-b16b-c74cafad0f1e','8132B',100,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('22cd28dc-ea7e-4c35-a6f1-25f6e8eabbe6','8265B',60,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d551b802-7035-4288-ba24-94800cc22f97','6209T',300,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7940058b-f8d3-49e8-aa23-83d0b1604ed6','6364Y',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d551b802-7035-4288-ba24-94800cc22f97','8650G',150,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7940058b-f8d3-49e8-aa23-83d0b1604ed6','8651H',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7940058b-f8d3-49e8-aa23-83d0b1604ed6','9500B',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d551b802-7035-4288-ba24-94800cc22f97','9502D',300,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c967f5a3-a288-436a-afdb-ccd14ada362c','8649F',300,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c967f5a3-a288-436a-afdb-ccd14ada362c','1836P',300,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c967f5a3-a288-436a-afdb-ccd14ada362c','6208R',600,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c967f5a3-a288-436a-afdb-ccd14ada362c','1837Q',600,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c967f5a3-a288-436a-afdb-ccd14ada362c','9501C',600,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c967f5a3-a288-436a-afdb-ccd14ada362c','1839T',600,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d297cf12-e551-4140-972f-02904eedf5d5','8163P',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0454e23f-e416-47a6-bc78-f52c391b00b3','8164Q',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a89246fa-c1f2-4c5b-b982-589746f38485','8165R',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d26cb3ea-98c9-40b1-84c6-e6f484e8e73f','8166T',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6790b549-f605-40f6-bc93-d6b6299fc79d','8371N',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a772ffb4-34dc-41e8-921b-a634fc1a42a6','8372P',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('69fc0c7d-ce47-4706-acfd-5b74195685a7','8520K',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a035a65c-2400-40c8-b4b1-d864174168d2','8512B',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3634fc14-2fbd-449e-ba67-7514451e8706','8174F',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('26adde34-ec33-4e47-b422-85c53723bf9d','8359Y',4,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('afb9d459-0b2e-49e4-9ab3-41ff8c4afc15','9294E',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c9aae669-225b-42c5-ab2c-68859c4be5c6','9295F',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7220979a-25d8-4ed1-9f3c-f1ff9c4befd6','9303P',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a602c3e-2dd7-48b6-89fe-73e51e78641f','3385E',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('56e5faa7-cea7-4022-97b9-40867db80c67','8434X',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a3b181e-f27a-4059-a038-b142b79aff30','3384D',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('415b3499-1919-4dc9-b227-48d070dc05ad','8952E',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6788d1cc-81a6-4a0f-b4b6-dc94b62f8594','3381Y',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b049bbf1-882d-4b6c-8637-ec1967a33781','8433W',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('17f37bdb-2c6f-4692-b331-c882cdaac4aa','3382B',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f99621a5-82c9-4f8d-a272-5d2950af4e85','8953F',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('08aecaaf-f683-4c8a-898c-95b76e069c0f','1024X',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('08aecaaf-f683-4c8a-898c-95b76e069c0f','8170B',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e9d95250-6cec-4dde-a40b-24d388defbee','1037N',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e9d95250-6cec-4dde-a40b-24d388defbee','8185T',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('101e456c-2a69-4dd2-85ed-7feb7116d985','1041T',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('101e456c-2a69-4dd2-85ed-7feb7116d985','8186W',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('06fd39a2-3d5c-4f95-ae6f-e2b1decb8315','1042W',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('06fd39a2-3d5c-4f95-ae6f-e2b1decb8315','8187X',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f85a31cf-d312-4ba2-a244-d99d4212cf57','8179L',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2bfcae74-37b3-46fb-942c-1c67aa1e49f4','6215D',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9dded24-4c71-4dc8-a22a-090625efea6b','9571R',10,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2bfcae74-37b3-46fb-942c-1c67aa1e49f4','9506H',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d9dded24-4c71-4dc8-a22a-090625efea6b','9507J',10,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c1f1f933-32b2-45ab-ad53-1fbf33fadee4','1132N',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c1f1f933-32b2-45ab-ad53-1fbf33fadee4','1129K',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5baeb337-13dc-4b67-8d8a-0d44ac3e36bc','8196J',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2a22f354-b0b7-44ec-bd9a-5742d0622eff','6216E',200,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('219028f0-9d16-41d2-a480-3fd1b5b507fe','6217F',100,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2a22f354-b0b7-44ec-bd9a-5742d0622eff','8647D',100,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('219028f0-9d16-41d2-a480-3fd1b5b507fe','8648E',50,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2a22f354-b0b7-44ec-bd9a-5742d0622eff','9560E',200,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('219028f0-9d16-41d2-a480-3fd1b5b507fe','9561F',100,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a0d672ee-44cc-491a-9079-696c22b8d875','5299X',30,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ab43aeb7-ea16-4b42-8790-4f3d1f9ea64a','5300Y',60,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6b9b391a-e553-44d4-af8e-81d45fe97c92','5451X',30,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a0d672ee-44cc-491a-9079-696c22b8d875','9664P',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ab43aeb7-ea16-4b42-8790-4f3d1f9ea64a','9665Q',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6b9b391a-e553-44d4-af8e-81d45fe97c92','9666R',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a0d672ee-44cc-491a-9079-696c22b8d875','9681M',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ab43aeb7-ea16-4b42-8790-4f3d1f9ea64a','9682N',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6b9b391a-e553-44d4-af8e-81d45fe97c92','9683P',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e0cfbf14-d5ef-4b67-80f5-767e4b8528ce','8646C',100,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e0cfbf14-d5ef-4b67-80f5-767e4b8528ce','6328C',200,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e0cfbf14-d5ef-4b67-80f5-767e4b8528ce','9558C',200,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1690a74d-e591-4170-aa3e-1e12618ff563','8188Y',90,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5a038626-2c1a-4aba-b522-710ef7036048','8189B',90,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8688705e-e97b-4011-8812-af6922a119cb','6335K',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('20518b14-05de-4c4f-83f0-b3ae58553268','6336L',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a0a8cfe0-222a-4112-8a3f-e13fc19ba4b9','6464F',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8688705e-e97b-4011-8812-af6922a119cb','8565T',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('20518b14-05de-4c4f-83f0-b3ae58553268','8566W',2,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a0a8cfe0-222a-4112-8a3f-e13fc19ba4b9','8871X',2,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('443701a8-2a51-4035-8384-1c03df650ddb','8203R',60,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bc6114cb-398a-445a-b64d-ab117a1fa4b8','5452Y',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8bbef916-4fe8-466e-ba5a-b2c606197c79','5669J',1,2,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8bbef916-4fe8-466e-ba5a-b2c606197c79','6288Y',1,2,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8bbef916-4fe8-466e-ba5a-b2c606197c79','8463K',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc5e029e-15cc-40e9-9d66-aba9a6a43a18','5667G',4,2,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4553a1b9-779b-460c-9dc4-daab74446ba5','5701C',1,2,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc5e029e-15cc-40e9-9d66-aba9a6a43a18','6286W',4,2,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4553a1b9-779b-460c-9dc4-daab74446ba5','6290C',1,2,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4553a1b9-779b-460c-9dc4-daab74446ba5','8208B',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc5e029e-15cc-40e9-9d66-aba9a6a43a18','8461H',4,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8d7eb6b5-d6da-48bc-b4af-d2be2a10ea85','5668H',2,2,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af4f5e06-8d40-4284-b9b1-ddddd8e5b546','5702D',1,2,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af4f5e06-8d40-4284-b9b1-ddddd8e5b546','6279L',1,2,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8d7eb6b5-d6da-48bc-b4af-d2be2a10ea85','6287X',2,2,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af4f5e06-8d40-4284-b9b1-ddddd8e5b546','8209C',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8d7eb6b5-d6da-48bc-b4af-d2be2a10ea85','8462J',2,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dcb0b3c5-90ec-417c-8b33-1391b15c80b9','5670K',1,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a09ab217-3806-4eac-ad32-8587a655a539','5703E',1,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a09ab217-3806-4eac-ad32-8587a655a539','6223M',1,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dcb0b3c5-90ec-417c-8b33-1391b15c80b9','6289B',1,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('79e377ea-0243-4004-9956-ecabf19c4e25','8216K',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('48c240ba-a626-4b8d-a19c-454549a25836','8213G',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8823bf23-b246-403a-ac27-2b6bc3a9bf60','8214H',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('29ec6926-d825-4e55-b968-9bc098d21104','8215J',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('702ef3a7-cd3e-4da1-9eb2-d8ae99af6c6c','8521L',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('48c240ba-a626-4b8d-a19c-454549a25836','9230T',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8823bf23-b246-403a-ac27-2b6bc3a9bf60','9231W',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('29ec6926-d825-4e55-b968-9bc098d21104','9232X',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('702ef3a7-cd3e-4da1-9eb2-d8ae99af6c6c','9233Y',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9b562c8f-7fed-4e39-8ac4-decb20468f3f','8220P',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0eb949cf-08d3-47b8-8644-54d6e21b691a','8702B',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('27f37274-cd99-4573-a991-b971270a0c61','8703C',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('70025996-2c66-409a-afaf-6e61cde5bb14','8221Q',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('43002833-c8bd-4598-96de-b1d5c7a3586c','8222R',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fb6b6d8a-3ba5-47a2-a20e-a1c45fbf1e9a','8223T',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2edb1d84-ff8a-464a-bd61-c1c616a4f305','8228C',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a41b5c98-a35a-4942-9f7b-8a16e0f6d18e','8229D',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('beb91bd1-dfe3-41f1-b456-dcf14d98323a','2349P',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('beb91bd1-dfe3-41f1-b456-dcf14d98323a','2350Q',5,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('beb91bd1-dfe3-41f1-b456-dcf14d98323a','8282X',5,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('beb91bd1-dfe3-41f1-b456-dcf14d98323a','8283Y',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2e774340-36bb-41d1-8346-3ca47e64f25f','6227R',90,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5918aca3-81c5-4855-998f-b28f2012112c','6228T',90,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('360c2265-b309-4f52-9180-8c9f05c203cb','6229W',90,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2abdc551-2690-4270-a76e-6f9ad603be7d','6426F',1,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('12581c0b-70a4-4b02-9238-cd0dd91ebc2e','6427G',1,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('525150b1-a230-4f86-9c26-b80109d1ad92','6428H',1,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2e774340-36bb-41d1-8346-3ca47e64f25f','9508K',90,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5918aca3-81c5-4855-998f-b28f2012112c','9509L',90,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('360c2265-b309-4f52-9180-8c9f05c203cb','9510M',90,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2abdc551-2690-4270-a76e-6f9ad603be7d','9511N',1,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('12581c0b-70a4-4b02-9238-cd0dd91ebc2e','9512P',1,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('525150b1-a230-4f86-9c26-b80109d1ad92','9513Q',1,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('316540a0-7793-4daa-a07d-808df91110ac','5552F',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('316540a0-7793-4daa-a07d-808df91110ac','8243W',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b51e30a5-8697-4211-8c9e-0617d8ba5cb0','8244X',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('65b5b40b-db4d-45ef-b074-fe3e282efd89','8245Y',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0bd1344e-9f28-4f89-8b5e-57165fd334c5','8246B',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('091badfe-5010-46f0-b14d-adc176baa8b3','8247C',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3399918c-4d9d-43b0-b68b-d74f152dd37d','8248D',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6bcd2e94-e93c-45ad-b136-022b55334f3a','8253J',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5a2a8bc1-3ee3-44a5-ab88-7f554e398277','4237B',60,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a6a47ff6-4767-499e-95a9-f98eb572b55d','4238C',30,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5f4e78fd-4443-41d3-bb94-530e4b89c26c','8255L',30,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9e5e1ff9-3b13-49e9-9b41-31ed6f393167','8256M',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d5cc4346-145e-4095-ac07-48c2c5e5d8f1','8257N',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('43090f45-32e6-459e-949b-9534456b5a75','8258P',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e57a1d85-e6b5-4b80-a7a3-02b74e987c81','8713N',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d407e83-302f-42c2-a037-1f5667e1dd54','8714P',3,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2ac49ad6-5b12-4919-b094-cd986def021a','8715Q',2,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e57a1d85-e6b5-4b80-a7a3-02b74e987c81','6431L',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d407e83-302f-42c2-a037-1f5667e1dd54','6432M',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2ac49ad6-5b12-4919-b094-cd986def021a','6433N',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad1009fe-76d5-438a-8589-42cd16cc6cb9','4662J',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad1009fe-76d5-438a-8589-42cd16cc6cb9','4718H',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad1009fe-76d5-438a-8589-42cd16cc6cb9','4719J',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a912a432-8c8b-4239-b677-82aed153a21e','4682K',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('32d586ed-13ad-489d-820f-c29018f223ed','1905G',10,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('32d586ed-13ad-489d-820f-c29018f223ed','4832H',10,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('becdb5da-22e0-4ddb-a553-8b3a1478f063','4806Y',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('becdb5da-22e0-4ddb-a553-8b3a1478f063','4911L',2,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('08fdec30-537b-40ce-b40b-9448d455ddc3','8267D',56,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93371c16-4baf-4802-adb7-8e6bef258a68','8266C',4,5,'SB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93371c16-4baf-4802-adb7-8e6bef258a68','9736K',4,5,'SB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bfd0ef91-b478-4e3e-8342-887dda0f6704','8272J',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('409b4bde-e053-4de6-b2e0-e4efaa49adc4','4906F',2,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('409b4bde-e053-4de6-b2e0-e4efaa49adc4','4905E',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('298bb9e0-f8fd-4edb-89a5-d24a9f4242b0','4653X',6,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1f95446b-6ecb-4aa8-8621-b7acfcd39bba','4671W',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1f95446b-6ecb-4aa8-8621-b7acfcd39bba','4672X',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1f95446b-6ecb-4aa8-8621-b7acfcd39bba','4673Y',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b5655072-bdaa-43ec-add8-7d07a79849ee','4681J',10,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b5655072-bdaa-43ec-add8-7d07a79849ee','4742N',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b5655072-bdaa-43ec-add8-7d07a79849ee','4743P',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('25283c1e-1fb9-4aeb-b4df-891191d277e9','4880W',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce7d7e78-0d03-4349-be76-d48f4bd111b7','4795J',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03b8fcba-4be1-427a-a7b8-2cfa521eeed6','4692Y',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03b8fcba-4be1-427a-a7b8-2cfa521eeed6','4693B',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03b8fcba-4be1-427a-a7b8-2cfa521eeed6','4695D',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03b8fcba-4be1-427a-a7b8-2cfa521eeed6','4696E',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9b2eecf1-0ff3-463c-8a54-2855dd8bc012','4927H',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a694e812-4483-43ec-b1da-703f8996d0bc','4928J',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9b2eecf1-0ff3-463c-8a54-2855dd8bc012','4929K',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a694e812-4483-43ec-b1da-703f8996d0bc','4930L',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b2c4738a-6685-491a-85ba-aac77a95c747','8629E',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('27e6bf50-af4a-490e-84d0-78a690d79b73','9383W',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('88f47054-0a16-4d27-8a3e-fe4b87496dff','1938B',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('88f47054-0a16-4d27-8a3e-fe4b87496dff','8478F',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9e2e184-5e80-4d09-b2b0-d4baee5fff1d','2676W',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fa233d3d-eb99-4feb-9672-23599a22073a','8259Q',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6dc64a86-aee5-46c7-9e24-8af13bbaf65e','6234D',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6dc64a86-aee5-46c7-9e24-8af13bbaf65e','5775Y',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1093ec00-65df-4679-bbcc-45f0266dba64','9009E',20,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d86ca0ae-46cf-4623-b2e3-e94ab00e53da','9010F',16,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8ba3ed36-1260-4102-869c-b4c9847b3947','5620T',4,3,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8ba3ed36-1260-4102-869c-b4c9847b3947','6247T',4,3,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eb596d66-5497-4c79-b3f2-c2083f02d98e','6498B',240,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eb596d66-5497-4c79-b3f2-c2083f02d98e','9545J',240,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bd39c19a-34e9-498e-9abb-4b83b6d49fb0','4348W',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('be1ccfa2-e5d2-46fe-9370-d5e1e621bd43','4350Y',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dae24fe1-4ba8-460b-9227-745f31a560c5','9440W',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c6c65532-fb05-4ede-a547-dac55a0f1176','4522B',30,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af24907f-e3e5-4ade-9685-2074fdd2d84c','4190M',60,2,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('201e1f19-4086-461c-896c-aa8116b4faed','4878R',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('201e1f19-4086-461c-896c-aa8116b4faed','4890J',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ab9a3600-9e8c-401a-bee8-58b59fa8ea35','4891K',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ab9a3600-9e8c-401a-bee8-58b59fa8ea35','4694C',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6c1db7a0-8d52-4f0b-b924-94f9be093e4d','4590N',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0bdb1202-264a-40f8-8fa4-065a0ffe5a8f','5705G',4,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0bdb1202-264a-40f8-8fa4-065a0ffe5a8f','6249X',4,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5469492d-91db-4124-ab04-f50f9d3e4101','8298R',4,5,'SB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5469492d-91db-4124-ab04-f50f9d3e4101','9734H',4,5,'SB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5ce4389e-2b7d-4d80-8867-f768566dbae5','8295N',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a45acce-7e12-401c-b9a2-2abe4ceaee40','8997M',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a45acce-7e12-401c-b9a2-2abe4ceaee40','8296P',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('485dc6cf-8dab-4cb0-93df-26556de3ea70','8998N',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('485dc6cf-8dab-4cb0-93df-26556de3ea70','8297Q',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fc3ea8e7-40f1-4186-908c-e55461fa3ae4','8999P',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fc3ea8e7-40f1-4186-908c-e55461fa3ae4','8889W',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a89072f-7d46-4572-a9d5-35961c186609','9544H',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a89072f-7d46-4572-a9d5-35961c186609','9611W',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b5094554-6035-4a71-8a50-4bdfb2977e5b','8289G',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1a3dc485-1667-45e3-93c4-9cd00dac2b1e','8403G',12,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff4f139f-1b6d-4ddd-869d-bec8b87be31b','8805K',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('51bf0213-95a0-4a0f-b4e1-af52b6cf5e09','9332E',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6a820209-96b5-4ee7-aeab-fd29afc504c6','8968B',12,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('388f5dd2-58ab-4001-bd89-ef83875b13c6','2080L',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4052d13c-5afe-4d28-8c98-a35fd4003baf','5052X',14,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4052d13c-5afe-4d28-8c98-a35fd4003baf','8292K',14,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e463026-8c63-4b7b-8fad-7cdb443324f2','5499K',1,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e463026-8c63-4b7b-8fad-7cdb443324f2','2002J',1,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('840a314b-fc74-45e9-80da-fb3918bd54c1','4176T',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('54d4780d-09d7-4d61-b28c-58fe1d07d832','4144D',50,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('965be75b-5d56-4f98-8b17-62c3ab519a96','4145E',50,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('442191c8-30df-497c-ac7e-5651918a2a39','2285G',42,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('442191c8-30df-497c-ac7e-5651918a2a39','2804N',42,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d785fc73-b0b5-4acd-addf-5678eaeec28c','4463X',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a4c2335b-001c-471f-8a8d-07357d978d88','9160D',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a4c2335b-001c-471f-8a8d-07357d978d88','4473K',1,1,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('442191c8-30df-497c-ac7e-5651918a2a39','4011D',42,1,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8958d199-9b4a-490a-b0b6-d667463f90ad','8315P',10,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cd2d0c12-2ff5-4495-9079-1004f35c1dbb','8316Q',10,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('04e85651-b379-4994-bc14-659447841496','8335Q',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('086c84e3-d431-4a29-b1f4-de88b03a133e','8878G',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1a95ee44-516c-439e-9777-1818ea060c3d','8891Y',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4d6f93c3-e30d-4d47-9cea-6704601067ce','5277R',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dbb6869d-136c-44c2-a293-65e3c5272b06','8892B',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4f3de969-1642-45d1-a17d-6123f68429ce','5278T',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5039755f-5d0d-484a-9902-f2c462c271ee','8893C',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3161dd0c-054a-4277-a4b7-a56e2b2f3318','5279W',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03c7b331-fb4b-48c2-8932-08270ec986da','8894D',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('052a31ae-9b7a-49ed-a058-857387214841','5280X',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('47731806-5cd1-4b76-b09a-29eae3212e8d','5265D',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f4a5c265-6fae-4374-9ef8-0ea5f87dc1b4','5437E',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1c125908-31d4-42e5-9d6f-c01e8e020aed','5438F',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d5fe481c-cf54-4aaf-abaf-16aed016d2e5','5439G',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a858a31f-5a39-4c57-9e43-639999553f9b','5440H',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2d48fd0e-93eb-49a2-b237-d93088576268','5441J',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ec9c9461-b781-491c-8f6a-6680059ebce5','5401G',9,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('314de5a4-34c4-4547-9895-4aed901d9ff1','5402H',9,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e81d820d-b344-4c51-9974-d035a9bb3a10','5403J',9,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffc02808-cafb-4ecd-a071-f589baee4121','5404K',9,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('db3ce779-b4ba-4e29-bdde-b96b1ed0992f','5405L',9,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('226e935f-1d44-41ad-a966-20092a939b7d','5406M',9,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('db3ce779-b4ba-4e29-bdde-b96b1ed0992f','5411T',60,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ec9c9461-b781-491c-8f6a-6680059ebce5','5407N',60,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('314de5a4-34c4-4547-9895-4aed901d9ff1','5408P',60,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e81d820d-b344-4c51-9974-d035a9bb3a10','5409Q',60,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffc02808-cafb-4ecd-a071-f589baee4121','5410R',60,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('226e935f-1d44-41ad-a966-20092a939b7d','5412W',60,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bc387ff8-b831-4774-8557-3f2275c97003','8341B',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7459be3e-baaa-4122-8fc7-61ce1bff6db0','8885P',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('308bd9f0-e57b-4829-b8b2-052054a0869c','1849H',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('308bd9f0-e57b-4829-b8b2-052054a0869c','8144P',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7dff25fe-1658-4088-8c55-204920cfebfb','6356M',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a5a56c2-c0ef-432a-8d9c-5f6a8aeb13eb','6372J',7,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d41d81ef-3804-4209-9753-9872c2bb0934','9618F',180,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7dff25fe-1658-4088-8c55-204920cfebfb','5706H',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a5a56c2-c0ef-432a-8d9c-5f6a8aeb13eb','5707J',7,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d41d81ef-3804-4209-9753-9872c2bb0934','5708K',180,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('679903ce-8f4f-4b46-9a87-db0d393f9dab','8350L',1,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad8a8574-d95f-4f5a-8be6-481393b2f4aa','8351M',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7d1f72dc-854d-480c-8fd7-cb016e0bf92f','5563T',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad8a8574-d95f-4f5a-8be6-481393b2f4aa','5534G',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7d1f72dc-854d-480c-8fd7-cb016e0bf92f','5298W',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('974ff5c4-d142-4149-a60c-890fb9dc3891','8726G',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dfb80373-fe61-4209-9a94-676ac7dd43cf','5494E',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8cfca4c7-eab1-4cc2-b5f0-64d61a85a827','5495F',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dfb80373-fe61-4209-9a94-676ac7dd43cf','8355R',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8cfca4c7-eab1-4cc2-b5f0-64d61a85a827','8356T',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('75035414-d837-4ac2-8479-b16cc8b64a74','8357W',180,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('858ed8d4-470c-44b3-bc4a-203ca3b9ca8b','6264Q',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e34005b2-c634-4f56-9b29-61f29a83d6ce','6265R',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('858ed8d4-470c-44b3-bc4a-203ca3b9ca8b','5601T',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e34005b2-c634-4f56-9b29-61f29a83d6ce','5602W',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9e4c7431-3c8a-43eb-8e41-c2ad999f63f9','5436D',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9e4c7431-3c8a-43eb-8e41-c2ad999f63f9','8358X',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9e4c7431-3c8a-43eb-8e41-c2ad999f63f9','9354H',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9e4c7431-3c8a-43eb-8e41-c2ad999f63f9','4179Y',28,3,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9e4c7431-3c8a-43eb-8e41-c2ad999f63f9','9317J',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('64d30046-90bf-4801-9efd-df9f49e7959b','8363E',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('96b77e52-cd51-4103-b541-feefdc1d4e7f','8361C',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5c01cf27-262c-4a74-ba48-5582f1f5cc7d','8362D',120,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0372a991-c5ae-4e9a-b423-2dc1365173b1','4416K',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e53b54aa-edea-4f28-95d8-82ebacd04460','4584G',4,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f58c2170-98de-483b-9f1f-09b89eb88f42','4585H',4,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0cda54fe-e1d4-4247-b0e0-9a290b38d1b4','4586J',4,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('233c474f-18bd-4ccb-b981-d5fa80c40752','9547L',90,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('233c474f-18bd-4ccb-b981-d5fa80c40752','9605M',90,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('caf574b6-4826-43ad-aa1c-45cc1fa702d1','8367J',200,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('63a14477-39dd-488e-9c03-ccdd2fbe7003','8369L',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f27e21ab-19f2-4b7b-959d-33277ec6aa28','8373Q',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03febb3e-9cbc-4525-9cdb-3ad79ecace67','8374R',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3cb30ba-3c44-4994-8d5e-08a477e34419','8375T',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03febb3e-9cbc-4525-9cdb-3ad79ecace67','5449T',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3cb30ba-3c44-4994-8d5e-08a477e34419','5450W',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a73d59e7-79b1-4853-bcdb-ca999ad30edb','8378Y',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('abbb8f94-194e-4849-9f24-c0c774244698','8379B',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a9ec70e-0a40-4a31-b66c-98e0ee18d8da','8380C',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3cd6f173-b8aa-4073-af70-1e32542ba2cb','8381D',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('198e5c76-4d94-4da5-8fb4-312576969913','9362R',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a73d59e7-79b1-4853-bcdb-ca999ad30edb','8819E',15,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffa3859b-c60a-4a5c-bcb8-95e277d0f3c3','8820F',15,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a9ec70e-0a40-4a31-b66c-98e0ee18d8da','8821G',15,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bb2ef659-b270-46d7-abd5-a0b5ddcfc22d','9361Q',15,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('918400a1-d3ed-408d-9679-4ed605440d3e','8370M',30,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7d0ecd3c-adf5-4dc4-801d-16ec6b0e7bd7','8382E',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('26ff2a20-da29-4ec7-b7cb-a9e02304e6ef','5503P',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('942edfa3-ed1d-4526-9bb2-ec3aeb9621ba','5504Q',3,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('26ff2a20-da29-4ec7-b7cb-a9e02304e6ef','8384G',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('942edfa3-ed1d-4526-9bb2-ec3aeb9621ba','8578L',3,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('26ff2a20-da29-4ec7-b7cb-a9e02304e6ef','9210R',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('79fe308b-bc35-4227-a7d6-bd92bdc5741f','8390N',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('99bae59b-6c9e-4e4a-8a1c-6b3feeeacc8c','8874C',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a05db975-9fba-455d-938d-5453bf01683e','8397Y',56,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a05db975-9fba-455d-938d-5453bf01683e','8951D',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('25fe5857-f916-469a-ba7a-ba4aa2f5b442','5491B',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('25fe5857-f916-469a-ba7a-ba4aa2f5b442','8447N',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6cd98295-a0ac-4af7-983f-fac93c425b90','8400D',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4bf216c9-8089-45ad-a8eb-ed5e87e530f8','8401E',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c827a669-48bc-44ec-8be6-02433d1311d6','2136K',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6af8045b-0e3f-4185-9639-420c4036af54','8404H',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a88bb611-6b35-45eb-a190-bd6a72ad34e6','8405J',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6c09d58d-6967-45f1-9f95-7b70aa2cab35','8439E',60,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aa22391c-f387-4aa6-8b36-9ddf69eae47c','8440F',30,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f6e23f95-74e5-41b1-afad-8cfa6260a496','4070F',30,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('26372e83-6336-4208-ae7f-60a1be9f3f49','8435Y',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9f636caa-e666-4ecf-9885-8637c903493c','8571D',5,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad1dae4a-235c-42ac-beeb-e11da88463d7','8420E',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('51d50dc8-869e-49fd-8def-a8c1a9f429cd','8421F',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e219c261-1b91-460b-9a86-8d61055a4861','5115F',20,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f985c808-de39-4270-a467-d292ae62e15e','5116G',20,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93c51e35-8ef3-4110-b02a-690110df63f4','5117H',20,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('efa12f27-f217-4787-9a13-7318ab2b190b','5132D',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d19701fa-4f02-4774-a835-4364044c1407','8423H',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('efa12f27-f217-4787-9a13-7318ab2b190b','8424J',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e219c261-1b91-460b-9a86-8d61055a4861','8541M',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f985c808-de39-4270-a467-d292ae62e15e','8542N',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93c51e35-8ef3-4110-b02a-690110df63f4','8543P',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('69463d9c-1889-4036-9524-45e7c7460c36','8422G',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5de1886a-1bea-4cab-a3b8-d9349cfcb4a9','9407D',14,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4d74ef34-ad80-4de1-a42a-6ca8fa52afab','9408E',14,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('79ddb0e6-9cd0-48b0-8255-15d4a8292f46','9299K',14,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('00aadc42-486c-4f80-940f-2f278c2f1115','9409F',14,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('57fe4c10-ac4c-4f6f-90c0-9cf2095cd3d8','9406C',14,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('86f6532b-6c34-4ad7-b846-95f5236ec654','8430Q',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e1b9820a-7425-400b-b16c-33d61a37d881','8431R',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c5380ff1-40b5-4752-91cc-394bd5c7e8b3','8432T',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d659b472-cc23-4f94-8d94-cb9a51f24201','8517G',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09153a02-f91a-45cb-ab62-dffec2c65cac','8518H',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('389d3069-b8d3-4b12-92ab-9f3b85de1f51','8519J',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bbe37022-e133-4d0f-800c-840944e10b67','8444K',3,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b7809ca-5d87-419f-895f-b848626a5285','8450R',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f29af3b-f532-4f4a-9a7f-62c10f960fe0','8451T',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('431770ae-9213-466c-ae03-528d32e1f577','8452W',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0c18e441-6cfc-452a-afaa-21a7baa4e1d9','8533D',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bf1888db-7c16-4e0b-9e1d-d963cbdff5fd','2190G',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2db72e8c-dcca-492b-992c-21d7383c31cf','2845R',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('420d64f9-149b-44b5-948e-755171c2e25f','8449Q',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b6d3938f-55d4-4b6f-b0e9-78092c6a4564','8448P',200,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7eb0cb66-9ae6-4e32-b69b-786876c675ca','8459F',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b4ef4d5c-85f3-41aa-b6d9-b0418eb66259','8503M',6,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b4ef4d5c-85f3-41aa-b6d9-b0418eb66259','9047E',6,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('82effd5c-2a93-4b54-ad02-34d976c94262','8456C',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aba568a7-7aa0-46de-8648-3f8da56bcc32','8457D',90,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e66a51d3-7dc9-497d-b824-e51d908ba927','8458E',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('511ff53e-6e91-4130-8e60-5aa5a69b32ba','8580N',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0939cb3e-6144-4137-8c49-29b373f7c4a8','9202H',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bcd6d368-2bf1-4a6b-b869-a8db878069f1','9203J',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f6d2bbad-6da4-45ae-aa66-f5a7baec08db','9204K',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('20b05c49-dfc6-47a8-aeeb-474394b9929c','9205L',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('013fcc55-dad5-41ae-b045-2d12f8f540c6','5458G',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('35fe0cf5-63f2-4b53-a493-d30a6e497999','3484J',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('022e5b6d-1c22-4aa0-bd7a-72a38bbd248c','5150C',1,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('35fe0cf5-63f2-4b53-a493-d30a6e497999','5231H',5,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1ff72be4-6086-44e2-8d5b-77baf11f3b3c','5232J',20,0,'DT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1ff72be4-6086-44e2-8d5b-77baf11f3b3c','8455B',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('35fe0cf5-63f2-4b53-a493-d30a6e497999','8582Q',5,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1ff72be4-6086-44e2-8d5b-77baf11f3b3c','8611F',20,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ec2e7131-2a91-405d-91d8-74f4f78b0c3f','2527B',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f3be3de4-1919-4f1a-832a-f8815b76d430','8523N',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19c6b2ad-31a7-4ae7-83f0-987ff6275c7a','8524P',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e70e883d-8100-435e-af4a-4b1921940747','8525Q',20,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('022e5b6d-1c22-4aa0-bd7a-72a38bbd248c','8843K',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f3be3de4-1919-4f1a-832a-f8815b76d430','9199E',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e70e883d-8100-435e-af4a-4b1921940747','9200F',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e12da54-2f0e-4529-8f96-6af919c99b3a','9201G',10,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ceb12e07-3b53-4aa2-a552-4c710a103d19','1291Y',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('06f1bfab-b25a-4e44-b6a1-526c54f07101','2509C',5,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('06f1bfab-b25a-4e44-b6a1-526c54f07101','3472R',5,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('19b762c2-4dd0-44b9-bbeb-3dc48dd52e52','4936T',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3cb44169-5357-42cc-91ad-c31bd915a766','4931M',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e9c51994-a2a0-4331-96e1-91da48bb9727','4932N',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b3617db7-c670-4d9d-9139-9bdf9e79e5ef','4933P',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dba58a2f-99e9-42b4-afaa-5890237c7209','4935R',1,2,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('047c551e-9fb2-49ea-b3a7-57d25e2c187e','4937W',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6532d2a7-ca14-4609-880a-305b584fcb87','8477E',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5bac853e-be29-49f9-8440-05c888c1e492','8465M',30,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5bac853e-be29-49f9-8440-05c888c1e492','8710K',90,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('69c58913-18ad-406c-8d92-b6340413b527','8482K',28,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('12a99355-1c8b-458d-bc4c-690ca0e73d1f','4444X',4,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2f93132-372a-46a6-852d-d4abcf7dc8fd','4443W',28,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2f93132-372a-46a6-852d-d4abcf7dc8fd','8481J',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('12a99355-1c8b-458d-bc4c-690ca0e73d1f','8621R',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3514a1da-2e07-4a36-9ec2-c329e885e420','9391G',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('12a99355-1c8b-458d-bc4c-690ca0e73d1f','8972F',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5de79c5e-56b5-4ba0-88ac-0ed1c7e46177','8487Q',1,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3a42ca13-5b51-4530-9bd3-e23d0c5a8022','8479G',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f1f769cd-a941-43fe-a4cb-58c9e2480b5d','5540N',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f1f769cd-a941-43fe-a4cb-58c9e2480b5d','8483L',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('772370a4-1910-4d73-9a89-4bb86f0bce40','8497F',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('16a8e774-abf8-40d6-9a84-3b2fed054556','8498G',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1d0165b7-624b-463a-b4a7-7d43d85ecc0e','8499H',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('12bddde5-26fd-421e-a86e-62fe69cee600','8500J',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2c383817-995f-495d-9282-b4561b630e24','8563Q',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1f532f9f-573a-4828-a0bd-dc5e27532cb2','8495D',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed5d33e5-bebb-4677-bd7f-25774c3de0e1','8496E',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('20302811-f187-407a-9f2e-1c8fb0fbab80','1152P',1,0,'MF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1aeab362-d738-4956-8d2a-d840703e97c3','6293F',1,0,'MF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('914b6d06-f5f7-4130-9e25-a8a3779d3b45','8504N',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c99052e5-3b6e-4e36-9fa9-0edd09190c3e','9314F',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('43ac936d-32d5-46e0-b4cf-135067a2e69a','9315G',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bd90726e-ea24-492c-98f5-288886487e72','8506Q',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4473b569-1003-405a-9c41-ca0e78176a10','5502N',3,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4473b569-1003-405a-9c41-ca0e78176a10','8514D',3,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31803978-dcb6-4b75-a806-8a57d2007545','8513C',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('528f1155-7943-4d22-b338-20edead0dbf8','8855C',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d73fdc99-5d1b-4375-835c-ef0090752c0c','8856D',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6b0a4752-4b77-48e6-8471-84646af48612','8857E',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6bd7fc98-a9ca-4dfe-9b3e-565d42eb7a46','8883M',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e4d2ea19-f48b-4ea8-81e9-cfc58962f89f','9365X',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f1b883a9-3651-4365-a3cd-b58990371445','8507R',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b353a563-d435-4b3c-94cf-b9a45714b5ac','8508T',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b353a563-d435-4b3c-94cf-b9a45714b5ac','8509W',30,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1b9de5e8-7893-4935-bf3e-7c04a52616bb','8526R',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('792075a9-8083-4da1-9831-447b695bc578','8527T',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('957194b1-3661-4248-86d9-4176d12a8fc6','5637Q',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6746108d-341a-4fdc-81da-322f238d9f3d','5638R',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c2ba0b30-4177-4ed3-9a0c-a5b0b6d0a530','5639T',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e3c4843-a7ed-4842-aad3-0f94dbe45fe1','5640W',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bca29277-e204-4feb-be59-7ff4aa497fa1','5641X',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('08cffff0-92c5-4666-82af-dc1a6c1b0774','5642Y',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6e8caf65-2963-4dc2-9549-8fac147a667a','5643B',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('18e5daa7-6fc3-4a5b-af44-a3d2c893b3c9','5644C',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eb86b68b-5dd2-463f-b3d5-08ed12a77381','5645D',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b3798943-f520-4260-9416-e6f0db2ef270','5646E',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('16e6cc2f-92c9-4602-a094-1ded355651ef','5647F',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8893d2b8-8074-4eb2-8abc-84cda921a157','5648G',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a32da1aa-116e-43f9-8639-97169b1a145a','5649H',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2da4bafb-2623-406c-83ef-5021002b9c3f','5650J',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('935f30e5-5c15-419d-a536-33e4e43be860','5651K',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('957194b1-3661-4248-86d9-4176d12a8fc6','6320P',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6746108d-341a-4fdc-81da-322f238d9f3d','6321Q',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c2ba0b30-4177-4ed3-9a0c-a5b0b6d0a530','6322R',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5e3c4843-a7ed-4842-aad3-0f94dbe45fe1','6323T',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bca29277-e204-4feb-be59-7ff4aa497fa1','6324W',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('08cffff0-92c5-4666-82af-dc1a6c1b0774','6325X',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('935f30e5-5c15-419d-a536-33e4e43be860','6326Y',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6e8caf65-2963-4dc2-9549-8fac147a667a','6365B',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('18e5daa7-6fc3-4a5b-af44-a3d2c893b3c9','6438W',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eb86b68b-5dd2-463f-b3d5-08ed12a77381','6488L',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b3798943-f520-4260-9416-e6f0db2ef270','6489M',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('16e6cc2f-92c9-4602-a094-1ded355651ef','6490N',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8893d2b8-8074-4eb2-8abc-84cda921a157','6491P',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a32da1aa-116e-43f9-8639-97169b1a145a','6492Q',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2da4bafb-2623-406c-83ef-5021002b9c3f','6493R',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('be647e90-c890-493f-bd2d-59de07a76fda','8534E',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('69527a68-f21c-4a3a-aed0-66593595c435','8679T',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('baf2013d-e938-4186-a4c3-1f3bf5368efe','8770N',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('63919a8a-2405-48ca-a798-db6c07adf8f7','8771P',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6778a0e3-4d43-427e-9047-10e50432b5f6','8772Q',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b07d6d66-5a2b-4414-a376-2fc396a1737b','6327B',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b07d6d66-5a2b-4414-a376-2fc396a1737b','5604Y',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6097cf7a-fbb0-445e-9e13-fa09b20474e4','9115R',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffb06baa-1197-44d4-9ce1-e68ee533ffde','9116T',30,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6097cf7a-fbb0-445e-9e13-fa09b20474e4','9123E',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffb06baa-1197-44d4-9ce1-e68ee533ffde','9124F',30,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6097cf7a-fbb0-445e-9e13-fa09b20474e4','9172R',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffb06baa-1197-44d4-9ce1-e68ee533ffde','9173T',30,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6097cf7a-fbb0-445e-9e13-fa09b20474e4','9174W',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffb06baa-1197-44d4-9ce1-e68ee533ffde','9175X',30,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6097cf7a-fbb0-445e-9e13-fa09b20474e4','9176Y',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffb06baa-1197-44d4-9ce1-e68ee533ffde','9177B',30,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6097cf7a-fbb0-445e-9e13-fa09b20474e4','9178C',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffb06baa-1197-44d4-9ce1-e68ee533ffde','9179D',30,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6097cf7a-fbb0-445e-9e13-fa09b20474e4','5443L',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffb06baa-1197-44d4-9ce1-e68ee533ffde','5444M',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6097cf7a-fbb0-445e-9e13-fa09b20474e4','9111M',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffb06baa-1197-44d4-9ce1-e68ee533ffde','9112N',30,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6097cf7a-fbb0-445e-9e13-fa09b20474e4','9113P',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ffb06baa-1197-44d4-9ce1-e68ee533ffde','9114Q',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2aca24f6-2fb7-4aad-80a8-1213151b284e','5776B',2,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('192df19c-f309-4331-80a8-005f3e0a7886','5777C',2,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0458b60a-619f-432f-a8ab-7c0b0b052ac6','5778D',2,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b23f37d6-fd17-4c7d-ba32-edde696416b3','5779E',2,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2aca24f6-2fb7-4aad-80a8-1213151b284e','6332G',2,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('192df19c-f309-4331-80a8-005f3e0a7886','6423C',2,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0458b60a-619f-432f-a8ab-7c0b0b052ac6','6424D',2,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b23f37d6-fd17-4c7d-ba32-edde696416b3','6425E',2,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('83f29604-7948-475d-9468-22576f855b72','8561N',30,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b66363a-6137-4fe7-8616-ec1d61389ae7','8887R',30,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('61ab70d9-01e9-472d-a85e-bfb350ca352a','8562P',30,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('39a9616c-f934-486c-a304-0a0d0cee6678','8888T',30,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4f70a73f-f354-4f25-8e1f-d251a047e05e','5519L',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4f70a73f-f354-4f25-8e1f-d251a047e05e','8564R',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4f70a73f-f354-4f25-8e1f-d251a047e05e','9215B',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce73c2f9-7b64-4f8f-a521-2ee4a4e35f1f','5542Q',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce73c2f9-7b64-4f8f-a521-2ee4a4e35f1f','8567X',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('004b261e-d99b-45d9-a22a-ef2f98911731','5790R',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3e2b5f6f-e5c3-47bb-94da-89f14558c5fe','5791T',240,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('004b261e-d99b-45d9-a22a-ef2f98911731','9633B',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3e2b5f6f-e5c3-47bb-94da-89f14558c5fe','6495W',240,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c4883de9-2352-4ebd-a688-f5ef17716dc5','6341R',10,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c4883de9-2352-4ebd-a688-f5ef17716dc5','5789Q',10,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e0c59f82-4e8e-4dc3-acb8-e6e7bee01a93','8577K',120,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae806e1e-0622-4ae6-9bb3-2c1d5ead310d','8584T',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8b2422a3-d584-4ed8-8dc2-3440a695511c','8585W',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a4feec0f-8ce7-47e9-acf9-f0118574a0ad','8586X',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3d96b37a-13c7-4bfb-a685-cea2963cd1e6','8588B',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('46b15758-6553-4731-ba15-d72f8363c832','8583R',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fec9797d-0fc5-460e-b17d-d37ee3701b65','9350D',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f8c1bd5e-6585-467e-81e1-5eec3c33f425','6371H',1,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f8c1bd5e-6585-467e-81e1-5eec3c33f425','9653C',1,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fec9797d-0fc5-460e-b17d-d37ee3701b65','9288W',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7367ee60-571e-4ffe-aaf1-fd3cdf79b0d2','8587Y',16,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fd839390-baff-4cad-92a0-85726d65f1ee','8589C',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('df4ce83d-12ff-4a7a-a169-274f96560afe','8590D',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a9a2392b-a715-447f-8c6c-a957667a87d5','8594H',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a816ce10-dc86-4e56-b756-d88726d87f98','8595J',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba22f3cb-8c93-4514-b67e-6987c8733781','8596K',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('08560428-95e7-4272-9122-f11e58aa04c2','8736T',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('59886fd6-6924-4efb-af27-c72bee8fdb1b','8600P',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b641da47-d8a0-48c5-87f8-b19867f2938f','8601Q',30,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('59886fd6-6924-4efb-af27-c72bee8fdb1b','8886Q',30,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b641da47-d8a0-48c5-87f8-b19867f2938f','3401B',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0475ed77-5e44-4afb-b8be-a9f2ca33da09','8604W',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('36d5a030-9cc7-4494-afea-cc010151c6a2','8605X',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6c16e342-09cf-48d7-86e6-853a8f68404d','8606Y',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b42bce8-04a9-4631-aae7-abe84081ebbc','5554H',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b42bce8-04a9-4631-aae7-abe84081ebbc','8597L',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4c6f2d0a-9600-41e2-9d46-f1482b12875b','8609D',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a60fe7e9-f51e-4ce2-8447-e11eaa7eee69','5553G',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a60fe7e9-f51e-4ce2-8447-e11eaa7eee69','8895E',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e495c336-dd7c-4219-bf63-39ce2d62857b','3278M',2,0,'PQ','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('980425a9-f8e3-4ed1-b564-42812a1cce90','3416T',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e495c336-dd7c-4219-bf63-39ce2d62857b','8612G',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e495c336-dd7c-4219-bf63-39ce2d62857b','5389P',2,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('980425a9-f8e3-4ed1-b564-42812a1cce90','5426N',2,3,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e495c336-dd7c-4219-bf63-39ce2d62857b','5390Q',2,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('980425a9-f8e3-4ed1-b564-42812a1cce90','5427P',2,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('da8a1345-e578-498f-bcaf-0c9685b8ce76','6358P',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('da8a1345-e578-498f-bcaf-0c9685b8ce76','9563H',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('41bad26d-0d4a-40ca-b13c-06a769a5b06a','6357N',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('41bad26d-0d4a-40ca-b13c-06a769a5b06a','9569P',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c139a738-94df-4b0a-a9a1-66362450a613','9655E',11,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c139a738-94df-4b0a-a9a1-66362450a613','9675F',11,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cf7e860e-c75e-40ee-847e-8eb33a565c30','8624X',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6ed27339-eb81-4cb7-b530-3bb7def58e39','8622T',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bd508c84-a28e-4cc2-a9cb-b49dcadf384b','8623W',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ccb855f9-ab0a-40fe-8cff-248c2af05e4c','9381R',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b8ee9b52-4fde-4daf-91cf-e50ea8f9ab6a','8626B',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d053a262-c176-48d3-98b4-93d07386a860','8625Y',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0ab5d38f-5193-4cbf-9eba-35d901de9fe8','8796Y',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('40007261-df74-440d-8ab0-9a95d4821b71','8750M',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('80d94407-a854-4876-8734-42174c9ce11f','8627C',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0bea90af-9961-427c-a4a5-ff80461ddafe','8628D',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24eee888-edf0-46f4-a157-5995d0c7820e','6363X',1,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24eee888-edf0-46f4-a157-5995d0c7820e','9514R',1,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5a0460dc-5ab8-4b00-9d3a-30892be48402','5551E',1,5,'OT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5a0460dc-5ab8-4b00-9d3a-30892be48402','8620Q',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9ad531d8-fe9a-448b-8d45-13d3f7381296','8630F',24,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('be3fd50f-f36d-4381-9b53-a342ab20cede','6366C',15,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5517fc46-70bb-48a2-a0ee-9bea6177c87e','9608Q',15,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f2932a46-2a6e-4da3-a972-bdbdc541bebb','9609R',15,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','4284L',1,2,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','5753T',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','6448J',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','5754W',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','9613Y',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','5755X',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','9612X',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','5756Y',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','6496X',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','5758C',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','9617E',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','9654D',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','9674E',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','5757B',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8157d9ce-d631-44cf-89e2-67ee4984db4a','6397Q',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('79c28331-6fa9-4122-bda6-ab3c4f9c9e11','8654L',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('63128de8-3b6d-461c-9348-24326ee5ffdc','8655M',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3ad339db-11af-4b8a-9823-35e363d652b0','8656N',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('658bc9ea-c68e-4f75-94ba-dea0a7c04145','9169N',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d194ede-dc9d-4d2e-aa4d-525baa0cd3da','8664B',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('23ffe4bb-6a1b-48a8-aaf7-f272958a9019','6369F',240,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('376e8310-a77b-4403-ba36-358214a32a52','6370G',240,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('23ffe4bb-6a1b-48a8-aaf7-f272958a9019','8652J',120,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('376e8310-a77b-4403-ba36-358214a32a52','8653K',120,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('23ffe4bb-6a1b-48a8-aaf7-f272958a9019','9503E',240,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('376e8310-a77b-4403-ba36-358214a32a52','9504F',240,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','3445H',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','3446J',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','3447K',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','3448L',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','3449M',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','3450N',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','8637N',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9089J',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9459W',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','8638P',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9090K',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9460X',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','8778B',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9085E',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9455P',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','8779C',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9086F',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9456Q',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','9035M',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9087G',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9457R',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','9036N',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9088H',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9458T',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','9037P',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9091L',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9461Y',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','9429G',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9431J',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9462B',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','6367D',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','5734T',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','5733R',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','5735W',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9615C',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','9641K',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a2a36bfa-e041-402d-bf71-732463feb63a','1954W',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','1963H',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed23fb8e-551a-4e23-9a6f-c6873b9ff13a','1964J',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c6c434ed-9ae2-49f6-be4f-cd4e10d56043','5524R',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03ca7275-4784-4344-ab0e-d4ac960dbba6','5532E',2,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c6c434ed-9ae2-49f6-be4f-cd4e10d56043','8676P',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('03ca7275-4784-4344-ab0e-d4ac960dbba6','9170P',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c6c434ed-9ae2-49f6-be4f-cd4e10d56043','9219F',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c3d84ad5-be90-419c-b5b6-1900a0fc4d1b','8775W',7,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','6407F',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','6409H',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','6410J',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','9536X',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','9538B',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','9539C',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','9540D',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','9634C',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','6402Y',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','9531P',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','6400W',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','6401X',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','6405D',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','9529M',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','9530N',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3c9ef7c-c8fd-4dd0-b0d5-441689b945f7','9534T',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42f58e69-50eb-406e-9083-ce46c32ee43f','9526J',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42f58e69-50eb-406e-9083-ce46c32ee43f','6395N',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42f58e69-50eb-406e-9083-ce46c32ee43f','9524G',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42f58e69-50eb-406e-9083-ce46c32ee43f','6392K',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42f58e69-50eb-406e-9083-ce46c32ee43f','9525H',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42f58e69-50eb-406e-9083-ce46c32ee43f','6394M',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42f58e69-50eb-406e-9083-ce46c32ee43f','9527K',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42f58e69-50eb-406e-9083-ce46c32ee43f','6396P',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('97355879-2e1b-4510-ad98-f88496b5de68','8694N',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef7f82b3-a541-4759-8fe9-bcc78799615a','8695P',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3199dc57-bdb3-439e-a822-3d03de20c777','8696Q',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3dc057ca-6357-4c44-91a5-d7efebb83807','8689H',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4545df30-7f6a-403d-a53f-ef15889d863d','8690J',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ced1a4b7-22bc-4ed0-89ba-ef6181636c85','8683B',2,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('adfed5c5-916b-4cdc-9685-7890cfd0fc57','8684C',3,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('80cdbc96-e3a7-427a-838f-2a4057e11b85','5657R',600,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cfd27be5-ed62-4b0f-b1ca-e14a3bec7e1f','5658T',5,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('80cdbc96-e3a7-427a-838f-2a4057e11b85','6416Q',600,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cfd27be5-ed62-4b0f-b1ca-e14a3bec7e1f','9638G',5,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ee533876-d22d-4ae5-af0f-48113798ad26','8700X',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d1bec1c2-8dd6-4dc5-add4-7b6a7032ee61','8701Y',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ee533876-d22d-4ae5-af0f-48113798ad26','9432K',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d1bec1c2-8dd6-4dc5-add4-7b6a7032ee61','9433L',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f61306b2-9606-4d57-a335-c293f9552b13','8849R',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6ee5681e-d2ad-4073-bb2a-c0c85efda397','4596X',4,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('baca06f3-ea80-44ac-b6e5-c2d5097d5e0d','4597Y',4,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('baca06f3-ea80-44ac-b6e5-c2d5097d5e0d','1308W',56,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('baca06f3-ea80-44ac-b6e5-c2d5097d5e0d','1304P',56,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae4c7f4a-53bf-4829-9b14-89771369299b','6429J',60,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0c5fd53e-753f-42eb-9c3b-57774b61eb17','6430K',60,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae4c7f4a-53bf-4829-9b14-89771369299b','5618Q',60,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0c5fd53e-753f-42eb-9c3b-57774b61eb17','5619R',60,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('76cec7c0-7dd6-4190-9fb6-b63e73d47a91','6436R',200,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('229b7474-97a9-4c0d-91be-8965abee15ec','6437T',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc9e1683-495e-485e-b7b0-ebcf50233e88','6457W',200,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('76cec7c0-7dd6-4190-9fb6-b63e73d47a91','8724E',100,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('229b7474-97a9-4c0d-91be-8965abee15ec','8725F',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc9e1683-495e-485e-b7b0-ebcf50233e88','8833X',100,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc9e1683-495e-485e-b7b0-ebcf50233e88','9548M',200,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('76cec7c0-7dd6-4190-9fb6-b63e73d47a91','9549N',200,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('229b7474-97a9-4c0d-91be-8965abee15ec','9550P',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c3e5a824-6a17-4cfb-baad-b5a779a43fe6','8984W',100,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c3e5a824-6a17-4cfb-baad-b5a779a43fe6','9747B',200,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c3e5a824-6a17-4cfb-baad-b5a779a43fe6','9748C',200,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e6fe613d-dd0a-4e7e-a42d-1ca4cf0c913a','9022W',60,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('737d625e-c4cc-4d19-b022-a0b2b355eaff','9023X',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e6fe613d-dd0a-4e7e-a42d-1ca4cf0c913a','9246P',60,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('737d625e-c4cc-4d19-b022-a0b2b355eaff','9247Q',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e4e00e8b-5608-4852-9032-79914b812b23','8717T',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('10cc3694-d819-4666-9fc6-8d846c721ea4','8718W',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8b511feb-5ba8-472f-b09e-508fefa15bb5','8719X',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bc4fa426-3ead-4d06-bbf7-dabfb005445c','8720Y',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85bf9ecc-9eeb-417c-9566-899bc9e75681','8732N',15,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('edd170c8-5210-455b-aebd-386c852df003','8733P',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('189f65ea-2efa-42d2-9775-267ad27a0b9d','8734Q',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c5e608cb-48c0-4f06-966b-2b748afe4f12','8735R',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('120b8da7-3786-4c30-a25d-a1d009f16683','5898K',2,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('120b8da7-3786-4c30-a25d-a1d009f16683','8873B',5,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('120b8da7-3786-4c30-a25d-a1d009f16683','8728J',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e5e97a17-bec5-4f8d-b588-de479e6a3b7d','8729K',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e5e97a17-bec5-4f8d-b588-de479e6a3b7d','8730L',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e5e97a17-bec5-4f8d-b588-de479e6a3b7d','5899L',1,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8bce29e1-20df-47c0-a1b6-9872181546a3','8962Q',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','5281Y',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','5282B',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','5283C',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','5284D',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','8737W',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9099X',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','8741C',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9100Y',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('123cdfcf-73cb-4322-af0f-d041440cac9d','8961P',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','8963R',2,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','8965W',2,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','8964T',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','8966X',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','9033K',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9101B',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','9034L',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9102C',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','9077R',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9103D',2,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','9078T',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9104E',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('123cdfcf-73cb-4322-af0f-d041440cac9d','9186L',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8bce29e1-20df-47c0-a1b6-9872181546a3','9187M',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','9188N',2,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9190Q',2,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','9189P',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9191R',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','9425C',2,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9426D',2,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','9427E',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9428F',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fbb9c37b-aa94-4c53-b3cb-e0321c04fa21','9661L',2,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fbb9c37b-aa94-4c53-b3cb-e0321c04fa21','9678J',2,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','9662M',2,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4a613b7c-65ab-45a3-b4c1-65fac62aa7ad','9679K',2,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9663N',2,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('71f0ec7e-1fb9-4c25-b30c-f3fc470ea728','9680L',2,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b3bb3e0-7dfe-4cb4-b294-129623e4ffa1','8738X',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a01ba7bb-0340-49be-8ca7-62a15c2d2c2d','8757X',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('51ab7033-67a9-481d-861b-100db3cbadc2','4106D',1,0,'R1','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff8f03b7-2796-4911-b06c-82f310274601','4570M',84,2,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2efae017-1e0a-4c04-8e07-3a0dbac76a67','6439X',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d41a1b6c-6048-471d-9d0c-2bbd08ffc483','6449K',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2efae017-1e0a-4c04-8e07-3a0dbac76a67','9515T',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d41a1b6c-6048-471d-9d0c-2bbd08ffc483','9516W',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8aa3eccf-b369-40be-9df3-1c9efb684ba2','6450L',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8aa3eccf-b369-40be-9df3-1c9efb684ba2','5606C',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d5e42a93-da66-4cd3-a89e-3ee46eb72434','8769M',30,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('45ef1698-a9e0-4f60-8a60-4262f1a32cf5','9646Q',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0315c31f-ec27-4593-ab6c-1ab1ae930040','6451M',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85d8d3be-d5ea-4021-a600-e2ccca426090','6452N',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dbd682e1-d3fa-4768-a255-a4dd0bdf4658','9614B',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('45ef1698-a9e0-4f60-8a60-4262f1a32cf5','5615M',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0315c31f-ec27-4593-ab6c-1ab1ae930040','5613K',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('85d8d3be-d5ea-4021-a600-e2ccca426090','5614L',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dbd682e1-d3fa-4768-a255-a4dd0bdf4658','5612J',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('448cc84e-eaa7-4bf9-bde4-5ed0558a5361','6453P',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce5a1bf7-f96c-405b-9c28-4bf6f2d0b676','6454Q',8,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('448cc84e-eaa7-4bf9-bde4-5ed0558a5361','5746K',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce5a1bf7-f96c-405b-9c28-4bf6f2d0b676','5745J',8,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8a993296-9315-4adc-863c-f9411685ffa1','6455R',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8a993296-9315-4adc-863c-f9411685ffa1','5710M',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9d39de90-2f06-4efb-86be-8ed00f340e55','2995P',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c586864e-2635-48a8-82ef-71a2731d86f1','2997R',15,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f71e9c4-5211-475e-acb2-672d03932695','8797B',200,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2d3c027f-0fac-410f-ade6-6f5217d40464','8798C',200,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e505e182-2fe3-4eb0-997f-38c1fe6ec3fd','8799D',200,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3c3448e4-6712-44b5-96fb-99a480572fb8','9292C',200,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e70de98-bc4a-476e-8656-d18c517f24d8','9344T',200,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0b33ff59-9e3c-4c98-918c-0d4859218b07','9345W',200,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d257599a-a853-424e-a1fb-aa4ec0837c93','8802G',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5ec562b2-e2a3-46af-af2b-10b4ccfc2b00','1272Y',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09266b51-eef1-4d47-bb62-4cbf0fdb17d0','8801F',100,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('639049f8-4460-482b-82b6-fc2f93fffa17','6137B',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('639049f8-4460-482b-82b6-fc2f93fffa17','5709L',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('43e59f04-b02d-481e-a7e1-c021ff7d406f','8807M',5,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('14564be9-8a6a-430e-88b7-d457ad620c1b','8808N',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('14564be9-8a6a-430e-88b7-d457ad620c1b','5888X',1,5,'CT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1b5e1812-9173-4b20-9bd7-1533d134a5d4','8810Q',90,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2604e5be-ef77-497a-925d-ff0dc2ef9f27','8811R',90,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e946ae71-21b9-4e1f-9b73-574b33e61a8e','8838E',90,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a3c2c979-3b9e-4a8f-94a0-5ab02dcec78b','5751Q',30,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a3c2c979-3b9e-4a8f-94a0-5ab02dcec78b','6456T',30,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fb5ff16a-83b2-4ea3-9c3b-883c6595fef2','8815Y',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cd8e2c98-7d7d-46c1-933c-5b9d3bd73ffc','8816B',120,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eacacaf2-799c-4244-ba26-2ac8e640a176','5737Y',240,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fced6066-1885-49ba-99c0-354c46c843a5','5738B',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('415156af-04d2-4822-aa76-cd0e6f8bac0d','5739C',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('53b67c69-82e1-4eb1-b210-735550c73897','5740D',240,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fced6066-1885-49ba-99c0-354c46c843a5','6459Y',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('415156af-04d2-4822-aa76-cd0e6f8bac0d','6460B',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('53b67c69-82e1-4eb1-b210-735550c73897','6461C',240,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fced6066-1885-49ba-99c0-354c46c843a5','8840G',60,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('415156af-04d2-4822-aa76-cd0e6f8bac0d','8841H',60,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('53b67c69-82e1-4eb1-b210-735550c73897','8842J',120,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eacacaf2-799c-4244-ba26-2ac8e640a176','9352F',120,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('eacacaf2-799c-4244-ba26-2ac8e640a176','9582H',240,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a1e58ea-851a-4405-bc8d-c3dafdaf224e','5535H',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a1e58ea-851a-4405-bc8d-c3dafdaf224e','8826M',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1ba14429-1816-4c25-aac5-add103ffeb7c','2172H',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('73cdc3af-32bd-49c9-8072-843a51ee17d8','2276T',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a845223d-7925-45b4-87b9-c0e217a5c344','2280B',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8732932b-6d5c-4ecb-ade7-ebb707b4965e','2283E',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6117d15c-847c-4c10-a14a-14f75c54e710','2387P',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b9b3ab05-942b-48ef-8a23-d0ce1fb2b4ee','2388Q',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9f374ad4-b21d-4d05-b770-524a1e9214e5','2432B',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9fa424a3-7687-454f-bd08-472e9a433557','3440C',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42d14dff-46cf-446a-8c1d-a6350814c28f','8839F',100,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('83c7284b-2753-4fad-8d19-861394986447','8822H',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c66c5c25-90ce-4710-a3ba-e5827be5fa8d','8860H',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('757c419a-b6bc-4fca-9ac9-5b1bae48c455','8844L',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d97408b4-e63d-4913-b4a0-f830308ec623','8845M',180,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('279e778c-8b66-4925-a50d-16c99a21c6ea','8853Y',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ac0dbdcf-503e-4703-93b8-b4620fa9ff38','8854B',1,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('92caee14-aca2-4bab-9a41-20c2135d059e','4949L',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('92caee14-aca2-4bab-9a41-20c2135d059e','4948K',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('92caee14-aca2-4bab-9a41-20c2135d059e','4950M',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e8da424-338f-43c2-a021-9c4b96167be4','6458X',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e8da424-338f-43c2-a021-9c4b96167be4','5603X',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4dd5c6b5-00a0-4b38-93ab-99cd63b1610d','8864M',1,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('079868f0-66a1-44db-9f3b-b1a8ff2dc8e1','6307Y',7,0,'MD','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('61af37ac-15fd-4c79-b382-990a5ad22fe3','6308B',7,0,'MD','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('daecdd4a-a058-4ad0-8435-3a511ad801e2','6309C',7,0,'MD','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0588c0b4-f098-48fc-b6b1-0548a5f5b1a2','8865N',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('091d70e5-471e-4760-aacf-5202b5675c5e','8866P',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ccac0ed4-8f38-4094-850f-f0a214151b3a','8867Q',2,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7cd4dfcb-3fb7-48dd-9c2e-c7734d82f531','6468K',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7cd4dfcb-3fb7-48dd-9c2e-c7734d82f531','9564J',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('28c676ab-f080-44fc-a2fd-68dcf5e21f5e','6469L',112,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('28c676ab-f080-44fc-a2fd-68dcf5e21f5e','9566L',112,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9c091e9f-641d-4de3-b00c-0f2ac6bf6e3b','9667T',56,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9c091e9f-641d-4de3-b00c-0f2ac6bf6e3b','9684Q',56,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4c273d32-40b8-4b70-b81d-74473138bb84','8879H',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('597f31a6-3a63-4528-8712-fb57e6bcb1e6','8880J',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('62295d7e-624e-43e2-b7ba-a324d09ed5a9','9483D',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1bb336a8-ac71-4b1e-b893-3278899d2637','9484E',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('32516b8f-d7df-4615-b814-0e39b2d63069','8881K',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('69f86c87-5251-4d2d-9087-d667ddf7f23c','8882L',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('acd50ed6-1f26-472b-b368-c801bc996491','2546B',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('acd50ed6-1f26-472b-b368-c801bc996491','4134N',1,1,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('acd50ed6-1f26-472b-b368-c801bc996491','4559Y',1,1,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e49a62ea-1b66-413a-a9aa-563392f1f07f','8898H',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b98d6d27-2971-4cc1-9e89-68734e01f960','8973G',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b98d6d27-2971-4cc1-9e89-68734e01f960','8899J',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f3dc9288-a220-4b84-bbdc-87f4392450f3','6470M',28,0,'MD','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('53712809-ebec-41a5-b2e2-34fa8700de7c','6471N',28,0,'MD','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae5ec29b-be8c-47df-a0ca-d0a82e55c7a2','9749D',28,0,'MD','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5987d0d3-a367-4711-83e9-f0295f121185','9750E',28,0,'MD','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('972e76a7-28dd-49dc-8a5b-722fb353cf23','5724G',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba7d13e6-971d-4b2a-b682-8f0245199238','5725H',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e461b1c5-19ec-46c4-962c-895f27a61314','5726J',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a3896921-624f-406e-9ec9-0749501349a8','5727K',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93b98d83-8546-4be3-9d9f-9494b4ac7d87','5728L',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e52bf7f7-c71b-4d17-b455-7fe8b68b936c','5729M',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9306b8bf-075c-46ce-b370-00c235e6e577','5730N',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('972e76a7-28dd-49dc-8a5b-722fb353cf23','6480C',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba7d13e6-971d-4b2a-b682-8f0245199238','6481D',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e461b1c5-19ec-46c4-962c-895f27a61314','6482E',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a3896921-624f-406e-9ec9-0749501349a8','6483F',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93b98d83-8546-4be3-9d9f-9494b4ac7d87','6484G',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e52bf7f7-c71b-4d17-b455-7fe8b68b936c','6485H',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9306b8bf-075c-46ce-b370-00c235e6e577','6486J',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b78f3cc-19ec-4dd5-a6e4-c6a4416297d9','9011G',60,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a4839829-a8f5-462c-a0b2-5099915ab5ba','5036C',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('59eb205b-a730-4c4a-9f03-a744ca01a1cc','5042J',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a4839829-a8f5-462c-a0b2-5099915ab5ba','5030R',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('59eb205b-a730-4c4a-9f03-a744ca01a1cc','5035B',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('be2d0a33-ecb1-45cf-9eae-c54fc69c40fd','9012H',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ff9a1aea-371d-4fbd-b038-5252cfc66f4d','9183H',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('120e975f-3ef9-434c-87ef-c27b46405828','9019Q',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('801779fc-a58c-495d-97e7-21066835c8e6','9020R',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8cbed4e5-fdcc-408a-ad4f-045135211ef5','9040T',5,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0e274d9b-04a7-48b6-be05-460a6ca22078','3051N',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('430b511f-2dfb-41bb-91e7-b473ff12d876','9008D',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2e04184d-c591-4b7c-acf9-6e6a249fb90d','9006B',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('24769385-ea0f-4383-b6d0-110f88823e19','9007C',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bdede778-f672-4a26-8268-c25cfb066642','3050M',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fe26961c-a71b-4c6c-b3e4-6f21c1a6b6fd','8704D',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f0ea5e70-44d1-4816-88e3-ec658c5a25f1','9039R',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5f804ae8-58a0-4dd8-93ca-ea4168a23103','5654N',168,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3fb2ced-6b60-4000-926b-4dd025b5ea1c','5655P',168,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('45bf45a2-d641-4647-a0ff-7d0e129fd56c','5656Q',168,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5f804ae8-58a0-4dd8-93ca-ea4168a23103','6499C',168,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e3fb2ced-6b60-4000-926b-4dd025b5ea1c','6500D',168,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('45bf45a2-d641-4647-a0ff-7d0e129fd56c','9600G',168,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c39f965d-a640-4eda-aab2-8d1ae88a67c0','3402C',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b75060f7-eaff-44e2-ac69-829701f8c68f','3403D',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8423ffb3-0bb0-4d41-9fc8-24771af31b52','3404E',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8fffb612-d971-418d-8e64-4af082b2aa8e','3405F',30,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c39f965d-a640-4eda-aab2-8d1ae88a67c0','9042X',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b75060f7-eaff-44e2-ac69-829701f8c68f','9043Y',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8423ffb3-0bb0-4d41-9fc8-24771af31b52','9044B',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8fffb612-d971-418d-8e64-4af082b2aa8e','9045C',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1487efb0-90e8-435a-868a-847434123d5c','5555J',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1487efb0-90e8-435a-868a-847434123d5c','9057Q',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('57b5d335-8b32-4ebd-bbde-fcf831b17c6c','9049G',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5483e965-a0e0-4ef0-bcc8-827ab83c7c17','9050H',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d6f1658-9ce8-467d-bb57-3fe84e487cdf','9051J',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('abb35a69-8da7-48fc-9ba0-2721e3376e49','9052K',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7cd1a4bc-f462-43d7-aacd-6d063e20fa12','9053L',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dc3ba74e-1e03-41d8-a672-25225afab58a','9054M',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('efb0b3a0-6ec7-4b21-aa11-d2fc27efc394','9055N',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3858389f-3f0e-43b9-9581-674e25cf9d7e','9056P',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('502f56ea-5c28-4bba-a9be-23cd8fffe650','9602J',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('502f56ea-5c28-4bba-a9be-23cd8fffe650','5711N',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('836e724a-7b46-4a58-ad13-8eba82af6502','9603K',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('836e724a-7b46-4a58-ad13-8eba82af6502','5712P',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('639e16fb-acf0-43a6-9705-fe8cf62497e3','9059T',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8a1bc689-3e18-4b71-85c3-deb1394edb58','9060W',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f6290117-d36a-41cf-a920-83163649aeb0','9061X',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3dd9a8a-f149-4b2b-a5fa-7f35bc5058f8','9062Y',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8e776ccd-05ab-4eba-8ee3-6e25b370d1f4','9064C',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8e776ccd-05ab-4eba-8ee3-6e25b370d1f4','9065D',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8e776ccd-05ab-4eba-8ee3-6e25b370d1f4','9066E',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('442fad60-003e-4177-8a84-c9ed90f326ef','9070J',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7b3026ac-8508-4704-81a7-736517afead8','9071K',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7f65931f-03f5-434a-9f13-80b42770a024','9072L',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('16ea267c-1b17-4763-99f6-c61a904e4d25','9073M',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f8e9acc9-d076-482f-9ed2-340f2e1f98dc','3036T',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7e0003f0-fc10-43d8-8d42-d04524dab810','9631X',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9efcf274-aea6-4b3a-9cf0-0d74b2b607fd','6182J',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('faa1fefa-5290-4edd-829d-a2eae82be9c3','2857J',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('41ed9dd7-5259-499f-b93a-e9e24377f552','9387C',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0ce068d8-12ec-482b-b4d1-0c56c0d1536f','1921D',5,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2a89f403-7238-4785-9b15-61306115df06','9224L',5,2,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('385c28a0-f6a7-42f7-9d1f-8f18470a4153','5750P',1,11,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('09313ccd-7f18-49a8-bed3-2f0510e9f3ad','9357L',28,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('385c28a0-f6a7-42f7-9d1f-8f18470a4153','9619G',1,11,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('634d1034-5682-43ce-86d4-cf9a8d037dd1','2650L',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3be5608b-a403-4ecc-b946-3b19c6e161e8','2646G',8,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3ad95821-d98d-4165-bf53-04ca20ecf40b','9438R',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('97cf6a11-523e-44c1-9e77-ba3f42bb7709','5484P',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('289e3a90-257a-45d5-9ece-94164f80dd57','2147B',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b18ee027-fdce-4490-9771-68226b612639','2148C',30,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('289e3a90-257a-45d5-9ece-94164f80dd57','5492C',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b18ee027-fdce-4490-9771-68226b612639','5493D',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('748c835d-6344-4562-b586-10eb34334a5e','2161R',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('51e0ae1c-a47b-4dbb-8b2c-a695f1730e97','2166B',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('08400886-eece-4227-a853-0af776d43244','2170F',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('02fb0938-369a-48b3-b61a-70d669034cff','9092M',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad80c85b-dcc0-4163-aaae-28abd774c84f','9093N',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('952092af-1862-49fb-a3f8-3c1ad87870fc','9094P',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('27bb16be-3a7b-4d8b-ad05-3583dc9637cf','9095Q',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b5fac7d3-44a2-4d4d-ad2e-5bd969b814a5','9096R',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('18890446-6aa7-42f1-8bcc-4a63846bcf5d','9289X',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('202148be-0498-463a-b36d-4470110bde70','9290Y',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('49af1fc9-d724-4b67-ba5f-ebbc5838d515','2626F',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d4fd6dcc-2d7f-4cdc-8af1-c7bf94964305','2629J',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a8546d43-608d-4cb5-a7b0-9893861dfb3e','2246F',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a8546d43-608d-4cb5-a7b0-9893861dfb3e','9339M',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a8546d43-608d-4cb5-a7b0-9893861dfb3e','2560R',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a8546d43-608d-4cb5-a7b0-9893861dfb3e','9340N',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6d314378-321b-4011-9cb7-99ed1d8e6a7f','1349B',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fedb7f2f-41d0-4ff6-bbe9-120fb5c5fce4','1382R',1,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e161637d-06fa-44ee-87f0-5cda3bf6b264','2700D',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('162f05ae-fa19-457f-a49f-ee8a7ebd4908','1354G',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7dcbd4a8-0659-47be-8c92-5782cbed6a79','1381Q',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('181d7702-f7f8-4e49-a3b2-a9dd6176fda1','1415L',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2e3aa0e6-d0db-4f73-a22a-493779cd90cc','1416M',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('162f05ae-fa19-457f-a49f-ee8a7ebd4908','2478K',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7dcbd4a8-0659-47be-8c92-5782cbed6a79','2482P',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('181d7702-f7f8-4e49-a3b2-a9dd6176fda1','2485T',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2e3aa0e6-d0db-4f73-a22a-493779cd90cc','9342Q',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('162f05ae-fa19-457f-a49f-ee8a7ebd4908','9125G',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7dcbd4a8-0659-47be-8c92-5782cbed6a79','9126H',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('181d7702-f7f8-4e49-a3b2-a9dd6176fda1','9127J',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2e3aa0e6-d0db-4f73-a22a-493779cd90cc','9343R',30,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f1755c42-57f8-494e-beb2-974a05d6446d','9610T',240,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f1755c42-57f8-494e-beb2-974a05d6446d','9567M',240,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2319cf72-8282-4d7e-91de-3341cc1fb58d','3012M',60,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('807e029e-8f26-4889-9a09-4c61e676ee69','9581G',240,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('807e029e-8f26-4889-9a09-4c61e676ee69','5653M',240,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e6d381b8-7c92-4918-b80a-9306db2cbbe5','5823L',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e6d381b8-7c92-4918-b80a-9306db2cbbe5','5821J',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cd5c3aae-98a8-4d4a-9029-249ee1fdd7ff','3392M',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cd5c3aae-98a8-4d4a-9029-249ee1fdd7ff','5000E',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b194b3b-d690-4df0-b916-6b7102781ec3','9546K',360,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b194b3b-d690-4df0-b916-6b7102781ec3','9620H',360,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2b194b3b-d690-4df0-b916-6b7102781ec3','2142R',180,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ee3aa5ee-f796-4362-acc7-69a9325a586c','9128K',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('94b454d2-d0e3-4c91-bd09-436eb6d569b4','9129L',112,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('94b454d2-d0e3-4c91-bd09-436eb6d569b4','5469W',56,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b64ded22-1db8-4001-bb4f-898c9de81450','4320J',56,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4213b951-d443-4dc0-b58d-dd84c28437c6','4322L',56,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b1136c7d-4b35-4941-a478-d3186a7e15b1','4323M',56,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('857d7e4b-39a8-4615-8597-a3d4cbf6bc9e','4324N',56,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('df2a1963-15d0-4e79-b5ad-95236594964d','5605B',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('df2a1963-15d0-4e79-b5ad-95236594964d','9621J',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1270dfd1-b668-4532-a4d7-0578c3644943','1220F',4,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1270dfd1-b668-4532-a4d7-0578c3644943','1221G',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8c8ea8e7-6517-4864-bd75-06a1fdd5f01c','4646M',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f97479de-d866-49d8-9d1c-d6b00feb7dd6','4647N',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f0b9f328-11f2-4b91-ba4f-c7ee59b2bbb2','4648P',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0d0d1132-e515-497f-a29c-6e37fdc85b17','4626L',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('26999a66-a639-41ec-9878-3c2a6be66238','9134R',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2ae2b3c5-a283-4e71-bd46-3b49d71ad329','9436P',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6409c6d8-d073-4389-85d4-91c73a23ae9d','4642H',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6409c6d8-d073-4389-85d4-91c73a23ae9d','4643J',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6409c6d8-d073-4389-85d4-91c73a23ae9d','4196W',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('96b68a75-9773-45e5-b719-da066e77360b','4207K',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6409c6d8-d073-4389-85d4-91c73a23ae9d','4230P',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c1736f87-3aca-4e3f-8653-84896ee91b50','9135T',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b01458a7-0199-45cc-9852-b5f287fd9a18','9434M',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2c531b82-5ecb-4e75-8f38-b2a302af8154','4644K',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4f9d81cf-276b-4ca3-9c24-ab6cc87d596c','4645L',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('986a5dc2-9200-4676-81c5-d1b0d628af49','2267H',10,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('986a5dc2-9200-4676-81c5-d1b0d628af49','5027N',10,0,'DT','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7ec0cfe6-69a5-4a20-bad8-72e9f489ac2e','9140C',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('69b39ecb-4c0a-4c2d-b103-1ee60ab01bed','9141D',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('522929fe-1818-4e98-bf66-495ca1c3941d','9142E',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e74cc766-f5fe-4d8b-940e-f36b7ec711c1','5100K',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0f3ca519-d615-4869-8a90-d91fcfe6f06f','5102M',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44ea11e7-3c9f-46a9-8ace-fbd1c1aac657','5103N',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f1b93cfa-2f94-4339-ba58-6ba1b809b9fa','5107T',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8b7a96c5-d75e-4345-a983-032ba3da1825','5109X',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c4c7ae66-263c-4097-ab1a-831f47a5496d','4380M',1,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c4c7ae66-263c-4097-ab1a-831f47a5496d','8974H',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0279a2ab-bc5d-4eb4-9c68-46279e32f6c5','9144G',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d034311a-9680-4b2d-98f1-2e387e4dd9b5','9145H',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0bbfc345-e862-46fb-95a5-eec6f306583e','4649Q',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f890d0f4-543a-4c56-bd8a-0920bc3d3e7b','4698G',1,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('764125ee-e9df-465a-9489-917a2d120dfa','4922C',2,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('55746511-16c3-4ea9-806c-74abe813132b','4909J',10,1,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2a0753e4-9e1c-4971-839d-9dded0ed7c0c','3419Y',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6e809f44-8b0b-4d20-82af-a15d0ce28a64','3420B',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3f8c57a5-ed9d-4298-b8cb-3ba5cc9e3366','3421C',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5a37c1c9-2e6d-4999-a718-e57a98168bdf','3422D',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6422684f-8235-4993-98d2-183c10142039','9151P',30,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('515d5078-4a40-48e5-aab5-83825fc780f4','9152Q',100,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('773f0c08-9c76-4519-be1e-62aa68361826','9153R',100,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6422684f-8235-4993-98d2-183c10142039','9393J',30,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('515d5078-4a40-48e5-aab5-83825fc780f4','9394K',100,2,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7504599c-6ece-4379-a758-8c6c745f9957','3418X',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d1aeb207-7333-4863-9562-8993d72c964c','5143Q',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7af2efd0-2345-44fc-a2f0-fdf734416f84','5145T',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b3a25575-852a-4e42-a83f-eab78654b98a','9148L',140,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8e81b081-a7ed-4c84-b34d-cd802a911987','9155W',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f43df20b-4245-478d-8dce-0fb087e6bce6','9156X',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f5263ed1-d59d-4061-a5a2-ef63cc3cea8f','1956Y',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a78ca839-b40d-447f-b95e-dc3e74da486a','9306T',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d1f6da59-bd0b-42bd-93a3-d4e789d11063','9161E',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b152b520-13d5-447f-bd7d-3c973fe332d1','9162F',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9d1cf349-f7b3-4ef1-a24a-64ff31a08a63','9629T',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9d1cf349-f7b3-4ef1-a24a-64ff31a08a63','9523F',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e0117dc0-aabb-4882-9bdc-a91f9ff8abea','9164H',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bad05c2d-e82a-43c0-a5b7-e431ea4f64b8','9165J',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8dbc3926-0541-4778-b07e-d4173a2c2dee','9157Y',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('72aab158-b028-4fd6-9dcf-8dae3b3259c0','9158B',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5f91b596-5a8e-4299-a7b9-fef3ecb866e9','9159C',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8dbc3926-0541-4778-b07e-d4173a2c2dee','9625N',56,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('72aab158-b028-4fd6-9dcf-8dae3b3259c0','9626P',56,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5f91b596-5a8e-4299-a7b9-fef3ecb866e9','9627Q',56,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8dbc3926-0541-4778-b07e-d4173a2c2dee','5621W',56,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('72aab158-b028-4fd6-9dcf-8dae3b3259c0','5622X',56,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5f91b596-5a8e-4299-a7b9-fef3ecb866e9','5623Y',56,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0f59604a-3835-4b8e-b2a6-c7b492405106','9624M',1,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0f59604a-3835-4b8e-b2a6-c7b492405106','9505G',1,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1ca0f815-0c83-4d0b-84a8-157c43c62fb6','9166K',30,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5d89dc8c-48d5-4fd7-be44-bd40ff629bee','9167L',30,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b0b2fb59-a393-4419-8c49-afb771cb663b','9168M',30,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e2649019-0e83-41a8-a799-76df89b87f08','9171Q',120,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('179eda1c-105b-48e6-abb3-88dd137fbf07','1309X',120,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5dab4456-a3a3-4249-b873-187e6719e47b','9180E',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d7daed4c-4c1e-45a6-bd14-92153a119759','9181F',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b3db2113-5feb-467d-96be-12d929809fb3','9182G',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a337e1f4-5a61-4460-8f33-2d2aa991ee4e','9630W',56,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a337e1f4-5a61-4460-8f33-2d2aa991ee4e','9562G',56,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0528afbc-552b-4468-9b8c-4085e9979b0e','9184J',20,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9fc70df1-1c7e-41ca-a215-d1090b33ecd2','5556K',1,3,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7af0ec5b-2e13-41f0-bad4-cdb514c1baf6','5561Q',3,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7af0ec5b-2e13-41f0-bad4-cdb514c1baf6','9307W',3,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9fc70df1-1c7e-41ca-a215-d1090b33ecd2','9355J',1,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9fc70df1-1c7e-41ca-a215-d1090b33ecd2','9356K',1,7,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6ca6ecae-1934-4ff6-a8d0-72258d99433f','9360P',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('78bb47de-0a8f-4966-847c-45a131ebe4ca','5297T',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c5ea6db5-526c-4438-afbb-2bdf36bf5814','9378N',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('056743fa-c46b-4e8b-831f-b317bae337a0','9379P',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('35c45c4b-68df-4ad7-8b37-033973e3b272','9363T',56,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5fe840d7-c965-4590-9ce7-4114bdac2763','9364W',56,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e96f4765-ea12-40e4-8ecf-a15710d8dd22','9452L',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('da08094d-6dc0-4697-a807-9a3d6c3bb14e','9366Y',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8e17c193-84cd-49f3-b18b-e93931e2a2ea','9367B',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1fe25cdb-4210-447e-8eff-bb7983899cbc','9380Q',120,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('be4c1d9f-074c-4d70-be91-b02fdba29870','9368C',28,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7c432414-08df-4998-a313-ce50d5107d11','9369D',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('876dcde1-4157-42f6-97b9-c0ff11f6d94a','9370E',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('982f66a7-f5be-4122-bfa7-75956c5cdef3','9371F',28,5,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5be30d27-53dc-4362-bbb9-fce44a9c6c91','9372G',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('726cfbf1-a4bc-44c8-b227-9882a198a23f','9373H',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('34b428f7-2667-487c-8ea5-0e8b3b453923','9374J',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bb4d712b-eabc-4fb6-bec0-dfb31bcb6312','9481B',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5c50799e-2026-415b-bfcd-f9aab3d1dcb6','9482C',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e80fe71c-9995-46d8-96f9-4a1b9fe9db86','9375K',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d81f054a-be8d-4267-841c-e5635cae5f6a','9376L',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('95936b0c-02c8-4a2f-b398-b4119044fb5b','9377M',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0ba9364f-7f43-4df2-aa7e-aebaf0161d0d','5459H',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fa7c16b0-d85c-4006-9136-e6a420b26775','5460J',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ac182fbc-5286-4478-8bcc-543ee2853699','9382T',9,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('89cd50d6-6351-4094-aac6-87ae2a8c5b63','9384X',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('928bd166-0cea-4503-8fdc-83dd9f76ab9c','9385Y',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('89b71544-a5f5-4bc8-bac3-9e3256951fc2','9386B',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9cf93dd3-ef18-5461-9b0f-bdf7e208ea75','9388D',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5213dc0a-39f9-5e40-a949-56e1865bb2a4','9389E',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('66967e6c-a7e5-503b-9dc7-dd33cf40f8f3','9390F',112,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('07a767c0-4fc2-4645-b856-38ac3d7db4cb','9411H',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fcdcd5c7-3096-44a8-b7ed-098c8b4cc679','9403X',90,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bf8c6fdd-afe0-4e64-b8d7-3e899c106425','9404Y',90,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7160ac5a-fdc1-4f4e-95b0-51c0e56e728f','9405B',90,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fcdcd5c7-3096-44a8-b7ed-098c8b4cc679','9635D',180,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bf8c6fdd-afe0-4e64-b8d7-3e899c106425','9636E',180,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7160ac5a-fdc1-4f4e-95b0-51c0e56e728f','9637F',180,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fcdcd5c7-3096-44a8-b7ed-098c8b4cc679','5780F',180,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bf8c6fdd-afe0-4e64-b8d7-3e899c106425','5781G',180,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7160ac5a-fdc1-4f4e-95b0-51c0e56e728f','5782H',180,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('60bf37e4-c053-4db3-a3d7-8a4486084e5e','9488J',28,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('191f6a04-6a18-41a4-b4af-c1868a1a30d6','9489K',28,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2cec828b-db57-4b84-ac6b-181fa4b38b19','9490L',28,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('60bf37e4-c053-4db3-a3d7-8a4486084e5e','9417P',28,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('191f6a04-6a18-41a4-b4af-c1868a1a30d6','9418Q',28,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2cec828b-db57-4b84-ac6b-181fa4b38b19','9419R',28,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('60bf37e4-c053-4db3-a3d7-8a4486084e5e','9420T',28,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('191f6a04-6a18-41a4-b4af-c1868a1a30d6','9421W',28,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2cec828b-db57-4b84-ac6b-181fa4b38b19','9422X',28,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af63c12b-fee9-4293-a586-9303ffe70cce','4389B',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dabd1a38-1c1b-4ff4-8266-6060ccfb06fe','4386W',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1a178afa-a2eb-41ce-b1a4-5525bab144d9','9437Q',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('446e9bcd-2a6d-467c-b281-5f6180c6ec6d','5482M',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a7e1a2dd-b15b-49a6-bb0a-61eef86bf881','9439T',12,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a37687a4-7c66-41f9-9caa-067387014abd','5062K',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a37687a4-7c66-41f9-9caa-067387014abd','5084N',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ef9d998f-0c8a-4df6-ad30-f33a08b402f0','9446E',24,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ec36e5cc-761c-4455-a8b7-6649584510c6','9447F',8,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e7bbfa43-84d1-46c2-9c96-3df43a94a164','5545W',2,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e7bbfa43-84d1-46c2-9c96-3df43a94a164','9448G',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5ba39e50-ed35-466d-8f60-aa5581c3d74a','9449H',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('53756a90-d01e-4bbe-bba5-3c07c3f891a8','9450J',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d3715956-8cb5-4c31-b049-c8a9e3129bd6','9451K',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b61e5fdd-fb49-4b0b-b3c2-eb6991ce6aa4','5558M',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b61e5fdd-fb49-4b0b-b3c2-eb6991ce6aa4','9464D',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ba69b789-8e1d-40f6-ae29-089aac2edc01','9454N',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('deef86ef-9abf-4dd9-9767-32cba2e6c17f','9469J',15,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('deef86ef-9abf-4dd9-9767-32cba2e6c17f','9466F',15,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('deef86ef-9abf-4dd9-9767-32cba2e6c17f','9465E',10,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('deef86ef-9abf-4dd9-9767-32cba2e6c17f','9467G',30,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('deef86ef-9abf-4dd9-9767-32cba2e6c17f','9468H',10,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6cc6601c-a3bc-4d91-b020-1fdab04d5f05','9475Q',2,4,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6cc6601c-a3bc-4d91-b020-1fdab04d5f05','9476R',2,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('96dcbe57-4acd-4325-9310-93ae2253fc4b','9479X',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ea925d01-a315-4bb7-915f-5ab2e704b953','5783J',21,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42aec2ae-246b-4e85-b008-d28b5c29e4ed','5784K',21,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d2662a27-f580-4e0c-8ead-852dd98a5ea3','5785L',21,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44a807f2-2e91-4bf3-a390-37bc8b777213','5786M',21,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ea925d01-a315-4bb7-915f-5ab2e704b953','9642L',21,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42aec2ae-246b-4e85-b008-d28b5c29e4ed','9643M',21,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d2662a27-f580-4e0c-8ead-852dd98a5ea3','9644N',21,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('44a807f2-2e91-4bf3-a390-37bc8b777213','9645P',21,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1db41006-fb29-4685-8c1f-6687a99fc654','9487H',3,0,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('849053ea-1c2a-41df-9e52-398633f22dcb','9495R',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d412a80a-7141-48de-9d48-d217ebfc801a','9496T',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('db2ca100-9fc6-4d6b-8b10-f39c08d2f914','9494Q',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('139e9ce1-c3d3-4bd8-97b5-b179ec511cc8','5276Q',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1e57a94a-b72a-419b-be14-261b9078630c','9499Y',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93572113-a179-4224-84c8-5e5986618b85','9498X',24,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('9f45521c-1e98-4b69-9fad-429f0279ed36','5296R',18,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('82990bfa-4068-4a40-a54e-445016b4653d','5559N',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2fcc8003-e6fa-43aa-b5bd-dfa4921ce3f3','5560P',5,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('82990bfa-4068-4a40-a54e-445016b4653d','9491M',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('82990bfa-4068-4a40-a54e-445016b4653d','9492N',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2fcc8003-e6fa-43aa-b5bd-dfa4921ce3f3','9493P',5,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2e2e3482-46f2-4618-9809-550e69f46fbc','9648T',30,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cc03f56c-9f59-490f-9edd-aedb3782f164','9649W',30,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2e2e3482-46f2-4618-9809-550e69f46fbc','5607D',30,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cc03f56c-9f59-490f-9edd-aedb3782f164','5608E',30,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('83cc5d85-31c1-4e0e-9180-d7d40c92e677','9296G',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cebe11f3-37d5-4355-928d-a3332ba9d7be','9650X',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('cebe11f3-37d5-4355-928d-a3332ba9d7be','9565K',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5c863268-ee6a-4537-9bb7-673d98aacde7','9313E',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('645c38f0-b3be-434e-b2bc-fa4768593ec5','9311C',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8805fc13-5966-4842-a1c3-e4b7e583e219','9312D',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('aad3cd88-7d2a-47cd-bff9-7842625ca6d8','9316H',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('df7b1b08-1d75-4c90-8536-4a731e3fa3c4','5424L',7,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('df7b1b08-1d75-4c90-8536-4a731e3fa3c4','5423K',3,0,'PL','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d313d43f-a8bd-4ebf-af14-79cc2b5db32d','9308X',6,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7371dd96-3842-4d5c-9a47-d6db90894fef','9309Y',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('90dbc84c-bcc6-4109-95f3-20b0202dbb76','9304Q',1,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('90dbc84c-bcc6-4109-95f3-20b0202dbb76','9305R',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('70532339-b808-4372-aaf2-24304df1f3f2','9318K',20,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('14f06720-bb63-48e0-b7f9-3cd3f0bf8fc3','9319L',20,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('70532339-b808-4372-aaf2-24304df1f3f2','9322P',20,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('14f06720-bb63-48e0-b7f9-3cd3f0bf8fc3','9323Q',20,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('70532339-b808-4372-aaf2-24304df1f3f2','9320M',60,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('14f06720-bb63-48e0-b7f9-3cd3f0bf8fc3','9321N',60,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8c2ea70b-0746-46cf-93d4-1b10b0ef6552','9572T',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('18551be6-19c0-4ca8-b145-408f46897bbf','9573W',120,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8c2ea70b-0746-46cf-93d4-1b10b0ef6552','5792W',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('18551be6-19c0-4ca8-b145-408f46897bbf','5793X',120,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a18c997e-a22c-44f0-8111-7af15eda136f','9330C',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af52cd5c-45b9-4a94-b468-01cf8270e70a','9329B',6,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('198a931a-2551-4316-abee-526da9c2db61','5794Y',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('96fcfe15-7512-4e2e-85f1-ce7626d6a18b','5795B',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f6baa89a-4ad6-4260-a2b4-da6e932b0f6e','5796C',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae6e0c64-e3d2-4f6c-b0fa-d3c0d518d812','5797D',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31710760-bbde-4752-b838-b2682da39e1b','5798E',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1f7bbb43-65b7-42ba-9350-943b9376f903','5799F',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('952a1457-3a05-448f-8e7c-c98a137dc6f9','5800G',2,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('198a931a-2551-4316-abee-526da9c2db61','9574X',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('96fcfe15-7512-4e2e-85f1-ce7626d6a18b','9575Y',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f6baa89a-4ad6-4260-a2b4-da6e932b0f6e','9576B',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ae6e0c64-e3d2-4f6c-b0fa-d3c0d518d812','9577C',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31710760-bbde-4752-b838-b2682da39e1b','9578D',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1f7bbb43-65b7-42ba-9350-943b9376f903','9579E',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('952a1457-3a05-448f-8e7c-c98a137dc6f9','9580F',2,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1eaf3bfb-4170-4e9f-876a-be30dde6b95b','9328Y',6,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('31bf0005-f8c6-43ce-904b-ee967a03536f','4239D',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('49787479-73d8-4cdd-a2d4-551f03ddab3a','4240E',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d06c00ae-8e1b-4d83-88fe-726289e77687','3489P',1,0,'DB','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('af850c2e-0b21-4cb5-9536-c821a423b8fc','9333F',14,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2375c31a-b2bd-45ad-a149-c2cc7d99ebe4','9334G',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('da616810-455b-4540-beb9-c53e7968c551','9335H',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a703e378-50c4-4062-9d21-c5f1c6abba85','9336J',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ca2ee461-38e5-43f9-8e4a-e1fd09fe6663','9337K',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a3dd099c-3391-4bbc-b336-50a47cc050eb','9338L',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b15fd84b-8282-41fc-a1b8-a89f7569162b','9351E',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d7175882-6158-429d-9993-b26d0df084a1','9346X',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e0d699f1-b948-4271-9468-f943268217ee','9347Y',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('33342b7b-39b3-4129-8c1f-a00eeff692a8','9348B',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('45eb4ed1-f2a3-476e-84e6-a2b299fcf38c','9349C',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e4632668-e6c8-457b-bba0-98c38245d319','3417W',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4ded4948-98bc-4c29-81a4-830ca6bbed0e','3438Y',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4ded4948-98bc-4c29-81a4-830ca6bbed0e','5562R',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('c5283b08-f075-4b0b-8334-a540bedc59bb','3425G',2,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d185eda5-23ae-40da-a5ad-2ef58a550a55','1419Q',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d185eda5-23ae-40da-a5ad-2ef58a550a55','9671B',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('302b1932-3818-48bb-b81a-dceb7670a3d7','1423X',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('302b1932-3818-48bb-b81a-dceb7670a3d7','9672C',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dadcc7bb-d823-4fd0-8bb3-a5834b7f0700','1464C',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dadcc7bb-d823-4fd0-8bb3-a5834b7f0700','9673D',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d185eda5-23ae-40da-a5ad-2ef58a550a55','1476Q',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d185eda5-23ae-40da-a5ad-2ef58a550a55','9657G',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('302b1932-3818-48bb-b81a-dceb7670a3d7','1481Y',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('302b1932-3818-48bb-b81a-dceb7670a3d7','9658H',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dadcc7bb-d823-4fd0-8bb3-a5834b7f0700','1482B',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('dadcc7bb-d823-4fd0-8bb3-a5834b7f0700','9659J',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('989c2d00-b5a0-51af-a4d5-a3dbba2b4b12','3426H',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('36654264-ca90-5bbb-94ff-bee3abde09a8','3427J',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('989c2d00-b5a0-51af-a4d5-a3dbba2b4b12','3430M',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('36654264-ca90-5bbb-94ff-bee3abde09a8','3431N',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('989c2d00-b5a0-51af-a4d5-a3dbba2b4b12','3432P',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('36654264-ca90-5bbb-94ff-bee3abde09a8','3433Q',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('989c2d00-b5a0-51af-a4d5-a3dbba2b4b12','3434R',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('36654264-ca90-5bbb-94ff-bee3abde09a8','3435T',1,3,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('989c2d00-b5a0-51af-a4d5-a3dbba2b4b12','3436W',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('36654264-ca90-5bbb-94ff-bee3abde09a8','3437X',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('989c2d00-b5a0-51af-a4d5-a3dbba2b4b12','3428K',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('36654264-ca90-5bbb-94ff-bee3abde09a8','3429L',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6aabc129-dee0-5700-b75e-361d647cd935','3415R',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0877ac8e-5575-450d-b7d0-f5ffec826d2e','3423E',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a5ec2957-5eb5-4167-8987-c47de464a837','3424F',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e1bccb86-c8d3-4fd1-9648-8b27d7785bdd','9583J',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e1bccb86-c8d3-4fd1-9648-8b27d7785bdd','9584K',5,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce935c83-092f-4767-b961-3abacef8b6a9','5285E',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6c17872c-470e-4306-bdf9-57e2037f7fa2','5286F',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ac17a793-8ceb-49e2-9f26-93dc61a6b4cd','5287G',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e2545fe8-1bff-492d-b9e2-b04292a5ffc6','5288H',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b17ef8bf-219e-4adb-9c20-989e71628154','5289J',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fb211dbd-2e1b-4833-8be9-0e1997c39991','5290K',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('42c79747-7ec1-4075-b177-ed3cc389ca1f','5291L',4,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7aa7ee6f-4432-4bb1-a883-bf22b8f0d61f','5292M',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0dfe12bb-3c02-4315-8d58-464ea9d9d3b5','5293N',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b92ab64a-6cf6-40de-b4bb-dac2d657abd4','5294P',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6abca1c7-d926-4d0b-b148-8576d7dbf0b9','5853C',1,0,'CT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6abca1c7-d926-4d0b-b148-8576d7dbf0b9','5295Q',1,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0362d0ea-c0f8-4762-b348-3b8f403bdbe4','5455D',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f962a5ab-469c-4134-81e1-f7067e9260ee','5456E',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('912bb80e-b2aa-4167-b496-52e974126284','9599F',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a43a3da0-338f-4636-9415-2475432c1d60','9668W',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0e089fb3-1015-451e-8060-e4a2224d4cc1','9591T',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('96726f19-62d9-4422-8b10-a2abd695649b','9594Y',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fd399727-c3e9-4ad4-8e8f-7b6b3d561da2','9669X',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a4d587c6-cdfb-4b87-9841-6a53cdb178dc','9670Y',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('45ac7a9d-2cbc-4598-89d7-936021ba2cd8','9587N',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('52ea7505-bf7f-45bf-b799-c718fb075f6e','9589Q',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed6d3ce4-3632-45a6-9ebc-ad4f9e1a011a','9596C',12,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a43a3da0-338f-4636-9415-2475432c1d60','9685R',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fd399727-c3e9-4ad4-8e8f-7b6b3d561da2','9686T',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a4d587c6-cdfb-4b87-9841-6a53cdb178dc','9687W',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('45ac7a9d-2cbc-4598-89d7-936021ba2cd8','9688X',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('52ea7505-bf7f-45bf-b799-c718fb075f6e','9588P',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('0e089fb3-1015-451e-8060-e4a2224d4cc1','9590R',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('96726f19-62d9-4422-8b10-a2abd695649b','9593X',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ed6d3ce4-3632-45a6-9ebc-ad4f9e1a011a','9595B',12,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('914711d1-068d-4727-9c34-cff9078888df','5110Y',1,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fe27a4dd-c22f-46ff-81e5-8adbff0e46c7','5457F',1,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('75696715-16a0-56e0-b9b1-7c9cf991d228','5468T',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('528b4c51-c4d5-5024-9fce-e7556390ba24','9597D',14,2,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('528b4c51-c4d5-5024-9fce-e7556390ba24','9598E',14,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('528b4c51-c4d5-5024-9fce-e7556390ba24','6100C',14,2,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('528b4c51-c4d5-5024-9fce-e7556390ba24','6138C',14,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a8546d43-608d-4cb5-a7b0-9893861dfb3e','1545H',12,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a8546d43-608d-4cb5-a7b0-9893861dfb3e','5466Q',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('a8546d43-608d-4cb5-a7b0-9893861dfb3e','5467R',8,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7a6b362f-1754-48da-95bf-04b907cea25f','5481L',4,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d25d9ee4-9c58-4463-86a6-4e46bc341d5b','5490Y',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('57b7e579-fa03-4375-a4ca-72fed24ef9ff','5474D',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b0a0b77d-76da-4833-96df-4deff55bf810','5475E',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('174ae1ca-a0f6-4da9-84fd-db6d3938c79c','5476F',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6aed57fb-76b9-4aec-b848-e580aa853d95','8955H',1,3,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6aed57fb-76b9-4aec-b848-e580aa853d95','8954G',1,1,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b1303f0c-f133-4ff0-9776-84c0ad0cb451','9696H',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b61d4a4b-d8fd-4f74-aa50-5a20b7e06bb5','9698K',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b1303f0c-f133-4ff0-9776-84c0ad0cb451','9697J',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b61d4a4b-d8fd-4f74-aa50-5a20b7e06bb5','9699L',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4e94fe25-ea47-44a8-a0ed-462eec4ee963','8978M',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('49b9fbd8-25f2-4bd1-97d0-c5c2f1212225','8979N',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('47b022be-3468-4b34-bec2-92464e1e71c8','8980P',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f7eddb36-b13a-4d98-af46-ca6410540a7c','8981Q',28,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('53d4c460-b27f-4459-a224-2cb89f8f9dfb','8983T',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93d9d258-c8f0-5cef-956b-6050ae1c635c','9746Y',1,0,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('93d9d258-c8f0-5cef-956b-6050ae1c635c','9745X',1,0,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('691ee528-ae9a-4570-b853-5084823a54ba','5825N',28,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1b5409b7-5e57-46b7-b58e-9cde6c88cceb','5826P',28,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('691ee528-ae9a-4570-b853-5084823a54ba','5827Q',28,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1b5409b7-5e57-46b7-b58e-9cde6c88cceb','5828R',28,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e495a2d1-5e1a-46ee-9823-52db9c1bb60b','8985X',60,1,'GE','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('828a5d94-3733-4822-978e-00ef770cc108','5262Y',28,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('4b3f6293-6757-46ee-92f5-54e5dedd4c98','5816D',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ce644f2a-e752-42cb-8677-3353f7792dba','5817E',1,0,'IF','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('6f6a0b03-205f-4bff-8628-b679ac1e5bab','8000C',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('941ca5d9-a665-4b94-a320-b6530dd04ab0','8934F',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3692a42d-c99e-4040-9633-6ddb17fb1ed6','8935G',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('978e75a2-a98a-41ca-b654-e53418d1712e','8936H',28,0,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('59d31e0d-81d6-4803-8f48-6089a4ef1047','5134F',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('bbb38782-40d3-41ce-9e21-ba86e192b1b0','5137J',30,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5d83538e-a649-4820-97c9-cadcc306b033','5140M',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('de840de0-aae9-42af-b0e4-f28aaaaf05e1','5141N',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('01ce0c69-a861-42be-b68e-53d396c5f484','5500L',20,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('01ce0c69-a861-42be-b68e-53d396c5f484','5054B',30,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('01ce0c69-a861-42be-b68e-53d396c5f484','5061J',60,0,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('58df492f-641e-449b-adb5-9a5cf21d9c96','3387G',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2d36ae8a-b340-4ef8-9f19-9f7fd006d2cf','4290T',4,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('e1e15b5d-fe14-4903-abcd-f45deff112e8','4302K',4,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ab38d611-4a91-4bbc-a5c8-7e7533babce9','4277D',30,5,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('79037b3f-84b5-4c89-9e7d-60192a214dcd','4306P',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1d1de054-d9e0-4433-bdc2-9fb939720748','4252T',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1d1de054-d9e0-4433-bdc2-9fb939720748','4255Y',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1d1de054-d9e0-4433-bdc2-9fb939720748','4258D',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('1d1de054-d9e0-4433-bdc2-9fb939720748','4259E',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('7b5af2b5-bc38-4ac4-b7cb-4fce7cc99827','4263J',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('b792c2cf-7339-448a-af42-6cdef2bdf889','4266M',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('ad1a33ad-a828-4a7c-8b11-015332d8a3b1','4270R',1,0,'R1','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('68c39736-12c1-430f-9491-4b65133c54aa','1173R',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('68c39736-12c1-430f-9491-4b65133c54aa','1170N',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2d1352be-1e91-4a0e-8ed1-9b3222c4b082','1491L',60,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('2d1352be-1e91-4a0e-8ed1-9b3222c4b082','1490K',60,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('55a50505-0162-46ab-8c8d-1f1e30dfd4c6','1952R',30,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('efc457b7-7772-49a5-ae43-4a16bd2f1c9e','1976B',1,1,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('d2110bc4-b2a0-48c7-b303-e3a62b893c3b','1418P',56,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b5818a1-ee06-413a-a885-a7a5f9f2e112','2015C',4,5,'HB','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('3b5818a1-ee06-413a-a885-a7a5f9f2e112','2008Q',4,5,'HS','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('5ece9315-9060-4bf9-85ae-713c67980876','4180B',1,0,'R1','U');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fdcbf0b8-d2ae-4710-8441-1084eff850a7','2041K',1,5,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fdcbf0b8-d2ae-4710-8441-1084eff850a7','2044N',1,11,'GE','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8cebb5b5-4a05-4d00-87de-26fda2a11c64','2058H',3,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('fdcbf0b8-d2ae-4710-8441-1084eff850a7','2082N',1,5,'OT','R');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('8cebb5b5-4a05-4d00-87de-26fda2a11c64','2090B',3,5,'OT','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f1dfe027-5140-437a-9061-eb3ee3b362d2','2030W',60,2,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('587735bd-c001-41a6-aed4-1ab7e5323a6c','2034C',90,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('f1dfe027-5140-437a-9061-eb3ee3b362d2','2035D',60,5,'GE','A');


insert into drugs.pbs (fk_product,pbscode,quantity,max_rpt,chapter,restrictionflag)
values ('587735bd-c001-41a6-aed4-1ab7e5323a6c','2029T',90,2,'GE','A');

truncate drugs.restriction;
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1003T','3632','t',$$<p>Moderate to severe initial genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is desirable but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1007B','3633','t',$$<p>Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1024X','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1024X','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1037N','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1037N','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1041T','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1041T','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1042W','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1042W','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1052J','3622','t',$$<p>Treatment of patients with herpes zoster within 72 hours of the onset of the rash</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1052J','3631','t',$$<p>Herpes zoster ophthalmicus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1070H','2384','t',$$<p>Prophylaxis of thiamine deficiency in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1165H','1461','f',$$<p>Use in attention deficit hyperactivity disorder, in accordance with State/Territory law</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1165H','1236','f',$$<p>Narcolepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1180D','4033','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated colic or reflux) in a child up to the age of 24&#160;months. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1180D','4034','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1180D','4035','f',$$<p>Initial treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1192R','4036','f',$$<p>Treatment, in consultation with a specialist allergist or clinical immunologist, for a child with cows' milk anaphylaxis, up to the age of 24&#160;months.  Anaphylaxis is defined as a severe and/or potentially life threatening allergic reaction.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1192R','4037','f',$$<p>Continuing treatment for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1192R','4038','f',$$<p>Continuing treatment for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed at least once or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist.  Then name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1192R','4039','f',$$<p>Continuing treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months.  The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist at intervals not greater than 12&#160;months.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1192R','1687','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1192R','1688','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1208N','1572','f',$$<p>Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1208N','1573','f',$$<p>Bacterial gastroenteritis in severely immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1208N','1431','f',$$<p>Treatment of infections proven to be due to Pseudomonas aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobials</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1208N','1432','f',$$<p>Treatment of joint and bone infections, epididymo-orchitis, prostatitis or perichondritis of the pinna, suspected or proven to be caused by gram-negative bacteria or gram-positive bacteria resistant to all other appropriate antimicrobials</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1208N','1143','f',$$<p>Gonorrhoea</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1209P','1572','f',$$<p>Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1209P','1573','f',$$<p>Bacterial gastroenteritis in severely immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1209P','1431','f',$$<p>Treatment of infections proven to be due to Pseudomonas aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobials</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1209P','1432','f',$$<p>Treatment of joint and bone infections, epididymo-orchitis, prostatitis or perichondritis of the pinna, suspected or proven to be caused by gram-negative bacteria or gram-positive bacteria resistant to all other appropriate antimicrobials</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1210Q','1572','f',$$<p>Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1210Q','1573','f',$$<p>Bacterial gastroenteritis in severely immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1210Q','1431','f',$$<p>Treatment of infections proven to be due to Pseudomonas aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobials</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1210Q','1432','f',$$<p>Treatment of joint and bone infections, epididymo-orchitis, prostatitis or perichondritis of the pinna, suspected or proven to be caused by gram-negative bacteria or gram-positive bacteria resistant to all other appropriate antimicrobials</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1217C','1031','f',$$<p>Bacterial keratitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1220F','3996','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Initial treatment with an I.V. loading dose: Two completed authority prescriptions must be submitted with the initial application.  One prescription must be for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats.  The second prescription must be written for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats.</p><p> Initial treatment with no loading dose: One completed authority prescription must be submitted with the initial application.  The prescription must be written with a maximum quantity of 4 and up to 3 repeats</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1220F','3997','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with abatacept and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised abatacept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Initial treatment with an I.V. loading dose: Two completed authority prescriptions must be submitted with the initial application.  One prescription must be for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats.  The second prescription must be written for the pre-filled syringes, with a maximum quantity of 4 and up to 3 repeats.</p><p> Initial treatment with no loading dose: One completed authority prescription must be submitted with the initial application.  The prescription must be written with a maximum quantity of 4 and up to 3 repeats.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised abatacept treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised abatacept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1221G','3998','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with abatacept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with abatacept.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with abatacept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with abatacept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1255C','1257','t',$$<p>Parkinson's disease where fluctuations in motor function are not adequately controlled by frequent dosing with conventional formulations of levodopa with decarboxylase inhibitor</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1269T','1230','t',$$<p>Moderate to severe androgenisation in non-pregnant women (acne alone is not a sufficient indication of androgenisation)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1270W','1014','t',$$<p>Advanced carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1270W','1404','t',$$<p>To reduce drive in sexual deviations in males</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1285P','1090','t',$$<p>Endometriosis, visually proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1285P','1151','t',$$<p>Hereditary angio-oedema</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1285P','2639','t',$$<p>Short-term treatment (up to 6 months) of intractable primary menorrhagia (Treatment of this indication is limited to 6 months. See Australian Product Information)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1285P','2640','t',$$<p>Short-term treatment (up to 6 months) of severe benign (fibrocystic) breast disease or mastalgia associated with severe symptomatic benign breast disease in patients refractory to other treatments (Treatment of this indication is limited to 6 months.  See Australian Product Information)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1287R','1090','t',$$<p>Endometriosis, visually proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1287R','1151','t',$$<p>Hereditary angio-oedema</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1287R','2639','t',$$<p>Short-term treatment (up to 6 months) of intractable primary menorrhagia (Treatment of this indication is limited to 6 months. See Australian Product Information)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1287R','2640','t',$$<p>Short-term treatment (up to 6 months) of severe benign (fibrocystic) breast disease or mastalgia associated with severe symptomatic benign breast disease in patients refractory to other treatments (Treatment of this indication is limited to 6 months.  See Australian Product Information)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1309X','4005','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, BCR-ABL tyrosine kinase, and who has a primary diagnosis of chronic myeloid leukaemia.</p><p> Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved.</p><p> Patients should be commenced on a dose of nilotinib of 300&#160;mg twice daily. Continuing therapy is dependent on patients demonstrating a response to nilotinib therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Chronic Phase, First Line - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow; and<br/> (4) a signed patient acknowledgement form</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1309X','4006','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with nilotinib for the chronic phase of chronic myeloid leukaemia and who has demonstrated either a major cytogenetic response or less than 1% BCR-ABL level in the blood.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) demonstration of continued response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1330B','1161','t',$$<p>Hyperkinetic extrapyramidal disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1349B','3860','f',$$<p>Initial treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), as diagnosed by fluorescein angiography, in a patient with a baseline visual acuity equal to or better than 6/60 (20/200).</p><p> Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.</p><p> The first authority application for each eye must be made in writing, and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au]; and<br/> (c) a copy of the fluorescein angiogram demonstrating that the CNV is predominantly classic (greater than or equal to 50%).</p><p> Written applications for authority to prescribe verteporfin should be forwarded to:</p><p> Medicare Australia<br/> Prior Written Approval of Specialised Drugs<br/> Reply Paid 9826<br/> GPO Box 9826<br/> HOBART TAS 7001</p><p> Alternatively, the first authority application may be faxed to Medicare Australia on 1300&#160;093&#160;177 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Medicare Australia will then contact the prescriber by telephone.  The original documentation must be posted to the above address after approval has been gained.</p><p> No more than 15 treatments (1 initial and 14 continuing) per eye will be authorised.</p><p> Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin.  Telephone 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  The reason treatment is abandoned must be provided.  Where such notification has been made, the treatment so affected will not count towards the maximum</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1349B','3861','f',$$<p>Initial PBS-subsidised treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to macular degeneration where the patient has been authorised by the Angiogram Review Panel to receive treatment with verteporfin in the same eye under the MBS Visudyne Therapy Program.</p><p> Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.</p><p> The first authority application for each eye must be made in writing, and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au], which includes the date of review by the Angiogram Review Panel and the number of treatments administered in that eye under the MBS Visudyne Therapy Program; and<br/> (c) a copy of the fluorescein angiogram demonstrating that the CNV is predominantly classic (greater than or equal to 50%).</p><p> Written applications for authority to prescribe verteporfin should be forwarded to:</p><p> Medicare Australia<br/> Prior Written Approval of Specialised Drugs<br/> Reply Paid 9826<br/> GPO Box 9826<br/> HOBART TAS 7001</p><p> Alternatively, the first authority application may be faxed to Medicare Australia on 1300&#160;093&#160;177 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Medicare Australia will then contact the prescriber by telephone.  The original documentation must be posted to the above address after approval has been gained.</p><p> A patient is eligible for a total of 15 subsidised treatments per eye.  This maximum includes treatments administered under the MBS Visudyne Therapy Program and the PBS.</p><p> Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin.  Telephone 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  The reason treatment is abandoned must be provided.  Where such notification has been made, the treatment so affected will not count towards the maximum</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1349B','3795','f',$$<p>Continuing treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of predominantly (greater than or equal to 50%) classic, subfoveal choroidal neovascularisation (CNV) due to macular degeneration where the patient has previously been granted an authority prescription for the same eye.</p><p> A patient is eligible for a total of 15 subsidised treatments per eye.  This maximum includes treatments administered under the MBS Visudyne Therapy Program and the PBS.</p><p> Medicare Australia should be notified if treatment is abandoned prior to completion of the laser activation step but after infusion of verteporfin.  Telephone 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  The reason treatment is abandoned must be provided.  Where such notification has been made, the treatment so affected will not count towards the maximum.</p><p> Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.  Authority applications for continuing treatment in the same eye may be made by telephone on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1354G','4003','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, BCR-ABL tyrosine kinase, and who has a primary diagnosis of chronic myeloid leukaemia.</p><p> Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved.</p><p> Patients should be commenced on a dose of dasatinib of at least 100&#160;mg (base) daily. Continuing therapy is dependent on patients demonstrating a response to dasatinib therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Chronic Phase, First Line - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow; and<br/> (4) a signed patient acknowledgement form</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1354G','4004','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with dasatinib for the chronic phase of chronic myeloid leukaemia and who has demonstrated either a major cytogenetic response or less than 1% BCR-ABL level in the blood.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) demonstration of continued response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1381Q','4003','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, BCR-ABL tyrosine kinase, and who has a primary diagnosis of chronic myeloid leukaemia.</p><p> Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved.</p><p> Patients should be commenced on a dose of dasatinib of at least 100&#160;mg (base) daily. Continuing therapy is dependent on patients demonstrating a response to dasatinib therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Chronic Phase, First Line - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow; and<br/> (4) a signed patient acknowledgement form</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1381Q','4004','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with dasatinib for the chronic phase of chronic myeloid leukaemia and who has demonstrated either a major cytogenetic response or less than 1% BCR-ABL level in the blood.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) demonstration of continued response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1382R','3859','f',$$<p>Initial treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), as diagnosed by fluorescein angiography.</p><p> Where a fluoroscein angiogram cannot be performed due to a contraindication as listed in the TGA-approved product information, details of the contraindication must be provided.  A copy of the report of an alternative method of diagnosis must be included in the application, for example, optical coherence tomography (OCT) or red free photography.</p><p> Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.</p><p> The first authority application for each eye must be made in writing, and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Subfoveal Choroidal Neovascularisation (CNV) - PBS Supporting Information Form [www.medicareaustralia.gov.au]; and<br/> (c) a copy of the fluorescein angiogram or alternative method of diagnosis where applicable.</p><p> Written applications for authority to prescribe ranibizumab should be forwarded to:</p><p> Medicare Australia<br/> Prior Written Approval of Specialised Drugs<br/> Reply Paid 9826<br/> GPO Box 9826<br/> HOBART TAS 7001</p><p> Alternatively, the first authority application may be faxed to Medicare Australia on 1300&#160;093&#160;177 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Medicare Australia will then contact the prescriber by telephone.  The original documentation must be posted to the above address after approval has been gained</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1382R','2677','f',$$<p>Continuing treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD) where the patient has previously been granted an authority prescription for the same eye.</p><p> Authority approvals will be administered by the PBS and Specialised Drugs Branch of Medicare Australia.  Authority applications for continuing treatment in the same eye may be made by telephone on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1415L','4003','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, BCR-ABL tyrosine kinase, and who has a primary diagnosis of chronic myeloid leukaemia.</p><p> Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved.</p><p> Patients should be commenced on a dose of dasatinib of at least 100&#160;mg (base) daily. Continuing therapy is dependent on patients demonstrating a response to dasatinib therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Chronic Phase, First Line - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow; and<br/> (4) a signed patient acknowledgement form</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1415L','4004','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with dasatinib for the chronic phase of chronic myeloid leukaemia and who has demonstrated either a major cytogenetic response or less than 1% BCR-ABL level in the blood.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) demonstration of continued response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1416M','4003','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, BCR-ABL tyrosine kinase, and who has a primary diagnosis of chronic myeloid leukaemia.</p><p> Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved.</p><p> Patients should be commenced on a dose of dasatinib of at least 100&#160;mg (base) daily. Continuing therapy is dependent on patients demonstrating a response to dasatinib therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Chronic Phase, First Line - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow; and<br/> (4) a signed patient acknowledgement form</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1416M','4004','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with dasatinib for the chronic phase of chronic myeloid leukaemia and who has demonstrated either a major cytogenetic response or less than 1% BCR-ABL level in the blood.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) demonstration of continued response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining requirements]. Where this has been supplied within the previous 12 months, only the date of the relevant pathology report need be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1417N','3674','t',$$<p>Metastatic (equivalent to stage D) prostatic carcinoma in combination with GnRH (LH-RH) analogue therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1418P','3879','t',$$<p>Treatment of acute coronary syndrome (myocardial infarction or unstable angina) in combination with aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1454M','1871','f',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1454M','1872','f',$$<p>Hormone-dependent locally advanced (equivalent to stage III) or metastatic (equivalent to stage IV) breast cancer in pre-menopausal women</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1454M','1377','f',$$<p>Short-term treatment (up to 6 months) of visually proven endometriosis (only 1 course of not more than 6 months' therapy will be authorised)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1454M','3228','f',$$<p>Hormone-dependent breast cancer as an alternative to adjuvant chemotherapy in peri- or pre-menopausal women</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1471K','3615','t',$$<p>Treatment of cryptococcal meningitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1471K','3616','t',$$<p>Maintenance therapy in patients with cryptococcal meningitis and immunosuppression</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1471K','3613','t',$$<p>Treatment of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1471K','3614','t',$$<p>Treatment of oesophageal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1471K','3617','t',$$<p>Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1471K','3618','t',$$<p>Treatment of serious and life-threatening candida infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1472L','3615','t',$$<p>Treatment of cryptococcal meningitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1472L','3616','t',$$<p>Maintenance therapy in patients with cryptococcal meningitis and immunosuppression</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1472L','3613','t',$$<p>Treatment of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1472L','3614','t',$$<p>Treatment of oesophageal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1472L','3617','t',$$<p>Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1472L','3618','t',$$<p>Treatment of serious and life-threatening candida infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1473M','3615','t',$$<p>Treatment of cryptococcal meningitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1473M','3616','t',$$<p>Maintenance therapy in patients with cryptococcal meningitis and immunosuppression</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1473M','3613','t',$$<p>Treatment of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1473M','3614','t',$$<p>Treatment of oesophageal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1473M','3617','t',$$<p>Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1473M','3618','t',$$<p>Treatment of serious and life-threatening candida infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1474N','3615','t',$$<p>Treatment of cryptococcal meningitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1474N','3616','t',$$<p>Maintenance therapy in patients with cryptococcal meningitis and immunosuppression</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1474N','3613','t',$$<p>Treatment of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1474N','3614','t',$$<p>Treatment of oesophageal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1474N','3617','t',$$<p>Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1474N','3618','t',$$<p>Treatment of serious and life-threatening candida infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1475P','3615','t',$$<p>Treatment of cryptococcal meningitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1475P','3616','t',$$<p>Maintenance therapy in patients with cryptococcal meningitis and immunosuppression</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1475P','3613','t',$$<p>Treatment of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1475P','3614','t',$$<p>Treatment of oesophageal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1475P','3617','t',$$<p>Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1475P','3618','t',$$<p>Treatment of serious and life-threatening candida infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1521C','2734','f',$$<p>Initial treatment for up to 3 months, by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who requires an amino acid based formula as a component of a dietary elimination programme.  Treatment with oral steroids should not be commenced during the period of initial treatment.</p><p> Eosinophilic oesophagitis is demonstrated by the following criteria:<br/> (i) Chronic symptoms of reflux that persisted despite a 2-month trial of a proton pump inhibitor or chronic dysphagia; and<br/> (ii) A lack of demonstrable anatomic abnormality with the exception of stricture, which can be attributable to eosinophilic oesophagitis; and<br/> (iii) Eosinophilic infiltration of the oesophagus, demonstrated by oesophageal biopsy specimens obtained by endoscopy and where the most densely involved oesophageal biopsy had 20 or more eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.</p><p> The date of birth of the patient must be included in the authority</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1521C','2735','f',$$<p>Continuing treatment by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who has responded to an initial course of PBS-subsidised treatment.  Response to initial treatment is demonstrated by oesophageal biopsy specimens obtained by endoscopy, where the most densely involved oesophageal biopsy had 5 or less eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.  The response criteria will not be deemed to have been met if oral steroids were commenced during initial treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1545H','2734','f',$$<p>Initial treatment for up to 3 months, by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who requires an amino acid based formula as a component of a dietary elimination programme.  Treatment with oral steroids should not be commenced during the period of initial treatment.</p><p> Eosinophilic oesophagitis is demonstrated by the following criteria:<br/> (i) Chronic symptoms of reflux that persisted despite a 2-month trial of a proton pump inhibitor or chronic dysphagia; and<br/> (ii) A lack of demonstrable anatomic abnormality with the exception of stricture, which can be attributable to eosinophilic oesophagitis; and<br/> (iii) Eosinophilic infiltration of the oesophagus, demonstrated by oesophageal biopsy specimens obtained by endoscopy and where the most densely involved oesophageal biopsy had 20 or more eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.</p><p> The date of birth of the patient must be included in the authority</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1545H','2735','f',$$<p>Continuing treatment by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who has responded to an initial course of PBS-subsidised treatment.  Response to initial treatment is demonstrated by oesophageal biopsy specimens obtained by endoscopy, where the most densely involved oesophageal biopsy had 5 or less eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.  The response criteria will not be deemed to have been met if oral steroids were commenced during initial treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1555W','3632','t',$$<p>Moderate to severe initial genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is desirable but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1572R','3604','t',$$<p>Oral candidiasis in severely immunocompromised persons where topical therapy has failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1572R','3605','t',$$<p>Systemic or deep mycoses where other forms of therapy have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1573T','3606','t',$$<p>Symptomatic genital candidiasis recurring after treatment of at least 2 episodes with topical therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1574W','2354','t',$$<p>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1594X','3611','t',$$<p>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1595Y','3611','t',$$<p>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1596B','3611','t',$$<p>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1597C','3611','t',$$<p>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1611T','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1611T','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1611T','2268','t',$$<p>Crohn disease where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1611T','2269','t',$$<p>Crohn disease where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1648R','2630','t',$$<p>Reduction in the incidence of gastrointestinal complications in patients who have a history of peptic ulcer disease and where NSAID therapy is essential</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1648R','2631','t',$$<p>Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery. The date and the method by which the ulcer was proven must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1648R','2632','t',$$<p>Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous 2 years. The date and the method by which the ulcer was proven must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1671Y','2024','f',$$<p>Monotherapy for osteoporosis, where other treatment has failed and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1671Y','2025','f',$$<p>Monotherapy for osteoporosis, where other treatment is not tolerated and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1671Y','2026','f',$$<p>Monotherapy for osteoporosis, where other treatment is contraindicated and where specialist advice confirms that this is the only suitable treatment option for the patient. Specialist advice need only be obtained for the first authority approval</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1671Y','1976','f',$$<p>Patients receiving PBS-subsidised therapy with this drug for osteoporosis prior to 1&#160;February 2004</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1671Y','1262','f',$$<p>Patients on long-term treatment with corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1698J','2354','t',$$<p>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1728Y','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1728Y','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1757L','3615','t',$$<p>Treatment of cryptococcal meningitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1757L','3616','t',$$<p>Maintenance therapy in patients with cryptococcal meningitis and immunosuppression</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1757L','3613','t',$$<p>Treatment of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1757L','3614','t',$$<p>Treatment of oesophageal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1757L','3617','t',$$<p>Prophylaxis of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1757L','3618','t',$$<p>Treatment of serious and life-threatening candida infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1805B','1574','f',$$<p>Neurologically proven epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1806C','1574','f',$$<p>Neurologically proven epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1808E','1574','f',$$<p>Neurologically proven epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1822X','1023','t',$$<p>Angina not responding to other therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1834M','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1835N','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1836P','1765','f',$$<p>renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1836P','1766','f',$$<p>cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1842Y','2061','t',$$<p>Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1842Y','3083','t',$$<p>Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.</p><p> Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.</p><p> Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.</p><p> The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1846E','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1849H','3233','t',$$<p>Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1952R','4053','t',$$<p>Parkinson disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1954W','4057','f',$$<p>Initial treatment [Whole body (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist of a patient under 18 years who:<br/> (a) has severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) has not received any prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) whose parent or authorised guardian has signed a patient acknowledgement; and<br/> (d) has failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 2 of the following 3 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg or 10&#160;mg per square metre weekly (whichever is lowest) for at least 6 weeks; and/or<br/> (iii) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the parent or authorised guardian signed patient and prescriber acknowledgements.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, when compared with the pre-etanercept treatment baseline value</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1954W','4058','f',$$<p>Re-Treatment [Whole body (Received prior etanercept under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for a patient under 18 years who has:<br/> (a) a documented history of severe chronic plaque psoriasis; and<br/> (b) received prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) not failed PBS-subsidised therapy with etanercept for the treatment of this condition more than once in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior etanercept treatment, including date.</p><p> A total maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1954W','4059','f',$$<p>Initial treatment [Face, hand, foot (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist of a patient under 18 years who:<br/> (a) has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) has not received any prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) whose parent or authorised guardian has signed a patient acknowledgement; and<br/> (d) has failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 2 of the following 3 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg or 10&#160;mg per square metre weekly (whichever is lowest) for at least 6 weeks; and/or<br/> (iii) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:<br/> (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or<br/> (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets  and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the parent or authorised guardian signed patient and prescriber acknowledgements.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, when compared with the pre-etanercept treatment baseline value</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1954W','4060','f',$$<p>Re-Treatment [Face, hand, foot (Received prior etanercept under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for a patient under 18 years who has:<br/> (a) a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) received prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) not failed PBS-subsidised therapy with etanercept for the treatment of this condition more than once in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets  and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior etanercept treatment, including date.</p><p> A total maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1956Y','3877','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 to 14.<br/> Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease.  Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 to 14.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1956Y','2609','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1956Y','3878','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 to 14 for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1956Y','2611','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1963H','4057','f',$$<p>Initial treatment [Whole body (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist of a patient under 18 years who:<br/> (a) has severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) has not received any prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) whose parent or authorised guardian has signed a patient acknowledgement; and<br/> (d) has failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 2 of the following 3 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg or 10&#160;mg per square metre weekly (whichever is lowest) for at least 6 weeks; and/or<br/> (iii) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the parent or authorised guardian signed patient and prescriber acknowledgements.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, when compared with the pre-etanercept treatment baseline value</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1963H','4058','f',$$<p>Re-Treatment [Whole body (Received prior etanercept under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for a patient under 18 years who has:<br/> (a) a documented history of severe chronic plaque psoriasis; and<br/> (b) received prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) not failed PBS-subsidised therapy with etanercept for the treatment of this condition more than once in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior etanercept treatment, including date.</p><p> A total maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1963H','4059','f',$$<p>Initial treatment [Face, hand, foot (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist of a patient under 18 years who:<br/> (a) has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) has not received any prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) whose parent or authorised guardian has signed a patient acknowledgement; and<br/> (d) has failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 2 of the following 3 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg or 10&#160;mg per square metre weekly (whichever is lowest) for at least 6 weeks; and/or<br/> (iii) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:<br/> (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or<br/> (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets  and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the parent or authorised guardian signed patient and prescriber acknowledgements.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, when compared with the pre-etanercept treatment baseline value</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1963H','4060','f',$$<p>Re-Treatment [Face, hand, foot (Received prior etanercept under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for a patient under 18 years who has:<br/> (a) a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) received prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) not failed PBS-subsidised therapy with etanercept for the treatment of this condition more than once in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets  and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior etanercept treatment, including date.</p><p> A total maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1964J','4057','f',$$<p>Initial treatment [Whole body (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist of a patient under 18 years who:<br/> (a) has severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) has not received any prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) whose parent or authorised guardian has signed a patient acknowledgement; and<br/> (d) has failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 2 of the following 3 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg or 10&#160;mg per square metre weekly (whichever is lowest) for at least 6 weeks; and/or<br/> (iii) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the parent or authorised guardian signed patient and prescriber acknowledgements.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, when compared with the pre-etanercept treatment baseline value</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1964J','4058','f',$$<p>Re-Treatment [Whole body (Received prior etanercept under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for a patient under 18 years who has:<br/> (a) a documented history of severe chronic plaque psoriasis; and<br/> (b) received prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) not failed PBS-subsidised therapy with etanercept for the treatment of this condition more than once in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior etanercept treatment, including date.</p><p> A total maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1964J','4059','f',$$<p>Initial treatment [Face, hand, foot (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist of a patient under 18 years who:<br/> (a) has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) has not received any prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) whose parent or authorised guardian has signed a patient acknowledgement; and<br/> (d) has failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 2 of the following 3 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg or 10&#160;mg per square metre weekly (whichever is lowest) for at least 6 weeks; and/or<br/> (iii) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:<br/> (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or<br/> (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets  and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the parent or authorised guardian signed patient and prescriber acknowledgements.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, when compared with the pre-etanercept treatment baseline value</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1964J','4060','f',$$<p>Re-Treatment [Face, hand, foot (Received prior etanercept under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for a patient under 18 years who has:<br/> (a) a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) received prior PBS-subsidised treatment with etanercept for this condition; and<br/> (c) not failed PBS-subsidised therapy with etanercept for the treatment of this condition more than once in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis in Patients Less Than 18 Years PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets  and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior etanercept treatment, including date.</p><p> A total maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.  A maximum of 16 weeks treatment with etanercept will be authorised for the primary application.  The balance of treatment, a further 8 weeks treatment, will be authorised if the submitted PASI assessment shows an adequate demonstrated response to treatment.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for a further 8 weeks of treatment under this restriction, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their initial 16 week treatment course to ensure continuity of treatment for those patients who meet the eligibility criterion for a further 8 weeks of PBS-subsidised etanercept treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1975Y','2142','t',$$<p>Malaria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1976B','4055','f',$$<p>Initial supply for anticipated emergency treatment of an acute attack of hereditary angioedema in a patient with confirmed diagnosis of C1-esterase inhibitor deficiency who has been assessed to be at significant risk of an acute attack of hereditary angioedema by or in consultation with a clinical immunologist, respiratory physician, specialist allergist or general physician experienced in the management of patients with hereditary angioedema.</p><p> The name of the specialist consulted must be provided at the time of application for initial supply.</p><p> The name of the Approved Pathology Authority and date of the diagnosing pathology test must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1976B','4056','f',$$<p>Continuing supply for anticipated emergency treatment of an acute attack of hereditary angioedema, where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1982H','1190','f',$$<p>Leprosy in adults</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1983J','1190','f',$$<p>Leprosy in adults</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2019G','1366','t',$$<p>Severe intractable psoriasis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2019G','1363','t',$$<p>Severe forms of disorders of keratinisation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2020H','1366','t',$$<p>Severe intractable psoriasis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2020H','1363','t',$$<p>Severe forms of disorders of keratinisation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2029T','4065','f',$$<p>Initial treatment, as the sole PBS-subsidised tyrosine kinase inhibitor therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who meets the Memorial Sloan Kettering Cancer Centre (MSKCC) low to intermediate risk group and has a WHO performance status of 2 or less</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2030W','4065','f',$$<p>Initial treatment, as the sole PBS-subsidised tyrosine kinase inhibitor therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who meets the Memorial Sloan Kettering Cancer Centre (MSKCC) low to intermediate risk group and has a WHO performance status of 2 or less</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2034C','4066','f',$$<p>Continuing treatment beyond 3 months, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who has previously been issued with an authority prescription for pazopanib and who has stable or responding disease according to RECIST criteria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2034C','4067','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who was receiving treatment with pazopanib prior to 1 October 2012</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2035D','4066','f',$$<p>Continuing treatment beyond 3 months, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who has previously been issued with an authority prescription for pazopanib and who has stable or responding disease according to RECIST criteria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2035D','4067','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who was receiving treatment with pazopanib prior to 1 October 2012</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2058H','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2065Q','1351','t',$$<p>Severe chronic asthma in patients who require long-term steroid therapy and who are unable to use other forms of inhaled steroid therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2066R','1351','t',$$<p>Severe chronic asthma in patients who require long-term steroid therapy and who are unable to use other forms of inhaled steroid therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2088X','1216','f',$$<p>Malignant neoplasia (late stage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2088X','1126','f',$$<p>For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2088X','1123','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2095G','1719','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2095G','1720','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2095G','1721','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2095G','1260','t',$$<p>Patients established on this drug as a pharmaceutical benefit prior to 1&#160;November 1999</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2114G','1022','f',$$<p>Androgen deficiency in males with established pituitary or testicular disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2114G','1021','f',$$<p>Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8&#160;nmol per L, or 8-15&#160;nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2114G','1226','f',$$<p>Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2115H','1022','f',$$<p>Androgen deficiency in males with established pituitary or testicular disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2115H','1021','f',$$<p>Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8&#160;nmol per L, or 8-15&#160;nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2115H','1226','f',$$<p>Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2129C','1678','t',$$<p>Cranial diabetes insipidus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2130D','1975','f',$$<p>Panic disorder where other treatments have failed or are inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2131E','1975','f',$$<p>Panic disorder where other treatments have failed or are inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2132F','1975','f',$$<p>Panic disorder where other treatments have failed or are inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2142R','3548','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with sevelamer hydrochloride, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2142R','3549','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with sevelamer hydrochloride, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2172H','3188','f',$$<p>Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 12 hours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2214M','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2214M','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2214M','2268','t',$$<p>Crohn disease where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2214M','2269','t',$$<p>Crohn disease where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2234N','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2234N','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2234N','2268','t',$$<p>Crohn disease where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2234N','2269','t',$$<p>Crohn disease where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2246F','4033','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated colic or reflux) in a child up to the age of 24&#160;months. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2246F','4034','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2246F','4035','f',$$<p>Initial treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2250K','2734','f',$$<p>Initial treatment for up to 3 months, by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who requires an amino acid based formula as a component of a dietary elimination programme.  Treatment with oral steroids should not be commenced during the period of initial treatment.</p><p> Eosinophilic oesophagitis is demonstrated by the following criteria:<br/> (i) Chronic symptoms of reflux that persisted despite a 2-month trial of a proton pump inhibitor or chronic dysphagia; and<br/> (ii) A lack of demonstrable anatomic abnormality with the exception of stricture, which can be attributable to eosinophilic oesophagitis; and<br/> (iii) Eosinophilic infiltration of the oesophagus, demonstrated by oesophageal biopsy specimens obtained by endoscopy and where the most densely involved oesophageal biopsy had 20 or more eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.</p><p> The date of birth of the patient must be included in the authority</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2250K','2735','f',$$<p>Continuing treatment by a clinical immunologist, suitably qualified allergist or gastroenterologist in a patient 18 years of age or less with eosinophilic oesophagitis who has responded to an initial course of PBS-subsidised treatment.  Response to initial treatment is demonstrated by oesophageal biopsy specimens obtained by endoscopy, where the most densely involved oesophageal biopsy had 5 or less eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.  The response criteria will not be deemed to have been met if oral steroids were commenced during initial treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2274Q','3624','t',$$<p>Episodic treatment of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2276T','3189','f',$$<p>Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2280B','3189','f',$$<p>Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2283E','3189','f',$$<p>Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2285G','2865','f',$$<p>Treatment of a dermatophyte infection in an Aboriginal or a Torres Strait Islander person where topical treatment has failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2285G','3244','f',$$<p>Treatment of a dermatophyte infection in a patient aged up to 18 years inclusive where topical treatment and griseofulvin have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2287J','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2287J','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2287J','2268','t',$$<p>Crohn disease where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2287J','2269','t',$$<p>Crohn disease where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2313R','2759','t',$$<p>Severe refractory hypertension. Treatment must be initiated by a consultant physician</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2318B','1219','t',$$<p>Management of patients with thyroid cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2318B','1858','t',$$<p>Replacement therapy for hypothyroid patients who have documented intolerance to thyroxine sodium</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2318B','1859','t',$$<p>Replacement therapy for hypothyroid patients who have documented resistance to thyroxine sodium</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2318B','1182','t',$$<p>Initiation of thyroid therapy in severely hypothyroid patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2324H','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2338C','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2349P','2760','f',$$<p>Proven chronic lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application. Lactose intolerance must have been proven by either:<br/> (a) relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food; or<br/> (b) not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet; or<br/> (c) hydrogen breath test</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2350Q','2762','f',$$<p>Acute lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2357C','2761','f',$$<p>Proven chronic lactose intolerance in children aged 1 year and over who are significantly malnourished. The date of birth of the patient must be included in the authority application. Lactose intolerance must have been proven by either:<br/> (a) relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food; or<br/> (b) not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet; or<br/> (c) hydrogen breath test</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2358D','1790','f',$$<p>Acute lactose intolerance in children aged 1 year and over. The date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2387P','3188','f',$$<p>Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 12 hours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2388Q','3188','f',$$<p>Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 12 hours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2432B','3188','f',$$<p>Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 12 hours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2478K','3999','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in any disease phase who has failed an adequate trial of imatinib or nilotinib as first-line treatment.</p><p> Failure of an adequate trial of imatinib or nilotinib is defined as:</p><p> (i) Lack of response to initial imatinib or nilotinib therapy, defined as either:<br/> &#8212; failure to achieve a haematological response after a minimum of 3 months therapy with imatinib or nilotinib for patients initially treated in chronic phase; or<br/> &#8212; failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib or nilotinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or<br/> &#8212; failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12&#160;months therapy with imatinib or nilotinib; OR</p><p> (ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib or nilotinib therapy; OR</p><p> (iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing imatinib or nilotinib therapy; OR</p><p> (iv) Development of accelerated phase or blast crisis in a patient previously prescribed imatinib or nilotinib for any phase of chronic myeloid leukaemia.</p><p> Accelerated phase is defined by the presence of 1 or more of the following:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or<br/> (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%, provided that blast count is less than 30%; or<br/> (3) Peripheral basophils greater than or equal to 20%; or<br/> (4) Progressive splenomegaly to a size greater than or equal to 10&#160;cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or<br/> (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome); OR</p><p> Blast crisis is defined as either:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or<br/> (2) Extramedullary involvement other than spleen and liver; OR</p><p> (v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib or nilotinib therapy in patients with accelerated phase or blast crisis chronic myeloid leukaemia.</p><p> Patients should be commenced on a dose of dasatinib of at least 100&#160;mg (base) daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to dasatinib therapy or a peripheral blood BCR-ABL level of less than 1% within 18 months and thereafter at 12 monthly intervals.</p><p> Applications for authorisation must be in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Chronic Myeloid Leukaemia - Second and Third Line - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 0.1% on the international scale. (The date of the relevant pathology report needs to be provided); and<br/> (e) where there has been a loss of response to imatinib or nilotinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2478K','4000','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with dasatinib for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 18&#160;months and thereafter at 12 monthly intervals.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Second and Third Line - Application Form for continuing treatment; and<br/> (3) demonstration of continued response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18&#160;months for the initial supply), only the date of the relevant pathology report needs to be provided; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2480M','2615','f',$$<p>Treatment of chronic suppurative otitis media in an Aboriginal or a Torres Strait Islander person aged 1 month or older</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2480M','3191','f',$$<p>Treatment of chronic suppurative otitis media in a patient less than 18 years of age with perforation of the tympanic membrane</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2480M','3192','f',$$<p>Treatment of chronic suppurative otitis media in a patient less than 18 years of age with a grommet in situ</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2482P','3999','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in any disease phase who has failed an adequate trial of imatinib or nilotinib as first-line treatment.</p><p> Failure of an adequate trial of imatinib or nilotinib is defined as:</p><p> (i) Lack of response to initial imatinib or nilotinib therapy, defined as either:<br/> &#8212; failure to achieve a haematological response after a minimum of 3 months therapy with imatinib or nilotinib for patients initially treated in chronic phase; or<br/> &#8212; failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib or nilotinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or<br/> &#8212; failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12&#160;months therapy with imatinib or nilotinib; OR</p><p> (ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib or nilotinib therapy; OR</p><p> (iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing imatinib or nilotinib therapy; OR</p><p> (iv) Development of accelerated phase or blast crisis in a patient previously prescribed imatinib or nilotinib for any phase of chronic myeloid leukaemia.</p><p> Accelerated phase is defined by the presence of 1 or more of the following:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or<br/> (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%, provided that blast count is less than 30%; or<br/> (3) Peripheral basophils greater than or equal to 20%; or<br/> (4) Progressive splenomegaly to a size greater than or equal to 10&#160;cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or<br/> (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome); OR</p><p> Blast crisis is defined as either:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or<br/> (2) Extramedullary involvement other than spleen and liver; OR</p><p> (v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib or nilotinib therapy in patients with accelerated phase or blast crisis chronic myeloid leukaemia.</p><p> Patients should be commenced on a dose of dasatinib of at least 100&#160;mg (base) daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to dasatinib therapy or a peripheral blood BCR-ABL level of less than 1% within 18 months and thereafter at 12 monthly intervals.</p><p> Applications for authorisation must be in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Chronic Myeloid Leukaemia - Second and Third Line - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 0.1% on the international scale. (The date of the relevant pathology report needs to be provided); and<br/> (e) where there has been a loss of response to imatinib or nilotinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2482P','4000','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with dasatinib for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 18&#160;months and thereafter at 12 monthly intervals.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Second and Third Line - Application Form for continuing treatment; and<br/> (3) demonstration of continued response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18&#160;months for the initial supply), only the date of the relevant pathology report needs to be provided; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2485T','3999','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in any disease phase who has failed an adequate trial of imatinib or nilotinib as first-line treatment.</p><p> Failure of an adequate trial of imatinib or nilotinib is defined as:</p><p> (i) Lack of response to initial imatinib or nilotinib therapy, defined as either:<br/> &#8212; failure to achieve a haematological response after a minimum of 3 months therapy with imatinib or nilotinib for patients initially treated in chronic phase; or<br/> &#8212; failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib or nilotinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or<br/> &#8212; failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12&#160;months therapy with imatinib or nilotinib; OR</p><p> (ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib or nilotinib therapy; OR</p><p> (iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing imatinib or nilotinib therapy; OR</p><p> (iv) Development of accelerated phase or blast crisis in a patient previously prescribed imatinib or nilotinib for any phase of chronic myeloid leukaemia.</p><p> Accelerated phase is defined by the presence of 1 or more of the following:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or<br/> (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%, provided that blast count is less than 30%; or<br/> (3) Peripheral basophils greater than or equal to 20%; or<br/> (4) Progressive splenomegaly to a size greater than or equal to 10&#160;cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or<br/> (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome); OR</p><p> Blast crisis is defined as either:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or<br/> (2) Extramedullary involvement other than spleen and liver; OR</p><p> (v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib or nilotinib therapy in patients with accelerated phase or blast crisis chronic myeloid leukaemia.</p><p> Patients should be commenced on a dose of dasatinib of at least 100&#160;mg (base) daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to dasatinib therapy or a peripheral blood BCR-ABL level of less than 1% within 18 months and thereafter at 12 monthly intervals.</p><p> Applications for authorisation must be in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Chronic Myeloid Leukaemia - Second and Third Line - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 0.1% on the international scale. (The date of the relevant pathology report needs to be provided); and<br/> (e) where there has been a loss of response to imatinib or nilotinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2485T','4000','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with dasatinib for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 18&#160;months and thereafter at 12 monthly intervals.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Second and Third Line - Application Form for continuing treatment; and<br/> (3) demonstration of continued response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18&#160;months for the initial supply), only the date of the relevant pathology report needs to be provided; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2502Q','1165','t',$$<p>Hypocalcaemia due to renal disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2502Q','1166','t',$$<p>Hypoparathyroidism</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2502Q','1167','t',$$<p>Hypophosphataemic rickets</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2502Q','1467','t',$$<p>Vitamin D-resistant rickets</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2502Q','2636','t',$$<p>Treatment for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2546B','2816','f',$$<p>Treatment of biopsy confirmed primary (previously untreated) superficial basal cell carcinoma (sBCC) in patients with normal immune function for whom surgical excision, cryotherapy, or curettage with diathermy are inappropriate and topical drug therapy is required.</p><p> The date of the pathology report and name of the Approved Pathology Authority must be provided at the time of application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2549E','1354','t',$$<p>Severe cystic acne not responsive to other therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2560R','4036','f',$$<p>Treatment, in consultation with a specialist allergist or clinical immunologist, for a child with cows' milk anaphylaxis, up to the age of 24&#160;months.  Anaphylaxis is defined as a severe and/or potentially life threatening allergic reaction.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2560R','4037','f',$$<p>Continuing treatment for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2560R','4038','f',$$<p>Continuing treatment for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed at least once or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist.  Then name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2560R','4039','f',$$<p>Continuing treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months.  The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist at intervals not greater than 12&#160;months.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2560R','1687','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2560R','1688','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2591J','1354','t',$$<p>Severe cystic acne not responsive to other therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2592K','1354','t',$$<p>Severe cystic acne not responsive to other therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2667J','1426','t',$$<p>Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2668K','1426','t',$$<p>Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','4040','f',$$<p>Initial treatment by, or in consultation with, a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child should have failed to respond to a strict soy-based cows' milk protein free diet. The date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','4041','f',$$<p>Continuing treatment by, or in consultation with, a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child up to the age of 24&#160;months, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides.  The date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','4042','f',$$<p>Treatment by a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child aged over 24&#160;months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','1034','f',$$<p>Biliary atresia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','1059','f',$$<p>Chronic liver failure with fat malabsorption</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','1670','f',$$<p>Chylous ascites</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','1068','f',$$<p>Chylothorax</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','1080','f',$$<p>Cystic fibrosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','1092','f',$$<p>Enterokinase deficiency</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','1310','f',$$<p>Proven fat malabsorption</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','2567','f',$$<p>Severe diarrhoea of greater than 2 weeks' duration in an infant aged less than 4 months.  The date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2676W','1364','f',$$<p>Severe intestinal malabsorption including short bowel syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2700D','3193','t',$$<p>Ablation of thyroid remnant tissue, in combination with radioactive iodine, in a post thyroidectomy patient without known metastatic disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2732T','1235','f',$$<p>Myoclonic epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2732T','1216','f',$$<p>Malignant neoplasia (late stage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2732T','1126','f',$$<p>For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2732T','1123','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2804N','2191','f',$$<p>Proximal or extensive (greater than 80% nail involvement) onychomycosis due to dermatophyte infection where topical treatment has failed.  This infection must be proven by microscopy or culture and confirmed by an Approved Pathology Authority.  The date of the pathology report must be provided at the time of application and must not be more than 12 months old</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2848X','1426','t',$$<p>Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2849Y','1426','t',$$<p>Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2850B','1426','t',$$<p>Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2851C','1426','t',$$<p>Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2946C','1099','t',$$<p>Familial hypophosphataemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2946C','1157','t',$$<p>Hypercalcaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2946C','1167','t',$$<p>Hypophosphataemic rickets</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2946C','1467','t',$$<p>Vitamin D-resistant rickets</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2962X','1172','f',$$<p>Initial treatment (up to 6 months) of visually proven endometriosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2962X','1389','f',$$<p>Subsequent treatment (up to 6 months) of visually proven endometriosis, where 2 years or more have elapsed since the end of the previous course and where a recent bone density assessment has been made. The date of the assessment must be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2995P','3256','t',$$<p>Symptomatic Paget disease of bone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2995P','1412','t',$$<p>Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2997R','3256','t',$$<p>Symptomatic Paget disease of bone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2997R','1412','t',$$<p>Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3010K','1002','f',$$<p>Acute bacterial enterocolitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3010K','1070','f',$$<p>Complicated urinary tract infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3036T','2758','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a woman aged 70 years or older with a bone mineral density (BMD) T-score of -3.0 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3036T','2647','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3092R','1158','f',$$<p>Hypercalcaemia in children under the age of 4 years</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3113W','1701','f',$$<p>Antibiotic associated pseudomembranous colitis due to Clostridium difficile which is unresponsive to metronidazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3113W','1702','f',$$<p>Antibiotic associated pseudomembranous colitis due to Clostridium difficile where there is intolerance to metronidazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3114X','1701','f',$$<p>Antibiotic associated pseudomembranous colitis due to Clostridium difficile which is unresponsive to metronidazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3114X','1702','f',$$<p>Antibiotic associated pseudomembranous colitis due to Clostridium difficile where there is intolerance to metronidazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3116B','2212','t',$$<p>Hyperphosphataemia associated with chronic renal failure</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3117C','2212','t',$$<p>Hyperphosphataemia associated with chronic renal failure</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3128P','1670','f',$$<p>Chylous ascites</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3128P','1068','f',$$<p>Chylothorax</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3128P','1671','f',$$<p>Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3128P','1513','f',$$<p>Hyperlipoproteinaemia type 1</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3128P','1672','f',$$<p>Intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect, requiring a ketogenic diet</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3128P','1511','f',$$<p>Long chain fatty acid oxidation disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3134Y','1216','f',$$<p>Malignant neoplasia (late stage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3134Y','1126','f',$$<p>For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3134Y','1123','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3135B','1216','f',$$<p>Malignant neoplasia (late stage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3135B','1126','f',$$<p>For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3135B','1123','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3169T','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3169T','2272','t',$$<p>Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3170W','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3170W','2272','t',$$<p>Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3171X','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3171X','2272','t',$$<p>Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3172Y','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3172Y','2272','t',$$<p>Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3381Y','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3381Y','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3382B','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3382B','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3384D','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3384D','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3385E','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3385E','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3387G','3540','t',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3401B','3429','f',$$<p>Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3401B','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3408J','3434','f',$$<p>has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician. The name of the specialist consulted must be provided at the time of application for initial supply</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3408J','3435','f',$$<p>has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3408J','3436','f',$$<p>Continuing sole PBS-subsidised supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis, where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3409K','3434','f',$$<p>has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician. The name of the specialist consulted must be provided at the time of application for initial supply</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3409K','3435','f',$$<p>has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3409K','3436','f',$$<p>Continuing sole PBS-subsidised supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis, where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3413P','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3413P','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3413P','2268','t',$$<p>Crohn disease where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3413P','2269','t',$$<p>Crohn disease where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3414Q','3447','f',$$<p>Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program.<br/> Details of the program must be specified in the initial authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3414Q','3448','f',$$<p>Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.<br/> Details of the program must be specified in the initial authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3415R','3540','t',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3423E','3540','t',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3423E','3542','t',$$<p>Triple oral combination therapy with metformin and a sulfonylurea<br/> Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with maximally tolerated doses of metformin and a sulfonylurea.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3424F','3540','t',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3424F','3542','t',$$<p>Triple oral combination therapy with metformin and a sulfonylurea<br/> Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with maximally tolerated doses of metformin and a sulfonylurea.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3425G','3714','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with certolizumab pegol, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 18 to 20 weeks of treatment depending on the dosage regimen will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 18 or 20 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with certolizumab pegol.</p><p> Patients who fail to demonstrate a response to treatment with certolizumab pegol under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3425G','3769','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with certolizumab pegol, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with certolizumab pegol and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised certolizumab pegol treatment, within the timeframes specified below.</p><p> A maximum of 18 to 20 weeks of treatment depending on the dosage regimen will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 18 or 20 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised certolizumab pegol treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised certolizumab pegol treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with certolizumab pegol under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3425G','3768','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with certolizumab pegol, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with certolizumab pegol; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with certolizumab pegol.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with certolizumab pegol must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with certolizumab pegol, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with certolizumab pegol under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3426H','3718','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with golimumab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with golimumab.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3426H','3782','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with golimumab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with golimumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised golimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised golimumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised golimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3427J','3718','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with golimumab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with golimumab.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3427J','3782','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with golimumab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with golimumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised golimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised golimumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised golimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3428K','3783','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with golimumab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with golimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with golimumab.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with golimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with golimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3429L','3783','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with golimumab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with golimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with golimumab.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with golimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with golimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3430M','3495','f',$$<p>Initial 1<br/> Initial PBS-subsidised treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have severe active psoriatic arthritis; and<br/> (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and<br/> (3) have failed to achieve an adequate response to:<br/> (a) methotrexate at a dose of at least 20&#160;mg weekly for a minimum period of 3 months; and<br/> (b) sulfasalazine at a dose of at least 2&#160;g per day for a minimum period of 3 months; or<br/> (c) leflunomide at a dose of up to 20&#160;mg daily for a minimum period of 3 months.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3430M','3784','f',$$<p>Initial 2<br/> Initial PBS-subsidised treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have a documented history of severe active psoriatic arthritis; and<br/> (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and<br/> (3) have not failed treatment with golimumab during the current Treatment Cycle.</p><p> Applications for patients who have received PBS-subsidised treatment with golimumab within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised golimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised golimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised golimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3431N','3495','f',$$<p>Initial 1<br/> Initial PBS-subsidised treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have severe active psoriatic arthritis; and<br/> (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and<br/> (3) have failed to achieve an adequate response to:<br/> (a) methotrexate at a dose of at least 20&#160;mg weekly for a minimum period of 3 months; and<br/> (b) sulfasalazine at a dose of at least 2&#160;g per day for a minimum period of 3 months; or<br/> (c) leflunomide at a dose of up to 20&#160;mg daily for a minimum period of 3 months.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3431N','3784','f',$$<p>Initial 2<br/> Initial PBS-subsidised treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have a documented history of severe active psoriatic arthritis; and<br/> (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and<br/> (3) have not failed treatment with golimumab during the current Treatment Cycle.</p><p> Applications for patients who have received PBS-subsidised treatment with golimumab within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised golimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised golimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised golimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3432P','3497','f',$$<p>Initial 3 &#8212; grandfather golimumab patients<br/> Initial PBS-subsidised supply for continuing treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have a documented history of severe active psoriatic arthritis; and<br/> (2) were receiving treatment with golimumab prior to 1&#160;March 2010; and<br/> (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with golimumab; and<br/> (4) are receiving treatment with golimumab at the time of application.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 24 weeks of treatment with golimumab will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3432P','3785','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:<br/> (1) who have a documented history of severe active psoriatic arthritis; and<br/> (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with golimumab; and<br/> (3) who, at the time of application, demonstrate an adequate response to treatment with golimumab.</p><p> An adequate response to treatment with golimumab is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline; AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with golimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with golimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3433Q','3497','f',$$<p>Initial 3 &#8212; grandfather golimumab patients<br/> Initial PBS-subsidised supply for continuing treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have a documented history of severe active psoriatic arthritis; and<br/> (2) were receiving treatment with golimumab prior to 1&#160;March 2010; and<br/> (3) have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with golimumab; and<br/> (4) are receiving treatment with golimumab at the time of application.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 24 weeks of treatment with golimumab will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3433Q','3785','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with golimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:<br/> (1) who have a documented history of severe active psoriatic arthritis; and<br/> (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with golimumab; and<br/> (3) who, at the time of application, demonstrate an adequate response to treatment with golimumab.</p><p> An adequate response to treatment with golimumab is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline; AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with golimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with golimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3434R','3516','f',$$<p>Initial 1 (new patients)<br/> Initial PBS-subsidised treatment with golimumab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND<br/> (a) who has at least 2 of the following:<br/> (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or<br/> (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or<br/> (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND<br/> (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.</p><p> The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p> If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p> If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:<br/> (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND<br/> (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 10&#160;mg per L.</p><p> The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p> Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:<br/> (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and<br/> (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and<br/> (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and<br/> (iv) a signed patient acknowledgment form.</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A maximum of 16 weeks of treatment with golimumab will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3434R','3786','f',$$<p>Initial 2 (change or re-commencement for all patients)<br/> Initial PBS-subsidised treatment with golimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with golimumab in the current treatment cycle.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Where the most recent course of PBS-subsidised golimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> A maximum of 16 weeks of treatment with golimumab will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3435T','3516','f',$$<p>Initial 1 (new patients)<br/> Initial PBS-subsidised treatment with golimumab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND<br/> (a) who has at least 2 of the following:<br/> (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or<br/> (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or<br/> (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND<br/> (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.</p><p> The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p> If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p> If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:<br/> (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND<br/> (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 10&#160;mg per L.</p><p> The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p> Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:<br/> (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and<br/> (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and<br/> (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and<br/> (iv) a signed patient acknowledgment form.</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A maximum of 16 weeks of treatment with golimumab will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3435T','3786','f',$$<p>Initial 2 (change or re-commencement for all patients)<br/> Initial PBS-subsidised treatment with golimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with golimumab in the current treatment cycle.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Where the most recent course of PBS-subsidised golimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> A maximum of 16 weeks of treatment with golimumab will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3436W','3518','f',$$<p>Initial ('grandfather' patients)<br/> Initial PBS-subsidised supply for continuing treatment with golimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who was receiving treatment with golimumab prior to 1&#160;March 2010; and<br/> (a) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with golimumab; and<br/> (b) is receiving treatment with golimumab at the time of application.</p><p> The BASDAI assessment and ESR and/or CRP measurements provided must be no more than 1 month old at the time of application.  Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes the following:<br/> (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and<br/> (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and<br/> (iii) a signed patient acknowledgment form.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of the course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is due in order to ensure continuity of treatment for those patients who meet the continuation criteria.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.</p><p> Patients may only qualify for PBS-subsidised treatment under this criterion once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3436W','3787','f',$$<p>Continuing treatment for all patients<br/> Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:<br/> (a) has demonstrated an adequate response to treatment with golimumab; and<br/> (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with golimumab.</p><p> An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:<br/> (a) an ESR measurement no greater than 25&#160;mm per hour; or<br/> (b) a CRP measurement no greater than 10&#160;mg per L; or<br/> (c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p> Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> All measurements provided must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</p><p> All applications for continuing treatment with golimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with golimumab.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3437X','3518','f',$$<p>Initial ('grandfather' patients)<br/> Initial PBS-subsidised supply for continuing treatment with golimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who was receiving treatment with golimumab prior to 1&#160;March 2010; and<br/> (a) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with golimumab; and<br/> (b) is receiving treatment with golimumab at the time of application.</p><p> The BASDAI assessment and ESR and/or CRP measurements provided must be no more than 1 month old at the time of application.  Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which includes the following:<br/> (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and<br/> (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and<br/> (iii) a signed patient acknowledgment form.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of the course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is due in order to ensure continuity of treatment for those patients who meet the continuation criteria.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle.</p><p> Patients may only qualify for PBS-subsidised treatment under this criterion once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3437X','3787','f',$$<p>Continuing treatment for all patients<br/> Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:<br/> (a) has demonstrated an adequate response to treatment with golimumab; and<br/> (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with golimumab.</p><p> An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:<br/> (a) an ESR measurement no greater than 25&#160;mm per hour; or<br/> (b) a CRP measurement no greater than 10&#160;mg per L; or<br/> (c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p> Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> All measurements provided must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with golimumab will be authorised under this criterion.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</p><p> All applications for continuing treatment with golimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with golimumab.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with golimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial golimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3440C','3189','f',$$<p>Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3445H','3524','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).</p><p> Initial treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND<br/> (b) has received no PBS-subsidised treatment with a bDMARD for this condition in the previous 12 months; and<br/> (c) has failed to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg per day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialed, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3445H','3770','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).</p><p> Initial PBS-subsidised treatment with etanercept by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with etanercept for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for a patient who has received PBS-subsidised treatment with etanercept in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with etanercept may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial etanercept after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3446J','3524','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).</p><p> Initial treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND<br/> (b) has received no PBS-subsidised treatment with a bDMARD for this condition in the previous 12 months; and<br/> (c) has failed to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg per day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialed, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3446J','3770','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).</p><p> Initial PBS-subsidised treatment with etanercept by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with etanercept for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for a patient who has received PBS-subsidised treatment with etanercept in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with etanercept may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial etanercept after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3447K','3524','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).</p><p> Initial treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND<br/> (b) has received no PBS-subsidised treatment with a bDMARD for this condition in the previous 12 months; and<br/> (c) has failed to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg per day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialed, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3447K','3770','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).</p><p> Initial PBS-subsidised treatment with etanercept by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with etanercept for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for a patient who has received PBS-subsidised treatment with etanercept in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with etanercept may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial etanercept after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3448L','3771','f',$$<p>Continuing treatment.</p><p> Continuing PBS-subsidised treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; and<br/> (b) who has demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with etanercept.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) an active joint count of fewer than 10 active (swollen and tender) joints; or<br/> (ii) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or<br/> (iii) a reduction in the number of the following active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial etanercept after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3449M','3771','f',$$<p>Continuing treatment.</p><p> Continuing PBS-subsidised treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; and<br/> (b) who has demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with etanercept.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) an active joint count of fewer than 10 active (swollen and tender) joints; or<br/> (ii) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or<br/> (iii) a reduction in the number of the following active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial etanercept after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3450N','3771','f',$$<p>Continuing treatment.</p><p> Continuing PBS-subsidised treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; and<br/> (b) who has demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with etanercept.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) an active joint count of fewer than 10 active (swollen and tender) joints; or<br/> (ii) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or<br/> (iii) a reduction in the number of the following active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial etanercept after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5054B','3991','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 15 days of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5054B','4044','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 15 days supply to complete a course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5061J','4046','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 30 days supply to complete a course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5100K','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5102M','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5103N','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5107T','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5109X','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5110Y','1035','f',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5110Y','4051','f',$$<p>Bone metastases from castration-resistant prostate cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5140M','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5140M','3935','t',$$<p>Treatment, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5140M','3936','t',$$<p>Maintenance treatment, as monotherapy, of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5141N','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5141N','3935','t',$$<p>Treatment, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5141N','3936','t',$$<p>Maintenance treatment, as monotherapy, of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5146W','3937','f',$$<p>Hypomagnesaemia in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5146W','3938','f',$$<p>Chronic renal disease in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5262Y','3845','f',$$<p>Initial treatment, as monotherapy, of clinically definite relapsing-remitting multiple sclerosis in an ambulatory (without assistance or support) patient who has experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5262Y','3846','f',$$<p>Continuing treatment, as monotherapy, of clinically definite relapsing-remitting multiple sclerosis in a patient previously issued with an authority prescription for this drug who does not show continuing progression of disability while on treatment with this drug and who has demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5281Y','3520','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).</p><p> Initial treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND<br/> (b) has received no PBS-subsidised treatment with a bDMARD for this condition in the previous 12 months; and<br/> (c) has failed to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg per day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialed, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5281Y','3743','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).</p><p> Initial PBS-subsidised treatment with adalimumab by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for a patient who has received PBS-subsidised treatment with adalimumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5282B','3520','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).</p><p> Initial treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND<br/> (b) has received no PBS-subsidised treatment with a bDMARD for this condition in the previous 12 months; and<br/> (c) has failed to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate. Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg per day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialed, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5282B','3743','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).</p><p> Initial PBS-subsidised treatment with adalimumab by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of juvenile idiopathic arthritis with onset prior to the age of 18 years; AND<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for a patient who has received PBS-subsidised treatment with adalimumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5283C','3522','f',$$<p>Initial 3 ('grandfather' patients).</p><p> Initial PBS-subsidised supply for continuing treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; and<br/> (b) was receiving treatment with adalimumab prior to 1&#160;March 2010; and<br/> (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab; and<br/> (d) is receiving treatment with adalimumab at the time of application.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 24 weeks of treatment with adalimumab will be approved under this criterion.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The same indices of disease severity used to establish baseline at the commencement of treatment with a bDMARD must be used for assessment of all continuing applications.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> A patient may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5283C','3744','f',$$<p>Continuing treatment.</p><p> Continuing PBS-subsidised treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; and<br/> (b) who has demonstrated an adequate response to treatment with adalimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with adalimumab.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) an active joint count of fewer than 10 active (swollen and tender) joints; or<br/> (ii) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or<br/> (iii) a reduction in the number of the following active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5284D','3522','f',$$<p>Initial 3 ('grandfather' patients).</p><p> Initial PBS-subsidised supply for continuing treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; and<br/> (b) was receiving treatment with adalimumab prior to 1&#160;March 2010; and<br/> (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab; and<br/> (d) is receiving treatment with adalimumab at the time of application.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 24 weeks of treatment with adalimumab will be approved under this criterion.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The same indices of disease severity used to establish baseline at the commencement of treatment with a bDMARD must be used for assessment of all continuing applications.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> A patient may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5284D','3744','f',$$<p>Continuing treatment.</p><p> Continuing PBS-subsidised treatment, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of a patient aged 18 years or older:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; and<br/> (b) who has demonstrated an adequate response to treatment with adalimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with adalimumab.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) an active joint count of fewer than 10 active (swollen and tender) joints; or<br/> (ii) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or<br/> (iii) a reduction in the number of the following active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 5 years have elapsed between the date of the last approval for PBS-subsidised bDMARD therapy in the last treatment cycle and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5290K','3233','t',$$<p>Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5291L','3233','t',$$<p>Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5296R','3551','f',$$<p>Treatment of suspected or confirmed malaria due to Plasmodium falciparum in a patient unable to swallow a solid dosage form of artemether with lumefantrine</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5297T','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5299X','3080','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5300Y','3080','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5436D','1719','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5436D','1720','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5436D','1721','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5436D','1722','t',$$<p>Prevention of recurrence of myocardial infarction or unstable angina in patients with a history of symptomatic cardiac ischaemic events while on therapy with low-dose aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5436D','1723','t',$$<p>Prevention of recurrence of myocardial infarction or unstable angina in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5436D','1724','t',$$<p>Prevention of recurrence of myocardial infarction or unstable angina in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5442K','3842','t',$$<p>Management of a proven Pseudomonas aeruginosa infection in a patient with cystic fibrosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5443L','3847','f',$$<p>Adjuvant treatment of a patient at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST) which has been histologically confirmed by the detection of CD117 on immunohistochemical staining, at a dose not exceeding 400&#160;mg per day for a period of 12 months.</p><p> High risk of recurrence is defined as:<br/> Primary GIST greater than 5&#160;cm with a mitotic count of greater than 5/50 high power fields (HPF); or<br/> Primary GIST greater than 10&#160;cm with any mitotic rate; or<br/> Primary GIST with a mitotic count of greater than 10/50 HPF.<br/> (Prognosis definition based on the Australian and New Zealand consensus approach to best practice management, see Zalcberg et al. Asia-Pacific Journal of Clinical Oncology 2008: 4.4: 188-98.)</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in Adjuvant Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and<br/> (ii) a copy of the pathology report must include the size and mitotic rate of the tumour, and the date of tumour resection must be documented, which must not be more than 3 months prior to the date of this application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5443L','3848','f',$$<p>Initial treatment of a patient who was receiving adjuvant imatinib mesylate for gastrointestinal stromal tumour (GIST) prior to 1&#160;September 2011 and who meets the PBS eligibility criteria for adjuvant treatment with imatinib mesylate of a patient at high risk of recurrence following complete resection of primary GIST. The patient is eligible to receive sufficient imatinib at a dose of 400&#160;mg per day to complete 12 months of combined PBS-subsidised and non-PBS-subsidised therapy.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in Adjuvant Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and<br/> (ii) a copy of the pathology report must include the size and mitotic rate of the tumour, and the date of tumour resection must be documented</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5444M','3847','f',$$<p>Adjuvant treatment of a patient at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST) which has been histologically confirmed by the detection of CD117 on immunohistochemical staining, at a dose not exceeding 400&#160;mg per day for a period of 12 months.</p><p> High risk of recurrence is defined as:<br/> Primary GIST greater than 5&#160;cm with a mitotic count of greater than 5/50 high power fields (HPF); or<br/> Primary GIST greater than 10&#160;cm with any mitotic rate; or<br/> Primary GIST with a mitotic count of greater than 10/50 HPF.<br/> (Prognosis definition based on the Australian and New Zealand consensus approach to best practice management, see Zalcberg et al. Asia-Pacific Journal of Clinical Oncology 2008: 4.4: 188-98.)</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in Adjuvant Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and<br/> (ii) a copy of the pathology report must include the size and mitotic rate of the tumour, and the date of tumour resection must be documented, which must not be more than 3 months prior to the date of this application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5444M','3848','f',$$<p>Initial treatment of a patient who was receiving adjuvant imatinib mesylate for gastrointestinal stromal tumour (GIST) prior to 1&#160;September 2011 and who meets the PBS eligibility criteria for adjuvant treatment with imatinib mesylate of a patient at high risk of recurrence following complete resection of primary GIST. The patient is eligible to receive sufficient imatinib at a dose of 400&#160;mg per day to complete 12 months of combined PBS-subsidised and non-PBS-subsidised therapy.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in Adjuvant Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and<br/> (ii) a copy of the pathology report must include the size and mitotic rate of the tumour, and the date of tumour resection must be documented</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5446P','3835','f',$$<p>Treatment of cryptococcal meningitis in a patient unable to take a solid dose form of fluconazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5446P','3836','f',$$<p>Maintenance therapy in a patient with cryptococcal meningitis and immunosuppression unable to take a solid dose form of fluconazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5446P','3837','f',$$<p>Treatment of oropharyngeal candidiasis in an immunosuppressed patient unable to take a solid dose form of fluconazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5446P','3838','f',$$<p>Treatment of oesophageal candidiasis in an immunosuppressed patient unable to take a solid dose form of fluconazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5446P','3839','f',$$<p>Prophylaxis of oropharyngeal candidiasis in an immunosuppressed patient unable to take a solid dose form of fluconazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5446P','3840','f',$$<p>Treatment of serious and life-threatening candida infections in a patient unable to take a solid dose form of fluconazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5449T','2682','t',$$<p>Treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5450W','2682','t',$$<p>Treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5451X','3080','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5455D','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5456E','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5457F','4054','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a woman aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -2.5 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5457F','3987','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in a woman with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5458G','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5458G','2765','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5458G','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5465P','3042','f',$$<p>Nicotine dependence in an Aboriginal or a Torres Strait Islander person as the sole PBS-subsidised therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5465P','3447','f',$$<p>Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program.<br/> Details of the program must be specified in the initial authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5465P','3448','f',$$<p>Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.<br/> Details of the program must be specified in the initial authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5466Q','4033','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated colic or reflux) in a child up to the age of 24&#160;months. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5466Q','4034','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5466Q','4035','f',$$<p>Initial treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5467R','4036','f',$$<p>Treatment, in consultation with a specialist allergist or clinical immunologist, for a child with cows' milk anaphylaxis, up to the age of 24&#160;months.  Anaphylaxis is defined as a severe and/or potentially life threatening allergic reaction.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5467R','4037','f',$$<p>Continuing treatment for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5467R','4038','f',$$<p>Continuing treatment for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed at least once or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist.  Then name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5467R','4039','f',$$<p>Continuing treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months.  The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist at intervals not greater than 12&#160;months.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5467R','1687','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5467R','1688','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5468T','3667','t',$$<p>Treatment, in combination with an alpha-antagonist, of lower urinary tract symptoms due to benign prostatic hyperplasia where treatment is initiated by a urologist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5469W','3671','f',$$<p>Completion of short-term sole PBS-subsidised therapy as an aid to achieving long-term abstinence after completion of an initial 12-week PBS-subsidised course in a patient who has ceased smoking, and who is enrolled in a comprehensive support and counselling program</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5472B','3611','t',$$<p>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5473C','3611','t',$$<p>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5474D','3543','t',$$<p>Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5474D','3686','t',$$<p>Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and vildagliptin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5475E','3543','t',$$<p>Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5475E','3686','t',$$<p>Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and vildagliptin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5476F','3543','t',$$<p>Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5476F','3686','t',$$<p>Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and vildagliptin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5480K','3623','t',$$<p>Suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5490Y','3687','t',$$<p>Treatment of lower urinary tract symptoms due to benign prostatic hyperplasia where treatment has been initiated by a urologist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5491B','1666','f',$$<p>Adverse effects occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5491B','1667','f',$$<p>Drug interactions occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5491B','1668','f',$$<p>Drug interactions expected to occur with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5491B','1406','f',$$<p>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5492C','1666','f',$$<p>Adverse effects occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5492C','1667','f',$$<p>Drug interactions occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5492C','1668','f',$$<p>Drug interactions expected to occur with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5492C','1406','f',$$<p>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5493D','1666','f',$$<p>Adverse effects occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5493D','1667','f',$$<p>Drug interactions occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5493D','1668','f',$$<p>Drug interactions expected to occur with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5493D','1406','f',$$<p>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5494E','1666','f',$$<p>Adverse effects occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5494E','1667','f',$$<p>Drug interactions occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5494E','1668','f',$$<p>Drug interactions expected to occur with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5494E','1406','f',$$<p>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5495F','1666','f',$$<p>Adverse effects occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5495F','1667','f',$$<p>Drug interactions occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5495F','1668','f',$$<p>Drug interactions expected to occur with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5495F','1406','f',$$<p>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5500L','3957','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 10 days of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5500L','4043','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 10 days supply to complete a course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5571F','3042','f',$$<p>Nicotine dependence in an Aboriginal or a Torres Strait Islander person as the sole PBS-subsidised therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5572G','3447','f',$$<p>Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program.<br/> Details of the program must be specified in the initial authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5572G','3448','f',$$<p>Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.<br/> Details of the program must be specified in the initial authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5573H','3447','f',$$<p>Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program.<br/> Details of the program must be specified in the initial authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5573H','3448','f',$$<p>Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.<br/> Details of the program must be specified in the initial authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8002E','3622','t',$$<p>Treatment of patients with herpes zoster within 72 hours of the onset of the rash</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8015W','3652','t',$$<p>Short-term treatment (up to 6 months) of visually proven endometriosis (only 1 course of not more than 6 months' therapy may be prescribed)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8019C','1014','t',$$<p>Advanced carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8019C','1404','t',$$<p>To reduce drive in sexual deviations in males</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8048N','1716','t',$$<p>Patients undergoing percutaneous coronary balloon angioplasty</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8048N','1717','t',$$<p>Patients undergoing percutaneous coronary atherectomy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8048N','1718','t',$$<p>Patients undergoing percutaneous coronary stent placement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8063J','1426','t',$$<p>Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8064K','3622','t',$$<p>Treatment of patients with herpes zoster within 72 hours of the onset of the rash</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8064K','3631','t',$$<p>Herpes zoster ophthalmicus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8086N','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8086N','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8090T','3256','t',$$<p>Symptomatic Paget disease of bone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8092X','3624','t',$$<p>Episodic treatment of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8093Y','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8094B','3674','t',$$<p>Metastatic (equivalent to stage D) prostatic carcinoma in combination with GnRH (LH-RH) analogue therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8098F','1022','f',$$<p>Androgen deficiency in males with established pituitary or testicular disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8098F','1021','f',$$<p>Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8&#160;nmol per L, or 8-15&#160;nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8098F','1226','f',$$<p>Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8099G','1022','f',$$<p>Androgen deficiency in males with established pituitary or testicular disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8099G','1021','f',$$<p>Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8&#160;nmol per L, or 8-15&#160;nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8099G','1226','f',$$<p>Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8100H','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8100H','2272','t',$$<p>Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8101J','1175','f',$$<p>Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8101J','1751','f',$$<p>Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8114C','2659','t',$$<p>Pathological hyperprolactinaemia where surgery is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8114C','2660','t',$$<p>Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8114C','2661','t',$$<p>Pathological hyperprolactinaemia where radiotherapy is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8114C','2662','t',$$<p>Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8118G','1975','f',$$<p>Panic disorder where other treatments have failed or are inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8131Y','3675','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) prostatic carcinoma, in combination with GnRH (LH-RH) analogue therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8131Y','3300','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) prostatic carcinoma, in conjunction with surgical orchidectomy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8133C','3632','t',$$<p>Moderate to severe initial genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is desirable but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8134D','3624','t',$$<p>Episodic treatment of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8144P','3233','t',$$<p>Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8163P','2797','t',$$<p>Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8163P','2799','t',$$<p>Prophylaxis of migraine in a patient who has experienced an average of 3 or more migraines per month over a period of at least 6 months, and who:<br/> (a) has a contraindication to beta-blockers, as described in the relevant TGA-approved Product Information; OR<br/> (b) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with a beta-blocker;<br/> AND<br/> (c) has a contraindication to pizotifen because the weight gain associated with this drug poses an unacceptable risk; OR<br/> (d) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with pizotifen.</p><p> Details of the contraindication and/or intolerance(s) must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8164Q','2797','t',$$<p>Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8164Q','2799','t',$$<p>Prophylaxis of migraine in a patient who has experienced an average of 3 or more migraines per month over a period of at least 6 months, and who:<br/> (a) has a contraindication to beta-blockers, as described in the relevant TGA-approved Product Information; OR<br/> (b) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with a beta-blocker;<br/> AND<br/> (c) has a contraindication to pizotifen because the weight gain associated with this drug poses an unacceptable risk; OR<br/> (d) has experienced intolerance of a severity necessitating permanent withdrawal during treatment with pizotifen.</p><p> Details of the contraindication and/or intolerance(s) must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8165R','2797','t',$$<p>Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8166T','2797','t',$$<p>Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8170B','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8170B','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8180M','1149','f',$$<p>Hairy cell leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8180M','1234','f',$$<p>Myeloproliferative disease with excessive thrombocytosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8181N','1196','f',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8182P','1196','f',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8183Q','1196','f',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8184R','1196','f',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8185T','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8185T','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8186W','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8186W','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8187X','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8187X','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8196J','3607','t',$$<p>Systemic aspergillosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8196J','3608','t',$$<p>Systemic sporotrichosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8196J','3609','t',$$<p>Systemic histoplasmosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8196J','3610','t',$$<p>Treatment and maintenance therapy in patients with AIDS who have disseminated pulmonary histoplasmosis infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8196J','3612','t',$$<p>Treatment and maintenance therapy in patients with AIDS who have chronic pulmonary histoplasmosis infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8196J','3613','t',$$<p>Treatment of oropharyngeal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8196J','3614','t',$$<p>Treatment of oesophageal candidiasis in immunosuppressed patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8208B','3256','t',$$<p>Symptomatic Paget disease of bone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8209C','3256','t',$$<p>Symptomatic Paget disease of bone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8217L','3623','t',$$<p>Suppressive therapy of moderate to severe recurrent genital herpes. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8221Q','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8222R','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8223T','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8233H','3611','t',$$<p>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8234J','3630','t',$$<p>Patients with advanced HIV disease (CD4 cell counts of less than 150&#160;million per litre)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8255L','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8255L','1735','t',$$<p>Patients receiving this drug as a pharmaceutical benefit prior to 1&#160;August 2002</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8256M','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8256M','1735','t',$$<p>Patients receiving this drug as a pharmaceutical benefit prior to 1&#160;August 2002</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8257N','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8257N','1735','t',$$<p>Patients receiving this drug as a pharmaceutical benefit prior to 1&#160;August 2002</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8258P','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8258P','1735','t',$$<p>Patients receiving this drug as a pharmaceutical benefit prior to 1&#160;August 2002</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8259Q','4040','f',$$<p>Initial treatment by, or in consultation with, a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child should have failed to respond to a strict soy-based cows' milk protein free diet. The date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8259Q','4041','f',$$<p>Continuing treatment by, or in consultation with, a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child up to the age of 24&#160;months, where clinical improvement has been demonstrated with the protein hydrolysate formula with medium chain triglycerides.  The date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8259Q','4042','f',$$<p>Treatment by a specialist allergist, clinical immunologist, paediatrician or specialist paediatric gastroenterologist for both cows' milk protein enteropathy and intolerance to soy protein (not isolated infant colic or reflux) in a child aged over 24&#160;months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8259Q','1034','f',$$<p>Biliary atresia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8259Q','1059','f',$$<p>Chronic liver failure with fat malabsorption</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8259Q','1670','f',$$<p>Chylous ascites</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8259Q','1080','f',$$<p>Cystic fibrosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8259Q','1092','f',$$<p>Enterokinase deficiency</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8259Q','1310','f',$$<p>Proven fat malabsorption</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8259Q','2567','f',$$<p>Severe diarrhoea of greater than 2 weeks' duration in an infant aged less than 4 months.  The date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8259Q','1364','f',$$<p>Severe intestinal malabsorption including short bowel syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8267D','3256','t',$$<p>Symptomatic Paget disease of bone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8282X','2762','f',$$<p>Acute lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8283Y','2760','f',$$<p>Proven chronic lactose intolerance in infants up to the age of 12 months. The date of birth of the patient must be included in the authority application. Lactose intolerance must have been proven by either:<br/> (a) relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food; or<br/> (b) not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet; or<br/> (c) hydrogen breath test</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8289G','1175','f',$$<p>Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8289G','1751','f',$$<p>Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8299T','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8300W','1433','t',$$<p>Treatment of mild to moderate Pneumocystis carinii pneumonia in adult patients who are intolerant of trimethoprim/sulfamethoxazole therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8315P','1427','f',$$<p>Treatment of febrile neutropenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8316Q','1427','f',$$<p>Treatment of febrile neutropenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8341B','3233','t',$$<p>Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8348J','1206','f',$$<p>Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8348J','1196','f',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8350L','1729','t',$$<p>Patients with high risk unstable angina who have new transient or persistent ST-T ischaemic changes and anginal pain lasting longer than 20 minutes</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8350L','1730','t',$$<p>Patients with high risk unstable angina who have new transient or persistent ST-T ischaemic changes and repetitive episodes of angina at rest or during minimal exercise in the previous 12 hours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8350L','1275','t',$$<p>Patients with non-Q-wave myocardial infarction</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8357W','2665','t',$$<p>For use within a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8358X','1719','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8358X','1720','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8358X','1721','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8358X','1722','t',$$<p>Prevention of recurrence of myocardial infarction or unstable angina in patients with a history of symptomatic cardiac ischaemic events while on therapy with low-dose aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8358X','1723','t',$$<p>Prevention of recurrence of myocardial infarction or unstable angina in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8358X','1724','t',$$<p>Prevention of recurrence of myocardial infarction or unstable angina in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8359Y','1242','t',$$<p>Onchocerciasis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8359Y','1388','t',$$<p>Strongyloidiasis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8361C','1738','f',$$<p>Advanced breast cancer after failure of prior therapy which includes a taxane and an anthracycline</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8361C','1739','f',$$<p>Advanced breast cancer where therapy with a taxane and/or an anthracycline is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8361C','1614','f',$$<p>Advanced breast cancer in combination with docetaxel after failure of prior anthracycline-containing chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8361C','1522','f',$$<p>Treatment of advanced or metastatic colorectal cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8361C','3942','f',$$<p>Adjuvant treatment of stage III (Dukes C) colon cancer, following complete resection of the primary tumour either as:<br/> (a) monotherapy; or<br/> (b) in combination with oxaliplatin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8361C','3509','f',$$<p>Advanced (Stage III or IV) oesophago-gastric cancer, previously untreated, in combination with a cisplatin-based regimen, in a patient with a WHO performance status of 2 or less</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8362D','1738','f',$$<p>Advanced breast cancer after failure of prior therapy which includes a taxane and an anthracycline</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8362D','1739','f',$$<p>Advanced breast cancer where therapy with a taxane and/or an anthracycline is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8362D','1614','f',$$<p>Advanced breast cancer in combination with docetaxel after failure of prior anthracycline-containing chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8362D','1522','f',$$<p>Treatment of advanced or metastatic colorectal cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8362D','3942','f',$$<p>Adjuvant treatment of stage III (Dukes C) colon cancer, following complete resection of the primary tumour either as:<br/> (a) monotherapy; or<br/> (b) in combination with oxaliplatin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8362D','3509','f',$$<p>Advanced (Stage III or IV) oesophago-gastric cancer, previously untreated, in combination with a cisplatin-based regimen, in a patient with a WHO performance status of 2 or less</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8363E','2647','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8367J','2067','t',$$<p>Parkinson's disease as adjunctive therapy in patients being treated with levodopa&#8212;decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8370M','1135','f',$$<p>For use within a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8371N','2798','t',$$<p>Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs in patients unable to take a solid dose form of topiramate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8372P','2798','t',$$<p>Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs in patients unable to take a solid dose form of topiramate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8373Q','2643','t',$$<p>Initial treatment of severe active rheumatoid arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8373Q','2681','t',$$<p>Initial treatment of severe active psoriatic arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8374R','2644','t',$$<p>Treatment of severe active rheumatoid arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8375T','2644','t',$$<p>Treatment of severe active rheumatoid arthritis where other disease modifying anti-rheumatic drugs (including methotrexate) are ineffective and/or inappropriate.  Treatment must be initiated by a physician</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8378Y','1736','f',$$<p>Recurrence of anaplastic astrocytoma following standard therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8378Y','1737','f',$$<p>Recurrence of glioblastoma multiforme following standard therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8378Y','2101','f',$$<p>Glioblastoma multiforme following radiotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8379B','1736','f',$$<p>Recurrence of anaplastic astrocytoma following standard therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8379B','1737','f',$$<p>Recurrence of glioblastoma multiforme following standard therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8379B','2101','f',$$<p>Glioblastoma multiforme following radiotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8380C','1736','f',$$<p>Recurrence of anaplastic astrocytoma following standard therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8380C','1737','f',$$<p>Recurrence of glioblastoma multiforme following standard therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8380C','2101','f',$$<p>Glioblastoma multiforme following radiotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8381D','1736','f',$$<p>Recurrence of anaplastic astrocytoma following standard therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8381D','1737','f',$$<p>Recurrence of glioblastoma multiforme following standard therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8381D','2101','f',$$<p>Glioblastoma multiforme following radiotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8383F','1031','f',$$<p>Bacterial keratitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8389M','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8403G','1175','f',$$<p>Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8403G','1751','f',$$<p>Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8412R','3611','t',$$<p>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8413T','3611','t',$$<p>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8433W','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8433W','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8434X','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8434X','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8448P','1700','t',$$<p>Primary biliary cirrhosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8453X','1499','f',$$<p>Chronic severe disabling pain due to cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8454Y','1499','f',$$<p>Chronic severe disabling pain due to cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8456C','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8456C','2765','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8456C','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8457D','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8457D','2765','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8457D','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8458E','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8458E','2765','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8458E','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8459F','1496','t',$$<p>For the treatment of hydatid disease in conjunction with surgery or when a surgical cure cannot be achieved or where surgery cannot be used</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8460G','1022','f',$$<p>Androgen deficiency in males with established pituitary or testicular disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8460G','1021','f',$$<p>Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8&#160;nmol per L, or 8-15&#160;nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8460G','1226','f',$$<p>Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8461H','3256','t',$$<p>Symptomatic Paget disease of bone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8462J','3256','t',$$<p>Symptomatic Paget disease of bone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8463K','3256','t',$$<p>Symptomatic Paget disease of bone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8465M','2774','f',$$<p>who has entered a comprehensive support and counselling program</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8465M','2775','f',$$<p>who is entering a comprehensive support and counselling program during the consultation at which this authority is requested</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8476D','1206','f',$$<p>Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8476D','1196','f',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8481J','3070','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8481J','2645','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8481J','2646','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8482K','3256','t',$$<p>Symptomatic Paget disease of bone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8495D','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8495D','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8495D','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8495D','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8496E','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8496E','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8496E','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8496E','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8497F','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8497F','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8497F','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8497F','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8498G','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8498G','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8498G','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8498G','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8499H','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8499H','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8499H','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8499H','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8500J','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8500J','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8500J','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8500J','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8503M','1525','t',$$<p>Treatment of tapeworm infestation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8505P','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8511Y','3070','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8511Y','3933','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -2.5 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8511Y','2646','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8514D','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8520K','2798','t',$$<p>Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs in patients unable to take a solid dose form of topiramate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8551C','1234','f',$$<p>Myeloproliferative disease with excessive thrombocytosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8552D','1234','f',$$<p>Myeloproliferative disease with excessive thrombocytosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8553E','1234','f',$$<p>Myeloproliferative disease with excessive thrombocytosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8559L','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8563Q','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8563Q','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8563Q','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8563Q','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8572E','1149','f',$$<p>Hairy cell leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8574G','4033','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated colic or reflux) in a child up to the age of 24&#160;months. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8574G','4034','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8574G','4035','f',$$<p>Initial treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8575H','4036','f',$$<p>Treatment, in consultation with a specialist allergist or clinical immunologist, for a child with cows' milk anaphylaxis, up to the age of 24&#160;months.  Anaphylaxis is defined as a severe and/or potentially life threatening allergic reaction.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8575H','4037','f',$$<p>Continuing treatment for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8575H','4038','f',$$<p>Continuing treatment for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed at least once or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist.  Then name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8575H','4039','f',$$<p>Continuing treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months.  The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist at intervals not greater than 12&#160;months.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8575H','1687','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8575H','1688','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8578L','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8580N','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8580N','2765','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8580N','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8584T','1587','t',$$<p>Treatment of partial epileptic seizures and primary generalised tonic-clonic seizures, which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8585W','1587','t',$$<p>Treatment of partial epileptic seizures and primary generalised tonic-clonic seizures, which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8586X','1587','t',$$<p>Treatment of partial epileptic seizures and primary generalised tonic-clonic seizures, which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8587Y','1596','f',$$<p>Infants and young children with chronic renal failure requiring treatment with a low protein and a low phosphorus diet, or a low protein, a low phosphorus and a low potassium diet</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8588B','1587','t',$$<p>Treatment of partial epileptic seizures and primary generalised tonic-clonic seizures, which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8594H','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8595J','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8596K','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8598M','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8598M','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8599N','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8599N','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8604W','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8605X','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8606Y','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8616L','1707','t',$$<p>Acute episode of mild to moderate ulcerative colitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8617M','1707','t',$$<p>Acute episode of mild to moderate ulcerative colitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8619P','1022','f',$$<p>Androgen deficiency in males with established pituitary or testicular disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8619P','1021','f',$$<p>Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8&#160;nmol per L, or 8-15&#160;nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8619P','1226','f',$$<p>Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8621R','3070','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8621R','2645','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8621R','2646','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8627C','2617','t',$$<p>First-line preventer medication, as the single preventer agent for children aged 2 to 5 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8628D','2618','t',$$<p>First-line preventer medication, as the single preventer agent for children aged 6 to 14 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8628D','3217','t',$$<p>Prevention of exercise-induced asthma, as an alternative to adding salmeterol xinafoate or eformoterol fumarate, in a child aged 6 to 14 years whose asthma is otherwise well controlled while receiving optimal dose inhaled corticosteroid, but who requires short-acting beta-2 agonist 3 or more times per week for prevention or relief of residual exercise-related symptoms</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8637N','3708','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8637N','3772','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with etanercept and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8638P','3773','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with etanercept.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8646C','3080','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8647D','3080','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8648E','3080','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus, of patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8649F','1765','f',$$<p>renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8649F','1766','f',$$<p>cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8650G','1765','f',$$<p>renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8650G','1766','f',$$<p>cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8651H','1765','f',$$<p>renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8651H','1766','f',$$<p>cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8652J','1763','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate sodium and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8653K','1763','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with mycophenolate sodium and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8654L','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8655M','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8656N','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8657P','2049','f',$$<p>patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8657P','2050','f',$$<p>patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8657P','2051','f',$$<p>patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life.  Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient.  The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8657P','2052','f',$$<p>patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired.  Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient.  The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8657P','2053','f',$$<p>patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8657P','1655','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8657P','1656','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8657P','1658','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8658Q','2049','f',$$<p>patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8658Q','2050','f',$$<p>patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8658Q','2051','f',$$<p>patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life.  Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient.  The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8658Q','2052','f',$$<p>patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired.  Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient.  The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8658Q','2053','f',$$<p>patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8658Q','1655','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8658Q','1656','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8658Q','1658','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8659R','2049','f',$$<p>patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8659R','2050','f',$$<p>patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8659R','2051','f',$$<p>patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life.  Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient.  The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8659R','2052','f',$$<p>patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired.  Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient.  The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8659R','2053','f',$$<p>patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8659R','1655','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8659R','1656','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8659R','1658','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8660T','2049','f',$$<p>patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8660T','2050','f',$$<p>patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8660T','2051','f',$$<p>patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life.  Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient.  The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8660T','2052','f',$$<p>patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired.  Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient.  The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8660T','2053','f',$$<p>patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8660T','1655','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8660T','1656','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8660T','1658','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8661W','2049','f',$$<p>patients with organ or tissue transplants.  Therapy must remain under the supervision and direction of the transplant unit reviewing the patient.  The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8661W','2050','f',$$<p>patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a dermatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the dermatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8661W','2051','f',$$<p>patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life.  Therapy must remain under the supervision and direction of a dermatologist or specialised unit reviewing the patient.  The name of the dermatologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8661W','2052','f',$$<p>patients with nephrotic syndrome in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired.  Therapy must remain under the supervision and direction of a nephrologist or specialised unit reviewing the patient.  The name of the nephrologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8661W','2053','f',$$<p>patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate.  Therapy must remain under the supervision and direction of a rheumatologist, clinical immunologist or specialised unit reviewing the patient.  The name of the rheumatologist, clinical immunologist or specialised unit reviewing treatment and the date of the latest review must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8661W','1655','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8661W','1656','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8661W','1658','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8662X','1678','t',$$<p>Cranial diabetes insipidus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8663Y','2641','t',$$<p>Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8663Y','2642','t',$$<p>Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8664B','2718','f',$$<p>Initial treatment of amyotrophic lateral sclerosis, as diagnosed by a neurologist, in patients with disease duration of 5 years or less and who have at least 60 percent of predicted forced vital capacity within 2 months prior to commencing riluzole therapy and who:<br/> (1) are ambulatory, and<br/> (a) have not undergone tracheostomy, and<br/> (b) have not experienced respiratory failure; OR<br/> (2) are not ambulatory, and<br/> (a) have not undergone tracheostomy, and<br/> (b) have not experienced respiratory failure, and<br/> (c) are either able to use upper limbs or able to swallow.<br/> The date of diagnosis and the date and results of spirometry (in terms of percent of predicted forced vital capacity) must be supplied with the initial authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8664B','1762','f',$$<p>Continuing treatment of amyotrophic lateral sclerosis in patients who have previously been issued with an authority prescription for this drug and who:<br/> (1) are ambulatory, and<br/> (a) have not undergone tracheostomy, and<br/> (b) have not experienced respiratory failure; OR<br/> (2) are not ambulatory, and<br/> (a) have not undergone tracheostomy, and<br/> (b) have not experienced respiratory failure, and<br/> (c) are either able to use upper limbs or able to swallow</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8683B','1884','t',$$<p>Patients undergoing non-urgent percutaneous intervention with intracoronary stenting</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8684C','1884','t',$$<p>Patients undergoing non-urgent percutaneous intervention with intracoronary stenting</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8689H','3722','f',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8690J','3722','f',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8694N','3540','t',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8694N','3541','t',$$<p>Combination therapy with insulin<br/> Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8694N','3542','t',$$<p>Triple oral combination therapy with metformin and a sulfonylurea<br/> Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with maximally tolerated doses of metformin and a sulfonylurea.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8695P','3540','t',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8695P','3541','t',$$<p>Combination therapy with insulin<br/> Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8695P','3542','t',$$<p>Triple oral combination therapy with metformin and a sulfonylurea<br/> Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with maximally tolerated doses of metformin and a sulfonylurea.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8696Q','3540','t',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8696Q','3541','t',$$<p>Combination therapy with insulin<br/> Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8696Q','3542','t',$$<p>Triple oral combination therapy with metformin and a sulfonylurea<br/> Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with maximally tolerated doses of metformin and a sulfonylurea.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8697R','3434','f',$$<p>has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician. The name of the specialist consulted must be provided at the time of application for initial supply</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8697R','3435','f',$$<p>has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8697R','3436','f',$$<p>Continuing sole PBS-subsidised supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis, where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8698T','3434','f',$$<p>has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician. The name of the specialist consulted must be provided at the time of application for initial supply</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8698T','3435','f',$$<p>has been discharged from hospital or an emergency department after treatment with adrenaline for acute allergic reaction with anaphylaxis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8698T','3436','f',$$<p>Continuing sole PBS-subsidised supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis, where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8707G','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8708H','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8709J','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8710K','2776','f',$$<p>Completion of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has previously been issued with an authority prescription for this drug and who is enrolled in a comprehensive support and counselling program</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8711L','1678','t',$$<p>Cranial diabetes insipidus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8712M','2641','t',$$<p>Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8712M','2642','t',$$<p>Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8717T','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8718W','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8719X','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8720Y','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8724E','1952','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with sirolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8725F','1952','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with sirolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8726G','1175','f',$$<p>Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8726G','1751','f',$$<p>Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8730L','3611','t',$$<p>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8731M','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8731M','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8731M','2268','t',$$<p>Crohn disease where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8731M','2269','t',$$<p>Crohn disease where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8732N','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8733P','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8734Q','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8735R','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8736T','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8737W','3706','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8737W','3745','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with adalimumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8741C','3746','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with adalimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with adalimumab.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8753Q','1707','t',$$<p>Acute episode of mild to moderate ulcerative colitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8754R','4033','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated colic or reflux) in a child up to the age of 24&#160;months. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8754R','4034','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8754R','4035','f',$$<p>Initial treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8755T','4036','f',$$<p>Treatment, in consultation with a specialist allergist or clinical immunologist, for a child with cows' milk anaphylaxis, up to the age of 24&#160;months.  Anaphylaxis is defined as a severe and/or potentially life threatening allergic reaction.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8755T','4037','f',$$<p>Continuing treatment for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8755T','4038','f',$$<p>Continuing treatment for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed at least once or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist.  Then name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8755T','4039','f',$$<p>Continuing treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months.  The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist at intervals not greater than 12&#160;months.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8755T','1687','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8755T','1688','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8757X','3724','t',$$<p>coronary heart disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8757X','3725','t',$$<p>diabetes mellitus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8757X','3726','t',$$<p>peripheral vascular disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8757X','3727','t',$$<p>heterozygous familial hypercholesterolaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8757X','3728','t',$$<p>symptomatic cerebrovascular disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8757X','3729','t',$$<p>family history of coronary heart disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8757X','3730','t',$$<p>hypertension</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8757X','1989','t',$$<p>Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8757X','3731','t',$$<p>Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) must be discontinued or reduced because the patient developed a clinically important product-related adverse event during treatment with a statin.<br/> A clinically important product-related adverse event is defined as follows:<br/> (i) Severe myalgia (muscle symptoms without creatine kinase elevation) which is proven to be temporally associated with statin treatment; or<br/> (ii) Myositis (clinically important creatine kinase elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or<br/> (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8757X','1991','t',$$<p>Homozygous sitosterolaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8757X','2438','t',$$<p>Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs), in combination with an HMG CoA reductase inhibitor (statin)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8768L','1707','t',$$<p>Acute episode of mild to moderate ulcerative colitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8769M','4029','f',$$<p>Initial PBS-subsidised treatment, as monotherapy, of locally advanced or metastatic non-small cell lung cancer in patients with a WHO performance status of 2 or less, where:<br/> (1) disease progression has occurred following treatment with at least 1 chemotherapy agent; and<br/> (2) there is evidence that the patient has an activating mutation(s) of the epidermal growth factor receptor (EGFR) gene in tumour material</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8769M','4030','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy, of locally advanced or metastatic non-small cell lung cancer in patients with a WHO performance status of 2 or less, where the patient has previously been issued with an authority prescription for gefitinib</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8770N','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8770N','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8770N','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8770N','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8771P','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8771P','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8771P','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8771P','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8772Q','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8772Q','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8772Q','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8772Q','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8775W','2005','t',$$<p>Prevention of venous thromboembolic events in patients undergoing major hip surgery</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8775W','2006','t',$$<p>Prevention of venous thromboembolic events in patients undergoing total knee replacement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8778B','3510','f',$$<p>Initial 1 (new patients)<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND<br/> (a) who has at least 2 of the following:<br/> (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or<br/> (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or<br/> (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND<br/> (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.</p><p> The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p> If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p> If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:<br/> (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND<br/> (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 10&#160;mg per L.</p><p> The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p> Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:<br/> (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and<br/> (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and<br/> (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and<br/> (iv) a signed patient acknowledgment form.</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8778B','3774','f',$$<p>Initial 2 (change or re-commencement for all patients)<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with etanercept in the current treatment cycle.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8779C','3775','f',$$<p>Continuing treatment for all patients<br/> Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:<br/> (a) has demonstrated an adequate response to treatment with etanercept; and<br/> (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with etanercept.</p><p> An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:<br/> (a) an ESR measurement no greater than 25&#160;mm per hour; or<br/> (b) a CRP measurement no greater than 10&#160;mg per L; or<br/> (c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p> Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> All measurements provided must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this criterion.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with etanercept.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8780D','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8780D','3841','t',$$<p>Maintenance treatment, in combination with lithium or sodium valproate, of treatment refractory bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8781E','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8781E','3841','t',$$<p>Maintenance treatment, in combination with lithium or sodium valproate, of treatment refractory bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8782F','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8782F','3841','t',$$<p>Maintenance treatment, in combination with lithium or sodium valproate, of treatment refractory bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8785J','2064','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8787L','2061','t',$$<p>Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8787L','3083','t',$$<p>Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.</p><p> Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.</p><p> Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.</p><p> The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8788M','2061','t',$$<p>Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8788M','3083','t',$$<p>Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.</p><p> Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.</p><p> Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.</p><p> The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8789N','2061','t',$$<p>Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8789N','3083','t',$$<p>Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.</p><p> Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.</p><p> Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.</p><p> The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8790P','2061','t',$$<p>Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8790P','3083','t',$$<p>Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.</p><p> Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.</p><p> Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.</p><p> The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8792R','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8792R','2272','t',$$<p>Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8794W','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8794W','2272','t',$$<p>Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8797B','3305','t',$$<p>Parkinson disease in patients being treated with levodopa&#8212;decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8797B','3306','t',$$<p>Parkinson disease in patients stabilised on concomitant treatment with levodopa&#8212;decarboxylase inhibitor combinations and entacapone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8798C','3305','t',$$<p>Parkinson disease in patients being treated with levodopa&#8212;decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8798C','3306','t',$$<p>Parkinson disease in patients stabilised on concomitant treatment with levodopa&#8212;decarboxylase inhibitor combinations and entacapone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8799D','3305','t',$$<p>Parkinson disease in patients being treated with levodopa&#8212;decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8799D','3306','t',$$<p>Parkinson disease in patients stabilised on concomitant treatment with levodopa&#8212;decarboxylase inhibitor combinations and entacapone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8802G','2455','f',$$<p>Treatment of facial or eyelid atopic dermatitis in patients aged at least 3 months with 1 or more of the following contraindications to topical corticosteroids:<br/> (i) perioral dermatitis;<br/> (ii) periorbital dermatitis;<br/> (iii) rosacea;<br/> (iv) epidermal atrophy;<br/> (v) dermal atrophy;<br/> (vi) allergy to topical corticosteroids;<br/> (vii) cataracts;<br/> (viii) glaucoma;<br/> (ix) raised intraocular pressure</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8802G','2456','f',$$<p>Short-term (up to 3 weeks) intermittent treatment of atopic dermatitis of the face or eyelids in patients aged at least 3 months who fail to achieve satisfactory disease control with intermittent topical corticosteroid therapy, and where more than 3 months have passed since the initial diagnosis of atopic dermatitis.</p><p> Failure to achieve satisfactory disease control with intermittent topical corticosteroid therapy is manifest by:<br/> (i) failure of the facial skin to clear despite at least 2 weeks of topical hydrocortisone 1% applied every day; or<br/> (ii) failure of the facial skin to clear despite at least 1 week of a moderate or potent topical corticosteroid applied every day; or<br/> (iii) clearing of the facial skin with at least 2 weeks of topical hydrocortisone 1% applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions; or<br/> (iv) clearing of the facial skin with at least 1 week of a moderate or potent topical corticosteroid applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8805K','1175','f',$$<p>Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8805K','1751','f',$$<p>Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8807M','2070','t',$$<p>Iron deficiency anaemia, in combination with either epoetin alfa or darbepoetin alfa, in patients undergoing chronic haemodialysis who have had a documented hypersensitivity reaction to iron polymaltose and in whom continued intravenous iron therapy is appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8808N','3619','t',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy, in combination with a 5HT3 antagonist and dexamethasone, where any 1 of the following chemotherapy agents are to be administered:<br/> (a) altretamine;<br/> (b) carmustine;<br/> (c) cisplatin when a single dose constitutes a cycle of chemotherapy;<br/> (d) cyclophosphamide at a dose of 1500&#160;mg per square metre per day or greater;<br/> (e) dacarbazine;<br/> (f) procarbazine when a single dose constitutes a cycle of chemotherapy;<br/> (g) streptozocin.<br/> No more than 1 pack containing 1 x 125&#160;mg capsule and 2 x 80&#160;mg capsules will be authorised per cycle of cytotoxic chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8808N','3620','t',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat breast cancer, in combination with a 5HT3 antagonist and dexamethasone, where cyclophosphamide and an anthracycline are to be co-administered.<br/> No more than 1 pack containing 1 x 125&#160;mg capsule and 2 x 80&#160;mg capsules will be authorised per cycle of cytotoxic chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8808N','3621','t',$$<p>Management of nausea and vomiting associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy, in combination with a 5HT3 antagonist and dexamethasone on day 1, where the patient has had a prior episode of chemotherapy induced nausea or vomiting where any 1 of the following intravenous chemotherapy agents is to be administered:<br/> (a) arsenic trioxide;<br/> (b) azacitidine;<br/> (c) carboplatin;<br/> (d) cyclophosphamide at a dose of less than 1500&#160;mg per square metre per day;<br/> (e) cytarabine at a dose of greater than 1&#160;g per square metre per day;<br/> (f) dactinomycin;<br/> (g) daunorubicin;<br/> (h) doxorubicin;<br/> (i) epirubicin;<br/> (j) fotemustine;<br/> (k) idarubicin;<br/> (l) ifosfamide;<br/> (m) irinotecan;<br/> (n) melphalan;<br/> (o) methotrexate at a dose of 250&#160;mg to 1&#160;g per square metre;<br/> (p) oxaliplatin;<br/> (q) raltitrexed.<br/> No more than one pack containing 1 x 125&#160;mg capsule and 2 x 80&#160;mg capsules will be authorised per cycle of cytotoxic chemotherapy. Concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8816B','3145','f',$$<p>Initial treatment, by a qualified sleep medicine practitioner or neurologist, of patients with narcolepsy where:<br/> (i) therapy with dexamphetamine sulfate poses an unacceptable medical risk; or<br/> (ii) intolerance to dexamphetamine sulfate of a severity necessitating treatment withdrawal develops.</p><p> The presence of any 1 of the following indicates treatment with dexamphetamine sulfate poses an unacceptable medical risk:<br/> (a) a psychiatric disorder;<br/> (b) a cardiovascular disorder;<br/> (c) a history of substance abuse;<br/> (d) glaucoma;<br/> (e) any other absolute contraindication to dexamphetamine sulfate as specified in the TGA-approved Product Information.</p><p> Patients must meet the following definition of narcolepsy:<br/> Excessive daytime sleepiness, recurrent naps or lapses into sleep occurring almost daily for at least 3 months and:<br/> (i) a definite history of cataplexy;<br/> or<br/> a mean sleep latency less than or equal to 10 minutes on a Multiple Sleep Latency Test (MSLT). The MSLT must be preceded by nocturnal polysomnography. Sleep prior to the MSLT must be at least 6 hours in duration;<br/> or<br/> an electroencephalographic (EEG) recording showing the pathologically rapid development of REM sleep; and<br/> (ii) absence of any medical or psychiatric disorder that could otherwise account for the hypersomnia.</p><p> The authority application must be made in writing and must include the following:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Modafinil (Modavigil) PBS Authority Application for Use in the Treatment of Narcolepsy - Supporting Information Form [www.medicareaustralia.gov.au]; and<br/> (c) details of the contraindication or intolerance to dexamphetamine sulfate; and<br/> (d) either:<br/> (i) the result and date of the polysomnography test and MSLT conducted by, or under the supervision of, a qualified sleep medicine practitioner; or<br/> (ii) the result and date of the EEG, conducted by, or under the supervision of, a neurologist.</p><p> The polysomnography, MSLT or EEG test reports must be provided with the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8816B','2090','f',$$<p>Continuing treatment of narcolepsy, where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8819E','2100','f',$$<p>Glioblastoma multiforme concomitantly with radiotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8820F','2100','f',$$<p>Glioblastoma multiforme concomitantly with radiotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8821G','2100','f',$$<p>Glioblastoma multiforme concomitantly with radiotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8822H','2659','t',$$<p>Pathological hyperprolactinaemia where surgery is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8822H','2660','t',$$<p>Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8822H','2661','t',$$<p>Pathological hyperprolactinaemia where radiotherapy is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8822H','2662','t',$$<p>Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8823J','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8824K','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8830R','1022','f',$$<p>Androgen deficiency in males with established pituitary or testicular disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8830R','1021','f',$$<p>Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8&#160;nmol per L, or 8-15&#160;nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8830R','1226','f',$$<p>Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8833X','1952','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with sirolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8839F','1461','f',$$<p>Use in attention deficit hyperactivity disorder, in accordance with State/Territory law</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8840G','2133','f',$$<p>renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8840G','2134','f',$$<p>cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8841H','2133','f',$$<p>renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8841H','2134','f',$$<p>cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8842J','2133','f',$$<p>renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8842J','2134','f',$$<p>cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8844L','3075','t',$$<p>A patient undergoing percutaneous coronary intervention</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8845M','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8845M','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8859G','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8860H','2659','t',$$<p>Pathological hyperprolactinaemia where surgery is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8860H','2660','t',$$<p>Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8860H','2661','t',$$<p>Pathological hyperprolactinaemia where radiotherapy is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8860H','2662','t',$$<p>Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8869T','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8870W','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8873B','3611','t',$$<p>Management of nausea and vomiting associated with radiotherapy being used to treat malignancy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8875D','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8876E','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8877F','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8879H','2637','t',$$<p>Heart failure with a left ventricular ejection fraction of 40% or less occurring within 3 to 14 days following an acute myocardial infarction. Treatment with eplerenone must be commenced within 14 days of an acute myocardial infarction.<br/> The date of the acute myocardial infarction and the date of initiation of eplerenone treatment must be documented in the patient's medical records when PBS-subsidised treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8880J','2637','t',$$<p>Heart failure with a left ventricular ejection fraction of 40% or less occurring within 3 to 14 days following an acute myocardial infarction. Treatment with eplerenone must be commenced within 14 days of an acute myocardial infarction.<br/> The date of the acute myocardial infarction and the date of initiation of eplerenone treatment must be documented in the patient's medical records when PBS-subsidised treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8881K','3732','t',$$<p>coronary heart disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8881K','3733','t',$$<p>diabetes mellitus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8881K','3734','t',$$<p>peripheral vascular disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8881K','3735','t',$$<p>heterozygous familial hypercholesterolaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8881K','3736','t',$$<p>cerebrovascular disease which has become symptomatic</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8881K','3737','t',$$<p>family history of coronary heart disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8881K','3738','t',$$<p>hypertension</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8881K','2431','t',$$<p>Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8882L','3732','t',$$<p>coronary heart disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8882L','3733','t',$$<p>diabetes mellitus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8882L','3734','t',$$<p>peripheral vascular disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8882L','3735','t',$$<p>heterozygous familial hypercholesterolaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8882L','3736','t',$$<p>cerebrovascular disease which has become symptomatic</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8882L','3737','t',$$<p>family history of coronary heart disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8882L','3738','t',$$<p>hypertension</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8882L','2431','t',$$<p>Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8885P','3233','t',$$<p>Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8896F','3626','t',$$<p>Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes in immunocompromised patients. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8896F','3627','t',$$<p>Episodic treatment of moderate to severe recurrent oral or labial herpes in a patient with HIV infection and a CD4 cell count of less than 500&#160;million per litre. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8896F','3628','t',$$<p>Suppressive therapy of moderate to severe recurrent oral or labial herpes in a patient with HIV infection and a CD4 cell count of less than 150&#160;million per litre. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8896F','3629','t',$$<p>Suppressive therapy of moderate to severe recurrent oral or labial herpes in a patient with HIV infection and other opportunistic infections or AIDS defining tumours. Microbiological confirmation of diagnosis (viral culture, antigen detection or nucleic acid amplification by PCR) is required but need not delay treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8897G','3625','t',$$<p>Treatment of immunocompromised patients with herpes zoster within 72 hours of the onset of the rash</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8899J','3070','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8899J','2645','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8899J','2646','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8903N','1666','f',$$<p>Adverse effects occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8903N','1667','f',$$<p>Drug interactions occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8903N','1668','f',$$<p>Drug interactions expected to occur with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8903N','1406','f',$$<p>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8905Q','1666','f',$$<p>Adverse effects occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8905Q','1667','f',$$<p>Drug interactions occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8905Q','1668','f',$$<p>Drug interactions expected to occur with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8905Q','1406','f',$$<p>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8951D','1666','f',$$<p>Adverse effects occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8951D','1667','f',$$<p>Drug interactions occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8951D','1668','f',$$<p>Drug interactions expected to occur with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8951D','1406','f',$$<p>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8952E','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8952E','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8953F','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8953F','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8961P','3695','f',$$<p>Initial 1<br/> Initial treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has an externally draining enterocutaneous or rectovaginal fistula; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/> (ii) a signed patient acknowledgement.</p><p> The most recent fistula assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> An assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8961P','3747','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Initial PBS-subsidised treatment with adalimumab of complex refractory fistulising Crohn disease by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has a documented history of complex refractory fistulising Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or infliximab for a draining enterocutaneous or rectovaginal fistula; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the time frames specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/>  details of prior TNF-alfa antagonist treatment including details of date and duration of treatment.</p><p> The most recent fistula assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> An assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8962Q','3695','f',$$<p>Initial 1<br/> Initial treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has an externally draining enterocutaneous or rectovaginal fistula; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/> (ii) a signed patient acknowledgement.</p><p> The most recent fistula assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> An assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8962Q','3747','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Initial PBS-subsidised treatment with adalimumab of complex refractory fistulising Crohn disease by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has a documented history of complex refractory fistulising Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or infliximab for a draining enterocutaneous or rectovaginal fistula; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the time frames specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/>  details of prior TNF-alfa antagonist treatment including details of date and duration of treatment.</p><p> The most recent fistula assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> An assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8963R','3695','f',$$<p>Initial 1<br/> Initial treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has an externally draining enterocutaneous or rectovaginal fistula; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/> (ii) a signed patient acknowledgement.</p><p> The most recent fistula assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> An assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8963R','3747','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Initial PBS-subsidised treatment with adalimumab of complex refractory fistulising Crohn disease by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has a documented history of complex refractory fistulising Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or infliximab for a draining enterocutaneous or rectovaginal fistula; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the time frames specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/>  details of prior TNF-alfa antagonist treatment including details of date and duration of treatment.</p><p> The most recent fistula assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> An assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8964T','3697','f',$$<p>Initial 3 (grandfather)<br/> Initial PBS-subsidised treatment of complex refractory FISTULISING CROHN DISEASE in a patient who has previously received non-PBS-subsidised therapy with adalimumab.</p><p> Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who satisfies the following criteria:<br/> (a) has a documented history of complex refractory fistulising Crohn disease and was receiving treatment with adalimumab prior to 4&#160;November 2010; and<br/> (b) had a draining enterocutaneous or rectovaginal fistula(e) prior to commencing treatment with adalimumab; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) is receiving treatment with adalimumab at the time of application; and<br/> (e) has demonstrated or sustained an adequate response to treatment with adalimumab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to adalimumab treatment is defined as:<br/> (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or<br/> (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current and baseline Fistula Assessment form including the date of assessment of the patient's condition; and<br/> (ii) a signed patient acknowledgement.</p><p> The current fistula assessment must be no more than 1 month old at the time of application.</p><p> The baseline fistula assessment must be from immediately prior to commencing treatment with adalimumab.</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> A maximum of 24 weeks treatment will be approved under this criterion.</p><p> Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8964T','3748','f',$$<p>Continuing treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of complex refractory fistulising Crohn disease; and<br/> (b) has demonstrated or sustained an adequate response to treatment with adalimumab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response is defined as:<br/> (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or<br/> (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes a completed Fistula Assessment form including the date of the assessment of the patient's condition.</p><p> The fistula assessment must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response must be made following a minimum of 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> A maximum of 24 weeks treatment will be authorised under this criterion.</p><p> Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8965W','3695','f',$$<p>Initial 1<br/> Initial treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has an externally draining enterocutaneous or rectovaginal fistula; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/> (ii) a signed patient acknowledgement.</p><p> The most recent fistula assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> An assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8965W','3747','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Initial PBS-subsidised treatment with adalimumab of complex refractory fistulising Crohn disease by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has a documented history of complex refractory fistulising Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or infliximab for a draining enterocutaneous or rectovaginal fistula; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the time frames specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/>  details of prior TNF-alfa antagonist treatment including details of date and duration of treatment.</p><p> The most recent fistula assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40 mg and no repeats.  The second prescription must be written for 2 doses of 40 mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> An assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8966X','3697','f',$$<p>Initial 3 (grandfather)<br/> Initial PBS-subsidised treatment of complex refractory FISTULISING CROHN DISEASE in a patient who has previously received non-PBS-subsidised therapy with adalimumab.</p><p> Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who satisfies the following criteria:<br/> (a) has a documented history of complex refractory fistulising Crohn disease and was receiving treatment with adalimumab prior to 4&#160;November 2010; and<br/> (b) had a draining enterocutaneous or rectovaginal fistula(e) prior to commencing treatment with adalimumab; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) is receiving treatment with adalimumab at the time of application; and<br/> (e) has demonstrated or sustained an adequate response to treatment with adalimumab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to adalimumab treatment is defined as:<br/> (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or<br/> (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current and baseline Fistula Assessment form including the date of assessment of the patient's condition; and<br/> (ii) a signed patient acknowledgement.</p><p> The current fistula assessment must be no more than 1 month old at the time of application.</p><p> The baseline fistula assessment must be from immediately prior to commencing treatment with adalimumab.</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> A maximum of 24 weeks treatment will be approved under this criterion.</p><p> Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8966X','3748','f',$$<p>Continuing treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of complex refractory fistulising Crohn disease; and<br/> (b) has demonstrated or sustained an adequate response to treatment with adalimumab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response is defined as:<br/> (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or<br/> (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes a completed Fistula Assessment form including the date of the assessment of the patient's condition.</p><p> The fistula assessment must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response must be made following a minimum of 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> A maximum of 24 weeks treatment will be authorised under this criterion.</p><p> Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8968B','1175','f',$$<p>Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8968B','1751','f',$$<p>Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8970D','3703','f',$$<p>Maintenance therapy following treatment which was commenced in a hospital-based movement disorder clinic, of a patient with advanced Parkinson disease with severe disabling motor fluctuations not adequately controlled by oral therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8972F','3070','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8972F','2645','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8972F','2646','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8973G','3070','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8973G','2645','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8973G','2646','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8974H','3070','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8974H','2645','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8974H','2646','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8975J','2641','t',$$<p>Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8975J','2642','t',$$<p>Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8983T','3540','t',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8984W','1952','f',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with sirolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8997M','1666','f',$$<p>Adverse effects occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8997M','1667','f',$$<p>Drug interactions occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8997M','1668','f',$$<p>Drug interactions expected to occur with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8997M','1406','f',$$<p>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8998N','1666','f',$$<p>Adverse effects occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8998N','1667','f',$$<p>Drug interactions occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8998N','1668','f',$$<p>Drug interactions expected to occur with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8998N','1406','f',$$<p>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8999P','1666','f',$$<p>Adverse effects occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8999P','1667','f',$$<p>Drug interactions occurring with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8999P','1668','f',$$<p>Drug interactions expected to occur with all of the base-priced drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8999P','1406','f',$$<p>Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9004X','1022','f',$$<p>Androgen deficiency in males with established pituitary or testicular disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9004X','1021','f',$$<p>Androgen deficiency in males 40 years and older who do not have established pituitary or testicular disorders other than aging, confirmed by at least 2 morning blood samples taken on different mornings. Androgen deficiency is confirmed by testosterone less than 8&#160;nmol per L, or 8-15&#160;nmol per L with high LH (greater than 1.5 times the upper limit of the eugonadal reference range for young men)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9004X','1226','f',$$<p>Micropenis, pubertal induction, or constitutional delay of growth or puberty, in males under 18 years of age</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9009E','1194','f',$$<p>Locally advanced or metastatic non-small cell lung cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9010F','1194','f',$$<p>Locally advanced or metastatic non-small cell lung cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9012H','3070','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9012H','3933','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -2.5 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9012H','2646','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9024Y','2354','t',$$<p>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9025B','2354','t',$$<p>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9026C','2354','t',$$<p>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9027D','2354','t',$$<p>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9028E','2354','t',$$<p>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9029F','2354','t',$$<p>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9030G','2354','t',$$<p>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9031H','2354','t',$$<p>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9033K','3486','f',$$<p>Initial 1<br/> Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have severe active psoriatic arthritis; and<br/> (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and<br/> (3) have failed to achieve an adequate response to:<br/> (a) methotrexate at a dose of at least 20&#160;mg weekly for a minimum period of 3 months; and<br/> (b) sulfasalazine at a dose of at least 2&#160;g per day for a minimum period of 3 months; or<br/> (c) leflunomide at a dose of up to 20&#160;mg daily for a minimum period of 3 months.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial adalimimab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9033K','3749','f',$$<p>Initial 2<br/> Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have a documented history of severe active psoriatic arthritis; and<br/> (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and<br/> (3) have not failed treatment with adalimumab during the current Treatment Cycle.</p><p> Applications for patients who have received PBS-subsidised treatment with adalimumab within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9034L','3750','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:<br/> (1) who have a documented history of severe active psoriatic arthritis; and<br/> (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with adalimumab; and<br/> (3) who, at the time of application, demonstrate an adequate response to treatment with adalimumab.</p><p> An adequate response to treatment with adalimumab is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline; AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9035M','3489','f',$$<p>Initial 1<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have severe active psoriatic arthritis; and<br/> (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and<br/> (3) have failed to achieve an adequate response to:<br/> (a) methotrexate at a dose of at least 20&#160;mg weekly for a minimum period of 3 months; and<br/> (b) sulfasalazine at a dose of at least 2&#160;g per day for a minimum period of 3 months; or<br/> (c) leflunomide at a dose of up to 20&#160;mg daily for a minimum period of 3 months.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9035M','3776','f',$$<p>Initial 2<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have a documented history of severe active psoriatic arthritis; and<br/> (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and<br/> (3) have not failed treatment with etanercept during the current Treatment Cycle.</p><p> Applications for patients who have received PBS-subsidised treatment with etanercept within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9036N','3777','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:<br/> (1) who have a documented history of severe active psoriatic arthritis; and<br/> (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with etanercept; and<br/> (3) who, at the time of application, demonstrate an adequate response to treatment with etanercept.</p><p> An adequate response to treatment with etanercept is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline; AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9037P','3273','f',$$<p>Initial treatment [Initial 1, Whole body (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9037P','3778','f',$$<p>Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9037P','3275','f',$$<p>Initial treatment [Initial 1, Face, hand, foot (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where: <br/> (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or<br/> (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9037P','3779','f',$$<p>Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9047E','2446','t',$$<p>Treatment of whipworm infestation in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9047E','1388','t',$$<p>Strongyloidiasis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9047E','3241','t',$$<p>Treatment of hookworm infestation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9059T','3723','f',$$<p>Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9060W','3723','f',$$<p>Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9061X','3723','f',$$<p>Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9062Y','3723','f',$$<p>Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated. The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9064C','3239','t',$$<p>Metastatic (equivalent to stage D) prostatic carcinoma in patients for whom a combination of an antiandrogen and a GnRH (LH-RH) agonist is required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9065D','3239','t',$$<p>Metastatic (equivalent to stage D) prostatic carcinoma in patients for whom a combination of an antiandrogen and a GnRH (LH-RH) agonist is required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9066E','3239','t',$$<p>Metastatic (equivalent to stage D) prostatic carcinoma in patients for whom a combination of an antiandrogen and a GnRH (LH-RH) agonist is required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9070J','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9070J','3084','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9071K','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9071K','3084','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9072L','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9072L','3084','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9073M','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9073M','3084','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9075P','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9075P','2272','t',$$<p>Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9076Q','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9076Q','2272','t',$$<p>Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9077R','3502','f',$$<p>Initial 1 (new patients)<br/> Initial PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND<br/> (a) who has at least 2 of the following:<br/> (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or<br/> (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or<br/> (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND<br/> (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.</p><p> The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p> If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p> If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:<br/> (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND<br/> (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 10&#160;mg per L.</p><p> The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p> Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:<br/> (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and<br/> (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and<br/> (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and<br/> (iv) a signed patient acknowledgment form.</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9077R','3751','f',$$<p>Initial 2 (change or re-commencement for all patients)<br/> Initial PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with adalimumab in the current treatment cycle.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9078T','3752','f',$$<p>Continuing treatment for all patients<br/> Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:<br/> (a) has demonstrated an adequate response to treatment with adalimumab; and<br/> (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with adalimumab.</p><p> An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:<br/> (a) an ESR measurement no greater than 25&#160;mm per hour; or<br/> (b) a CRP measurement no greater than 10&#160;mg per L; or<br/> (c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p> Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> All measurements provided must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</p><p> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with adalimumab.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9079W','3083','t',$$<p>Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.</p><p> Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.</p><p> Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.</p><p> The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9080X','3083','t',$$<p>Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.</p><p> Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.</p><p> Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.</p><p> The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9085E','3510','f',$$<p>Initial 1 (new patients)<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND<br/> (a) who has at least 2 of the following:<br/> (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or<br/> (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or<br/> (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND<br/> (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.</p><p> The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p> If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p> If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:<br/> (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND<br/> (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 10&#160;mg per L.</p><p> The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p> Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:<br/> (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and<br/> (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and<br/> (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and<br/> (iv) a signed patient acknowledgment form.</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9085E','3774','f',$$<p>Initial 2 (change or re-commencement for all patients)<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with etanercept in the current treatment cycle.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9086F','3775','f',$$<p>Continuing treatment for all patients<br/> Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:<br/> (a) has demonstrated an adequate response to treatment with etanercept; and<br/> (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with etanercept.</p><p> An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:<br/> (a) an ESR measurement no greater than 25&#160;mm per hour; or<br/> (b) a CRP measurement no greater than 10&#160;mg per L; or<br/> (c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p> Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> All measurements provided must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this criterion.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with etanercept.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9087G','3489','f',$$<p>Initial 1<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have severe active psoriatic arthritis; and<br/> (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and<br/> (3) have failed to achieve an adequate response to:<br/> (a) methotrexate at a dose of at least 20&#160;mg weekly for a minimum period of 3 months; and<br/> (b) sulfasalazine at a dose of at least 2&#160;g per day for a minimum period of 3 months; or<br/> (c) leflunomide at a dose of up to 20&#160;mg daily for a minimum period of 3 months.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9087G','3776','f',$$<p>Initial 2<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have a documented history of severe active psoriatic arthritis; and<br/> (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and<br/> (3) have not failed treatment with etanercept during the current Treatment Cycle.</p><p> Applications for patients who have received PBS-subsidised treatment with etanercept within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9088H','3777','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:<br/> (1) who have a documented history of severe active psoriatic arthritis; and<br/> (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with etanercept; and<br/> (3) who, at the time of application, demonstrate an adequate response to treatment with etanercept.</p><p> An adequate response to treatment with etanercept is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline; AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9089J','3708','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9089J','3772','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with etanercept and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9090K','3773','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with etanercept.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9091L','3273','f',$$<p>Initial treatment [Initial 1, Whole body (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9091L','3778','f',$$<p>Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9091L','3275','f',$$<p>Initial treatment [Initial 1, Face, hand, foot (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where: <br/> (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or<br/> (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9091L','3779','f',$$<p>Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9092M','3025','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:<br/> (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or<br/> (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or<br/> (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9092M','3026','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9092M','3027','f',$$<p>treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:<br/> (1) Adverse effects on growth and weight; and/or<br/> (2) Adverse effects on sleep including insomnia; and/or<br/> (3) Adverse effects on appetite including anorexia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9092M','3028','f',$$<p>Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9093N','3025','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:<br/> (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or<br/> (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or<br/> (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9093N','3026','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9093N','3027','f',$$<p>treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:<br/> (1) Adverse effects on growth and weight; and/or<br/> (2) Adverse effects on sleep including insomnia; and/or<br/> (3) Adverse effects on appetite including anorexia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9093N','3028','f',$$<p>Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9094P','3025','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:<br/> (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or<br/> (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or<br/> (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9094P','3026','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9094P','3027','f',$$<p>treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:<br/> (1) Adverse effects on growth and weight; and/or<br/> (2) Adverse effects on sleep including insomnia; and/or<br/> (3) Adverse effects on appetite including anorexia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9094P','3028','f',$$<p>Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9095Q','3025','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:<br/> (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or<br/> (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or<br/> (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9095Q','3026','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9095Q','3027','f',$$<p>treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:<br/> (1) Adverse effects on growth and weight; and/or<br/> (2) Adverse effects on sleep including insomnia; and/or<br/> (3) Adverse effects on appetite including anorexia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9095Q','3028','f',$$<p>Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9096R','3025','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:<br/> (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or<br/> (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or<br/> (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9096R','3026','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9096R','3027','f',$$<p>treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:<br/> (1) Adverse effects on growth and weight; and/or<br/> (2) Adverse effects on sleep including insomnia; and/or<br/> (3) Adverse effects on appetite including anorexia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9096R','3028','f',$$<p>Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9099X','3706','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9099X','3745','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with adalimumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9100Y','3746','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with adalimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with adalimumab.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9101B','3486','f',$$<p>Initial 1<br/> Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have severe active psoriatic arthritis; and<br/> (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and<br/> (3) have failed to achieve an adequate response to:<br/> (a) methotrexate at a dose of at least 20&#160;mg weekly for a minimum period of 3 months; and<br/> (b) sulfasalazine at a dose of at least 2&#160;g per day for a minimum period of 3 months; or<br/> (c) leflunomide at a dose of up to 20&#160;mg daily for a minimum period of 3 months.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial adalimimab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9101B','3749','f',$$<p>Initial 2<br/> Initial PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have a documented history of severe active psoriatic arthritis; and<br/> (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and<br/> (3) have not failed treatment with adalimumab during the current Treatment Cycle.</p><p> Applications for patients who have received PBS-subsidised treatment with adalimumab within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9102C','3750','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:<br/> (1) who have a documented history of severe active psoriatic arthritis; and<br/> (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with adalimumab; and<br/> (3) who, at the time of application, demonstrate an adequate response to treatment with adalimumab.</p><p> An adequate response to treatment with adalimumab is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline; AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9103D','3502','f',$$<p>Initial 1 (new patients)<br/> Initial PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND<br/> (a) who has at least 2 of the following:<br/> (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or<br/> (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or<br/> (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND<br/> (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.</p><p> The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p> If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p> If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:<br/> (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND<br/> (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 10&#160;mg per L.</p><p> The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p> Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:<br/> (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and<br/> (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and<br/> (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and<br/> (iv) a signed patient acknowledgment form.</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9103D','3751','f',$$<p>Initial 2 (change or re-commencement for all patients)<br/> Initial PBS-subsidised treatment with adalimumab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with adalimumab in the current treatment cycle.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> A maximum of 16 weeks of treatment with adalimumab will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9104E','3752','f',$$<p>Continuing treatment for all patients<br/> Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:<br/> (a) has demonstrated an adequate response to treatment with adalimumab; and<br/> (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with adalimumab.</p><p> An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:<br/> (a) an ESR measurement no greater than 25&#160;mm per hour; or<br/> (b) a CRP measurement no greater than 10&#160;mg per L; or<br/> (c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p> Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> All measurements provided must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with adalimumab will be authorised under this criterion.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</p><p> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with adalimumab.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with adalimumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial adalimumab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9111M','3849','f',$$<p>Initial PBS-subsidised treatment, for up to 3 months, of a patient with a metastatic or unresectable malignant gastrointestinal stromal tumour which has been histologically confirmed by the detection of CD117 on immunohistochemical staining.</p><p> Patients must commence treatment at a dose not exceeding 400&#160;mg per day for at least 3 months.  Authority prescriptions for a higher dose will not be approved during this initial 3 month treatment period.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Metastatic or Unresectable Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and<br/> (ii) a copy of the most recent (within 2 months of the application) computed tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasound assessment of the tumour(s), including whether or not there is evidence of metastatic disease; and<br/> (iii) where the application for authority to prescribe is being sought on the basis of an unresectable tumour, written evidence in support of that claim must be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9111M','3850','f',$$<p>Continuing PBS-subsidised treatment, at a dose of up to 600&#160;mg per day, of a patient with a metastatic or unresectable malignant gastrointestinal stromal tumour who has previously been issued with an authority prescription for this drug.</p><p> Applications for continuing treatment may be made by telephone (1800&#160;700&#160;270, hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9112N','3849','f',$$<p>Initial PBS-subsidised treatment, for up to 3 months, of a patient with a metastatic or unresectable malignant gastrointestinal stromal tumour which has been histologically confirmed by the detection of CD117 on immunohistochemical staining.</p><p> Patients must commence treatment at a dose not exceeding 400&#160;mg per day for at least 3 months.  Authority prescriptions for a higher dose will not be approved during this initial 3 month treatment period.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Metastatic or Unresectable Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and<br/> (ii) a copy of the most recent (within 2 months of the application) computed tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasound assessment of the tumour(s), including whether or not there is evidence of metastatic disease; and<br/> (iii) where the application for authority to prescribe is being sought on the basis of an unresectable tumour, written evidence in support of that claim must be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9112N','3850','f',$$<p>Continuing PBS-subsidised treatment, at a dose of up to 600&#160;mg per day, of a patient with a metastatic or unresectable malignant gastrointestinal stromal tumour who has previously been issued with an authority prescription for this drug.</p><p> Applications for continuing treatment may be made by telephone (1800&#160;700&#160;270, hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9113P','4007','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, BCR-ABL tyrosine kinase, and who has a primary diagnosis of chronic myeloid leukaemia.</p><p> Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved.</p><p> Patients should be commenced on a dose of imatinib mesylate of 400&#160;mg (base) daily. Continuing therapy is dependent on patients demonstrating a response to imatinib mesylate therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Chronic Phase, First Line - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow; and<br/> (4) a signed patient acknowledgement form</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9113P','4008','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with imatinib mesylate for the chronic phase of chronic myeloid leukaemia and who has demonstrated either a major cytogenetic response or less than 1% BCR-ABL level in the blood.</p><p> First continuing applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) demonstration of a response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining requirements]; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining requirements].</p><p> Second and subsequent authority applications for continuing therapy with imatinib mesylate may be made on the telephone by contacting Medicare Australia on 1800&#160;700&#160;720 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Patients must maintain a major cytogenetic response or have a peripheral blood BCR-ABL of less than 1% to receive continuing therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9114Q','4007','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, BCR-ABL tyrosine kinase, and who has a primary diagnosis of chronic myeloid leukaemia.</p><p> Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved.</p><p> Patients should be commenced on a dose of imatinib mesylate of 400&#160;mg (base) daily. Continuing therapy is dependent on patients demonstrating a response to imatinib mesylate therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Chronic Phase, First Line - Supporting Information form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow; and<br/> (4) a signed patient acknowledgement form</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9114Q','4008','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with imatinib mesylate for the chronic phase of chronic myeloid leukaemia and who has demonstrated either a major cytogenetic response or less than 1% BCR-ABL level in the blood.</p><p> First continuing applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) demonstration of a response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining requirements]; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining requirements].</p><p> Second and subsequent authority applications for continuing therapy with imatinib mesylate may be made on the telephone by contacting Medicare Australia on 1800&#160;700&#160;720 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Patients must maintain a major cytogenetic response or have a peripheral blood BCR-ABL of less than 1% to receive continuing therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9115R','1816','f',$$<p>Treatment of patients in the accelerated phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to the accelerated phase is defined by the presence of 1 or more of the following:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or<br/> (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%; or<br/> (3) Peripheral basophils greater than or equal to 20%; or<br/> (4) Progressive splenomegaly to a size greater than or equal to 10&#160;cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or<br/> (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome).</p><p> Applications for authorisation must be in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and<br/> (c) a copy of the confirming pathology report from an Approved Pathology Authority in the case of criteria (1), (2), (3) and (5) above, or details of the dates of assessments in the case of progressive splenomegaly</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9115R','1817','f',$$<p>Treatment of patients in the blast phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to myeloid blast crisis is defined as either:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or<br/> (2) Extramedullary involvement other than spleen and liver.</p><p> Applications for authorisation must be in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and<br/> (c) a copy of the confirming pathology report from an Approved Pathology Authority in the case of criterion (1) above, or details of the date of assessment in the case of extramedullary involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9115R','1818','f',$$<p>the accelerated phase of chronic myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9115R','1819','f',$$<p>the blast phase of chronic myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9116T','1816','f',$$<p>Treatment of patients in the accelerated phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to the accelerated phase is defined by the presence of 1 or more of the following:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or<br/> (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%; or<br/> (3) Peripheral basophils greater than or equal to 20%; or<br/> (4) Progressive splenomegaly to a size greater than or equal to 10&#160;cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or<br/> (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome).</p><p> Applications for authorisation must be in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and<br/> (c) a copy of the confirming pathology report from an Approved Pathology Authority in the case of criteria (1), (2), (3) and (5) above, or details of the dates of assessments in the case of progressive splenomegaly</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9116T','1817','f',$$<p>Treatment of patients in the blast phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, and who have a primary diagnosis of chronic myeloid leukaemia. Progress to myeloid blast crisis is defined as either:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or<br/> (2) Extramedullary involvement other than spleen and liver.</p><p> Applications for authorisation must be in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Chronic Myeloid Leukaemia - Supporting Information form, stating which of the above criteria are satisfied by the patient; and<br/> (c) a copy of the confirming pathology report from an Approved Pathology Authority in the case of criterion (1) above, or details of the date of assessment in the case of extramedullary involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9116T','1818','f',$$<p>the accelerated phase of chronic myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9116T','1819','f',$$<p>the blast phase of chronic myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9123E','2766','f',$$<p>Initial treatment in combination with chemotherapy as induction or consolidation of a newly diagnosed patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and<br/> (d) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9123E','2767','f',$$<p>Initial treatment of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript BCR-ABL who was previously treated with imatinib mesylate under the Imatinib Compassionate Program and who meets all the PBS criteria.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and<br/> (d) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9123E','3144','f',$$<p>Continuing treatment in combination with chemotherapy as maintenance of first complete remission of patients with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.</p><p> Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Imatinib mesylate is available with a lifetime maximum of 24&#160;months for continuing treatment with imatinib mesylate therapy for patients with acute lymphoblastic leukaemia reimbursed through the PBS.</p><p> Any queries concerning the arrangements to prescribe imatinib mesylate beyond 24&#160;months may be directed to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9124F','2766','f',$$<p>Initial treatment in combination with chemotherapy as induction or consolidation of a newly diagnosed patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and<br/> (d) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9124F','2767','f',$$<p>Initial treatment of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript BCR-ABL who was previously treated with imatinib mesylate under the Imatinib Compassionate Program and who meets all the PBS criteria.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia to confirm eligibility for treatment, with either cytogenetic evidence of the Philadelphia chromosome, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow. (The date of the relevant pathology report needs to be provided); and<br/> (d) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9124F','3144','f',$$<p>Continuing treatment in combination with chemotherapy as maintenance of first complete remission of patients with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL.</p><p> Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Imatinib mesylate is available with a lifetime maximum of 24&#160;months for continuing treatment with imatinib mesylate therapy for patients with acute lymphoblastic leukaemia reimbursed through the PBS.</p><p> Any queries concerning the arrangements to prescribe imatinib mesylate beyond 24&#160;months may be directed to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9125G','2769','f',$$<p>Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has failed treatment with chemotherapy AND imatinib and where appropriate, allogeneic haemopoietic stem cell transplantation.</p><p> Failure of treatment is defined as either:<br/> (i) Failure to achieve a complete morphological and cytogenetic remission after a minimum of 2 months treatment with intensive chemotherapy and imatinib;<br/> (ii) Morphological or cytogenetic relapse of leukaemia after achieving a complete remission induced by chemotherapy and imatinib;<br/> (iii) Morphological or cytogenetic relapse or persistence of leukaemia after allogeneic haemopoietic stem cell transplantation.</p><p> Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9125G','2770','f',$$<p>Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has been treated prior to 1&#160;December&#160;2007 and has failed treatment with chemotherapy and where appropriate, allogeneic haemopoietic stem cell transplantation.</p><p> Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9125G','2771','f',$$<p>Continuing treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, where the patient has previously been issued with an authority prescription for dasatinib and does not have progressive disease.</p><p> Authority applications for continuing treatment may be made by telephone on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9126H','2769','f',$$<p>Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has failed treatment with chemotherapy AND imatinib and where appropriate, allogeneic haemopoietic stem cell transplantation.</p><p> Failure of treatment is defined as either:<br/> (i) Failure to achieve a complete morphological and cytogenetic remission after a minimum of 2 months treatment with intensive chemotherapy and imatinib;<br/> (ii) Morphological or cytogenetic relapse of leukaemia after achieving a complete remission induced by chemotherapy and imatinib;<br/> (iii) Morphological or cytogenetic relapse or persistence of leukaemia after allogeneic haemopoietic stem cell transplantation.</p><p> Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9126H','2770','f',$$<p>Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has been treated prior to 1&#160;December&#160;2007 and has failed treatment with chemotherapy and where appropriate, allogeneic haemopoietic stem cell transplantation.</p><p> Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9126H','2771','f',$$<p>Continuing treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, where the patient has previously been issued with an authority prescription for dasatinib and does not have progressive disease.</p><p> Authority applications for continuing treatment may be made by telephone on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9127J','2769','f',$$<p>Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has failed treatment with chemotherapy AND imatinib and where appropriate, allogeneic haemopoietic stem cell transplantation.</p><p> Failure of treatment is defined as either:<br/> (i) Failure to achieve a complete morphological and cytogenetic remission after a minimum of 2 months treatment with intensive chemotherapy and imatinib;<br/> (ii) Morphological or cytogenetic relapse of leukaemia after achieving a complete remission induced by chemotherapy and imatinib;<br/> (iii) Morphological or cytogenetic relapse or persistence of leukaemia after allogeneic haemopoietic stem cell transplantation.</p><p> Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9127J','2770','f',$$<p>Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has been treated prior to 1&#160;December&#160;2007 and has failed treatment with chemotherapy and where appropriate, allogeneic haemopoietic stem cell transplantation.</p><p> Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9127J','2771','f',$$<p>Continuing treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, where the patient has previously been issued with an authority prescription for dasatinib and does not have progressive disease.</p><p> Authority applications for continuing treatment may be made by telephone on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9128K','2774','f',$$<p>who has entered a comprehensive support and counselling program</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9128K','2775','f',$$<p>who is entering a comprehensive support and counselling program during the consultation at which this authority is requested</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9129L','3670','f',$$<p>Continuation of short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has previously been issued with an authority prescription for this drug and who is enrolled in a comprehensive support and counselling program</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9140C','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9141D','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9142E','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9148L','3433','f',$$<p>Initial treatment, in combination with capecitabine, of a patient with HER2 positive metastatic breast cancer (equivalent to Stage IIIC or Stage IV) who has received prior therapy with a taxane, for at least 3 cycles, and whose disease has progressed despite treatment with trastuzumab for metastatic disease.</p><p> Authority applications for initial treatment must be made in writing and must include:<br/> (a) a completed authority prescription form;<br/> (b) a pathology report demonstrating HER2 positivity has been demonstrated by in situ hybridisation (ISH);<br/> (c) date of last treatment with a taxane and total number of cycles;<br/> (d) a signed patient acknowledgment;<br/> (e) dates of treatment with trastuzumab; and<br/> (f) date of demonstration of progression whilst on treatment with trastuzumab</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9148L','2890','f',$$<p>Continuing treatment, in combination with capecitabine, of a patient with HER2 positive metastatic breast cancer who has previously received treatment with PBS-subsidised lapatinib and who does not have progressive disease.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a statement from the prescribing doctor that the disease has not progressed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9157Y','3673','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has a decrease of at least 30% in iPTH concentrations after 6 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9157Y','3672','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has iPTH greater than 15&#160;pmol per L and an (adjusted) serum calcium concentration of less than 2.6&#160;mmol per L after 6 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9158B','3673','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has a decrease of at least 30% in iPTH concentrations after 6 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9158B','3672','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has iPTH greater than 15&#160;pmol per L and an (adjusted) serum calcium concentration of less than 2.6&#160;mmol per L after 6 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9159C','3673','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has a decrease of at least 30% in iPTH concentrations after 6 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9159C','3672','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with cinacalcet, of a patient with chronic kidney disease on dialysis who has iPTH greater than 15&#160;pmol per L and an (adjusted) serum calcium concentration of less than 2.6&#160;mmol per L after 6 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9160D','2354','t',$$<p>Treatment of a fungal or a yeast infection in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9160D','3243','t',$$<p>Treatment of a fungal or a yeast infection in a patient aged up to 18 years inclusive</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9161E','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9161E','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9161E','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9161E','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9162F','3875','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 or more.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 or more. If this score is 25 - 30 points, the result of a baseline Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) may also be specified.</p><p> If an ADAS-Cog score is not supplied with the initial application, this scale cannot be used for the purpose of fulfilling the criteria for continued PBS supply.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9162F','2934','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE or ADAS-Cog improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by:<br/> (a) for patients with a baseline (S)MMSE score of 10 or more and less than 25, an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE);<br/> (b) for patients with a baseline (S)MMSE score of at least 25 points, a decrease of at least 4 points from baseline on the Alzheimer's Disease Assessment Scale, cognitive sub-scale (ADAS-Cog) or an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE or the ADAS-Cog and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9162F','3876','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 or more for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9162F','2938','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of mild to moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9166K','2971','f',$$<p>Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer with a WHO performance status of 3 or less, after prior treatment with platinum-based chemotherapy, where:<br/> (1) (a) disease progression has occurred following treatment with docetaxel or pemetrexed; or<br/> (b) treatment with docetaxel and pemetrexed is either contraindicated or cannot be tolerated; and<br/> (2) further cytotoxic chemotherapy is not appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9166K','2972','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer who has previously been issued with an authority prescription for this drug and who does not have progressive disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9167L','2971','f',$$<p>Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer with a WHO performance status of 3 or less, after prior treatment with platinum-based chemotherapy, where:<br/> (1) (a) disease progression has occurred following treatment with docetaxel or pemetrexed; or<br/> (b) treatment with docetaxel and pemetrexed is either contraindicated or cannot be tolerated; and<br/> (2) further cytotoxic chemotherapy is not appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9167L','2972','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer who has previously been issued with an authority prescription for this drug and who does not have progressive disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9168M','2971','f',$$<p>Initial PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer with a WHO performance status of 3 or less, after prior treatment with platinum-based chemotherapy, where:<br/> (1) (a) disease progression has occurred following treatment with docetaxel or pemetrexed; or<br/> (b) treatment with docetaxel and pemetrexed is either contraindicated or cannot be tolerated; and<br/> (2) further cytotoxic chemotherapy is not appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9168M','2972','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy, in a patient with locally advanced or metastatic (stage IIIB or IV) non-small cell lung cancer who has previously been issued with an authority prescription for this drug and who does not have progressive disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9169N','3291','t',$$<p>Treatment of partial epileptic seizures, which are not controlled satisfactorily by other anti-epileptic drugs in a patient unable to take a solid dose form of levetiracetam</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9170P','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9171Q','4001','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in chronic or accelerated phase who has failed an adequate trial of imatinib or dasatinib as first-line treatment.</p><p> Failure of an adequate trial of imatinib or dasatinib is defined as:</p><p> (i) Lack of response to initial imatinib or dasatinib therapy, defined as either:<br/> &#8212; failure to achieve a haematological response after a minimum of 3 months therapy with imatinib or dasatinib for patients initially treated in chronic phase; or<br/> &#8212; failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib or dasatinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or<br/> &#8212; failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12 months therapy with imatinib or dasatinib; OR</p><p> (ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib or dasatinib therapy; OR</p><p> (iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing imatinib or dasatinib therapy; OR</p><p> (iv) Development of accelerated phase in a patient previously prescribed imatinib or dasatinib for the chronic phase of chronic myeloid leukaemia.</p><p> Accelerated phase is defined by the presence of 1 or more of the following:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or<br/> (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%, provided that blast count is less than 30%; or<br/> (3) Peripheral basophils greater than or equal to 20%; or<br/> (4) Progressive splenomegaly to a size greater than or equal to 10&#160;cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or<br/> (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome); OR</p><p> (v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib or dasatinib therapy in patients with accelerated phase chronic myeloid leukaemia, provided that  blast crisis has been excluded on bone marrow biopsy.</p><p> Patients should be commenced on a dose of nilotinib of 400&#160;mg twice daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to nilotinib therapy or a peripheral blood BCR-ABL level of less than 1% within 18 months and thereafter at 12 monthly intervals.</p><p> Applications for authorisation must be in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Chronic Myeloid Leukaemia - Second and Third Line - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 0.1% on the international scale. (The date of the relevant pathology report needs to be provided); and<br/> (e) where there has been a loss of response to imatinib or dasatinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9171Q','4002','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with nilotinib for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 18 months and thereafter at 12 monthly intervals.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Second and Third Line - Application Form for continuing treatment; and<br/> (3) demonstration of continued response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9172R','2978','f',$$<p>Initial PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans.</p><p> Maximum dose: 800&#160;mg per day.</p><p> (1) Where the application for authority to prescribe is being sought on the basis of unresectable tumour, written evidence in support of that claim must be provided; and<br/> (2) Where the application for authority to prescribe is being sought on the basis of locally recurrent disease, the site of the local recurrence must be specified; and<br/> (3) Where the application for authority to prescribe is being sought on the basis of metastatic disease, the site(s) of metastatic disease must be provided.</p><p> Applications for authorisation for initial treatment must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9172R','2979','f',$$<p>Continuing PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans who has previously been issued with an authority prescription for imatinib and who has demonstrated a response, but whose disease remains unresectable.</p><p> Maximum dose: 800&#160;mg per day.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a statement that the disease has not progressed on imatinib therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9173T','2978','f',$$<p>Initial PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans.</p><p> Maximum dose: 800&#160;mg per day.</p><p> (1) Where the application for authority to prescribe is being sought on the basis of unresectable tumour, written evidence in support of that claim must be provided; and<br/> (2) Where the application for authority to prescribe is being sought on the basis of locally recurrent disease, the site of the local recurrence must be specified; and<br/> (3) Where the application for authority to prescribe is being sought on the basis of metastatic disease, the site(s) of metastatic disease must be provided.</p><p> Applications for authorisation for initial treatment must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9173T','2979','f',$$<p>Continuing PBS-subsidised treatment of a patient with unresectable, locally recurrent or metastatic dermatofibrosarcoma protuberans who has previously been issued with an authority prescription for imatinib and who has demonstrated a response, but whose disease remains unresectable.</p><p> Maximum dose: 800&#160;mg per day.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a statement that the disease has not progressed on imatinib therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9174W','2980','f',$$<p>Initial PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia requiring treatment and confirmed to carry the FIP1L1-PDGFRA fusion gene.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation for initial treatment must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the pathology report confirming the presence of the FIP1L1-PDGFRA fusion gene; and<br/> (d) a copy of the full blood examination report confirming the presence of hypereosinophilic syndrome or chronic eosinophilic leukaemia; and<br/> (e) details of organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and<br/> (f) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9174W','2981','f',$$<p>Continuing PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia who has previously been issued with an authority prescription for imatinib and who has achieved and maintained a complete haematological response.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the full blood examination report which demonstrates a complete haematological response, with a normal eosinophil count; and<br/> (d) a statement that the disease has not progressed on imatinib therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9175X','2980','f',$$<p>Initial PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia requiring treatment and confirmed to carry the FIP1L1-PDGFRA fusion gene.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation for initial treatment must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the pathology report confirming the presence of the FIP1L1-PDGFRA fusion gene; and<br/> (d) a copy of the full blood examination report confirming the presence of hypereosinophilic syndrome or chronic eosinophilic leukaemia; and<br/> (e) details of organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and<br/> (f) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9175X','2981','f',$$<p>Continuing PBS-subsidised treatment of a patient with hypereosinophilic syndrome or chronic eosinophilic leukaemia who has previously been issued with an authority prescription for imatinib and who has achieved and maintained a complete haematological response.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the full blood examination report which demonstrates a complete haematological response, with a normal eosinophil count; and<br/> (d) a statement that the disease has not progressed on imatinib therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9176Y','2982','f',$$<p>Initial PBS-subsidised treatment of a patient with a myelodysplastic or myeloproliferative disorder where:<br/> (1) there is confirmed evidence of a platelet-derived growth factor receptor (PDGFR) gene re-arrangement either by standard karyotyping, or FISH or PDGFRB fusion gene transcript; and<br/> (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:<br/> &#8212; cytarabine;<br/> &#8212; etoposide;<br/> &#8212; hydroxyurea.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation for initial treatment must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the pathology report confirming the platelet-derived growth factor receptor (PDGFR) gene re-arrangement; and<br/> (d) a copy of the bone marrow biopsy report which demonstrates the presence of a myelodysplastic or myeloproliferative disorder; and<br/> (e) details of the prior therapy trialled and the response; and<br/> (f) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9176Y','3033','f',$$<p>Continuing PBS-subsidised treatment of a patient with a PDGFRB fusion gene-positive myelodysplastic or myeloproliferative disorder who has previously been issued with an authority prescription for imatinib and who has demonstrated a complete haematological response.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the full blood examination report which demonstrates a complete haematological response; and<br/> (d) a statement that the disease has not progressed on imatinib therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9177B','2982','f',$$<p>Initial PBS-subsidised treatment of a patient with a myelodysplastic or myeloproliferative disorder where:<br/> (1) there is confirmed evidence of a platelet-derived growth factor receptor (PDGFR) gene re-arrangement either by standard karyotyping, or FISH or PDGFRB fusion gene transcript; and<br/> (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:<br/> &#8212; cytarabine;<br/> &#8212; etoposide;<br/> &#8212; hydroxyurea.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation for initial treatment must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the pathology report confirming the platelet-derived growth factor receptor (PDGFR) gene re-arrangement; and<br/> (d) a copy of the bone marrow biopsy report which demonstrates the presence of a myelodysplastic or myeloproliferative disorder; and<br/> (e) details of the prior therapy trialled and the response; and<br/> (f) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9177B','3033','f',$$<p>Continuing PBS-subsidised treatment of a patient with a PDGFRB fusion gene-positive myelodysplastic or myeloproliferative disorder who has previously been issued with an authority prescription for imatinib and who has demonstrated a complete haematological response.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the full blood examination report which demonstrates a complete haematological response; and<br/> (d) a statement that the disease has not progressed on imatinib therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9178C','2984','f',$$<p>Initial PBS-subsidised treatment of a patient with aggressive systemic mastocytosis with eosinophilia where:<br/> (1) there is confirmed evidence of the FIP1L1-PDGFRA fusion gene; and<br/> (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:<br/> &#8212; corticosteroids;<br/> &#8212; hydroxyurea.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation for initial treatment must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the pathology report confirming the presence of the FIP1L1-PDGFRA fusion gene; and<br/> (d) a copy of the bone marrow biopsy report and/or other tissue biopsy report confirming the diagnosis of aggressive systemic mastocytosis and a copy of the full blood examination report demonstrating eosinophilia; and<br/> (e) details of symptomatic organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and<br/> (f) details of prior treatment trialled and the response; and<br/> (g) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9178C','3034','f',$$<p>Continuing PBS-subsidised treatment of a patient with aggressive systemic mastocytosis confirmed to carry the FIP1L1-PDGFRA fusion gene, who has previously been issued with an authority prescription for imatinib and who has demonstrated a complete haematological response.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the full blood examination report which demonstrates a complete haematological response; and<br/> (d) a statement that the disease has not progressed on imatinib therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9179D','2984','f',$$<p>Initial PBS-subsidised treatment of a patient with aggressive systemic mastocytosis with eosinophilia where:<br/> (1) there is confirmed evidence of the FIP1L1-PDGFRA fusion gene; and<br/> (2) the patient has previously failed an adequate trial of one or more of the following conventional therapies:<br/> &#8212; corticosteroids;<br/> &#8212; hydroxyurea.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation for initial treatment must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the pathology report confirming the presence of the FIP1L1-PDGFRA fusion gene; and<br/> (d) a copy of the bone marrow biopsy report and/or other tissue biopsy report confirming the diagnosis of aggressive systemic mastocytosis and a copy of the full blood examination report demonstrating eosinophilia; and<br/> (e) details of symptomatic organ involvement requiring treatment, including a copy of the radiology, nuclear medicine, respiratory function or anatomical pathology reports as appropriate; and<br/> (f) details of prior treatment trialled and the response; and<br/> (g) a signed patient acknowledgement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9179D','3034','f',$$<p>Continuing PBS-subsidised treatment of a patient with aggressive systemic mastocytosis confirmed to carry the FIP1L1-PDGFRA fusion gene, who has previously been issued with an authority prescription for imatinib and who has demonstrated a complete haematological response.</p><p> Maximum dose: 400&#160;mg per day.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Rare Diseases Imatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the full blood examination report which demonstrates a complete haematological response; and<br/> (d) a statement that the disease has not progressed on imatinib therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9180E','3540','t',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9181F','3540','t',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9182G','3540','t',$$<p>Dual oral combination therapy with metformin or a sulfonylurea<br/> Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9183H','3070','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9183H','3933','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -2.5 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9183H','2646','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9184J','3015','f',$$<p>B-cell chronic lymphocytic leukaemia in combination with cyclophosphamide where the patient has advanced disease (Binet Stage B or C) or evidence of progressive Stage A disease.</p><p> Stage A progressive disease is defined by at least one of the following: persistent rise in lymphocyte count with doubling time less than 12 months; a downward trend in haemoglobin or platelets, or both; more than 50% increase in the size of liver, spleen, or lymph nodes, or appearance of these signs if not previously present; constitutional symptoms attributable to disease.</p><p> The diagnosis of chronic lymphocytic leukaemia (CLL) must have been established based on:<br/> (a) a lymphocytosis, with more than 5,000 million lymphocytes per L in the peripheral blood; and<br/> (b) a clonal population of B-cells (CD5/CD19) documented by flow cytometry</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9186L','2986','f',$$<p>Initial 1 (new patients)<br/> Initial treatment of Crohn disease in a patient assessed by CDAI.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (c) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application. </p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au). </p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> The most recent CDAI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and<br/> (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (iii) the signed patient acknowledgement.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9186L','3753','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and<br/> (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9186L','2990','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:<br/> (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and<br/> (c) has evidence of intestinal inflammation; and<br/> (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (e) has failed to achieve an adequate response to prior systemic drug therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have evidence of intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (b) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and<br/> (iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.</p><p> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9186L','3754','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and<br/> (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.</p><p> A maximum of 16 weeks of treatment will be approved under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9186L','2993','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with extensive small intestine disease.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50&#160;cm of the small intestine; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;<br/> AND/OR<br/> (b) have evidence of active intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (c) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or<br/> (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and<br/> (iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.</p><p> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.</p><p> A maximum of 16 weeks treatment of adalimumab will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9187M','2986','f',$$<p>Initial 1 (new patients)<br/> Initial treatment of Crohn disease in a patient assessed by CDAI.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (c) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application. </p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au). </p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> The most recent CDAI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and<br/> (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (iii) the signed patient acknowledgement.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9187M','3753','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and<br/> (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9187M','2990','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:<br/> (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and<br/> (c) has evidence of intestinal inflammation; and<br/> (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (e) has failed to achieve an adequate response to prior systemic drug therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have evidence of intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (b) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and<br/> (iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.</p><p> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9187M','3754','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and<br/> (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.</p><p> A maximum of 16 weeks of treatment will be approved under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9187M','2993','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with extensive small intestine disease.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50&#160;cm of the small intestine; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;<br/> AND/OR<br/> (b) have evidence of active intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (c) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or<br/> (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and<br/> (iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.</p><p> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.</p><p> A maximum of 16 weeks treatment of adalimumab will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9188N','2986','f',$$<p>Initial 1 (new patients)<br/> Initial treatment of Crohn disease in a patient assessed by CDAI.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (c) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application. </p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au). </p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> The most recent CDAI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and<br/> (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (iii) the signed patient acknowledgement.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9188N','3753','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and<br/> (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9188N','2990','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:<br/> (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and<br/> (c) has evidence of intestinal inflammation; and<br/> (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (e) has failed to achieve an adequate response to prior systemic drug therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have evidence of intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (b) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and<br/> (iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.</p><p> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9188N','3754','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and<br/> (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.</p><p> A maximum of 16 weeks of treatment will be approved under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9188N','2993','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with extensive small intestine disease.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50&#160;cm of the small intestine; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;<br/> AND/OR<br/> (b) have evidence of active intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (c) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or<br/> (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and<br/> (iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.</p><p> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.</p><p> A maximum of 16 weeks treatment of adalimumab will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9189P','2988','f',$$<p>Initial 3 (grandfather)<br/> Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with adalimumab.</p><p> Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9&#160;November 2007; and<br/> (b) had a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 prior to commencing treatment with adalimumab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has demonstrated or sustained an adequate response to treatment with adalimumab. For advice please contact Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and<br/> (ii) the signed patient acknowledgement.</p><p> The current CDAI assessment must be no more than 1 month old at the time of application.  The baseline CDAI assessment must be from immediately prior to commencing treatment with adalimumab.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> A maximum of 24 weeks treatment will be approved under this criterion.<br/> Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9189P','3755','f',$$<p>Continuing treatment of Crohn disease in a patient assessed by CDAI.</p><p> Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) has demonstrated or sustained an adequate response to treatment with adalimumab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.</p><p> The CDAI assessment must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with adalimumab, a CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> A maximum of 24 weeks treatment will be authorised under this criterion.<br/> Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9189P','3756','f',$$<p>Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.</p><p> Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and<br/> (b) has demonstrated or sustained an adequate response to treatment with adalimumab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to adalimumab treatment is defined as:<br/> (a) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (b) reversal of high faecal output state; or<br/> (c) avoidance of the need for surgery or total parenteral nutrition (TPN).</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.</p><p> The patient's assessment must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> A maximum of 24 weeks of treatment will be authorised under this criterion.<br/> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9189P','3757','f',$$<p>Continuing treatment of Crohn disease in a patient with extensive small intestine disease.</p><p> Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50&#160;cm of the small intestine; and<br/> (b) has demonstrated or sustained an adequate response to treatment with adalimumab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to adalimumab treatment is defined as:<br/> (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or<br/> (b) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (c) reversal of high faecal output state; or<br/> (d) avoidance of the need for surgery or total parenteral nutrition (TPN).</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or<br/> (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy; or<br/> (iii) the date of clinical assessment.</p><p> All assessments must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> A maximum of 24 weeks treatment will be authorised under this criterion.<br/> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9189P','2995','f',$$<p>Initial 3<br/> Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with adalimumab.</p><p> Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9&#160;November 2007; and<br/> (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50&#160;cm of the small intestine; or<br/> (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has demonstrated or sustained an adequate response to treatment with adalimumab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.</p><p> An adequate response to adalimumab treatment is defined as:<br/> (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or<br/> (b) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (c) reversal of high faecal output state; or<br/> (d) avoidance of the need for surgery or total parenteral nutrition (TPN).</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au) ] which includes the following:<br/> (i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or<br/> (2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or<br/> (3) the date of clinical assessment(s); and<br/> (ii) the signed patient acknowledgement.</p><p> The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with adalimumab. Where a baseline assessment is not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> Patients who fail to demonstrate or sustain a response to treatment with adalimumab for Crohn disease as specified in the criteria for continuing treatment with adalimumab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.</p><p> A maximum of 24 weeks treatment will be authorised under this criterion.<br/> Where fewer than 5 repeats are requested at the time of this application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9190Q','2986','f',$$<p>Initial 1 (new patients)<br/> Initial treatment of Crohn disease in a patient assessed by CDAI.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (c) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application. </p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au). </p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> The most recent CDAI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and<br/> (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (iii) the signed patient acknowledgement.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9190Q','3753','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and<br/> (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> A CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9190Q','2990','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:<br/> (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and<br/> (c) has evidence of intestinal inflammation; and<br/> (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (e) has failed to achieve an adequate response to prior systemic drug therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have evidence of intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (b) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and<br/> (iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.</p><p> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.</p><p> A maximum of 16 weeks treatment will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9190Q','3754','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and<br/> (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.</p><p> A maximum of 16 weeks of treatment will be approved under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9190Q','2993','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with extensive small intestine disease.</p><p> Initial PBS-subsidised treatment with adalimumab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50&#160;cm of the small intestine; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;<br/> AND/OR<br/> (b) have evidence of active intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (c) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of adalimumab.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) two completed authority prescription forms; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or<br/> (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and<br/> (iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.</p><p> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.</p><p> A maximum of 16 weeks treatment of adalimumab will be authorised under this criterion.</p><p> Two completed authority prescriptions must be submitted with every initial application for adalimumab.  One prescription must be for the induction pack containing a quantity of 6 doses of 40&#160;mg and no repeats.  The second prescription must be written for 2 doses of 40&#160;mg and 2 repeats.  Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9191R','2988','f',$$<p>Initial 3 (grandfather)<br/> Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with adalimumab.</p><p> Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9&#160;November 2007; and<br/> (b) had a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 prior to commencing treatment with adalimumab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has demonstrated or sustained an adequate response to treatment with adalimumab. For advice please contact Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and<br/> (ii) the signed patient acknowledgement.</p><p> The current CDAI assessment must be no more than 1 month old at the time of application.  The baseline CDAI assessment must be from immediately prior to commencing treatment with adalimumab.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> A maximum of 24 weeks treatment will be approved under this criterion.<br/> Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9191R','3755','f',$$<p>Continuing treatment of Crohn disease in a patient assessed by CDAI.</p><p> Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) has demonstrated or sustained an adequate response to treatment with adalimumab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to adalimumab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.</p><p> The CDAI assessment must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with adalimumab, a CDAI assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> A maximum of 24 weeks treatment will be authorised under this criterion.<br/> Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9191R','3756','f',$$<p>Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.</p><p> Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and<br/> (b) has demonstrated or sustained an adequate response to treatment with adalimumab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to adalimumab treatment is defined as:<br/> (a) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (b) reversal of high faecal output state; or<br/> (c) avoidance of the need for surgery or total parenteral nutrition (TPN).</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.</p><p> The patient's assessment must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy after the first dose so that there is adequate time for a response to be demonstrated.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> A maximum of 24 weeks of treatment will be authorised under this criterion.<br/> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9191R','3757','f',$$<p>Continuing treatment of Crohn disease in a patient with extensive small intestine disease.</p><p> Continuing PBS-subsidised treatment with adalimumab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50&#160;cm of the small intestine; and<br/> (b) has demonstrated or sustained an adequate response to treatment with adalimumab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to adalimumab treatment is defined as:<br/> (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or<br/> (b) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (c) reversal of high faecal output state; or<br/> (d) avoidance of the need for surgery or total parenteral nutrition (TPN).</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or<br/> (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy; or<br/> (iii) the date of clinical assessment.</p><p> All assessments must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with adalimumab, an assessment of the patient's response must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> A maximum of 24 weeks treatment will be authorised under this criterion.<br/> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9191R','2995','f',$$<p>Initial 3<br/> Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with adalimumab.</p><p> Initial PBS-subsidised supply for continuing treatment with adalimumab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease and was receiving treatment with adalimumab prior to 9&#160;November 2007; and<br/> (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50&#160;cm of the small intestine; or<br/> (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has demonstrated or sustained an adequate response to treatment with adalimumab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.</p><p> An adequate response to adalimumab treatment is defined as:<br/> (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or<br/> (b) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (c) reversal of high faecal output state; or<br/> (d) avoidance of the need for surgery or total parenteral nutrition (TPN).</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au) ] which includes the following:<br/> (i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or<br/> (2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or<br/> (3) the date of clinical assessment(s); and<br/> (ii) the signed patient acknowledgement.</p><p> The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with adalimumab. Where a baseline assessment is not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with adalimumab.</p><p> Patients are eligible to receive continuing adalimumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> Patients who fail to demonstrate or sustain a response to treatment with adalimumab for Crohn disease as specified in the criteria for continuing treatment with adalimumab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.</p><p> A maximum of 24 weeks treatment will be authorised under this criterion.<br/> Where fewer than 5 repeats are requested at the time of this application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9198D','3042','f',$$<p>Nicotine dependence in an Aboriginal or a Torres Strait Islander person as the sole PBS-subsidised therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9198D','3447','f',$$<p>Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program.<br/> Details of the program must be specified in the initial authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9198D','3448','f',$$<p>Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.<br/> Details of the program must be specified in the initial authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9202H','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9202H','2765','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9202H','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9203J','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9203J','2765','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9203J','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9204K','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9204K','2765','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9204K','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9205L','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9205L','2765','t',$$<p>Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9205L','2044','t',$$<p>Maintenance treatment of bipolar I disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9206M','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9206M','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9288W','3945','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.<br/> Only 1 treatment each year per patient will be PBS-subsidised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9288W','3947','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.<br/> Only 1 treatment each year per patient will be PBS-subsidised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9288W','3946','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in a patient with fracture due to minimal trauma.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.<br/> In all cases, the fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> Only 1 treatment each year per patient will be PBS-subsidised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9289X','3025','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:<br/> (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or<br/> (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or<br/> (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9289X','3026','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9289X','3027','f',$$<p>treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:<br/> (1) Adverse effects on growth and weight; and/or<br/> (2) Adverse effects on sleep including insomnia; and/or<br/> (3) Adverse effects on appetite including anorexia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9289X','3028','f',$$<p>Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9290Y','3025','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride poses an unacceptable medical risk due to the following contraindications as specified in the TGA-approved product information:<br/> (1) The patient has a history of substance abuse or misuse (other than alcohol); and/or<br/> (2) The patient has comorbid motor tics or Tourette's Syndrome; and/or<br/> (3) The patient has comorbid severe anxiety diagnosed according to the DSM-IV</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9290Y','3026','f',$$<p>treatment with dexamphetamine sulfate or methylphenidate hydrochloride has resulted in the development or worsening of a comorbid mood disorder (diagnosed according to the DSM-IV criteria i.e. anxiety disorder, obsessive compulsive disorder, depressive disorder) of a severity necessitating permanent stimulant treatment withdrawal; or where the combination of stimulant treatment with another agent would pose an unacceptable medical risk of a severity necessitating permanent stimulant treatment withdrawal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9290Y','3027','f',$$<p>treatment with dexamphetamine sulfate AND methylphenidate hydrochloride has resulted in the development of adverse reactions of a severity necessitating permanent treatment withdrawal:<br/> (1) Adverse effects on growth and weight; and/or<br/> (2) Adverse effects on sleep including insomnia; and/or<br/> (3) Adverse effects on appetite including anorexia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9290Y','3028','f',$$<p>Continuing sole PBS-subsidised treatment where the patient has previously been issued with an authority prescription for this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9292C','3305','t',$$<p>Parkinson disease in patients being treated with levodopa&#8212;decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9292C','3306','t',$$<p>Parkinson disease in patients stabilised on concomitant treatment with levodopa&#8212;decarboxylase inhibitor combinations and entacapone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9293D','2061','t',$$<p>Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9293D','3083','t',$$<p>Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient aged less than 18 years with autism.</p><p> Continuing PBS-subsidised treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a patient 18 years of age or older with autism who was commenced on PBS-subsidised treatment with risperidone prior to turning 18 years of age.</p><p> Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.</p><p> The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9294E','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9295F','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9296G','3880','t',$$<p>Treatment of acute coronary syndrome (myocardial infarction or unstable angina)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9296G','3219','t',$$<p>Treatment following cardiac stent insertion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9296G','1722','t',$$<p>Prevention of recurrence of myocardial infarction or unstable angina in patients with a history of symptomatic cardiac ischaemic events while on therapy with low-dose aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9303P','1589','t',$$<p>Schizophrenia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9304Q','3248','f',$$<p>Initial treatment [Initial 1, Whole body (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 2 repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9304Q','3789','f',$$<p>Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with ustekinumab for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised ustekinumab treatment within this Treatment Cycle and who wish to re-commence ustekinumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised ustekinumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 2 repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.</p><p> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9304Q','3250','f',$$<p>Initial treatment [Initial 1, Face, hand, foot (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where: <br/> (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or<br/> (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 2 repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9304Q','3790','f',$$<p>Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with ustekinumab for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised ustekinumab treatment within this Treatment Cycle and who wish to re-commence ustekinumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised ustekinumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 28 weeks of treatment with ustekinumab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 2 repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 28 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.</p><p> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9305R','3791','f',$$<p>Continuing treatment (Whole body)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with ustekinumab; and<br/> (c) who have demonstrated an adequate response to their most recent course of treatment with ustekinumab.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with ustekinumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Approval will be based on the PASI assessment of response to the most recent course of treatment with ustekinumab.</p><p> A maximum of 24 weeks of treatment with ustekinumab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 1 repeat will be authorised.</p><p> Where fewer than 1 repeat is requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9305R','3792','f',$$<p>Continuing treatment (Face, hand, foot)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with ustekinumab; and<br/> (c) who have demonstrated an adequate response to treatment with ustekinumab.</p><p> An adequate response to ustekinumab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:<br/> (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or<br/> (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with ustekinumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with ustekinumab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single injection.  Up to a maximum of 1 repeat will be authorised.</p><p> Where fewer than 1 repeat is requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with ustekinumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised ustekinumab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9306T','3877','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 10 to 14.<br/> Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease.  Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> The authority application must include the result of the baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE). This baseline (S)MMSE must be a score of 10 to 14.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9306T','2609','f',$$<p>CONTINUING TREATMENT &#8212; (S)MMSE improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in cognitive function as measured by an increase of at least 2 points from baseline on the Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE).</p><p> The initial authority application for continuing treatment must include the relevant result from the (S)MMSE and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9306T','3878','f',$$<p>INITIAL APPLICATION FOR THE TREATMENT OF MODERATELY SEVERE ALZHEIMER'S DISEASE &#8212; Patients with an (S)MMSE of 9 or less who require a clinician's assessment.<br/> Initial treatment, as the sole PBS-subsidised therapy, of moderately severe Alzheimer's disease of patients with a baseline Mini-Mental State Examination (MMSE) or Standardised Mini-Mental State Examination (SMMSE) score of 9 or less, who are unable to register a score of 10 to 14 for reasons other than their Alzheimer's disease, as specified below. Confirmation of this diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist).</p><p> Such patients will need to be assessed using the Clinicians Interview Based Impression of Severity (CIBIS) scale.  The authority application must include the result of the baseline (S)MMSE and specify to which group(s) (see below) the patient belongs.</p><p> This application must be made in writing, but initial supply may be sought by telephone.<br/> For telephone applications, up to a maximum of 2 months' initial therapy will be authorised.  This telephone application must be followed by a written authority application for no more than 1 month's therapy and sufficient repeats to complete a maximum of up to 6 months' initial treatment.<br/> For written applications where no prior telephone approval has been issued, up to a maximum of 1 month's therapy plus 5 repeats will be authorised.</p><p> Patients who qualify under this criterion are from 1 or more of the following groups:<br/> (1) Unable to communicate adequately because of lack of competence in English, in people of non-English speaking background;<br/> (2) Limited education, as defined by less than 6 years of education, or who are illiterate or innumerate;<br/> (3) Aboriginal or Torres Strait Islanders who, by virtue of cultural factors, are unable to complete an (S)MMSE test;<br/> (4) Intellectual (developmental or acquired) disability, eg Down's syndrome;<br/> (5) Significant sensory impairment despite best correction, which precludes completion of an (S)MMSE test;<br/> (6) Prominent dysphasia, out of proportion to other cognitive and functional impairment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9306T','2611','f',$$<p>CONTINUING TREATMENT &#8212; Clinician assessed improvement.<br/> Continuing treatment, as the sole PBS-subsidised therapy, following initial PBS-subsidised therapy, of moderately severe Alzheimer's disease in patients with demonstrated improvement in function, based on a rating of "very much improved" or "much improved" on the Clinicians Interview Based Impression of Change (CIBIC) scale, which must be assessed by the same clinician who initiated treatment.</p><p> The initial authority application for continuing treatment must state the improvement achieved on the CIBIC scale and must be in writing.</p><p> Subsequent applications for continuing treatment can be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9307W','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9311C','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9312D','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9313E','3233','t',$$<p>Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9316H','3234','t',$$<p>Moderate to severe heart failure in a patient stabilised on conventional therapy which must include an ACE inhibitor or Angiotensin II antagonist, if tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9317J','3879','t',$$<p>Treatment of acute coronary syndrome (myocardial infarction or unstable angina) in combination with aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9317J','3146','t',$$<p>Treatment in combination with aspirin following cardiac stent insertion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9318K','4047','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 20 days supply to complete a course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9319L','4047','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 20 days supply to complete a course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9320M','4048','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 30 days supply to complete a course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9321N','4048','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 30 days supply to complete a course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9322P','3957','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 10 days of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9323Q','3957','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 10 days of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9327X','1670','f',$$<p>Chylous ascites</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9327X','1068','f',$$<p>Chylothorax</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9327X','1671','f',$$<p>Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9327X','1513','f',$$<p>Hyperlipoproteinaemia type 1</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9327X','1672','f',$$<p>Intractable childhood epilepsy or cerebrospinal fluid glucose transporter defect, requiring a ketogenic diet</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9327X','1511','f',$$<p>Long chain fatty acid oxidation disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9328Y','3301','f',$$<p>Infants and children whose vitamin and mineral intake is insufficient due to a specific diagnosis requiring a highly restrictive therapeutic diet, and whose vitamin, mineral and trace element needs cannot be adequately met with other proprietary vitamin and mineral preparations</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9332E','1175','f',$$<p>Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9332E','1751','f',$$<p>Continuing treatment of clinically definite relapsing-remitting multiple sclerosis in patients previously issued with an authority prescription for this drug who do not show continuing progression of disability while on treatment with this drug and who have demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in the schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9333F','3303','f',$$<p>Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.<br/> A patient must have trialled and failed to achieve satisfactory seizure control with:<br/> (i) at least one first-line anti-epileptic agent; and<br/> (ii) at least two second-line adjunctive anti-epileptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9333F','3304','f',$$<p>Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9334G','3303','f',$$<p>Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.<br/> A patient must have trialled and failed to achieve satisfactory seizure control with:<br/> (i) at least one first-line anti-epileptic agent; and<br/> (ii) at least two second-line adjunctive anti-epileptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9334G','3304','f',$$<p>Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9335H','3303','f',$$<p>Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.<br/> A patient must have trialled and failed to achieve satisfactory seizure control with:<br/> (i) at least one first-line anti-epileptic agent; and<br/> (ii) at least two second-line adjunctive anti-epileptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9335H','3304','f',$$<p>Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9336J','3303','f',$$<p>Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.<br/> A patient must have trialled and failed to achieve satisfactory seizure control with:<br/> (i) at least one first-line anti-epileptic agent; and<br/> (ii) at least two second-line adjunctive anti-epileptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9336J','3304','f',$$<p>Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9337K','3303','f',$$<p>Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.<br/> A patient must have trialled and failed to achieve satisfactory seizure control with:<br/> (i) at least one first-line anti-epileptic agent; and<br/> (ii) at least two second-line adjunctive anti-epileptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9337K','3304','f',$$<p>Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9338L','3303','f',$$<p>Treatment, initiated by a neurologist, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs in a patient aged 16 years or older with intractable epilepsy.<br/> A patient must have trialled and failed to achieve satisfactory seizure control with:<br/> (i) at least one first-line anti-epileptic agent; and<br/> (ii) at least two second-line adjunctive anti-epileptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9338L','3304','f',$$<p>Continuing treatment, in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent, of partial epileptic seizures in a patient aged 16 years or older, who has previously been treated with PBS-subsidised lacosamide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9339M','4033','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated colic or reflux) in a child up to the age of 24&#160;months. Combined intolerance is demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9339M','4034','f',$$<p>Initial treatment, in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist, for up to 6 months, for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9339M','4035','f',$$<p>Initial treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months. The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9340N','4036','f',$$<p>Treatment, in consultation with a specialist allergist or clinical immunologist, for a child with cows' milk anaphylaxis, up to the age of 24&#160;months.  Anaphylaxis is defined as a severe and/or potentially life threatening allergic reaction.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9340N','4037','f',$$<p>Continuing treatment for cows' milk protein enteropathy with combined intolerance to both soy protein and protein hydrolysate formulae (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist. The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9340N','4038','f',$$<p>Continuing treatment for severe cows' milk protein enteropathy with failure to thrive (not isolated infant colic or reflux) in a child up to the age of 24&#160;months.  The child must have been assessed at least once or have an appointment to be assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist.  Then name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9340N','4039','f',$$<p>Continuing treatment for combined intolerance (not isolated infant colic or reflux) to cows' milk protein, soy protein and protein hydrolysate formulae in a child aged over 24&#160;months.  The child must have been assessed by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist at intervals not greater than 12&#160;months.  The name of the specialist and the date of birth of the patient must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9340N','1687','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9340N','1688','f',$$<p>Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9342Q','3999','f',$$<p>Initial treatment, as the sole PBS-subsidised therapy, of a patient with chronic myeloid leukaemia in any disease phase who has failed an adequate trial of imatinib or nilotinib as first-line treatment.</p><p> Failure of an adequate trial of imatinib or nilotinib is defined as:</p><p> (i) Lack of response to initial imatinib or nilotinib therapy, defined as either:<br/> &#8212; failure to achieve a haematological response after a minimum of 3 months therapy with imatinib or nilotinib for patients initially treated in chronic phase; or<br/> &#8212; failure to achieve any cytogenetic response after a minimum of 6 months therapy with imatinib or nilotinib for patients initially treated in chronic phase as demonstrated on bone marrow biopsy by presence of greater than 95% Philadelphia chromosome positive cells; or<br/> &#8212; failure to achieve a major cytogenetic response or a peripheral blood BCR-ABL level of less than 1% after a minimum of 12&#160;months therapy with imatinib or nilotinib; OR</p><p> (ii) Loss of a previously documented major cytogenetic response (demonstrated by the presence of greater than 35% Ph positive cells on bone marrow biopsy), during ongoing imatinib or nilotinib therapy; OR</p><p> (iii) Loss of a previously demonstrated molecular response (demonstrated by peripheral blood BCR-ABL levels increasing consecutively in value by at least 5 fold to a level of greater than 0.1% confirmed on a subsequent test), during ongoing imatinib or nilotinib therapy; OR</p><p> (iv) Development of accelerated phase or blast crisis in a patient previously prescribed imatinib or nilotinib for any phase of chronic myeloid leukaemia.</p><p> Accelerated phase is defined by the presence of 1 or more of the following:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 15% but less than 30%; or<br/> (2) Percentage of blasts plus promyelocytes in the peripheral blood or bone marrow greater than or equal to 30%, provided that blast count is less than 30%; or<br/> (3) Peripheral basophils greater than or equal to 20%; or<br/> (4) Progressive splenomegaly to a size greater than or equal to 10&#160;cm below the left costal margin to be confirmed on 2 occasions at least 4 weeks apart, or a greater than or equal to 50% increase in size below the left costal margin over 4 weeks; or<br/> (5) Karyotypic evolution (chromosomal abnormalities in addition to a single Philadelphia chromosome); OR</p><p> Blast crisis is defined as either:<br/> (1) Percentage of blasts in the peripheral blood or bone marrow greater than or equal to 30%; or<br/> (2) Extramedullary involvement other than spleen and liver; OR</p><p> (v) Disease progression (defined as a greater than or equal to 50% increase in peripheral white blood cell count, blast count, basophils or platelets) during first-line imatinib or nilotinib therapy in patients with accelerated phase or blast crisis chronic myeloid leukaemia.</p><p> Patients should be commenced on a dose of dasatinib of at least 100&#160;mg (base) daily. Continuing therapy is dependent on patients demonstrating a major cytogenetic response to dasatinib therapy or a peripheral blood BCR-ABL level of less than 1% within 18 months and thereafter at 12 monthly intervals.</p><p> Applications for authorisation must be in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Chronic Myeloid Leukaemia - Second and Third Line - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a bone marrow biopsy pathology report demonstrating the patient has active chronic myeloid leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or RT-PCR level of BCR-ABL transcript greater than 0.1% on the international scale. (The date of the relevant pathology report needs to be provided); and<br/> (e) where there has been a loss of response to imatinib or nilotinib, a copy of the current confirming pathology report(s) from an Approved Pathology Authority or details of the dates of assessment in the case of progressive splenomegaly or extramedullary involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9342Q','4000','f',$$<p>Continuing treatment, as the sole PBS-subsidised therapy, of a patient who has received initial PBS-subsidised treatment with dasatinib for chronic myeloid leukaemia, and who has demonstrated either a major cytogenetic response, or less than 1% BCR-ABL level in the blood, to dasatinib in the preceding 18&#160;months and thereafter at 12 monthly intervals.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Chronic Myeloid Leukaemia - Second and Third Line - Application Form for continuing treatment; and<br/> (3) demonstration of continued response to treatment as evidenced by either:<br/> (a) major cytogenetic response [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18&#160;months for the initial supply), only the date of the relevant pathology report needs to be provided; or<br/> (b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining definitions of response]. Where this has been supplied within the previous 12 months (or 18 months for the initial supply), only the date of the relevant pathology report needs to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9343R','2769','f',$$<p>Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia (ALL) bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has failed treatment with chemotherapy AND imatinib and where appropriate, allogeneic haemopoietic stem cell transplantation.</p><p> Failure of treatment is defined as either:<br/> (i) Failure to achieve a complete morphological and cytogenetic remission after a minimum of 2 months treatment with intensive chemotherapy and imatinib;<br/> (ii) Morphological or cytogenetic relapse of leukaemia after achieving a complete remission induced by chemotherapy and imatinib;<br/> (iii) Morphological or cytogenetic relapse or persistence of leukaemia after allogeneic haemopoietic stem cell transplantation.</p><p> Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9343R','2770','f',$$<p>Initial treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, who has been treated prior to 1&#160;December&#160;2007 and has failed treatment with chemotherapy and where appropriate, allogeneic haemopoietic stem cell transplantation.</p><p> Patients must have active leukaemia, as defined by presence on current pathology assessments of either morphological infiltration of the bone marrow (greater than 5% lymphoblasts) or cerebrospinal fluid or other sites; OR the presence of cells bearing the Philadelphia chromosome on cytogenetic or FISH analysis in the bone marrow of patients in morphological remission.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Acute Lymphoblastic Leukaemia Dasatinib PBS Authority Application - Supporting Information Form; and<br/> (c) a signed patient acknowledgement; and<br/> (d) a pathology report demonstrating that the patient has active acute lymphoblastic leukaemia, either manifest as cytogenetic evidence of the Philadelphia chromosome, or morphological evidence of acute lymphoblastic leukaemia plus qualitative RT-PCR evidence of BCR-ABL transcript. The date of the relevant pathology report(s) need(s) to be provided</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9343R','2771','f',$$<p>Continuing treatment, as monotherapy, of a patient with acute lymphoblastic leukaemia bearing the Philadelphia chromosome or expressing the transcript, BCR-ABL, where the patient has previously been issued with an authority prescription for dasatinib and does not have progressive disease.</p><p> Authority applications for continuing treatment may be made by telephone on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9344T','3305','t',$$<p>Parkinson disease in patients being treated with levodopa&#8212;decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9344T','3306','t',$$<p>Parkinson disease in patients stabilised on concomitant treatment with levodopa&#8212;decarboxylase inhibitor combinations and entacapone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9345W','3305','t',$$<p>Parkinson disease in patients being treated with levodopa&#8212;decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9345W','3306','t',$$<p>Parkinson disease in patients stabilised on concomitant treatment with levodopa&#8212;decarboxylase inhibitor combinations and entacapone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9350D','3290','f',$$<p>Symptomatic Paget disease of bone.<br/> Only 1 treatment each year per patient will be PBS-subsidised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9351E','3070','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9351E','3933','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -2.5 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9351E','2646','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9352F','2133','f',$$<p>renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9352F','2134','f',$$<p>cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9353G','1708','t',$$<p>Ulcerative colitis where hypersensitivity to sulfonamides exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9353G','1709','t',$$<p>Ulcerative colitis where intolerance to sulfasalazine exists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9354H','1719','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9354H','1720','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9354H','1721','t',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9354H','1722','t',$$<p>Prevention of recurrence of myocardial infarction or unstable angina in patients with a history of symptomatic cardiac ischaemic events while on therapy with low-dose aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9354H','1723','t',$$<p>Prevention of recurrence of myocardial infarction or unstable angina in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9354H','1724','t',$$<p>Prevention of recurrence of myocardial infarction or unstable angina in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9360P','3058','f',$$<p>Treatment of invasive aspergillosis in patients intolerant to, or with disease refractory to, alternative therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9360P','3059','f',$$<p>Treatment of fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis and mycetoma in patients intolerant to, or with disease refractory to, alternative therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9360P','3060','f',$$<p>Prophylaxis of invasive fungal infections, including both yeasts and moulds, in a patient who is at high risk of developing these infections, defined as follows:</p><p> (1) Neutropenia<br/> Patients with anticipated neutropenia (an absolute neutrophil count of less than 500 cells per cubic millimetre) for at least 10 days, who are receiving chemotherapy for acute myelogenous leukaemia or myelodysplastic syndrome.<br/> Treatment should continue until recovery of the neutrophil count to at least 500 cells per cubic millimetre.<br/> Patients who have had a previous invasive fungal infection should have secondary prophylaxis during subsequent episodes of neutropenia.</p><p> (2) Graft versus host disease (GVHD)<br/> Patients with acute GVHD grades II to IV or extensive chronic GVHD, who are receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant.<br/> No more than 6 months therapy per episode will be PBS-subsidised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9361Q','2100','f',$$<p>Glioblastoma multiforme concomitantly with radiotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9362R','1736','f',$$<p>Recurrence of anaplastic astrocytoma following standard therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9362R','1737','f',$$<p>Recurrence of glioblastoma multiforme following standard therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9362R','2101','f',$$<p>Glioblastoma multiforme following radiotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9363T','3061','f',$$<p>For the treatment and maintenance therapy of definite or probable invasive aspergillosis in immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9363T','3062','f',$$<p>For the treatment and maintenance therapy of serious fungal infections caused by Scedosporium species or Fusarium species</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9363T','3297','f',$$<p>the causative species is not susceptible to fluconazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9363T','3065','f',$$<p>treatment with fluconazole has failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9363T','3066','f',$$<p>treatment with fluconazole is not tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9363T','3298','f',$$<p>For the treatment and maintenance therapy of other serious invasive mycosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9364W','3061','f',$$<p>For the treatment and maintenance therapy of definite or probable invasive aspergillosis in immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9364W','3062','f',$$<p>For the treatment and maintenance therapy of serious fungal infections caused by Scedosporium species or Fusarium species</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9364W','3297','f',$$<p>the causative species is not susceptible to fluconazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9364W','3065','f',$$<p>treatment with fluconazole has failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9364W','3066','f',$$<p>treatment with fluconazole is not tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9364W','3298','f',$$<p>For the treatment and maintenance therapy of other serious invasive mycosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9378N','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9379P','3229','t',$$<p>Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9380Q','3071','f',$$<p>Initial treatment, as the sole PBS-subsidised agent, of advanced (BCLC Stage C) hepatocellular carcinoma in a patient with a WHO performance status of 2 or less and Child Pugh class A</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9380Q','3072','f',$$<p>Continuing treatment, as the sole PBS-subsidised agent, of advanced hepatocellular carcinoma in a patient who has previously been treated with PBS-subsidised sorafenib and who does not have progressive disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9382T','1596','f',$$<p>Infants and young children with chronic renal failure requiring treatment with a low protein and a low phosphorus diet, or a low protein, a low phosphorus and a low potassium diet</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9383W','1670','f',$$<p>Chylous ascites</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9383W','1068','f',$$<p>Chylothorax</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9383W','1671','f',$$<p>Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9383W','1513','f',$$<p>Hyperlipoproteinaemia type 1</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9383W','1511','f',$$<p>Long chain fatty acid oxidation disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9388D','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9389E','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9390F','2664','t',$$<p>Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9391G','3070','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for corticosteroid-induced osteoporosis in a patient currently on long-term (at least 3 months), high-dose (at least 7.5&#160;mg per day prednisolone or equivalent) corticosteroid therapy with a Bone Mineral Density (BMD) T-score of -1.5 or less.<br/> The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9391G','2645','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less.<br/> The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9391G','2646','t',$$<p>Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated.<br/> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9398P','2641','t',$$<p>Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9398P','2642','t',$$<p>Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9403X','3546','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9403X','3547','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9404Y','3546','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9404Y','3547','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9405B','3546','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9405B','3547','t',$$<p>Maintenance therapy, following initiation and stabilisation of treatment with lanthanum carbonate, of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9411H','4031','f',$$<p>Initial treatment, as the sole PBS-subsidised agent, by a specialist or consultant physician, for severe, established osteoporosis in a patient with a very high risk of fracture who:<br/> (a) has a bone mineral density (BMD) T-score of -3.0 or less; and<br/> (b) has had 2 or more fractures due to minimal trauma; and<br/> (c) has experienced at least 1 symptomatic new fracture after at least 12 months continuous therapy with an anti-resorptive agent at adequate doses.</p><p> A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.</p><p> If treatment with anti-resorptive therapy is contraindicated according to the relevant TGA-approved Product Information, details of the contraindication must be provided at the time of application.</p><p> If an intolerance of a severity necessitating permanent treatment withdrawal develops during the relevant period of use of one anti-resorptive agent, alternate anti-resorptive agents must be trialled so that the patient achieves the minimum requirement of 12 months continuous therapy.  Details of accepted toxicities including severity can be found on the Medicare Australia website at www.medicareaustralia.gov.au and must be provided at the time of application.</p><p> Anti-resorptive therapies for osteoporosis and their adequate doses which will be accepted for the purposes of administering this restriction are alendronate sodium 10&#160;mg per day or 70&#160;mg once weekly, risedronate sodium 5&#160;mg per day or 35&#160;mg once weekly or 150&#160;mg once monthly, raloxifene hydrochloride 60&#160;mg per day (women only), denosumab 60&#160;mg once every 6 months, disodium etidronate 200&#160;mg with calcium carbonate 1.25&#160;g per day, strontium ranelate 2&#160;g per day and zoledronic acid 5&#160;mg per annum.</p><p> Details of prior anti-resorptive therapy, fracture history including the date(s), site(s), the symptoms associated with the fracture(s) which developed during the course of anti-resorptive therapy and the score of the qualifying BMD measurement must be provided to Medicare Australia at the time of application</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9411H','4032','f',$$<p>Continuing treatment for severe established osteoporosis where the patient has previously been issued with an authority prescription for this drug.</p><p> Teriparatide must only be used for a lifetime maximum of 18 months therapy (18 pens).  Up to a maximum of 18 pens will be reimbursed through the PBS.</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9417P','4065','f',$$<p>Initial treatment, as the sole PBS-subsidised tyrosine kinase inhibitor therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who meets the Memorial Sloan Kettering Cancer Centre (MSKCC) low to intermediate risk group and has a WHO performance status of 2 or less</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9418Q','4065','f',$$<p>Initial treatment, as the sole PBS-subsidised tyrosine kinase inhibitor therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who meets the Memorial Sloan Kettering Cancer Centre (MSKCC) low to intermediate risk group and has a WHO performance status of 2 or less</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9419R','4065','f',$$<p>Initial treatment, as the sole PBS-subsidised tyrosine kinase inhibitor therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who meets the Memorial Sloan Kettering Cancer Centre (MSKCC) low to intermediate risk group and has a WHO performance status of 2 or less</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9420T','3109','f',$$<p>Continuing treatment beyond 3 months, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who has previously been issued with an authority prescription for sunitinib and who has stable or responding disease according to RECIST criteria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9421W','3109','f',$$<p>Continuing treatment beyond 3 months, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who has previously been issued with an authority prescription for sunitinib and who has stable or responding disease according to RECIST criteria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9422X','3109','f',$$<p>Continuing treatment beyond 3 months, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who has previously been issued with an authority prescription for sunitinib and who has stable or responding disease according to RECIST criteria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9425C','3265','f',$$<p>Initial treatment [Initial 1, Whole body (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9425C','3758','f',$$<p>Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with adalimumab for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9425C','3267','f',$$<p>Initial treatment [Initial 1, Face, hand, foot (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where: <br/> (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or<br/> (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9425C','3759','f',$$<p>Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with adalimumab for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9426D','3265','f',$$<p>Initial treatment [Initial 1, Whole body (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9426D','3758','f',$$<p>Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with adalimumab for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9426D','3267','f',$$<p>Initial treatment [Initial 1, Face, hand, foot (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where: <br/> (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or<br/> (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9426D','3759','f',$$<p>Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with adalimumab for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised adalimumab treatment within this Treatment Cycle and who wish to re-commence adalimumab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised adalimumab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 16 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 4 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9427E','3760','f',$$<p>Continuing treatment (Whole body)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with adalimumab; and<br/> (c) who have demonstrated an adequate response to their most recent course of treatment with adalimumab.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Approval will be based on the PASI assessment of response to the most recent course of treatment with adalimumab.</p><p> A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9427E','3761','f',$$<p>Continuing treatment (Face, hand, foot)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with adalimumab; and<br/> (c) who have demonstrated an adequate response to treatment with adalimumab.</p><p> An adequate response to adalimumab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:<br/> (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or<br/> (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9428F','3760','f',$$<p>Continuing treatment (Whole body)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with adalimumab; and<br/> (c) who have demonstrated an adequate response to their most recent course of treatment with adalimumab.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Approval will be based on the PASI assessment of response to the most recent course of treatment with adalimumab.</p><p> A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9428F','3761','f',$$<p>Continuing treatment (Face, hand, foot)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with adalimumab; and<br/> (c) who have demonstrated an adequate response to treatment with adalimumab.</p><p> An adequate response to adalimumab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:<br/> (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or<br/> (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with adalimumab will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised adalimumab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9429G','3780','f',$$<p>Continuing treatment (Whole body)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and<br/> (c) who have demonstrated an adequate response to their most recent course of treatment with etanercept.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Approval will be based on the PASI assessment of response to the most recent course of treatment with etanercept.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9429G','3781','f',$$<p>Continuing treatment (Face, hand, foot)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and<br/> (c) who have demonstrated an adequate response to treatment with etanercept.</p><p> An adequate response to etanercept treatment is defined as the plaque or plaques assessed prior to biological treatment showing:<br/> (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or<br/> (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9431J','3780','f',$$<p>Continuing treatment (Whole body)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and<br/> (c) who have demonstrated an adequate response to their most recent course of treatment with etanercept.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Approval will be based on the PASI assessment of response to the most recent course of treatment with etanercept.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9431J','3781','f',$$<p>Continuing treatment (Face, hand, foot)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and<br/> (c) who have demonstrated an adequate response to treatment with etanercept.</p><p> An adequate response to etanercept treatment is defined as the plaque or plaques assessed prior to biological treatment showing:<br/> (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or<br/> (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9439T','3135','f',$$<p>Treatment of suspected or confirmed Plasmodium falciparum malaria in a patient aged 3 years or older where quinine containing regimens are inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9440W','3136','t',$$<p>Nasal colonisation with Staphylococcus aureus in an Aboriginal or a Torres Strait Islander person</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9447F','3147','t',$$<p>Schistosomiasis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9448G','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9449H','3543','t',$$<p>Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9449H','3149','t',$$<p>Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and sitagliptin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9450J','3543','t',$$<p>Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9450J','3149','t',$$<p>Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and sitagliptin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9451K','3543','t',$$<p>Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with metformin and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.</p><p> The date and level of the qualifying HbA1c must be documented in the patient's medical records at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.  The HbA1c must be no more than 4 months old at the time treatment with a gliptin, a glitazone or a glucagon-like peptide-1 is initiated.</p><p> Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:<br/> (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or<br/> (b) red cell transfusion within the previous 3 months.<br/> A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10&#160;mmol per L in more than 20% of tests.  The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of treatment with a gliptin, a glitazone or a glucagon-like peptide-1, must be documented in the patient's medical records</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9451K','3149','t',$$<p>Continuation of therapy in type 2 diabetes mellitus in a patient who has previously received and been stabilised on a PBS-subsidised regimen of oral diabetic medicines which includes metformin and sitagliptin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9452L','3061','f',$$<p>For the treatment and maintenance therapy of definite or probable invasive aspergillosis in immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9452L','3062','f',$$<p>For the treatment and maintenance therapy of serious fungal infections caused by Scedosporium species or Fusarium species</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9452L','3297','f',$$<p>the causative species is not susceptible to fluconazole</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9452L','3065','f',$$<p>treatment with fluconazole has failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9452L','3066','f',$$<p>treatment with fluconazole is not tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9452L','3298','f',$$<p>For the treatment and maintenance therapy of other serious invasive mycosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9455P','3510','f',$$<p>Initial 1 (new patients)<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND<br/> (a) who has at least 2 of the following:<br/> (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or<br/> (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or<br/> (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND<br/> (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.</p><p> The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p> If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p> If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:<br/> (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND<br/> (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 10&#160;mg per L.</p><p> The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p> Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:<br/> (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and<br/> (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and<br/> (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and<br/> (iv) a signed patient acknowledgment form.</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9455P','3774','f',$$<p>Initial 2 (change or re-commencement for all patients)<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with etanercept in the current treatment cycle.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> A maximum of 16 weeks of treatment with etanercept will be approved under this criterion.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9456Q','3775','f',$$<p>Continuing treatment for all patients<br/> Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:<br/> (a) has demonstrated an adequate response to treatment with etanercept; and<br/> (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with etanercept.</p><p> An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:<br/> (a) an ESR measurement no greater than 25&#160;mm per hour; or<br/> (b) a CRP measurement no greater than 10&#160;mg per L; or<br/> (c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p> Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> All measurements provided must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this criterion.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with etanercept.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9457R','3489','f',$$<p>Initial 1<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have severe active psoriatic arthritis; and<br/> (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and<br/> (3) have failed to achieve an adequate response to:<br/> (a) methotrexate at a dose of at least 20&#160;mg weekly for a minimum period of 3 months; and<br/> (b) sulfasalazine at a dose of at least 2&#160;g per day for a minimum period of 3 months; or<br/> (c) leflunomide at a dose of up to 20&#160;mg daily for a minimum period of 3 months.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9457R','3776','f',$$<p>Initial 2<br/> Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have a documented history of severe active psoriatic arthritis; and<br/> (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and<br/> (3) have not failed treatment with etanercept during the current Treatment Cycle.</p><p> Applications for patients who have received PBS-subsidised treatment with etanercept within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9458T','3777','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:<br/> (1) who have a documented history of severe active psoriatic arthritis; and<br/> (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with etanercept; and<br/> (3) who, at the time of application, demonstrate an adequate response to treatment with etanercept.</p><p> An adequate response to treatment with etanercept is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline; AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial etanercept after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9459W','3708','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9459W','3772','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with etanercept and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9460X','3773','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with etanercept.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with etanercept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9461Y','3273','f',$$<p>Initial treatment [Initial 1, Whole body (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9461Y','3778','f',$$<p>Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9461Y','3275','f',$$<p>Initial treatment [Initial 1, Face, hand, foot (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where: <br/> (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or<br/> (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9461Y','3779','f',$$<p>Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with etanercept for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised etanercept treatment within this Treatment Cycle and who wish to re-commence etanercept treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised etanercept treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 16 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 16 weeks.</p><p> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9462B','3780','f',$$<p>Continuing treatment (Whole body)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and<br/> (c) who have demonstrated an adequate response to their most recent course of treatment with etanercept.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Approval will be based on the PASI assessment of response to the most recent course of treatment with etanercept.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9462B','3781','f',$$<p>Continuing treatment (Face, hand, foot)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with etanercept; and<br/> (c) who have demonstrated an adequate response to treatment with etanercept.</p><p> An adequate response to etanercept treatment is defined as the plaque or plaques assessed prior to biological treatment showing:<br/> (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or<br/> (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with etanercept will be authorised under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the authority application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised etanercept treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9465E','4047','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 20 days supply to complete a course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9466F','4048','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 30 days supply to complete a course of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9467G','3993','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total hip replacement who requires up to 30 days of therarpy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9468H','3957','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 10 days of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9469J','4050','f',$$<p>Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 15 days of therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9475Q','3182','f',$$<p>Initial PBS-subsidised treatment, for facial administration only, of severe facial lipoatrophy caused by therapy for HIV infection.</p><p> Accreditation following completion of injection administration training with Sanofi-Aventis is required to prescribe poly-l-lactic acid under the PBS. Patients must be referred from the HIV physician to the accredited injector</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9476R','3183','f',$$<p>Maintenance PBS-subsidised treatment, for facial administration only, of severe facial lipoatrophy caused by therapy for HIV infection.</p><p> Accreditation following completion of injection administration training with Sanofi-Aventis is required to prescribe poly-l-lactic acid under the PBS. Patients must be referred from the HIV physician to the accredited injector</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9483D','2431','t',$$<p>Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9483D','3739','t',$$<p>Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) must be reduced because the patient developed a clinically important product-related adverse event during treatment with a statin.<br/> A clinically important product-related adverse event is defined as follows:<br/> (i) Severe myalgia (muscle symptoms without creatine kinase elevation) which is proven to be temporally associated with statin treatment; or<br/> (ii) Myositis (clinically important creatine kinase elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or<br/> (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9484E','2431','t',$$<p>Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9484E','3739','t',$$<p>Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) must be reduced because the patient developed a clinically important product-related adverse event during treatment with a statin.<br/> A clinically important product-related adverse event is defined as follows:<br/> (i) Severe myalgia (muscle symptoms without creatine kinase elevation) which is proven to be temporally associated with statin treatment; or<br/> (ii) Myositis (clinically important creatine kinase elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or<br/> (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9488J','3206','f',$$<p>Initial PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour after failure of imatinib mesylate treatment due to resistance or intolerance.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Sunitinib Malate (Sutent) PBS Authority Application for Use in the Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9488J','3207','f',$$<p>Continuing PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour who has previously been issued with an authority prescription for sunitinib and who does not have progressive disease.</p><p> Applications for continuing treatment may be made by telephone (1800&#160;700&#160;270, hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients who have failed to respond or who are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib.</p><p> Patients who have progressive disease on sunitinib are no longer eligible for PBS-subsidised sunitinib</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9489K','3206','f',$$<p>Initial PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour after failure of imatinib mesylate treatment due to resistance or intolerance.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Sunitinib Malate (Sutent) PBS Authority Application for Use in the Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9489K','3207','f',$$<p>Continuing PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour who has previously been issued with an authority prescription for sunitinib and who does not have progressive disease.</p><p> Applications for continuing treatment may be made by telephone (1800&#160;700&#160;270, hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients who have failed to respond or who are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib.</p><p> Patients who have progressive disease on sunitinib are no longer eligible for PBS-subsidised sunitinib</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9490L','3206','f',$$<p>Initial PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour after failure of imatinib mesylate treatment due to resistance or intolerance.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Sunitinib Malate (Sutent) PBS Authority Application for Use in the Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> Patients who have failed to respond or are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9490L','3207','f',$$<p>Continuing PBS-subsidised treatment as monotherapy of a patient with WHO performance status of 2 or less with a metastatic or unresectable malignant gastrointestinal stromal tumour who has previously been issued with an authority prescription for sunitinib and who does not have progressive disease.</p><p> Applications for continuing treatment may be made by telephone (1800&#160;700&#160;270, hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients who have failed to respond or who are intolerant to imatinib are no longer eligible to receive PBS-subsidised imatinib.</p><p> Patients who have progressive disease on sunitinib are no longer eligible for PBS-subsidised sunitinib</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9493P','1359','t',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9495R','3208','t',$$<p>Treatment of acute coronary syndrome (myocardial infarction or unstable angina) managed by percutaneous coronary intervention in combination with aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9496T','3208','t',$$<p>Treatment of acute coronary syndrome (myocardial infarction or unstable angina) managed by percutaneous coronary intervention in combination with aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9498X','3210','f',$$<p>Treatment of suspected or confirmed malaria due to Plasmodium falciparum</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2912','f',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2913','f',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2914','f',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2915','f',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2916','f',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2917','f',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','3087','f',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2918','f',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2919','f',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2920','f',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2921','f',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2922','f',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','3187','f',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2923','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2924','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2925','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2926','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2927','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2928','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2929','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','2930','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1082Y','3833','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2912','f',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2913','f',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2914','f',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2915','f',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2916','f',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2917','f',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','3087','f',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2918','f',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2919','f',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2920','f',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2921','f',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2922','f',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','3187','f',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2923','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2924','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2925','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2926','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2927','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2928','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2929','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','2930','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1113N','3833','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1129K','3994','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient who has been stabilised on nevirapine immediate release with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1129K','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1170N','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1170N','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1304P','4021','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with tadalafil of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.</p><p> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1304P','4022','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with tadalafil of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO;</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1304P','4023','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial treatment with tadalafil of patients with one of the following:<br/> (a) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised tadalafil after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with tadalafil; OR<br/> (b) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with a PAH agent other than tadalafil.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1304P','4024','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with tadalafil of patients who have received approval for initial PBS-subsidised treatment with tadalafil, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of tadalafil treatment [see Note for definition of response].</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.</p><p> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.  Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1419Q','4025','f',$$<p>Initial 1 (new and recommencing patients after a break of more than 12 months)</p><p> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a)  has been diagnosed with systemic juvenile idiopathic arthritis; AND<br/> (b)  has polyarticular course disease and either:<br/> (i)  failure to achieve an adequate response to the following treatment regimen (see (1) below for definition of failure to achieve an adequate response):<br/> &#8212; oral or parenteral methotrexate at a dose of at least 15&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids for a minimum of 3 months; or<br/> (ii)  severe intolerance of, or toxicity due to, methotrexate (see (2) below for definition of severe intolerance and toxicity); OR<br/> (c)  has refractory systemic symptoms, demonstrated by:<br/> &#8212; an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5&#160;mg per kg per day following a minimum of 2 months of therapy; AND<br/> (d)  has not received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months.</p><p> (1)  The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy and must be demonstrated in all patients at the time of the initial application:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (ii)  at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); AND/OR<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with  refractory systemic symptoms:<br/> (i)  an active joint count of at least 2 active joints; AND<br/> (ii)  persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; AND/OR<br/> (iii)  a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN).</p><p> (2)  Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/> Toxicity to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonia, or serious sepsis.<br/> If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.</p><p> The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.</p><p> To ensure consistency in determining response, the same indices of disease severity used to establish baseline must be provided for all subsequent continuing treatment applications.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  the date of assessment of severe active systemic juvenile idiopathic arthritis;<br/> (ii) details of prior treatment including dose and duration of treatment;<br/> (iii) pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.</p><p> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.</p><p> If a patient fails to respond to 2 courses of treatment in a treatment cycle they will not be eligible to receive further PBS-subsidised tocilizumab therapy in that treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1419Q','4026','f',$$<p>Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)</p><p> Initial PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months; AND<br/> (c)  has not failed PBS-subsidised therapy with tocilizumab for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate.</p><p> Applications for a patient who has received PBS-subsidised treatment with tocilizumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with tocilizumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria. Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that course of tocilizumab.</p><p> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1419Q','4027','f',$$<p>Initial 3 ('grandfather' patients)</p><p> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; and<br/> (b)  was receiving treatment with tocilizumab prior 1&#160;November 2011; and<br/> (c)  has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with tocilizumab; and<br/> (d)  is receiving treatment with tocilizumab at the time of application.</p><p> To ensure consistency in determining response, the same indices of disease severity used to establish the baseline must be provided for all subsequent continuing treatment applications.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.</p><p> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.</p><p> The baseline systemic juvenile idiopathic arthritis assessment must be provided and must be from immediately prior to commencing treatment with tocilizumab.  (See NOTE (3) above for definition of baseline measurements to determine response.)</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.</p><p> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient,  for two infusions (one months supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1419Q','4028','f',$$<p>Continuing treatment</p><p> Continuing treatment with tocilizumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has demonstrated an adequate response to treatment with tocilizumab.</p><p> An adequate response to treatment is defined as:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii)  a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with refractory systemic symptoms:<br/> (i)  absence of fever greater than 38 degrees Celsius in the preceding seven days; AND/OR<br/> (ii)  a reduction in the CRP level and platelet count by at least 30% from baseline; AND/OR<br/> (iii)  a reduction in the dose of corticosteroid by at least 30% from baseline.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  baseline and current pathology reports detailing CRP and platelet count where appropriate.</p><p> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the Initial treatment restriction, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1423X','4025','f',$$<p>Initial 1 (new and recommencing patients after a break of more than 12 months)</p><p> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a)  has been diagnosed with systemic juvenile idiopathic arthritis; AND<br/> (b)  has polyarticular course disease and either:<br/> (i)  failure to achieve an adequate response to the following treatment regimen (see (1) below for definition of failure to achieve an adequate response):<br/> &#8212; oral or parenteral methotrexate at a dose of at least 15&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids for a minimum of 3 months; or<br/> (ii)  severe intolerance of, or toxicity due to, methotrexate (see (2) below for definition of severe intolerance and toxicity); OR<br/> (c)  has refractory systemic symptoms, demonstrated by:<br/> &#8212; an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5&#160;mg per kg per day following a minimum of 2 months of therapy; AND<br/> (d)  has not received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months.</p><p> (1)  The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy and must be demonstrated in all patients at the time of the initial application:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (ii)  at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); AND/OR<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with  refractory systemic symptoms:<br/> (i)  an active joint count of at least 2 active joints; AND<br/> (ii)  persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; AND/OR<br/> (iii)  a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN).</p><p> (2)  Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/> Toxicity to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonia, or serious sepsis.<br/> If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.</p><p> The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.</p><p> To ensure consistency in determining response, the same indices of disease severity used to establish baseline must be provided for all subsequent continuing treatment applications.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  the date of assessment of severe active systemic juvenile idiopathic arthritis;<br/> (ii) details of prior treatment including dose and duration of treatment;<br/> (iii) pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.</p><p> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.</p><p> If a patient fails to respond to 2 courses of treatment in a treatment cycle they will not be eligible to receive further PBS-subsidised tocilizumab therapy in that treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1423X','4026','f',$$<p>Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)</p><p> Initial PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months; AND<br/> (c)  has not failed PBS-subsidised therapy with tocilizumab for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate.</p><p> Applications for a patient who has received PBS-subsidised treatment with tocilizumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with tocilizumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria. Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that course of tocilizumab.</p><p> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1423X','4027','f',$$<p>Initial 3 ('grandfather' patients)</p><p> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; and<br/> (b)  was receiving treatment with tocilizumab prior 1&#160;November 2011; and<br/> (c)  has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with tocilizumab; and<br/> (d)  is receiving treatment with tocilizumab at the time of application.</p><p> To ensure consistency in determining response, the same indices of disease severity used to establish the baseline must be provided for all subsequent continuing treatment applications.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.</p><p> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.</p><p> The baseline systemic juvenile idiopathic arthritis assessment must be provided and must be from immediately prior to commencing treatment with tocilizumab.  (See NOTE (3) above for definition of baseline measurements to determine response.)</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.</p><p> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient,  for two infusions (one months supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1423X','4028','f',$$<p>Continuing treatment</p><p> Continuing treatment with tocilizumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has demonstrated an adequate response to treatment with tocilizumab.</p><p> An adequate response to treatment is defined as:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii)  a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with refractory systemic symptoms:<br/> (i)  absence of fever greater than 38 degrees Celsius in the preceding seven days; AND/OR<br/> (ii)  a reduction in the CRP level and platelet count by at least 30% from baseline; AND/OR<br/> (iii)  a reduction in the dose of corticosteroid by at least 30% from baseline.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  baseline and current pathology reports detailing CRP and platelet count where appropriate.</p><p> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the Initial treatment restriction, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1464C','4025','f',$$<p>Initial 1 (new and recommencing patients after a break of more than 12 months)</p><p> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a)  has been diagnosed with systemic juvenile idiopathic arthritis; AND<br/> (b)  has polyarticular course disease and either:<br/> (i)  failure to achieve an adequate response to the following treatment regimen (see (1) below for definition of failure to achieve an adequate response):<br/> &#8212; oral or parenteral methotrexate at a dose of at least 15&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids for a minimum of 3 months; or<br/> (ii)  severe intolerance of, or toxicity due to, methotrexate (see (2) below for definition of severe intolerance and toxicity); OR<br/> (c)  has refractory systemic symptoms, demonstrated by:<br/> &#8212; an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5&#160;mg per kg per day following a minimum of 2 months of therapy; AND<br/> (d)  has not received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months.</p><p> (1)  The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy and must be demonstrated in all patients at the time of the initial application:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (ii)  at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); AND/OR<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with  refractory systemic symptoms:<br/> (i)  an active joint count of at least 2 active joints; AND<br/> (ii)  persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; AND/OR<br/> (iii)  a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN).</p><p> (2)  Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/> Toxicity to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonia, or serious sepsis.<br/> If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.</p><p> The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.</p><p> To ensure consistency in determining response, the same indices of disease severity used to establish baseline must be provided for all subsequent continuing treatment applications.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  the date of assessment of severe active systemic juvenile idiopathic arthritis;<br/> (ii) details of prior treatment including dose and duration of treatment;<br/> (iii) pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.</p><p> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.</p><p> If a patient fails to respond to 2 courses of treatment in a treatment cycle they will not be eligible to receive further PBS-subsidised tocilizumab therapy in that treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1464C','4026','f',$$<p>Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)</p><p> Initial PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months; AND<br/> (c)  has not failed PBS-subsidised therapy with tocilizumab for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate.</p><p> Applications for a patient who has received PBS-subsidised treatment with tocilizumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with tocilizumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria. Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that course of tocilizumab.</p><p> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1464C','4027','f',$$<p>Initial 3 ('grandfather' patients)</p><p> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; and<br/> (b)  was receiving treatment with tocilizumab prior 1&#160;November 2011; and<br/> (c)  has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with tocilizumab; and<br/> (d)  is receiving treatment with tocilizumab at the time of application.</p><p> To ensure consistency in determining response, the same indices of disease severity used to establish the baseline must be provided for all subsequent continuing treatment applications.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.</p><p> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.</p><p> The baseline systemic juvenile idiopathic arthritis assessment must be provided and must be from immediately prior to commencing treatment with tocilizumab.  (See NOTE (3) above for definition of baseline measurements to determine response.)</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.</p><p> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient,  for two infusions (one months supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1464C','4028','f',$$<p>Continuing treatment</p><p> Continuing treatment with tocilizumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has demonstrated an adequate response to treatment with tocilizumab.</p><p> An adequate response to treatment is defined as:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii)  a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with refractory systemic symptoms:<br/> (i)  absence of fever greater than 38 degrees Celsius in the preceding seven days; AND/OR<br/> (ii)  a reduction in the CRP level and platelet count by at least 30% from baseline; AND/OR<br/> (iii)  a reduction in the dose of corticosteroid by at least 30% from baseline.</p><p> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  baseline and current pathology reports detailing CRP and platelet count where appropriate.</p><p> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the Initial treatment restriction, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1490K','3983','f',$$<p>Initial treatment of HIV infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1490K','3984','f',$$<p>Continuing treatment of HIV infection where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1837Q','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1837Q','1651','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2008Q','4061','f',$$<p>Treatment of cystic fibrosis in a patient who satisfies all of the following criteria:<br/> (1) Prior to mannitol therapy, the patient must have been assessed for bronchial hyperresponsiveness as per the TGA approved PI mannitol initiation dose assessment.  If the patient has a negative hyperresponsiveness test they may be eligible for PBS subsidised treatment with mannitol;<br/> (2) Is 6 years of age or older;<br/> (3) Has a FEV1 greater than 30% predicted for age, gender and height;<br/> (4) Is intolerant or inadequately responsive to dornase alfa;<br/> (5) Has evidence of chronic suppurative lung disease (cough and sputum most days of the week, or greater than 3 respiratory tract infections of more than 2 weeks' duration in any 12 months, or objective evidence of obstructive airways disease);<br/> (6) Is participating in a 4 week trial, as detailed below, or has achieved a 10% or greater improvement in FEV1 (compared to baseline established prior to mannitol treatment) after a 4 week trial.</p><p> In order for patients to be eligible for participation in the HSD program, the following conditions must be met:<br/> (1) Patients must be assessed at cystic fibrosis clinics/centres which are under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis and the prescribing of mannitol therapy under the HSD program is limited to such physicians. If attendance at such units is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;<br/> (2) The measurement of lung function is to be conducted by independent (other than the treating doctor) experienced personnel at established lung function testing laboratories, unless this is not possible because of geographical isolation;<br/> (3) Prior to mannitol therapy, a baseline measurement of FEV1 must be undertaken during a stable period of the disease;<br/> (4) Initial therapy is limited to 4 weeks' treatment with mannitol at a dose of 400&#160;mg twice daily;<br/> (5) At or towards the end of the initial 4 weeks' trial, patients must be reassessed and a further FEV1 measurement be undertaken (single test under conditions as above). Patients who achieve a 10% or greater improvement in FEV1 (compared to baseline established prior to mannitol treatment) are eligible for continued subsidy under the HSD program at a dose of 400mg twice daily;<br/> (6) Patients who fail to meet a 10% or greater improvement in FEV1 after the initial 4 weeks' treatment at a dose of 400&#160;mg twice daily, may have 1 further trial in the next 12 months but not before 3 months after the initial trial;<br/> (7) Following an initial 6 months' therapy, a global assessment must be undertaken involving the patient, the patient's family (in the case of paediatric patients) and the treating physician(s) to establish that all agree that mannitol powder for inhalation treatment is continuing to produce worthwhile benefits. (Mannitol therapy should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.) Further reassessments are to be undertaken at six-monthly intervals;<br/> (8) Other aspects of treatment, such as physiotherapy, must be continued;<br/> (9) Where there is documented evidence that a patient already receiving mannitol therapy would have met the criteria for subsidy (i.e. satisfied the criteria for the 4 week trial and achieved a 10% or greater improvement in FEV1) then the patient is eligible to continue treatment under the HSD program. Where such evidence is not available, patients will need to satisfy the initiation and continuation criteria as for new patients. (Four weeks is considered a suitable wash-out period)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2008Q','4062','f',$$<p>Grandfather &#8212; for patients who initiated mannitol treatment prior to 1&#160;August&#160;2012</p><p> Continuation of treatment of cystic fibrosis in a patient 6 years of age or older, who initiated treatment with mannitol prior to 1&#160;August 2012 and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis team, documents agreement that mannitol treatment is continuing to produce worthwhile benefit.  Further reassessments are to be undertaken and documented yearly.  Treatment with mannitol should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5000E','3594','f',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100&#160;mg ritonavir twice daily in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5036C','4013','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with epoprostenol sodium of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (b) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5036C','4014','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial PBS-subsidised treatment with epoprostenol sodium of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR<br/> (b) WHO Functional Class IV primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have received prior treatment with a PBS-subsidised PAH agent other than epoprostenol sodium; OR<br/> (c) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have failed to respond to a prior PBS-subsidised PAH agent.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and<br/> (5) for WHO Functional Class III patients, where this is the first application for epoprostenol sodium, assessment details of the PBS-subsidised PAH agent they have failed to respond to.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5036C','3167','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with epoprostenol sodium of patients who have received approval for initial PBS-subsidised treatment with epoprostenol sodium, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of epoprostenol sodium treatment [see Note for definition of response].</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.</p><p> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5042J','4013','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with epoprostenol sodium of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (b) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5042J','4014','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial PBS-subsidised treatment with epoprostenol sodium of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR<br/> (b) WHO Functional Class IV primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have received prior treatment with a PBS-subsidised PAH agent other than epoprostenol sodium; OR<br/> (c) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have failed to respond to a prior PBS-subsidised PAH agent.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and<br/> (5) for WHO Functional Class III patients, where this is the first application for epoprostenol sodium, assessment details of the PBS-subsidised PAH agent they have failed to respond to.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5042J','3167','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with epoprostenol sodium of patients who have received approval for initial PBS-subsidised treatment with epoprostenol sodium, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of epoprostenol sodium treatment [see Note for definition of response].</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.</p><p> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5062K','3596','f',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5823L','3940','f',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100&#160;mg ritonavir in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance, and who has not demonstrated darunavir resistance associated mutations detected on resistance testing.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5827Q','3855','f',$$<p>Initial (new patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:<br/> (1) Splenectomised and:<br/> (a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and<br/> (b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;<br/> OR<br/> (2) Not splenectomised and:<br/> (a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2&#160;mg/kg/day of prednisone for at least 4-6 weeks; and<br/> (b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and<br/> (c) in whom splenectomy is contraindicated for medical reasons.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:<br/> (a) a platelet count of less than or equal to 20,000&#160;million per L;<br/> OR<br/> (b) a platelet count of 20-30,000&#160;million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],<br/> (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and<br/> (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.</p><p> The full blood count must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5827Q','3856','f',$$<p>Initial (grandfather patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with eltrombopag prior to 1&#160;November 2011 and in whom the criteria for initial treatment can be demonstrated to have been met at the time eltrombopag was commenced.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.</p><p> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5827Q','3857','f',$$<p>Continuing therapy or re-initiation after a break in therapy<br/> First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with eltrombopag during the initial period of PBS-subsidised treatment.</p><p> For the purposes of this restriction, a sustained platelet response is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised eltrombopag,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L on at least four (4) occasions, each at least one week apart;<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.</p><p> Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:<br/> (1) a completed authority prescription form, and<br/> (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).</p><p> The most recent platelet count must be no more than one month old at the time of application.</p><p> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5827Q','3858','f',$$<p>Second and subsequent applications for continuing therapy<br/> Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with eltrombopag and who continues to display a response to treatment with eltrombopag.</p><p> For the purposes of this restriction, a continuing response to treatment with eltrombopag is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with eltrombopag,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline platelet count.</p><p> Platelet counts must be no more than 1 month old at the time of application.</p><p> Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5828R','3855','f',$$<p>Initial (new patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:<br/> (1) Splenectomised and:<br/> (a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and<br/> (b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;<br/> OR<br/> (2) Not splenectomised and:<br/> (a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2&#160;mg/kg/day of prednisone for at least 4-6 weeks; and<br/> (b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and<br/> (c) in whom splenectomy is contraindicated for medical reasons.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:<br/> (a) a platelet count of less than or equal to 20,000&#160;million per L;<br/> OR<br/> (b) a platelet count of 20-30,000&#160;million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],<br/> (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and<br/> (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.</p><p> The full blood count must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5828R','3856','f',$$<p>Initial (grandfather patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with eltrombopag prior to 1&#160;November 2011 and in whom the criteria for initial treatment can be demonstrated to have been met at the time eltrombopag was commenced.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.</p><p> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5828R','3857','f',$$<p>Continuing therapy or re-initiation after a break in therapy<br/> First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with eltrombopag during the initial period of PBS-subsidised treatment.</p><p> For the purposes of this restriction, a sustained platelet response is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised eltrombopag,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L on at least four (4) occasions, each at least one week apart;<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.</p><p> Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:<br/> (1) a completed authority prescription form, and<br/> (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).</p><p> The most recent platelet count must be no more than one month old at the time of application.</p><p> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5828R','3858','f',$$<p>Second and subsequent applications for continuing therapy<br/> Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with eltrombopag and who continues to display a response to treatment with eltrombopag.</p><p> For the purposes of this restriction, a continuing response to treatment with eltrombopag is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with eltrombopag,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline platelet count.</p><p> Platelet counts must be no more than 1 month old at the time of application.</p><p> Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2912','f',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2913','f',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2914','f',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2915','f',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2916','f',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2917','f',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','3087','f',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2918','f',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2919','f',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2920','f',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2921','f',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2922','f',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','3187','f',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2923','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2924','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2925','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2926','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2927','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2928','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2929','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','2930','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5830W','3833','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6100C','3668','f',$$<p>Initial PBS-subsidised treatment of a patient with:<br/> (1)  Myelodysplastic syndrome classified as Intermediate-2 or high risk according to the International Prognostic Scoring System (IPSS); OR<br/> (2)  Chronic Myelomonocytic Leukaemia (10% to 29% marrow blasts without Myeloproliferative Disorder); OR<br/> (3)  Acute Myeloid Leukaemia with 20 to 30% marrow blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) Classification.</p><p> Classification of a patient as Intermediate-2 requires a score of 1.5 to 2.0 on the IPSS, achieved with the possible combinations:<br/> 1.  11% to 30% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 0 to 1 cytopenias; OR<br/> 2.  11% to 20% marrow blasts with intermediate karyotypic status (other abnormalities), and 0 to 1 cytopenias; OR<br/> 3.  11% to 20% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 2 to 3 cytopenias; OR<br/> 4.  5% to 10% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR<br/> 5.  5% to 10% marrow blasts with intermediate karyotypic status (other abnormalities), and 2 to 3 cytopenias; OR<br/> 6.  less than 5% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), and 2 to 3 cytopenias.</p><p> Classification of a patient as high risk requires a score of 2.5 or more on the IPSS, achieved with the possible combinations:<br/> 1.  21% to 30% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 2 to 3 cytopenias; OR<br/> 2.  21% to 30% marrow blasts with intermediate (other abnormalities) or poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR<br/> 3.  11% to 20% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR<br/> 4.  11% to 20% marrow blasts with intermediate karyotypic status (other abnormalities), and 2 to 3 cytopenias.</p><p> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Azacitidine PBS Authority Application - Supporting Information Form; and<br/> (c) a copy of the bone marrow biopsy report demonstrating that the patient has myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia; and<br/> (d) a copy of the full blood examination report; and<br/> (e) for myelodysplastic syndrome, a copy of the pathology report detailing the cytogenetics demonstrating intermediate-2 or high risk disease according to the International Prognostic Scoring System (IPSS); and<br/> (f) a signed patient acknowledgment form.</p><p> No more than three cycles will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6101D','1826','f',$$<p>Schizophrenia in patients who are non-responsive to other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6101D','1827','f',$$<p>Schizophrenia in patients who are intolerant of other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6102E','1826','f',$$<p>Schizophrenia in patients who are non-responsive to other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6102E','1827','f',$$<p>Schizophrenia in patients who are intolerant of other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6109M','1504','f',$$<p>For use by organ or tissue transplant recipients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6113R','1085','f',$$<p>Disorders of erythropoiesis associated with treatment-related chronic iron overload</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6120D','1507','f',$$<p>Use by cystic fibrosis patients who satisfy all of the following criteria:<br/> (1) are 5 years of age or older;<br/> (2) have a FVC greater than 40% predicted for age, gender and height;<br/> (3) have evidence of chronic suppurative lung disease (cough and sputum most days of the week, or greater than 3 respiratory tract infections of more than 2 weeks' duration in any 12 months, or objective evidence of obstructive airways disease);<br/> (4) are participating in a 4 week trial as detailed below or have achieved a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) after a 4 week trial.</p><p> In order for patients to be eligible for participation in the HSD program, the following conditions must be met:<br/> (1) Patients must be assessed at cystic fibrosis clinics/centres which are under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis and the prescribing of dornase alfa under the HSD program is limited to such physicians.  If attendance at such units is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;<br/> (2) The measurement of lung function is to be conducted by independent (other than the treating doctor) experienced personnel at established lung function testing laboratories, unless this is not possible because of geographical isolation;<br/> (3) Prior to dornase alfa therapy, a baseline measurement of FEV1 must be undertaken during a stable period of the disease;<br/> (4) Initial therapy is limited to 4 weeks' treatment with dornase alfa at a dose of 2.5&#160;mg daily;<br/> (5) At or towards the end of the initial 4 weeks' trial, patients must be reassessed and a further FEV1 measurement be undertaken (single test under conditions as above). Patients who achieve a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) are eligible for continued subsidy under the HSD program at a dose of 2.5&#160;mg daily;<br/> (6) Patients who fail to meet a 10% or greater improvement in FEV1 after the initial 4 weeks' treatment at a dose of 2.5&#160;mg daily, may have 1 further trial in the next 12 months but not before 3 months after the initial trial;<br/> (7) Following an initial 6 months' therapy, a global assessment must be undertaken involving the patient, the patient's family (in the case of paediatric patients) and the treating physician(s) to establish that all agree that dornase alfa treatment is continuing to produce worthwhile benefits. (Dornase alfa therapy should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.) Further reassessments are to be undertaken at six-monthly intervals;<br/> (8) Other aspects of treatment, such as physiotherapy, must be continued;<br/> (9) Where there is documented evidence that a patient already receiving dornase alfa therapy would have met the criteria for subsidy (i.e. satisfied the criteria for the 4 week trial and achieved a 10% or greater improvement in FEV1) then the patient is eligible to continue treatment under the HSD program. Where such evidence is not available, patients will need to satisfy the initiation and continuation criteria as for new patients. (Four weeks is considered a suitable wash-out period)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6120D','3200','f',$$<p>Treatment of cystic fibrosis in a patient less than 5 years of age who has:<br/> (1) A severe clinical course with frequent respiratory exacerbations or chronic respiratory symptoms (including chronic or recurrent cough, wheeze or tachypnoea) requiring frequent hospital admissions more frequently than 3 times per year; or<br/> (2) Significant bronchiectasis on chest high resolution computed tomography scan; or<br/> (3) Severe cystic fibrosis bronchiolitis with persistent wheeze non-responsive to conventional medicines; or<br/> (4) Severe physiological deficit measure by forced oscillation technique or multiple breath nitrogen washout and failure to respond to conventional therapy.</p><p> In order for the patient to be eligible for participation in the HSD program, the following conditions must be met:<br/> (1) The patient must be assessed at a cystic fibrosis clinic/centre which is under the supervision of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis, and the prescribing of dornase alfa under the HSD program is limited to such physicians. If attendance at such a unit is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;<br/> (2) Following an initial 6 months therapy, a comprehensive assessment must be undertaken and documented involving the patient, the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team to establish agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use. Further reassessments are to be undertaken and documented yearly</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6120D','3201','f',$$<p>Grandfather &#8212; continuing for patients five years or older<br/> Continuation of treatment of cystic fibrosis in a patient 5 years of age or older, who initiated treatment with dornase alfa at an age of less than 5 years and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team, documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6120D','3202','f',$$<p>Grandfather &#8212; for patients less than five years of age who initiated dornase alfa prior to listing<br/> Treatment of cystic fibrosis in a patient less than 5 years of age who initiated treatment with dornase alfa prior to 1&#160;November&#160;2009 and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team, documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6125J','1654','f',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6125J','1655','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6125J','1656','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6125J','1657','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6125J','1658','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2912','f',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2913','f',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2914','f',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2915','f',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2916','f',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2917','f',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','3087','f',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2918','f',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2919','f',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2920','f',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2921','f',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2922','f',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','3187','f',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2923','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2924','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2925','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2926','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2927','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2928','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2929','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','2930','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6126K','3833','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2912','f',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2913','f',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2914','f',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2915','f',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2916','f',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2917','f',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','3087','f',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2918','f',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2919','f',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2920','f',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2921','f',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2922','f',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','3187','f',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2923','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2924','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2925','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2926','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2927','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2928','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2929','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','2930','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6127L','3833','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6134W','1610','f',$$<p>Treatment of cytomegalovirus retinitis in patients with AIDS</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6134W','1413','f',$$<p>Treatment of aciclovir-resistant herpes simplex virus infection in immunocompromised patients with HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6136Y','1612','f',$$<p>Cytomegalovirus retinitis in severely immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6136Y','1830','f',$$<p>Prophylaxis of cytomegalovirus disease in bone marrow transplant patients at risk of cytomegalovirus disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6136Y','1831','f',$$<p>Prophylaxis of cytomegalovirus disease in solid organ transplant patients at risk of cytomegalovirus disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6137B','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6137B','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6138C','3669','f',$$<p>Continuing treatment of a patient with:<br/> (1)  Myelodysplastic syndrome classified as Intermediate-2 or high risk according to the International Prognostic Scoring System (IPSS); OR<br/> (2)  Chronic Myelomonocytic Leukaemia (10% to 29% marrow blasts without Myeloproliferative Disorder); OR<br/> (3)  Acute Myeloid Leukaemia with 20 to 30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) Classification;<br/> who has previously been issued with an authority prescription for azacitidine and does not have progressive disease.</p><p> Authority applications for continuing treatment may be made by telephone on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Up to six cycles will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6148N','1058','f',$$<p>Treatment of chronic granulomatous disease in patients with frequent and severe infections despite adequate prophylaxis with antimicrobial agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6151R','1434','f',$$<p>Treatment of Mycobacterium avium complex infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6152T','1434','f',$$<p>Treatment of Mycobacterium avium complex infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6153W','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6153W','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6154X','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6154X','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6155Y','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6155Y','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6186N','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6186N','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6189R','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6189R','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6190T','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6190T','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6193Y','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6193Y','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6194B','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6194B','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6195C','1435','f',$$<p>Treatment of Mycobacterium avium complex infections in HIV-positive patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6195C','1299','f',$$<p>Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6202K','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6202K','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6204M','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6205N','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6206P','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6207Q','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6208R','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6208R','1651','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6209T','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6209T','1651','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6210W','1463','f',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6210W','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6210W','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6211X','1463','f',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6211X','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6211X','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6212Y','1463','f',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6212Y','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6212Y','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6213B','1463','f',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6213B','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6213B','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6215D','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6215D','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6216E','1654','f',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6217F','1654','f',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6218G','1009','f',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6218G','1463','f',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6218G','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6218G','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6219H','1009','f',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6219H','1463','f',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6219H','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6219H','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6221K','1299','f',$$<p>Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6223M','1500','f',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6223M','1233','f',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6223M','1035','f',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6227R','2622','f',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100&#160;micrograms 3 times daily</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6227R','2623','f',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6228T','2622','f',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100&#160;micrograms 3 times daily</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6228T','2623','f',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6229W','2622','f',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100&#160;micrograms 3 times daily</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6229W','2623','f',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6232B','1654','f',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6232B','1655','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6232B','1656','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6232B','1657','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6232B','1658','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6234D','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6234D','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6246R','1009','f',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6246R','1463','f',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6246R','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6246R','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6247T','1610','f',$$<p>Treatment of cytomegalovirus retinitis in patients with AIDS</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6249X','1828','f',$$<p>Treatment of AIDS-related Kaposi's sarcoma in patients with CD4 cell counts of less than 200 per cubic millimetre and extensive mucocutaneous involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6249X','1829','f',$$<p>Treatment of AIDS-related Kaposi's sarcoma in patients with CD4 cell counts of less than 200 per cubic millimetre and extensive visceral involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6251B','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6253D','1009','f',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6253D','1463','f',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6253D','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6253D','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6254E','1009','f',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6254E','1463','f',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6254E','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6254E','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6255F','1009','f',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6255F','1463','f',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6255F','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6255F','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6256G','1612','f',$$<p>Cytomegalovirus retinitis in severely immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6257H','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6257H','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6264Q','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6264Q','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6265R','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6265R','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6270B','1085','f',$$<p>Disorders of erythropoiesis associated with treatment-related chronic iron overload</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6271C','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6271C','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6279L','1500','f',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6280M','1494','f',$$<p>Prophylaxis of cytomegalovirus (CMV) infection and disease following renal transplantation in patients at risk of CMV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6284R','1637','f',$$<p>Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity of cerebral origin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6284R','1638','f',$$<p>Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to multiple sclerosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6284R','1639','f',$$<p>Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to spinal cord injury</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6284R','1640','f',$$<p>Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to spinal cord disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6286W','1500','f',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6287X','1500','f',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6288Y','1500','f',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6289B','1500','f',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6289B','1233','f',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6289B','1035','f',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6290C','1500','f',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2912','f',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2913','f',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2914','f',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2915','f',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2916','f',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2917','f',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','3087','f',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2918','f',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2919','f',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2920','f',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2921','f',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2922','f',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','3187','f',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2923','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2924','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2925','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2926','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2927','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2928','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2929','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','2930','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6291D','3833','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2912','f',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2913','f',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2914','f',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2915','f',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2916','f',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2917','f',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','3087','f',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2918','f',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2919','f',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2920','f',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2921','f',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2922','f',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','3187','f',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2923','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2924','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2925','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2926','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2927','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2928','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2929','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','2930','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6292E','3833','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6298L','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6298L','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6299M','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6299M','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6300N','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6300N','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6301P','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6301P','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6302Q','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6303R','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6305W','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6320P','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6321Q','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6322R','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6323T','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6324W','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6325X','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6326Y','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6327B','3979','f',$$<p>Initial treatment of HIV infection in a patient over 12 years of age, weighing 40&#160;kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6327B','3980','f',$$<p>Continuing treatment of HIV infection where the patient over 12 years of age, weighing 40&#160;kg or more, has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6328C','1654','f',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6332G','2619','f',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (6 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1228','f',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for reinfusion into patients with non-myeloid malignancies who have had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1555','f',$$<p>Mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic transplantation to facilitate harvest of such cells in healthy donors</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1274','f',$$<p>Patients with non-myeloid malignancies receiving marrow-ablative chemotherapy and subsequent peripheral blood progenitor cell or bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1046','f',$$<p>Patients with breast cancer receiving standard dose adjuvant chemotherapy who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1051','f',$$<p>Patients receiving first-line chemotherapy for Hodgkin's disease who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1005','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1097','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Ewing's sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1140','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1168','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1238','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1240','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin's lymphoma (intermediate or high grade)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1249','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in osteosarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1324','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin's disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6337M','1333','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in rhabdomyosarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1228','f',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for reinfusion into patients with non-myeloid malignancies who have had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1555','f',$$<p>Mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic transplantation to facilitate harvest of such cells in healthy donors</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1274','f',$$<p>Patients with non-myeloid malignancies receiving marrow-ablative chemotherapy and subsequent peripheral blood progenitor cell or bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1046','f',$$<p>Patients with breast cancer receiving standard dose adjuvant chemotherapy who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1051','f',$$<p>Patients receiving first-line chemotherapy for Hodgkin's disease who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1005','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1097','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Ewing's sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1140','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1168','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1238','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1240','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin's lymphoma (intermediate or high grade)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1249','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in osteosarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1324','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin's disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6338N','1333','f',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in rhabdomyosarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6339P','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6341R','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6341R','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6352H','1654','f',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6352H','1655','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6352H','1656','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6352H','1657','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6352H','1658','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6353J','1654','f',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6353J','1655','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6353J','1656','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6353J','1657','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6353J','1658','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6354K','1654','f',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6354K','1655','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6354K','1656','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6354K','1657','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6354K','1658','f',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6356M','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6356M','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6357N','1620','f',$$<p>Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6357N','1964','f',$$<p>Prophylaxis of cytomegalovirus infection and disease in solid organ transplant patients at risk of cytomegalovirus disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6358P','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6358P','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6358P','3967','f',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6358P','3968','f',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6358P','3971','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:<br/> (a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or<br/> (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6358P','3972','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2912','f',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2917','f',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','3087','f',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2918','f',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2919','f',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','3187','f',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2923','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2924','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2925','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2926','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2927','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2928','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2929','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','2930','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6363X','3833','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6364Y','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6364Y','1651','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6365B','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6367D','3531','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).</p><p> Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:<br/> (a) who has severe active juvenile idiopathic arthritis; AND<br/> (b) whose parent or authorised guardian has signed a patient acknowledgement; AND<br/> (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND<br/> (d) who has demonstrated either:<br/> (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or<br/> (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:<br/> &#8212; oral or parenteral methotrexate at a dose of at least 20&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or<br/> &#8212; oral methotrexate at a dose of at least 10&#160;mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months.  (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)</p><p> Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.</p><p> Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.</p><p> If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> (a) an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (b) at least 4 active joints from the following list:<br/> (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6367D','3800','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).</p><p> Initial PBS-subsidised treatment with etanercept by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with etanercept for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for a patient who has received PBS-subsidised treatment with etanercept in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with etanercept may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6367D','3801','f',$$<p>Continuing treatment.</p><p> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.</p><p> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6369F','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6370G','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6371H','1233','f',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6371H','1035','f',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6371H','4051','f',$$<p>Bone metastases from castration-resistant prostate cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6371H','1500','f',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6372J','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6372J','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6392K','3055','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6392K','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6394M','3055','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6394M','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6395N','3055','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6395N','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6396P','3055','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6396P','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6397Q','3710','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 22 weeks of treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3&#160;mg per kg.  Up to a maximum of 3 repeats may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6397Q','3814','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with infliximab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment, within the timeframes specified below.</p><p> A maximum of 22 weeks of treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3&#160;mg per kg.  Up to a maximum of 3 repeats may be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6397Q','3813','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with infliximab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with infliximab.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3&#160;mg per kg.  Up to a maximum of 2 repeats may be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6400W','3948','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients weighing at least 27&#160;kg who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6400W','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6401X','3948','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients weighing at least 27&#160;kg who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6401X','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6402Y','3055','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6402Y','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6405D','3948','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients weighing at least 27&#160;kg who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6405D','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6407F','3055','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6407F','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6409H','3055','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6409H','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6410J','3055','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6410J','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6416Q','1911','f',$$<p>Iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6416Q','1912','f',$$<p>Iron overload in patients with thalassaemia major in whom desferrioxamine therapy has proven ineffective</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6417R','1826','f',$$<p>Schizophrenia in patients who are non-responsive to other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6417R','1827','f',$$<p>Schizophrenia in patients who are intolerant of other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6418T','1826','f',$$<p>Schizophrenia in patients who are non-responsive to other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6418T','1827','f',$$<p>Schizophrenia in patients who are intolerant of other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6423C','2620','f',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6423C','2621','f',$$<p>Functional carcinoid tumour causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120&#160;mg every 28 days.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6424D','2620','f',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6424D','2621','f',$$<p>Functional carcinoid tumour causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120&#160;mg every 28 days.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6425E','2620','f',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6425E','2621','f',$$<p>Functional carcinoid tumour causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120&#160;mg every 28 days.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6426F','2624','f',$$<p>Acromegaly in a patient controlled on Sandostatin subcutaneous injections.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6426F','2625','f',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30&#160;mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6427G','2624','f',$$<p>Acromegaly in a patient controlled on Sandostatin subcutaneous injections.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6427G','2625','f',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30&#160;mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6428H','2624','f',$$<p>Acromegaly in a patient controlled on Sandostatin subcutaneous injections.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6428H','2625','f',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30&#160;mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6429J','4009','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.</p><p> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6429J','4010','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (c) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR</p><p> (e) WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).</p><p> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6429J','4011','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial treatment with bosentan monohydrate of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR<br/> (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than bosentan monohydrate.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6429J','3162','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with bosentan monohydrate of patients who have received approval for initial PBS-subsidised treatment with bosentan monohydrate and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of bosentan monohydrate treatment [see Note for definition of response].</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.</p><p> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6429J','4012','f',$$<p>Cessation of treatment (all patients)<br/> Final PBS-subsidised supply for patients with WHO Functional Class III or IV primary pulmonary hypertension or WHO Functional Class III or IV pulmonary arterial hypertension secondary to connective tissue disease or WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who have not responded to bosentan monohydrate therapy [see Note for definition of response], to allow for gradual cessation of treatment.</p><p> Applications for authorisation under this criterion should be made on the telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday) [see Note on authority approval requirements].</p><p> Approval will only be granted for the 62.5&#160;mg tablet strength.  The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment.</p><p> Under no circumstances will telephone approvals be granted for treatment that would extend the final treatment period beyond 1 month</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6430K','4009','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.</p><p> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6430K','4010','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (c) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR</p><p> (e) WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).</p><p> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6430K','4011','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial treatment with bosentan monohydrate of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR<br/> (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than bosentan monohydrate.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6430K','3162','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with bosentan monohydrate of patients who have received approval for initial PBS-subsidised treatment with bosentan monohydrate and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of bosentan monohydrate treatment [see Note for definition of response].</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.</p><p> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6430K','4012','f',$$<p>Cessation of treatment (all patients)<br/> Final PBS-subsidised supply for patients with WHO Functional Class III or IV primary pulmonary hypertension or WHO Functional Class III or IV pulmonary arterial hypertension secondary to connective tissue disease or WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who have not responded to bosentan monohydrate therapy [see Note for definition of response], to allow for gradual cessation of treatment.</p><p> Applications for authorisation under this criterion should be made on the telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday) [see Note on authority approval requirements].</p><p> Approval will only be granted for the 62.5&#160;mg tablet strength.  The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment.</p><p> Under no circumstances will telephone approvals be granted for treatment that would extend the final treatment period beyond 1 month</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6434P','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6435Q','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6435Q','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6436R','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6437T','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6438W','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6439X','3975','f',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy;<br/> (3) Has received no prior peginterferon alfa therapy for the treatment of hepatitis B</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6439X','3976','f',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</p><p> Treatment is limited to 1 course of treatment for a duration of up to 48 weeks</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6439X','2334','f',$$<p>Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.<br/> The treatment course is limited to up to 48 weeks. <br/> Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6448J','3513','f',$$<p>Initial 1 (new patients)<br/> Initial PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND<br/> (a) who has at least 2 of the following:<br/> (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or<br/> (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or<br/> (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND<br/> (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.</p><p> The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p> If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p> If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:<br/> (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND<br/> (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 10&#160;mg per L.</p><p> The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p> Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:<br/> (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and<br/> (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and<br/> (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and<br/> (iv) a signed patient acknowledgment form.</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.</p><p> At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 18 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6448J','3803','f',$$<p>Initial 2 (change or re-commencement for all patients)<br/> Initial PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with infliximab in the current treatment cycle.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.</p><p> At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 18 weeks of treatment may be requested by telephone.</p><p> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6448J','3804','f',$$<p>Continuing treatment for all patients<br/> Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:<br/> (a) has demonstrated an adequate response to treatment with infliximab; and<br/> (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with infliximab.</p><p> An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:<br/> (a) an ESR measurement no greater than 25&#160;mm per hour; or<br/> (b) a CRP measurement no greater than 10&#160;mg per L; or<br/> (c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p> Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].</p><p> All measurements provided must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with infliximab will be authorised under this criterion.</p><p> At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.</p><p> All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment following an initial treatment course it must be made following a minimum of 12 weeks of treatment with infliximab.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6449K','3975','f',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy;<br/> (3) Has received no prior peginterferon alfa therapy for the treatment of hepatitis B</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6449K','3976','f',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.</p><p> Treatment is limited to 1 course of treatment for a duration of up to 48 weeks</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6449K','2334','f',$$<p>Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.<br/> The treatment course is limited to up to 48 weeks. <br/> Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6450L','3971','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:<br/> (a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or<br/> (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6450L','3972','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6451M','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6451M','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6452N','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6452N','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6453P','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6453P','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6454Q','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6454Q','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6455R','3596','f',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6456T','4015','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with iloprost and who have been assessed by a physician from a designated hospital to have:<br/> WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.</p><p> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6456T','4016','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (c) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR<br/> (d) WHO Functional Class IV drug-induced pulmonary arterial hypertension.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6456T','3170','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial PBS-subsidised treatment with iloprost trometamol of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised iloprost trometamol after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with iloprost trometamol; OR<br/> (b) WHO Functional Class IV primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have received prior treatment with a PBS-subsidised PAH agent other than iloprost trometamol; OR<br/> (c) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have failed to respond to a prior PBS-subsidised PAH agent.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and<br/> (5) for WHO Functional Class III patients, where this is the first application for iloprost trometamol, assessment details of the PBS-subsidised PAH agent they have failed to respond to.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6456T','3171','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with iloprost trometamol of patients who have received approval for initial PBS-subsidised treatment with iloprost trometamol, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of iloprost trometamol treatment [see Note for definition of response].</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.</p><p> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6457W','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6458X','3590','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient over 12 years of age, weighing 40&#160;kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6458X','3591','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient over 12 years of age, weighing 40&#160;kg or more, has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6459Y','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6459Y','1651','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6460B','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6460B','1651','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6461C','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6461C','1651','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6468K','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6468K','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6469L','1233','f',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6480C','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6481D','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6482E','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6483F','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6484G','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6485H','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6486J','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6488L','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6489M','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6490N','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6491P','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6492Q','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6493R','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6494T','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6494T','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6495W','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6495W','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6496X','3492','f',$$<p>Initial 1<br/> Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have severe active psoriatic arthritis; and<br/> (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and<br/> (3) have failed to achieve an adequate response to:<br/> (a) methotrexate at a dose of at least 20&#160;mg weekly for a minimum period of 3 months; and<br/> (b) sulfasalazine at a dose of at least 2&#160;g per day for a minimum period of 3 months; or<br/> (c) leflunomide at a dose of up to 20&#160;mg daily for a minimum period of 3 months.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 22 weeks treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats may be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).</p><p> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6496X','3811','f',$$<p>Initial 2<br/> Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have a documented history of severe active psoriatic arthritis; and<br/> (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and<br/> (3) have not failed treatment with infliximab during the current Treatment Cycle.</p><p> Applications for patients who have received PBS-subsidised treatment with infliximab within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment, within the timeframes specified below.</p><p> A maximum of 22 weeks treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats may be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6496X','3812','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:<br/> (1) who have a documented history of severe active psoriatic arthritis; and<br/> (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with infliximab; and<br/> (3) who, at the time of application, demonstrate an adequate response to treatment with infliximab.</p><p> An adequate response to treatment with infliximab is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline; AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 2 repeats may be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6498B','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6498B','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6499C','3829','f',$$<p>Chronic iron overload in patients with disorders of erythropoiesis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6500D','3829','f',$$<p>Chronic iron overload in patients with disorders of erythropoiesis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9571R','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9571R','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9572T','3598','f',$$<p>Treatment, in addition to optimised background therapy in combination with other antiretroviral agents, of an antiretroviral experienced patient infected with only CCR5-tropic HIV-1, who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.  A tropism assay to determine CCR5 only strain status is required prior to initiation.  Individuals with CXCR4 tropism demonstrated at any time point are not eligible.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9573W','3598','f',$$<p>Treatment, in addition to optimised background therapy in combination with other antiretroviral agents, of an antiretroviral experienced patient infected with only CCR5-tropic HIV-1, who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.  A tropism assay to determine CCR5 only strain status is required prior to initiation.  Individuals with CXCR4 tropism demonstrated at any time point are not eligible.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9574X','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9575Y','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9576B','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9577C','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9578D','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9579E','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9580F','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9581G','3594','f',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100&#160;mg ritonavir twice daily in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9582H','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9582H','1651','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9588P','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9590R','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9593X','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9595B','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9600G','3829','f',$$<p>Chronic iron overload in patients with disorders of erythropoiesis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9602J','3960','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9602J','3959','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9603K','3963','f',$$<p>Chronic hepatitis B in a patient without cirrhosis who has failed lamivudine and who satisfies all of the following criteria:<br/> (a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or<br/> (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9603K','3965','f',$$<p>Chronic hepatitis B in a patient with cirrhosis who has failed lamivudine and who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9605M','4017','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.</p><p> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9605M','4018','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9605M','3174','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial PBS-subsidised treatment with sildenafil citrate of patients with one of the following:<br/> (a) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised sildenafil citrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with sildenafil citrate; OR<br/> (b) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with a PAH agent other than sildenafil citrate.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9605M','3175','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with sildenafil citrate of patients who have received approval for initial PBS-subsidised treatment with sildenafil citrate, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of sildenafil citrate treatment [see Note for definition of response].</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.</p><p> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9607P','1256','f',$$<p>Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9610T','3600','f',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 200&#160;mg ritonavir twice daily in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9611W','3720','f',$$<p>Initial 1 (patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have failed to respond to at least 1 PBS-subsidised TNF-alfa antagonist; and<br/> (c) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (d) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of two infusions will be authorised under this restriction.</p><p> Assessment of a patient's response to an initial course of treatment must be made at least 12 weeks after the first infusion so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date it was conducted</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9611W','3824','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have failed to respond to at least 1 PBS-subsidised TNF-alfa antagonist; and<br/> (c) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with rituximab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised rituximab treatment, within the timeframes specified below.</p><p> A maximum of two infusions will be authorised under this restriction.</p><p> Where the most recent course of PBS-subsidised rituximab treatment was approved under either of the initial 1 or 2 treatment restrictions patients must be assessed for response at least 12 weeks after the first infusion.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date of assessment.</p><p> A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.</p><p> A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction.</p><p> Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p><p> Patients who fail to demonstrate a response to rituximab treatment and who qualify to trial an alternate bDMARD according to the interchangeability arrangements for bDMARDs for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9611W','3823','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with rituximab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with rituximab.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of two infusions will be authorised under this restriction.</p><p> Patients may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.</p><p> A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction.</p><p> Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9612X','3585','f',$$<p>Initial treatment of Crohn disease in a paediatric patient.</p><p> Initial PBS-subsidised treatment by a gastroenterologist, paediatrician or consultant physician as specified in the NOTE below, of a patient aged 6 to 17 years inclusive with moderate to severe refractory Crohn disease who satisfies the following criteria:<br/> (a)  has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b)  whose parent or authorised guardian has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (c) has failed to achieve an adequate response to 2 of the following 3 conventional prior therapies including:<br/> (i) a tapered course of steroids, starting at a dose of at least 1&#160;mg per kg or 40&#160;mg (whichever is the lesser) prednisolone (or equivalent), over a 6 week period;<br/> (ii) an 8 week course of enteral nutrition;<br/> (iii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 10&#160;mg per square metre weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastoenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) severity of disease activity which results in a Paediatric Crohn Disease Activity Index (PCDAI) Score greater than or equal to 30 as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) The most recent PCDAI assessment must be no more than 1 month old at the time of application.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet including the date of assessment of the patient's condition; and<br/> (ii) details of previous systemic drug therapy [dosage, date of commencement and duration of therapy], or dates of enteral nutrition; and<br/> (iii) the signed patient acknowledgement.</p><p> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> A PCDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9612X','3810','f',$$<p>Continuing treatment of Crohn disease in a patient initiated on PBS-subsidised treatment as a paediatric patient.</p><p> Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of moderate to severe refractory Crohn disease; and<br/> (b) has demonstrated or sustained an adequate response to treatment with infliximab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition.</p><p> The PCDAI assessment must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with infliximab, a PCDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.</p><p> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to receive PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9612X','3008','f',$$<p>Initial PBS-subsidised treatment of Crohn disease in a paediatric patient who has previously received non-PBS-subsidised therapy with infliximab.</p><p> Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient aged 6 to 17 years inclusive who:<br/> (a) has a documented history of moderate to severe refractory Crohn disease and was receiving treatment with infliximab prior to 4&#160;July 2007; and<br/> (b) had a Paediatric Crohn Disease Activity Index (PCDAI) Score of greater than 30 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss; and<br/> (c) whose parent or authorised guardian has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has demonstrated or sustained an adequate response to treatment with infliximab.  For advice please contact Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and baseline Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition; and<br/> (ii) the signed patient acknowledgement.</p><p> The current PCDAI assessment must be no more than 1 month old at the time of application. The baseline PCDAI assessment must be from immediately prior to commencing treatment with infliximab.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.</p><p> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9613Y','2996','f',$$<p>Initial 1 (new patients)<br/> Initial treatment of Crohn disease in a patient assessed by CDAI.</p><p> Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (c) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application. </p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au). </p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> The most recent CDAI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and<br/> (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (iii) the signed patient acknowledgement.</p><p> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9613Y','3805','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.</p><p> Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and<br/> (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.</p><p> A maximum quantity and number of repeats to provide for an initial course of infliximb consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9613Y','3806','f',$$<p>Continuing treatment of Crohn disease in a patient assessed by CDAI.</p><p> Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) has demonstrated or sustained an adequate response to treatment with infliximab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.</p><p> The CDAI assessment must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with infliximab, a CDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.</p><p> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9613Y','2999','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.</p><p> Initial PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:<br/> (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and<br/> (c) has evidence of intestinal inflammation; and<br/> (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (e) has failed to achieve an adequate response to prior systemic drug therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have evidence of intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (b) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and<br/> (iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.</p><p> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.</p><p> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9613Y','3807','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.</p><p> Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criteria, if relevant; and<br/> (ii). details of prior TNF alfa antagonist treatment including details of date and duration of treatment.</p><p> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9613Y','3808','f',$$<p>Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.</p><p> Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and<br/> (b) has demonstrated or sustained an adequate response to treatment with infliximab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to infliximab treatment is defined as:<br/> (a) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (b) reversal of high faecal output state; or<br/> (c) avoidance of the need for surgery or total parenteral nutrition (TPN).</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.</p><p> The patient's assessment must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.</p><p> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9613Y','3002','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with extensive small intestine disease.</p><p> Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50&#160;cm of the small intestine; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;<br/> AND/OR<br/> (b) have evidence of active intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (c) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.</p><p> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.</p><p> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or<br/> (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and<br/> (iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.</p><p> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.</p><p> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9613Y','3809','f',$$<p>Continuing treatment of Crohn disease in a patient with extensive small intestine disease.</p><p> Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50&#160;cm of the small intestine; and<br/> (b) has demonstrated or sustained an adequate response to treatment with infliximab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to infliximab treatment is defined as:<br/> (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or<br/> (b) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (c) reversal of high faecal output state; or<br/> (d) avoidance of the need for surgery or total parenteral nutrition (TPN).</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or<br/> (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy; or<br/> (iii) the date of clinical assessment.</p><p> All assessments must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.</p><p> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9613Y','3004','f',$$<p>Initial 3 (grandfather)<br/> Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with infliximab.</p><p> Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7&#160;March 2007; and<br/> (b) had a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has demonstrated or sustained an adequate response to treatment with infliximab. For advice please contact Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and<br/> (ii) the signed patient acknowledgement.</p><p> The current CDAI assessment must be no more than 1 month old at the time of application.  The baseline CDAI assessment must be from immediately prior to commencing treatment with infliximab.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.</p><p> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9613Y','3005','f',$$<p>Initial 3<br/> Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with infliximab.</p><p> Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7&#160;March 2007; and<br/> (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50&#160;cm of the small intestine; or<br/> (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has demonstrated or sustained an adequate response to treatment with infliximab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.</p><p> An adequate response to infliximab treatment is defined as:<br/> (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or<br/> (b) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (c) reversal of high faecal output state; or<br/> (d) avoidance of the need for surgery or total parenteral nutrition (TPN).</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au) ] which includes the following:<br/> (i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or<br/> (2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or<br/> (3) the date of clinical assessment(s); and<br/> (ii) the signed patient acknowledgement.</p><p> The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with infliximab. Where a baseline assessment is not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.</p><p> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9614B','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9614B','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9615C','3802','f',$$<p>Continuing treatment.</p><p> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient 18 years or older:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.</p><p> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.</p><p> Where a patient with severe active juvenile idiopathic arthritis continues treatment with etanercept and is 18 years or older, etanercept 50&#160;mg may be prescribed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9617E','3259','f',$$<p>Initial treatment [Initial 1, Whole body (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9617E','3815','f',$$<p>Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.</p><p> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9617E','3816','f',$$<p>Continuing treatment (Whole body)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and<br/> (c) who have demonstrated an adequate response to their most recent course of treatment with infliximab.</p><p> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Approval will be based on the PASI assessment of response to the most recent course of treatment with infliximab.</p><p> A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 2 repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9617E','3262','f',$$<p>Initial treatment [Initial 1, Face, hand, foot (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.</p><p> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).</p><p> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where: <br/> (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or<br/> (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.</p><p> A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.</p><p> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9617E','3817','f',$$<p>Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.</p><p> Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.</p><p> A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.</p><p> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9617E','3818','f',$$<p>Continuing treatment (Face, hand, foot)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and<br/> (c) who have demonstrated an adequate response to treatment with infliximab.</p><p> An adequate response to infliximab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:<br/> (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or<br/> (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.</p><p> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> The most recent PASI assessment must be no more than 1 month old at the time of application.</p><p> A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 2 repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.</p><p> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.</p><p> The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.</p><p> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9618F','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9618F','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9619G','1035','f',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9620H','3103','f',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9620H','3104','f',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9621J','3712','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9621J','3797','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with abatacept and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised abatacept treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised.</p><p> Where fewer than 4 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised abatacept treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised abatacept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9621J','3796','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with abatacept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with abatacept.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 5 repeats may be authorised.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with abatacept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with abatacept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9624M','3423','f',$$<p>Initial treatment, as monotherapy, by a neurologist, of clinically definite relapsing-remitting multiple sclerosis in an ambulatory (without assistance or support) patient 18 years of age or older, who has experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years.</p><p> The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9624M','3424','f',$$<p>Continuing treatment, as monotherapy, of clinically definite relapsing-remitting multiple sclerosis in a patient previously issued with an authority prescription for this drug who does not show continuing progression of disability while on treatment with this drug, and who has demonstrated compliance with, and an ability to tolerate, this therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9625N','2893','f',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50&#160;pmol per L, not responding to conventional therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9625N','2894','f',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15&#160;pmol per L and less than 50&#160;pmol per L AND an (adjusted) serum calcium concentration at least 2.6&#160;mmol per L, not responding to conventional treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9626P','2893','f',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50&#160;pmol per L, not responding to conventional therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9626P','2894','f',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15&#160;pmol per L and less than 50&#160;pmol per L AND an (adjusted) serum calcium concentration at least 2.6&#160;mmol per L, not responding to conventional treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9627Q','2893','f',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50&#160;pmol per L, not responding to conventional therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9627Q','2894','f',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15&#160;pmol per L and less than 50&#160;pmol per L AND an (adjusted) serum calcium concentration at least 2.6&#160;mmol per L, not responding to conventional treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9629T','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9629T','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9630W','3967','f',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9630W','3968','f',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA.</p><p> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9632Y','1826','f',$$<p>Schizophrenia in patients who are non-responsive to other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9632Y','1827','f',$$<p>Schizophrenia in patients who are intolerant of other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9633B','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9633B','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9634C','3055','f',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9634C','3053','f',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)</p><p> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9635D','3103','f',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9635D','3104','f',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9636E','3103','f',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9636E','3104','f',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9637F','3103','f',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9637F','3104','f',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9638G','1911','f',$$<p>Iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9638G','1912','f',$$<p>Iron overload in patients with thalassaemia major in whom desferrioxamine therapy has proven ineffective</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9640J','1256','f',$$<p>Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9641K','3802','f',$$<p>Continuing treatment.</p><p> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient 18 years or older:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.</p><p> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.</p><p> Where a patient with severe active juvenile idiopathic arthritis continues treatment with etanercept and is 18 years or older, etanercept 50&#160;mg may be prescribed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9642L','3821','f',$$<p>Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100&#160;mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.</p><p> If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).</p><p> Oligo-secretory and non-secretory patients are defined as having active disease with less than 10&#160;g per L serum M protein and less than 200&#160;mg per 24 hour Bence-Jones proteinuria.</p><p> Thalidomide treatment failure is defined as:<br/> (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or<br/> (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.</p><p> Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.</p><p> Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.</p><p> Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:<br/> (1) less than a 25% reduction in serum or urine M protein; or<br/> (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.</p><p> Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.</p><p> To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:<br/> (a) the level of serum monoclonal protein; or<br/> (b) Bence-Jones proteinuria &#8212; the results of 24-hour urinary light chain M protein excretion; or<br/> (c) the serum level of free kappa and lambda light chains; or<br/> (d) bone marrow aspirate or trephine; or<br/> (e) if present, the size and location of lytic bone lesions (not including compression fractures); or<br/> (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or<br/> (g) if present, the level of hypercalcaemia, corrected for albumin concentration.</p><p> As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10&#160;g per L and urinary Bence-Jones protein undetectable or less than 200&#160;mg per 24 hours) must be provided; and<br/> (3) duration of thalidomide and daily dose prescribed; and<br/> (4) a signed patient acknowledgment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9642L','3205','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.</p><p> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).</p><p> Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9643M','3821','f',$$<p>Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100&#160;mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.</p><p> If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).</p><p> Oligo-secretory and non-secretory patients are defined as having active disease with less than 10&#160;g per L serum M protein and less than 200&#160;mg per 24 hour Bence-Jones proteinuria.</p><p> Thalidomide treatment failure is defined as:<br/> (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or<br/> (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.</p><p> Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.</p><p> Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.</p><p> Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:<br/> (1) less than a 25% reduction in serum or urine M protein; or<br/> (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.</p><p> Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.</p><p> To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:<br/> (a) the level of serum monoclonal protein; or<br/> (b) Bence-Jones proteinuria &#8212; the results of 24-hour urinary light chain M protein excretion; or<br/> (c) the serum level of free kappa and lambda light chains; or<br/> (d) bone marrow aspirate or trephine; or<br/> (e) if present, the size and location of lytic bone lesions (not including compression fractures); or<br/> (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or<br/> (g) if present, the level of hypercalcaemia, corrected for albumin concentration.</p><p> As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10&#160;g per L and urinary Bence-Jones protein undetectable or less than 200&#160;mg per 24 hours) must be provided; and<br/> (3) duration of thalidomide and daily dose prescribed; and<br/> (4) a signed patient acknowledgment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9643M','3205','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.</p><p> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).</p><p> Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9644N','3821','f',$$<p>Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100&#160;mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.</p><p> If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).</p><p> Oligo-secretory and non-secretory patients are defined as having active disease with less than 10&#160;g per L serum M protein and less than 200&#160;mg per 24 hour Bence-Jones proteinuria.</p><p> Thalidomide treatment failure is defined as:<br/> (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or<br/> (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.</p><p> Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.</p><p> Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.</p><p> Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:<br/> (1) less than a 25% reduction in serum or urine M protein; or<br/> (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.</p><p> Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.</p><p> To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:<br/> (a) the level of serum monoclonal protein; or<br/> (b) Bence-Jones proteinuria &#8212; the results of 24-hour urinary light chain M protein excretion; or<br/> (c) the serum level of free kappa and lambda light chains; or<br/> (d) bone marrow aspirate or trephine; or<br/> (e) if present, the size and location of lytic bone lesions (not including compression fractures); or<br/> (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or<br/> (g) if present, the level of hypercalcaemia, corrected for albumin concentration.</p><p> As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10&#160;g per L and urinary Bence-Jones protein undetectable or less than 200&#160;mg per 24 hours) must be provided; and<br/> (3) duration of thalidomide and daily dose prescribed; and<br/> (4) a signed patient acknowledgment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9644N','3205','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.</p><p> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).</p><p> Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9645P','3821','f',$$<p>Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100&#160;mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.</p><p> If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p><p> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).</p><p> Oligo-secretory and non-secretory patients are defined as having active disease with less than 10&#160;g per L serum M protein and less than 200&#160;mg per 24 hour Bence-Jones proteinuria.</p><p> Thalidomide treatment failure is defined as:<br/> (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or<br/> (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.</p><p> Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of daily living.</p><p> Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.</p><p> Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:<br/> (1) less than a 25% reduction in serum or urine M protein; or<br/> (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.</p><p> Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.</p><p> To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:<br/> (a) the level of serum monoclonal protein; or<br/> (b) Bence-Jones proteinuria &#8212; the results of 24-hour urinary light chain M protein excretion; or<br/> (c) the serum level of free kappa and lambda light chains; or<br/> (d) bone marrow aspirate or trephine; or<br/> (e) if present, the size and location of lytic bone lesions (not including compression fractures); or<br/> (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or<br/> (g) if present, the level of hypercalcaemia, corrected for albumin concentration.</p><p> As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10&#160;g per L and urinary Bence-Jones protein undetectable or less than 200&#160;mg per 24 hours) must be provided; and<br/> (3) duration of thalidomide and daily dose prescribed; and<br/> (4) a signed patient acknowledgment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9645P','3205','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.</p><p> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).</p><p> Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9646Q','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9646Q','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9647R','1256','f',$$<p>Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9648T','4019','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.</p><p> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9648T','4020','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (c) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9648T','3214','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial treatment with ambrisentan of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised ambrisentan after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with ambrisentan; OR<br/> (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than ambrisentan.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9648T','3215','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with ambrisentan of patients who have received approval for initial PBS-subsidised treatment with ambrisentan and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of ambrisentan treatment [see Note for definition of response].</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.</p><p> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.  Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9649W','4019','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.</p><p> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9649W','4020','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (c) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9649W','3214','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial treatment with ambrisentan of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised ambrisentan after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with ambrisentan; OR<br/> (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than ambrisentan.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.</p><p> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9649W','3215','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with ambrisentan of patients who have received approval for initial PBS-subsidised treatment with ambrisentan and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of ambrisentan treatment [see Note for definition of response].</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.</p><p> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.</p><p> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.  Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9650X','3983','f',$$<p>Initial treatment of HIV infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9650X','3984','f',$$<p>Continuing treatment of HIV infection where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9671B','3716','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.</p><p> Up to a maximum of 3 repeats of each strength may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9671B','3826','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with tocilizumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats of each strength may be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9671B','3825','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with tocilizumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with tocilizumab.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats of each strength may be authorised.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with tocilizumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with tocilizumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9672C','3716','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.</p><p> Up to a maximum of 3 repeats of each strength may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9672C','3826','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with tocilizumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats of each strength may be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9672C','3825','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with tocilizumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with tocilizumab.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats of each strength may be authorised.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with tocilizumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with tocilizumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9673D','3716','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)</p><p> Initial PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.</p><p> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.</p><p> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.</p><p> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p><p> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.</p><p> Up to a maximum of 3 repeats of each strength may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9673D','3826','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)</p><p> Initial course of PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for patients who have received PBS-subsidised treatment with tocilizumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats of each strength may be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9673D','3825','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with tocilizumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with tocilizumab.</p><p> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats of each strength may be authorised.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with tocilizumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with tocilizumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9674E','3691','f',$$<p>Initial 1<br/> Initial treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has an externally draining enterocutaneous or rectovaginal fistula; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/> (ii) a signed patient acknowledgement.</p><p> The most recent fistula assessment must be no more than 1 month old at the time of application.</p><p> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6 will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> An assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (up to 6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.</p><p> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9674E','3819','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Initial PBS-subsidised treatment with infliximab of complex refractory fistulising Crohn disease by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has a documented history of complex refractory fistulising Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or infliximab for a draining enterocutaneous or rectovaginal fistula; and<br/> (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.</p><p> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/> (ii) details of prior TNF-alfa antagonist treatment including details of date and duration of treatment.</p><p> The most recent fistula assessment must be no more than 1 month old at the time of application.</p><p> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.</p><p> An assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (up to 6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.</p><p> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9674E','3693','f',$$<p>Initial 3 (grandfather)<br/> Initial PBS-subsidised treatment of complex refractory FISTULISING CROHN DISEASE in a patient who has previously received non-PBS-subsidised therapy with infliximab.</p><p> Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who satisfies the following criteria:<br/> (a) has a documented history of complex refractory fistulising Crohn disease and was receiving treatment with infliximab prior to 1&#160;March 2010; and<br/> (b) had a draining enterocutaneous or rectovaginal fistula(e) prior to commencing treatment with infliximab; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) is receiving treatment with infliximab at the time of application; and<br/> (e) has demonstrated or sustained an adequate response to treatment with infliximab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response to infliximab treatment is defined as:<br/> (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or<br/> (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.</p><p> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current and baseline Fistula Assessment form including the date of assessment of the patient's condition; and<br/> (ii) a signed patient acknowledgement.</p><p> The current fistula assessment must be no more than 1 month old at the time of application.</p><p> The baseline fistula assessment must be from immediately prior to commencing treatment with infliximab.</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.</p><p> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 2 repeats will be authorised.  No applications for increased repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9674E','3820','f',$$<p>Continuing treatment of complex refractory FISTULISING CROHN DISEASE.</p><p> Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of complex refractory fistulising Crohn disease; and<br/> (b) has demonstrated or sustained an adequate response to treatment with infliximab.</p><p> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].</p><p> An adequate response is defined as:<br/> (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or<br/> (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.</p><p> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes a completed Fistula Assessment form including the date of the assessment of the patient's condition.</p><p> The fistula assessment must be no more than 1 month old at the time of application.</p><p> If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.</p><p> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.</p><p> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.</p><p> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.</p><p> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 2 repeats will be authorised.  No applications for increased repeats will be authorised.</p><p> Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9675F','1620','f',$$<p>Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9675F','1964','f',$$<p>Prophylaxis of cytomegalovirus infection and disease in solid organ transplant patients at risk of cytomegalovirus disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9677H','3586','f',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9677H','3587','f',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9678J','3527','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).</p><p> Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:<br/> (a) who has severe active juvenile idiopathic arthritis; AND<br/> (b) whose parent or authorised guardian has signed a patient acknowledgement; AND<br/> (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND<br/> (d) who has demonstrated either:<br/> (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or<br/> (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:<br/> &#8212; oral or parenteral methotrexate at a dose of at least 20&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or<br/> &#8212; oral methotrexate at a dose of at least 10&#160;mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months.  (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)</p><p> Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.</p><p> Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.</p><p> If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> (a) an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (b) at least 4 active joints from the following list:<br/> (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9678J','3798','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).</p><p> Initial PBS-subsidised treatment with adalimumab by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for a patient who has received PBS-subsidised treatment with adalimumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9678J','3529','f',$$<p>Initial 3 ('grandfather' patients).</p><p> Initial PBS-subsidised supply for continuing treatment with adalimumab, by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) was receiving treatment with adalimumab prior to 1&#160;March 2010; and<br/> (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab; and<br/> (d) is receiving treatment with adalimumab at the time of application.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.</p><p> A maximum of 24 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The assessment of the patient's response to this initial course of PBS-subsidised therapy must be made within the 4 weeks prior to completion of the course in order to ensure continuity of treatment.</p><p> A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9678J','3799','f',$$<p>Continuing treatment.</p><p> Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with adalimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with adalimumab.</p><p> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9679K','3527','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).</p><p> Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:<br/> (a) who has severe active juvenile idiopathic arthritis; AND<br/> (b) whose parent or authorised guardian has signed a patient acknowledgement; AND<br/> (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND<br/> (d) who has demonstrated either:<br/> (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or<br/> (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:<br/> &#8212; oral or parenteral methotrexate at a dose of at least 20&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or<br/> &#8212; oral methotrexate at a dose of at least 10&#160;mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months.  (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)</p><p> Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.</p><p> Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.</p><p> If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> (a) an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (b) at least 4 active joints from the following list:<br/> (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9679K','3798','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).</p><p> Initial PBS-subsidised treatment with adalimumab by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for a patient who has received PBS-subsidised treatment with adalimumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9679K','3529','f',$$<p>Initial 3 ('grandfather' patients).</p><p> Initial PBS-subsidised supply for continuing treatment with adalimumab, by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) was receiving treatment with adalimumab prior to 1&#160;March 2010; and<br/> (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab; and<br/> (d) is receiving treatment with adalimumab at the time of application.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.</p><p> A maximum of 24 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The assessment of the patient's response to this initial course of PBS-subsidised therapy must be made within the 4 weeks prior to completion of the course in order to ensure continuity of treatment.</p><p> A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9679K','3799','f',$$<p>Continuing treatment.</p><p> Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with adalimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with adalimumab.</p><p> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9680L','3527','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).</p><p> Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:<br/> (a) who has severe active juvenile idiopathic arthritis; AND<br/> (b) whose parent or authorised guardian has signed a patient acknowledgement; AND<br/> (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND<br/> (d) who has demonstrated either:<br/> (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or<br/> (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:<br/> &#8212; oral or parenteral methotrexate at a dose of at least 20&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or<br/> &#8212; oral methotrexate at a dose of at least 10&#160;mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months.  (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)</p><p> Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.</p><p> Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.</p><p> If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.</p><p> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> (a) an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (b) at least 4 active joints from the following list:<br/> (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with adalimumab.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9680L','3798','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).</p><p> Initial PBS-subsidised treatment with adalimumab by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> Applications for a patient who has received PBS-subsidised treatment with adalimumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.</p><p> A maximum of 16 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.</p><p> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9680L','3529','f',$$<p>Initial 3 ('grandfather' patients).</p><p> Initial PBS-subsidised supply for continuing treatment with adalimumab, by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) was receiving treatment with adalimumab prior to 1&#160;March 2010; and<br/> (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab; and<br/> (d) is receiving treatment with adalimumab at the time of application.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.</p><p> A maximum of 24 weeks of treatment will be authorised under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The assessment of the patient's response to this initial course of PBS-subsidised therapy must be made within the 4 weeks prior to completion of the course in order to ensure continuity of treatment.</p><p> A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.</p><p> If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.</p><p> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9680L','3799','f',$$<p>Continuing treatment.</p><p> Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with adalimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with adalimumab.</p><p> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].</p><p> A maximum of 24 weeks of treatment will be approved under this restriction.</p><p> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.</p><p> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.</p><p> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9681M','1654','f',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9682N','1654','f',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9683P','1654','f',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9684Q','1233','f',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9685R','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9686T','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9687W','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9688X','1957','f',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2912','f',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2913','f',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2914','f',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2915','f',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2916','f',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2917','f',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','3087','f',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2918','f',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2919','f',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2920','f',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2921','f',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2922','f',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','3187','f',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2923','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2924','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2925','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2926','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2927','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2928','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2929','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','2930','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9693E','3833','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2912','f',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2913','f',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2914','f',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2915','f',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2916','f',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2917','f',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','3087','f',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2918','f',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2919','f',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2920','f',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2921','f',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2922','f',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','3187','f',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2923','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2924','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2925','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2926','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2927','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2928','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2929','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','2930','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9695G','3833','f',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9697J','3851','f',$$<p>Initial (new patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:<br/> (1) Splenectomised and:<br/> (a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and<br/> (b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;<br/> OR<br/> (2) Not splenectomised and:<br/> (a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2&#160;mg/kg/day of prednisone for at least 4-6 weeks; and<br/> (b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and<br/> (c) in whom splenectomy is contraindicated for medical reasons.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:<br/> (a) a platelet count of less than or equal to 20,000&#160;million per L;<br/> OR<br/> (b) a platelet count of 20-30,000&#160;million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],<br/> (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and<br/> (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.</p><p> The full blood count must be no more than 1 month old at the time of application.</p><p> At the time of the written authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1&#160;microgram/kg.  Up to 1 repeat may be requested with the initial written application.</p><p> Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  The dose (microgram/kg/week) must be provided at the time of application.</p><p> Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.</p><p> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9697J','3852','f',$$<p>Initial (grandfather patients)<br/> Initial PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with romiplostim prior to 1&#160;April&#160;2011 and in whom the criteria for initial treatment can be demonstrated to have been met at the time romiplostim was commenced.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.</p><p> For patients whose dose of romiplostim had been stable for at least 4 weeks at the time of the initial application for PBS-subsidy, the medical practitioner should request sufficient number of vials based on the weight of the patient and dose (microgram/kg/week) to provide up to 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.</p><p> Where the patient is in the titration phase of treatment with romiplostim, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1&#160;microgram/kg.  Up to 1 repeat may be requested with the initial written application.</p><p> Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  The dose (microgram/kg/week) must be provided at the time of application.</p><p> Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.</p><p> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9697J','3853','f',$$<p>Continuing therapy or re-initiation after a break in therapy<br/> First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with romiplostim during the initial period of PBS-subsidised treatment.</p><p> For the purposes of this restriction, a sustained platelet response is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised romiplostim,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L on at least four (4) occasions, each at least one week apart;<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.</p><p> Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:<br/> (1) a completed authority prescription form, and<br/> (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).</p><p> The most recent platelet count must be no more than one month old at the time of application.</p><p> The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone.</p><p> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9697J','3854','f',$$<p>Second and subsequent applications for continuing therapy<br/> Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with romiplostim and who continues to display a response to treatment with romiplostim.</p><p> For the purposes of this restriction, a continuing response to treatment with romiplostim is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with romiplostim,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline platelet count.</p><p> Platelet counts must be no more than 1 month old at the time of application.</p><p> Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.</p><p> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9699L','3851','f',$$<p>Initial (new patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:<br/> (1) Splenectomised and:<br/> (a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and<br/> (b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;<br/> OR<br/> (2) Not splenectomised and:<br/> (a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2&#160;mg/kg/day of prednisone for at least 4-6 weeks; and<br/> (b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and<br/> (c) in whom splenectomy is contraindicated for medical reasons.</p><p> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:<br/> (a) a platelet count of less than or equal to 20,000&#160;million per L;<br/> OR<br/> (b) a platelet count of 20-30,000&#160;million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],<br/> (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and<br/> (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.</p><p> The full blood count must be no more than 1 month old at the time of application.</p><p> At the time of the written authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1&#160;microgram/kg.  Up to 1 repeat may be requested with the initial written application.</p><p> Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  The dose (microgram/kg/week) must be provided at the time of application.</p><p> Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.</p><p> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9699L','3852','f',$$<p>Initial (grandfather patients)<br/> Initial PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with romiplostim prior to 1&#160;April&#160;2011 and in whom the criteria for initial treatment can be demonstrated to have been met at the time romiplostim was commenced.</p><p> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.</p><p> For patients whose dose of romiplostim had been stable for at least 4 weeks at the time of the initial application for PBS-subsidy, the medical practitioner should request sufficient number of vials based on the weight of the patient and dose (microgram/kg/week) to provide up to 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.</p><p> Where the patient is in the titration phase of treatment with romiplostim, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1&#160;microgram/kg.  Up to 1 repeat may be requested with the initial written application.</p><p> Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  The dose (microgram/kg/week) must be provided at the time of application.</p><p> Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.</p><p> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9699L','3853','f',$$<p>Continuing therapy or re-initiation after a break in therapy<br/> First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with romiplostim during the initial period of PBS-subsidised treatment.</p><p> For the purposes of this restriction, a sustained platelet response is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised romiplostim,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L on at least four (4) occasions, each at least one week apart;<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.</p><p> Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:<br/> (1) a completed authority prescription form, and<br/> (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).</p><p> The most recent platelet count must be no more than one month old at the time of application.</p><p> The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.</p><p> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone.</p><p> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9699L','3854','f',$$<p>Second and subsequent applications for continuing therapy<br/> Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with romiplostim and who continues to display a response to treatment with romiplostim.</p><p> For the purposes of this restriction, a continuing response to treatment with romiplostim is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with romiplostim,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline platelet count.</p><p> Platelet counts must be no more than 1 month old at the time of application.</p><p> Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.</p><p> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9744W','3705','f',$$<p>Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy.</p><p> Treatment must be commenced in a hospital-based movement disorder clinic</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9746Y','3740','f',$$<p>Initial treatment of uncontrolled severe allergic asthma</p><p> Initial PBS-subsidised treatment with omalizumab by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient aged 12 years or older with uncontrolled severe allergic asthma who has been under the care of this physician for at least 12 months, and satisfies the following criteria:</p><p> (a) has a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by standard clinical features, including:<br/> (i)  forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200&#160;mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or<br/> (ii)  airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or<br/> (iii)  peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; and</p><p> (b) duration of asthma of at least 1 year; and</p><p> (c) FEV1 less than or equal to 80% predicted, documented on 3 or more occasions in the previous 12 months; and</p><p> (d) past or current evidence of atopy, documented by skin prick testing or RAST; and</p><p> (e) total serum human immunoglobulin E (IgE) greater than or equal to 76&#160;IU/mL; and</p><p> (f) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and</p><p> (g) has failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented (see NOTE).  Optimised asthma therapy includes:<br/> (i)  adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (budesonide 1600&#160;micrograms per day or fluticasone propionate 1000&#160;micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50&#160;micrograms bd or eformoterol 12&#160;micrograms bd) for at least 12 months, unless contraindicated or not tolerated, AND<br/> (ii)  oral corticosteroids (at least 10&#160;mg per day prednisolone (or equivalent)) for at least 6 weeks, unless contraindicated or not tolerated.</p><p> If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the authority application.  Details of the accepted toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement of treatment with optimised asthma therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The initial IgE assessment must be no more than 12 months old at the time of application.  A re-assessment of free IgE can only be made at least 12 months after the last dose of omalizumab.  For patients re-commencing omalizumab within 12 months of the last dose the previous pre-omalizumab IgE level should be used.</p><p> The IgE pathology report must be provided with the authority application.</p><p> The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application:<br/> (a) an Asthma Control Questionnaire (ACQ-5) score of at least 2.0, as assessed in the previous month, AND<br/> (b) while on oral corticosteroids and in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician.</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes the following:<br/> (i)  details of prior optimised asthma drug therapy (dosage, date of commencement and duration of therapy); and<br/> (ii)  details of severe exacerbation/s experienced while on oral corticosteroids (date and treatment); and<br/> (iii)  the signed patient acknowledgement; and<br/> (c) a completed Asthma Control Questionnaire (ACQ-5) calculation sheet including the date of assessment of the patient's symptoms. (For copies of the ACQ please contact Novartis Medical Information on 1800&#160;671&#160;203 or medinfo.phauno@novartis.com)</p><p> At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information) to be administered every 2 or 4 weeks.</p><p> Where fewer than the required number of repeats to complete 28 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 28 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.</p><p> The Asthma Control Questionnaire (5 item version) assessment of the patient's response to this initial course of treatment, and the assessment of oral corticosteroid dose, must be made at around 24 to 26 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply.  Where a response assessment is not undertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9746Y','3822','f',$$<p>Continuing treatment</p><p> Continuing PBS-subsidised treatment with omalizumab, by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient who:<br/> (a) has a documented history of severe allergic asthma; and<br/> (b) has demonstrated or sustained an adequate response to treatment with omalizumab.</p><p> An adequate response to omalizumab treatment is defined as:<br/> (a) a reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 0.5 from baseline, OR<br/> (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ-5 score from baseline.</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes details of maintenance oral corticosteroid dose; and<br/> (c) a completed Asthma Control Questionnaire (ACQ-5) calculation sheet including the date of assessment of the patient's symptoms. (For copies of the ACQ please contact Novartis Medical Information on 1800&#160;671&#160;203 or medinfo.phauno@novartis.com)</p><p> All applications for continuing treatment with omalizumab must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to the prior course of treatment, and the assessment of oral corticosteroid dose, must be made at around 20 to 22 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.</p><p> The first assessment should, where possible, be completed by the same physician who initiated treatment with omalizumab.  If the same physician cannot assess the patient please call Medicare Australia on 1800&#160;700&#160;270.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply.  Where a response assessment is not undertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 20 to 22 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised omalizumab treatment.</p><p> Patients are eligible to receive continuing courses of omalizumab treatment of up to 24 weeks providing they continue to demonstrate an adequate response to treatment.</p><p> At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for a continuing course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information), sufficient for 24 weeks of therapy.</p><p> Where fewer than the required number of repeats to complete 24 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).</p><p> A patient who fails to respond to a course of PBS-subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS-subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9746Y','3742','f',$$<p>Initial PBS-subsidised treatment of severe allergic asthma in a patient who has previously received non-PBS-subsidised therapy with omalizumab (grandfather patients)</p><p> Initial PBS-subsidised supply for continuing treatment with omalizumab by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient aged 12 years or older with severe allergic asthma who satisfies the following criteria:</p><p> (a) has a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by standard clinical features, including:<br/> (i)  forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200&#160;mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or<br/> (ii)  airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or<br/> (iii)  peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; and</p><p> (b) duration of asthma of at least 1 year; and</p><p> (c) past or current evidence of atopy, documented by skin prick testing or RAST; and</p><p> (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment for grandfathered patients; and</p><p> (e) prior to omalizumab therapy had failed to achieve adequate control with optimised asthma therapy. Optimised asthma therapy includes:<br/> (i)  adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (budesonide 1600&#160;micrograms per day or fluticasone propionate 1000&#160;micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50&#160;micrograms bd or eformoterol 12&#160;micrograms bd) for at least 12 months, and<br/> (ii)  may have included maintenance dose oral corticosteroids; and</p><p> (f) has demonstrated an adequate response to treatment with omalizumab.</p><p> A review of the patient's records should be conducted to extract pre- and post-omalizumab data on symptoms, quality of life, medication doses, exacerbations and hospitalisations.  Examples of parameters to establish response include:<br/> (i)  a reduction in Asthma Control Questionnaire (ACQ-5) score of at least 0.5;<br/> (ii)  an improvement of at least 0.5 in the Asthma Quality of Life Questionnaire (AQLQ or mini-AQLQ);<br/> (iii)  maintenance oral corticosteroid dose reduced by at least 25% from baseline; and/or<br/> (iv)  a reduction in the number of hospitalisations or severe exacerbations requiring use of systemic corticosteroids, compared to the 12 months prior to commencement of omalizumab.</p><p> Where baseline assessments are not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.</p><p> If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the authority application.  Details of the accepted contraindications and toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement of treatment with optimised asthma therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].</p><p> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes the following:<br/> (i)  details of prior optimised asthma drug therapy (dosage, date of commencement and duration of therapy); and<br/> (ii)  details of pre- and post-omalizumab data on symptoms, quality of life, medication doses, exacerbations and hospitalisations; and<br/> (iii)  the signed patient acknowledgement.</p><p> At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information) to be administered every 2 or 4 weeks.</p><p> Where fewer than the required number of repeats to complete 24 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 24 weeks.</p><p> An assessment of the patient's continued response to this course of PBS-subsidised treatment must be made at around 20 to 22 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.  The same parameters used to establish response to non-PBS-subsidised therapy with omalizumab should be used for the assessment.</p><p> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply.  Where a response assessment is not undertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab.</p><p> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 20 to 22 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised omalizumab treatment.</p><p> Patients are eligible to receive continuing courses of omalizumab treatment of up to 24 weeks providing they continue to demonstrate an adequate response to treatment.</p><p> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9748C','1650','f',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3357','t',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3358','t',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3359','t',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3360','t',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3361','t',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3362','t',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3363','t',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3364','t',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3365','t',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3366','t',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3367','t',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3368','t',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3369','t',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3370','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3371','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3372','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3373','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3374','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3375','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3376','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3377','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1123D','3834','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3357','t',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3358','t',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3359','t',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3360','t',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3361','t',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3362','t',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3363','t',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3364','t',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3365','t',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3366','t',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3367','t',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3368','t',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3369','t',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3370','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3371','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3372','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3373','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3374','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3375','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3376','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3377','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1126G','3834','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1132N','3995','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient who has been stabilised on nevirapine immediate release with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1132N','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1173R','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1173R','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1308W','4021','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with tadalafil of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.<br/><br/> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particulartest/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1308W','4022','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with tadalafil of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO;<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1308W','4023','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial treatment with tadalafil of patients with one of the following:<br/> (a) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised tadalafil after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with tadalafil; OR<br/> (b) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with a PAH agent other than tadalafil.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1308W','4024','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with tadalafil of patients who have received approval for initial PBS-subsidised treatment with tadalafil, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of tadalafil treatment [see Note for definition of response].<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.<br/><br/> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.  Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9657G','3716','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)<br/><br/> Initial PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.<br/><br/> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/>&#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.<br/><br/> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.<br/><br/> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/>The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.<br/><br/> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.<br/><br/> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.<br/><br/> Up to a maximum of 3 repeats of each strength may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9657G','3826','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)<br/><br/> Initial course of PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for patients who have received PBS-subsidised treatment with tocilizumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats of each strength may be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessmentmust be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9657G','3825','f',$$<p>Continuing treatment<br/><br/> Continuing PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with tocilizumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats of each strength may be authorised.<br/><br/>Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with tocilizumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with tocilizumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1476Q','4025','f',$$<p>Initial 1 (new and recommencing patients after a break of more than 12 months)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a)  has been diagnosed with systemic juvenile idiopathic arthritis; AND<br/> (b)  has polyarticular course disease and either:<br/> (i)  failure to achieve an adequate response to the following treatment regimen (see (1) below for definition of failure to achieve an adequate response):<br/> &#8212; oral or parenteral methotrexate at a dose of at least 15&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids for a minimum of 3 months; or<br/> (ii)  severe intolerance of, or toxicity due to, methotrexate (see (2) below for definition of severe intolerance and toxicity); OR<br/> (c)  has refractory systemic symptoms, demonstrated by:<br/> &#8212; an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5&#160;mg per kg per day following a minimum of 2 months of therapy; AND<br/> (d)  has not received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months.<br/><br/> (1)  The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy and must be demonstrated in all patients at the time of the initial application:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (ii)  at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); AND/OR<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with  refractory systemic symptoms:<br/> (i)  an active joint count of at least 2 active joints; AND<br/> (ii)  persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; AND/OR<br/>(iii)  a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN).<br/><br/> (2)  Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/> Toxicity to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonia, or serious sepsis.<br/> If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.<br/><br/> The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  the date of assessment of severe active systemic juvenile idiopathic arthritis;<br/> (ii) details of prior treatment including dose and duration of treatment;<br/> (iii) pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/>The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment in a treatment cycle they will not be eligible to receive further PBS-subsidised tocilizumab therapy in that treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1476Q','4026','f',$$<p>Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)<br/><br/> Initial PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months; AND<br/> (c)  has not failed PBS-subsidised therapy with tocilizumab for this condition more than once in the current treatment cycle.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate.<br/><br/> Applications for a patient who has received PBS-subsidised treatment with tocilizumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with tocilizumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior tothe date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria. Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that course of tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1476Q','4027','f',$$<p>Initial 3 ('grandfather' patients)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; and<br/> (b)  was receiving treatment with tocilizumab prior 1&#160;November 2011; and<br/> (c)  has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with tocilizumab; and<br/> (d)  is receiving treatment with tocilizumab at the time of application.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish the baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> The baseline systemic juvenile idiopathic arthritis assessment must be provided and must be from immediately prior to commencing treatment with tocilizumab.  (See NOTE (3) above for definition of baseline measurements to determine response.)<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/>Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient,  for two infusions (one months supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1476Q','4028','f',$$<p>Continuing treatment<br/><br/> Continuing treatment with tocilizumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has demonstrated an adequate response to treatment with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii)  a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with refractory systemic symptoms:<br/> (i)  absence of fever greater than 38 degrees Celsius in the preceding seven days; AND/OR<br/> (ii)  a reduction in the CRP level and platelet count by at least 30% from baseline; AND/OR<br/> (iii)  a reduction in the dose of corticosteroid by at least 30% from baseline.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  baseline and current pathology reports detailing CRP and platelet count where appropriate.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatmentwas approved under the Initial treatment restriction, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9658H','3716','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)<br/><br/> Initial PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.<br/><br/> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/>&#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.<br/><br/> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.<br/><br/> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/>The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.<br/><br/> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.<br/><br/> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.<br/><br/> Up to a maximum of 3 repeats of each strength may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9658H','3826','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)<br/><br/> Initial course of PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for patients who have received PBS-subsidised treatment with tocilizumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats of each strength may be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessmentmust be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9658H','3825','f',$$<p>Continuing treatment<br/><br/> Continuing PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with tocilizumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats of each strength may be authorised.<br/><br/>Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with tocilizumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with tocilizumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1481Y','4025','f',$$<p>Initial 1 (new and recommencing patients after a break of more than 12 months)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a)  has been diagnosed with systemic juvenile idiopathic arthritis; AND<br/> (b)  has polyarticular course disease and either:<br/> (i)  failure to achieve an adequate response to the following treatment regimen (see (1) below for definition of failure to achieve an adequate response):<br/> &#8212; oral or parenteral methotrexate at a dose of at least 15&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids for a minimum of 3 months; or<br/> (ii)  severe intolerance of, or toxicity due to, methotrexate (see (2) below for definition of severe intolerance and toxicity); OR<br/> (c)  has refractory systemic symptoms, demonstrated by:<br/> &#8212; an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5&#160;mg per kg per day following a minimum of 2 months of therapy; AND<br/> (d)  has not received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months.<br/><br/> (1)  The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy and must be demonstrated in all patients at the time of the initial application:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (ii)  at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); AND/OR<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with  refractory systemic symptoms:<br/> (i)  an active joint count of at least 2 active joints; AND<br/> (ii)  persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; AND/OR<br/>(iii)  a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN).<br/><br/> (2)  Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/> Toxicity to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonia, or serious sepsis.<br/> If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.<br/><br/> The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  the date of assessment of severe active systemic juvenile idiopathic arthritis;<br/> (ii) details of prior treatment including dose and duration of treatment;<br/> (iii) pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/>The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment in a treatment cycle they will not be eligible to receive further PBS-subsidised tocilizumab therapy in that treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1481Y','4026','f',$$<p>Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)<br/><br/> Initial PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months; AND<br/> (c)  has not failed PBS-subsidised therapy with tocilizumab for this condition more than once in the current treatment cycle.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate.<br/><br/> Applications for a patient who has received PBS-subsidised treatment with tocilizumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with tocilizumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior tothe date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria. Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that course of tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1481Y','4027','f',$$<p>Initial 3 ('grandfather' patients)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; and<br/> (b)  was receiving treatment with tocilizumab prior 1&#160;November 2011; and<br/> (c)  has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with tocilizumab; and<br/> (d)  is receiving treatment with tocilizumab at the time of application.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish the baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> The baseline systemic juvenile idiopathic arthritis assessment must be provided and must be from immediately prior to commencing treatment with tocilizumab.  (See NOTE (3) above for definition of baseline measurements to determine response.)<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/>Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient,  for two infusions (one months supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1481Y','4028','f',$$<p>Continuing treatment<br/><br/> Continuing treatment with tocilizumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has demonstrated an adequate response to treatment with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii)  a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with refractory systemic symptoms:<br/> (i)  absence of fever greater than 38 degrees Celsius in the preceding seven days; AND/OR<br/> (ii)  a reduction in the CRP level and platelet count by at least 30% from baseline; AND/OR<br/> (iii)  a reduction in the dose of corticosteroid by at least 30% from baseline.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  baseline and current pathology reports detailing CRP and platelet count where appropriate.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatmentwas approved under the Initial treatment restriction, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9659J','3716','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)<br/><br/> Initial PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.<br/><br/> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/>&#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.<br/><br/> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.<br/><br/> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/>The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.<br/><br/> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.<br/><br/> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.<br/><br/> Up to a maximum of 3 repeats of each strength may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9659J','3826','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)<br/><br/> Initial course of PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for patients who have received PBS-subsidised treatment with tocilizumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats of each strength may be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessmentmust be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9659J','3825','f',$$<p>Continuing treatment<br/><br/> Continuing PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with tocilizumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats of each strength may be authorised.<br/><br/>Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with tocilizumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with tocilizumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1482B','4025','f',$$<p>Initial 1 (new and recommencing patients after a break of more than 12 months)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a)  has been diagnosed with systemic juvenile idiopathic arthritis; AND<br/> (b)  has polyarticular course disease and either:<br/> (i)  failure to achieve an adequate response to the following treatment regimen (see (1) below for definition of failure to achieve an adequate response):<br/> &#8212; oral or parenteral methotrexate at a dose of at least 15&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids for a minimum of 3 months; or<br/> (ii)  severe intolerance of, or toxicity due to, methotrexate (see (2) below for definition of severe intolerance and toxicity); OR<br/> (c)  has refractory systemic symptoms, demonstrated by:<br/> &#8212; an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5&#160;mg per kg per day following a minimum of 2 months of therapy; AND<br/> (d)  has not received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months.<br/><br/> (1)  The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy and must be demonstrated in all patients at the time of the initial application:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (ii)  at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); AND/OR<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with  refractory systemic symptoms:<br/> (i)  an active joint count of at least 2 active joints; AND<br/> (ii)  persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; AND/OR<br/>(iii)  a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN).<br/><br/> (2)  Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/> Toxicity to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonia, or serious sepsis.<br/> If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.<br/><br/> The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  the date of assessment of severe active systemic juvenile idiopathic arthritis;<br/> (ii) details of prior treatment including dose and duration of treatment;<br/> (iii) pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/>The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment in a treatment cycle they will not be eligible to receive further PBS-subsidised tocilizumab therapy in that treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1482B','4026','f',$$<p>Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)<br/><br/> Initial PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months; AND<br/> (c)  has not failed PBS-subsidised therapy with tocilizumab for this condition more than once in the current treatment cycle.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate.<br/><br/> Applications for a patient who has received PBS-subsidised treatment with tocilizumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with tocilizumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior tothe date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria. Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that course of tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1482B','4027','f',$$<p>Initial 3 ('grandfather' patients)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; and<br/> (b)  was receiving treatment with tocilizumab prior 1&#160;November 2011; and<br/> (c)  has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with tocilizumab; and<br/> (d)  is receiving treatment with tocilizumab at the time of application.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish the baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> The baseline systemic juvenile idiopathic arthritis assessment must be provided and must be from immediately prior to commencing treatment with tocilizumab.  (See NOTE (3) above for definition of baseline measurements to determine response.)<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/>Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient,  for two infusions (one months supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1482B','4028','f',$$<p>Continuing treatment<br/><br/> Continuing treatment with tocilizumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has demonstrated an adequate response to treatment with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii)  a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with refractory systemic symptoms:<br/> (i)  absence of fever greater than 38 degrees Celsius in the preceding seven days; AND/OR<br/> (ii)  a reduction in the CRP level and platelet count by at least 30% from baseline; AND/OR<br/> (iii)  a reduction in the dose of corticosteroid by at least 30% from baseline.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  baseline and current pathology reports detailing CRP and platelet count where appropriate.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatmentwas approved under the Initial treatment restriction, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1491L','3985','t',$$<p>Initial treatment of HIV infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1491L','3986','t',$$<p>Continuing treatment of HIV infection where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9501C','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9501C','3356','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1839T','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1839T','3356','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2015C','4063','t',$$<p>Treatment of cystic fibrosis in a patient who satisfies all of the following criteria:<br/> (1) Prior to mannitol therapy, the patient must have been assessed for bronchial hyperresponsiveness as per the TGA approved PI mannitol initiation dose assessment.  If the patient has a negative hyperresponsiveness test they may be eligible for PBS subsidised treatment with mannitol;<br/> (2) Is 6 years of age or older;<br/> (3) Has a FEV1 greater than 30% predicted for age, gender and height;<br/> (4) Is intolerant or inadequately responsive to dornase alfa;<br/> (5) Has evidence of chronic suppurative lung disease (cough and sputum most days of the week, or greater than 3 respiratory tract infections of more than 2 weeks' duration in any 12 months, or objective evidence of obstructive airways disease);<br/> (6) Is participating in a 4 week trial, as detailed below, or has achieved a 10% or greater improvement in FEV1 (compared to baseline established prior to mannitol treatment) after a 4 week trial.<br/><br/> In order for patients to be eligible for participation in the HSD program, the following conditions must be met:<br/> (1) Patients must be assessed at cystic fibrosis clinics/centres which are under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis and the prescribing of mannitol therapy under the HSD program is limited to such physicians. If attendance at such units is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;<br/> (2) The measurement of lung function is to be conducted by independent (other than the treating doctor) experienced personnel at established lung function testing laboratories, unless this is not possible because of geographical isolation;<br/> (3) Prior to mannitol therapy, a baseline measurement of FEV1 must be undertaken during a stable period of the disease;<br/> (4) Initial therapy is limited to 4 weeks' treatment with mannitol at a dose of 400&#160;mg twice daily;<br/> (5) At or towards the end of the initial 4 weeks' trial, patients must be reassessed and a further FEV1 measurement be undertaken (single test under conditions as above). Patients who achieve a 10% or greater improvement in FEV1 (compared to baseline establishedprior to mannitol treatment) are eligible for continued subsidy under the HSD program at a dose of 400mg twice daily;<br/> (6) Patients who fail to meet a 10% or greater improvement in FEV1 after the initial 4 weeks' treatment at a dose of 400&#160;mg twice daily, may have 1 further trial in the next 12 months but not before 3 months after the initial trial;<br/> (7) Following an initial 6 months' therapy, a global assessment must be undertaken involving the patient, the patient's family (in the case of paediatric patients) and the treating physician(s) to establish that all agree that mannitol powder for inhalation treatment is continuing to produce worthwhile benefits. (Mannitol therapy should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.) Further reassessments are to be undertaken at six-monthly intervals;<br/> (8) Other aspects of treatment, such as physiotherapy, must be continued;<br/> (9) Where there is documented evidence that a patient already receiving mannitol therapy would have met the criteria for subsidy (i.e. satisfied the criteria for the 4 week trial and achieved a 10% or greater improvement in FEV1) then the patient is eligible to continue treatment under the HSD program. Where such evidence is not available, patients will need to satisfy the initiation and continuation criteria as for new patients. (Four weeks is considered a suitable wash-out period)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2015C','4064','t',$$<p>Grandfather &#8212; for patients who initiated mannitol treatment prior to 1&#160;August&#160;2012<br/><br/> Continuation of treatment of cystic fibrosis in a patient 6 years of age or older, who initiated treatment with mannitol prior to 1&#160;August 2012 and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis team, documents agreement that mannitol treatment is continuing to produce worthwhile benefit.  Further reassessments are to be undertaken and documented yearly.  Treatment with mannitol should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3392M','3595','t',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100&#160;mg ritonavir twice daily in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5030R','4013','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with epoprostenol sodium of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (b) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5030R','4014','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial PBS-subsidised treatment with epoprostenol sodium of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR<br/> (b) WHO Functional Class IV primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have received prior treatment with a PBS-subsidised PAH agent other than epoprostenol sodium; OR<br/> (c) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have failed to respond to a prior PBS-subsidised PAH agent.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and<br/> (5) for WHO Functional Class III patients, where this is the first application for epoprostenol sodium, assessment details of the PBS-subsidised PAH agent they have failed to respond to.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficientsupply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5030R','3167','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with epoprostenol sodium of patients who have received approval for initial PBS-subsidised treatment with epoprostenol sodium, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of epoprostenol sodium treatment [see Note for definition of response].<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.<br/><br/> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5035B','4013','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with epoprostenol sodium of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (b) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5035B','4014','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial PBS-subsidised treatment with epoprostenol sodium of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised epoprostenol sodium after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with epoprostenol sodium; OR<br/> (b) WHO Functional Class IV primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have received prior treatment with a PBS-subsidised PAH agent other than epoprostenol sodium; OR<br/> (c) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have failed to respond to a prior PBS-subsidised PAH agent.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and<br/> (5) for WHO Functional Class III patients, where this is the first application for epoprostenol sodium, assessment details of the PBS-subsidised PAH agent they have failed to respond to.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficientsupply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5035B','3167','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with epoprostenol sodium of patients who have received approval for initial PBS-subsidised treatment with epoprostenol sodium, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of epoprostenol sodium treatment [see Note for definition of response].<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.<br/><br/> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5084N','3597','t',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5821J','3941','t',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100&#160;mg ritonavir in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance, and who has not demonstrated darunavir resistance associated mutations detected on resistance testing.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5825N','3855','f',$$<p>Initial (new patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:<br/> (1) Splenectomised and:<br/> (a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and<br/> (b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;<br/> OR<br/> (2) Not splenectomised and:<br/> (a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2&#160;mg/kg/day of prednisone for at least 4-6 weeks; and<br/> (b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and<br/> (c) in whom splenectomy is contraindicated for medical reasons.<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:<br/> (a) a platelet count of less than or equal to 20,000&#160;million per L;<br/> OR<br/> (b) a platelet count of 20-30,000&#160;million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],<br/> (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and<br/> (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.<br/><br/>The full blood count must be no more than 1 month old at the time of application.<br/><br/> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5825N','3856','f',$$<p>Initial (grandfather patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with eltrombopag prior to 1&#160;November 2011 and in whom the criteria for initial treatment can be demonstrated to have been met at the time eltrombopag was commenced.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.<br/><br/> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5825N','3857','f',$$<p>Continuing therapy or re-initiation after a break in therapy<br/> First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with eltrombopag during the initial period of PBS-subsidised treatment.<br/><br/> For the purposes of this restriction, a sustained platelet response is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised eltrombopag,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L on at least four (4) occasions, each at least one week apart;<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.<br/><br/> Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:<br/> (1) a completed authority prescription form, and<br/> (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).<br/><br/> The most recent platelet count must be no more than one month old at the time of application.<br/><br/> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5825N','3858','f',$$<p>Second and subsequent applications for continuing therapy<br/> Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with eltrombopag and who continues to display a response to treatment with eltrombopag.<br/><br/> For the purposes of this restriction, a continuing response to treatment with eltrombopag is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with eltrombopag,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline platelet count.<br/><br/> Platelet counts must be no more than 1 month old at the time of application.<br/><br/> Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5826P','3855','f',$$<p>Initial (new patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:<br/> (1) Splenectomised and:<br/> (a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and<br/> (b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;<br/> OR<br/> (2) Not splenectomised and:<br/> (a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2&#160;mg/kg/day of prednisone for at least 4-6 weeks; and<br/> (b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and<br/> (c) in whom splenectomy is contraindicated for medical reasons.<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:<br/> (a) a platelet count of less than or equal to 20,000&#160;million per L;<br/> OR<br/> (b) a platelet count of 20-30,000&#160;million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],<br/> (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and<br/> (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.<br/><br/>The full blood count must be no more than 1 month old at the time of application.<br/><br/> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5826P','3856','f',$$<p>Initial (grandfather patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with eltrombopag prior to 1&#160;November 2011 and in whom the criteria for initial treatment can be demonstrated to have been met at the time eltrombopag was commenced.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.<br/><br/> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5826P','3857','f',$$<p>Continuing therapy or re-initiation after a break in therapy<br/> First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with eltrombopag during the initial period of PBS-subsidised treatment.<br/><br/> For the purposes of this restriction, a sustained platelet response is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised eltrombopag,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L on at least four (4) occasions, each at least one week apart;<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.<br/><br/> Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:<br/> (1) a completed authority prescription form, and<br/> (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).<br/><br/> The most recent platelet count must be no more than one month old at the time of application.<br/><br/> A maximum of 24 weeks of treatment with eltrombopag will be authorised under this criterion.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5826P','3858','f',$$<p>Second and subsequent applications for continuing therapy<br/> Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with eltrombopag and who continues to display a response to treatment with eltrombopag.<br/><br/> For the purposes of this restriction, a continuing response to treatment with eltrombopag is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with eltrombopag,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline platelet count.<br/><br/> Platelet counts must be no more than 1 month old at the time of application.<br/><br/> Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3357','t',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3358','t',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3359','t',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3360','t',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3361','t',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3362','t',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3363','t',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3364','t',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3365','t',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3366','t',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3367','t',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3368','t',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3369','t',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3370','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3371','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3372','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3373','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3374','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3375','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3376','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3377','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5829T','3834','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9597D','3668','f',$$<p>Initial PBS-subsidised treatment of a patient with:<br/> (1)  Myelodysplastic syndrome classified as Intermediate-2 or high risk according to the International Prognostic Scoring System (IPSS); OR<br/> (2)  Chronic Myelomonocytic Leukaemia (10% to 29% marrow blasts without Myeloproliferative Disorder); OR<br/> (3)  Acute Myeloid Leukaemia with 20 to 30% marrow blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) Classification.<br/><br/> Classification of a patient as Intermediate-2 requires a score of 1.5 to 2.0 on the IPSS, achieved with the possible combinations:<br/> 1.  11% to 30% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 0 to 1 cytopenias; OR<br/> 2.  11% to 20% marrow blasts with intermediate karyotypic status (other abnormalities), and 0 to 1 cytopenias; OR<br/> 3.  11% to 20% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 2 to 3 cytopenias; OR<br/> 4.  5% to 10% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR<br/> 5.  5% to 10% marrow blasts with intermediate karyotypic status (other abnormalities), and 2 to 3 cytopenias; OR<br/> 6.  less than 5% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), and 2 to 3 cytopenias.<br/><br/> Classification of a patient as high risk requires a score of 2.5 or more on the IPSS, achieved with the possible combinations:<br/> 1.  21% to 30% marrow blasts with good karyotypic status (normal, -Y alone, del(5q) alone, del(20q) alone), and 2 to 3 cytopenias; OR<br/> 2.  21% to 30% marrow blasts with intermediate (other abnormalities) or poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR<br/> 3.  11% to 20% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR<br/> 4.  11% to 20% marrow blasts with intermediate karyotypic status (other abnormalities), and 2 to 3 cytopenias.<br/><br/> The first authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Azacitidine PBS Authority Application - SupportingInformation Form; and<br/> (c) a copy of the bone marrow biopsy report demonstrating that the patient has myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia; and<br/> (d) a copy of the full blood examination report; and<br/> (e) for myelodysplastic syndrome, a copy of the pathology report detailing the cytogenetics demonstrating intermediate-2 or high risk disease according to the International Prognostic Scoring System (IPSS); and<br/> (f) a signed patient acknowledgment form.<br/><br/> No more than three cycles will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5628F','3326','t',$$<p>Schizophrenia in patients who are non-responsive to other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5628F','3327','t',$$<p>Schizophrenia in patients who are intolerant of other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5629G','3326','t',$$<p>Schizophrenia in patients who are non-responsive to other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5629G','3327','t',$$<p>Schizophrenia in patients who are intolerant of other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5631J','3333','t',$$<p>For use by organ or tissue transplant recipients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5662B','3340','t',$$<p>Disorders of erythropoiesis associated with treatment-related chronic iron overload</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5704F','3344','t',$$<p>Use by cystic fibrosis patients who satisfy all of the following criteria:<br/> (1) are 5 years of age or older;<br/> (2) have a FVC greater than 40% predicted for age, gender and height;<br/> (3) have evidence of chronic suppurative lung disease (cough and sputum most days of the week, or greater than 3 respiratory tract infections of more than 2 weeks' duration in any 12 months, or objective evidence of obstructive airways disease);<br/> (4) are participating in a 4 week trial as detailed below or have achieved a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) after a 4 week trial.<br/><br/> In order for patients to be eligible for participation in the HSD program, the following conditions must be met:<br/> (1) Patients must be assessed at cystic fibrosis clinics/centres which are under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis and the prescribing of dornase alfa under the HSD program is limited to such physicians.  If attendance at such units is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;<br/> (2) The measurement of lung function is to be conducted by independent (other than the treating doctor) experienced personnel at established lung function testing laboratories, unless this is not possible because of geographical isolation;<br/> (3) Prior to dornase alfa therapy, a baseline measurement of FEV1 must be undertaken during a stable period of the disease;<br/> (4) Initial therapy is limited to 4 weeks' treatment with dornase alfa at a dose of 2.5&#160;mg daily;<br/> (5) At or towards the end of the initial 4 weeks' trial, patients must be reassessed and a further FEV1 measurement be undertaken (single test under conditions as above). Patients who achieve a 10% or greater improvement in FEV1 (compared to baseline established prior to dornase alfa treatment) are eligible for continued subsidy under the HSD program at a dose of 2.5&#160;mg daily;<br/> (6) Patients who fail to meet a 10% or greater improvement in FEV1 after the initial 4 weeks' treatment at a dose of 2.5&#160;mg daily, may have 1 further trial in the next 12 months but not before 3 monthsafter the initial trial;<br/> (7) Following an initial 6 months' therapy, a global assessment must be undertaken involving the patient, the patient's family (in the case of paediatric patients) and the treating physician(s) to establish that all agree that dornase alfa treatment is continuing to produce worthwhile benefits. (Dornase alfa therapy should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use.) Further reassessments are to be undertaken at six-monthly intervals;<br/> (8) Other aspects of treatment, such as physiotherapy, must be continued;<br/> (9) Where there is documented evidence that a patient already receiving dornase alfa therapy would have met the criteria for subsidy (i.e. satisfied the criteria for the 4 week trial and achieved a 10% or greater improvement in FEV1) then the patient is eligible to continue treatment under the HSD program. Where such evidence is not available, patients will need to satisfy the initiation and continuation criteria as for new patients. (Four weeks is considered a suitable wash-out period)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5704F','3345','t',$$<p>Treatment of cystic fibrosis in a patient less than 5 years of age who has:<br/> (1) A severe clinical course with frequent respiratory exacerbations or chronic respiratory symptoms (including chronic or recurrent cough, wheeze or tachypnoea) requiring frequent hospital admissions more frequently than 3 times per year; or<br/> (2) Significant bronchiectasis on chest high resolution computed tomography scan; or<br/> (3) Severe cystic fibrosis bronchiolitis with persistent wheeze non-responsive to conventional medicines; or<br/> (4) Severe physiological deficit measure by forced oscillation technique or multiple breath nitrogen washout and failure to respond to conventional therapy.<br/><br/> In order for the patient to be eligible for participation in the HSD program, the following conditions must be met:<br/> (1) The patient must be assessed at a cystic fibrosis clinic/centre which is under the supervision of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis, and the prescribing of dornase alfa under the HSD program is limited to such physicians. If attendance at such a unit is not possible because of geographical isolation, management (including prescribing) may be by specialist physician or paediatrician in consultation with such a unit;<br/> (2) Following an initial 6 months therapy, a comprehensive assessment must be undertaken and documented involving the patient, the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team to establish agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use. Further reassessments are to be undertaken and documented yearly</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5704F','3346','t',$$<p>Grandfather &#8212; continuing for patients five years or older<br/> Continuation of treatment of cystic fibrosis in a patient 5 years of age or older, who initiated treatment with dornase alfa at an age of less than 5 years and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team, documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5704F','3347','t',$$<p>Grandfather &#8212; for patients less than five years of age who initiated dornase alfa prior to listing<br/> Treatment of cystic fibrosis in a patient less than 5 years of age who initiated treatment with dornase alfa prior to 1&#160;November&#160;2009 and for whom a comprehensive assessment, involving the patient's family, the treating physician and an additional independent member of the cystic fibrosis treatment team, documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Further reassessments are to be undertaken and documented yearly. Treatment with dornase alfa should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5633L','3328','t',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5633L','3329','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5633L','3330','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5633L','3331','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5633L','3332','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3357','t',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3358','t',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3359','t',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3360','t',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3361','t',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3362','t',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3363','t',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3364','t',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3365','t',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3366','t',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3367','t',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3368','t',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3369','t',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3370','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3371','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3372','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3373','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3374','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3375','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3376','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3377','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5741E','3834','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3357','t',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3358','t',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3359','t',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3360','t',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3361','t',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3362','t',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3363','t',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3364','t',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3365','t',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3366','t',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3367','t',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3368','t',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3369','t',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3370','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3371','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3372','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3373','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3374','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3375','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3376','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3377','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5743G','3834','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5747L','3322','t',$$<p>Treatment of cytomegalovirus retinitis in patients with AIDS</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5747L','3378','t',$$<p>Treatment of aciclovir-resistant herpes simplex virus infection in immunocompromised patients with HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5749N','3379','t',$$<p>Cytomegalovirus retinitis in severely immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5749N','3380','t',$$<p>Prophylaxis of cytomegalovirus disease in bone marrow transplant patients at risk of cytomegalovirus disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5749N','3381','t',$$<p>Prophylaxis of cytomegalovirus disease in solid organ transplant patients at risk of cytomegalovirus disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5709L','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5709L','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9598E','3669','f',$$<p>Continuing treatment of a patient with:<br/> (1)  Myelodysplastic syndrome classified as Intermediate-2 or high risk according to the International Prognostic Scoring System (IPSS); OR<br/> (2)  Chronic Myelomonocytic Leukaemia (10% to 29% marrow blasts without Myeloproliferative Disorder); OR<br/> (3)  Acute Myeloid Leukaemia with 20 to 30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) Classification;<br/> who has previously been issued with an authority prescription for azacitidine and does not have progressive disease.<br/><br/> Authority applications for continuing treatment may be made by telephone on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Up to six cycles will be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5769P','3385','t',$$<p>Treatment of chronic granulomatous disease in patients with frequent and severe infections despite adequate prophylaxis with antimicrobial agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5625C','3325','t',$$<p>Treatment of Mycobacterium avium complex infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5624B','3325','t',$$<p>Treatment of Mycobacterium avium complex infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9651Y','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9651Y','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9652B','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9652B','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9570Q','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9570Q','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9553T','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9553T','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9554W','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9554W','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9556Y','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9556Y','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5772T','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5772T','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5773W','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5773W','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9541E','3415','t',$$<p>Treatment of Mycobacterium avium complex infections in HIV-positive patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9541E','3317','t',$$<p>Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5752R','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5752R','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5719B','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5720C','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5721D','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5722E','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9501C','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9501C','3356','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1839T','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1839T','3356','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9502D','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9502D','3356','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5759D','3382','t',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5759D','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5759D','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5760E','3382','t',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5760E','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5760E','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5761F','3382','t',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5761F','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5761F','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5762G','3382','t',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5762G','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5762G','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9506H','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9506H','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9560E','3328','t',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9561F','3328','t',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5766L','3384','t',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5766L','3382','t',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5766L','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5766L','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5767M','3384','t',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5767M','3382','t',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5767M','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5767M','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5616N','3317','t',$$<p>Prophylaxis against Mycobacterium avium complex infections in HIV-positive patients with CD4 cell counts of less than 75 per cubic millimetre</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5703E','3341','t',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5703E','3342','t',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5703E','3343','t',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9508K','3407','t',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100&#160;micrograms 3 times daily</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9508K','3408','t',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9509L','3407','t',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100&#160;micrograms 3 times daily</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9509L','3408','t',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9510M','3407','t',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks. Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment at a dose of 100&#160;micrograms 3 times daily</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9510M','3408','t',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months' therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5632K','3328','t',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5632K','3329','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5632K','3330','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5632K','3331','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5632K','3332','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5775Y','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5775Y','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5768N','3384','t',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5768N','3382','t',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5768N','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5768N','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5620T','3322','t',$$<p>Treatment of cytomegalovirus retinitis in patients with AIDS</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5705G','3348','t',$$<p>Treatment of AIDS-related Kaposi's sarcoma in patients with CD4 cell counts of less than 200 per cubic millimetre and extensive mucocutaneous involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5705G','3349','t',$$<p>Treatment of AIDS-related Kaposi's sarcoma in patients with CD4 cell counts of less than 200 per cubic millimetre and extensive visceral involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5714R','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5763H','3384','t',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5763H','3382','t',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5763H','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5763H','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5764J','3384','t',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5764J','3382','t',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5764J','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5764J','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5765K','3384','t',$$<p>Adjunctive therapy of malignant melanoma following surgery in patients with nodal involvement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5765K','3382','t',$$<p>Use in the treatment of Philadelphia chromosome positive myelogenous leukaemia in the chronic phase</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5765K','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5765K','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5748M','3379','t',$$<p>Cytomegalovirus retinitis in severely immunocompromised patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5770Q','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5770Q','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5601T','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5601T','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5602W','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5602W','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5661Y','3340','t',$$<p>Disorders of erythropoiesis associated with treatment-related chronic iron overload</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5771R','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5771R','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5702D','3341','t',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9568N','3419','t',$$<p>Prophylaxis of cytomegalovirus (CMV) infection and disease following renal transplantation in patients at risk of CMV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5617P','3318','t',$$<p>Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity of cerebral origin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5617P','3319','t',$$<p>Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to multiple sclerosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5617P','3320','t',$$<p>Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to spinal cord injury</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5617P','3321','t',$$<p>Severe chronic spasticity, where oral antispastic agents have failed or have caused unacceptable side effects, in patients with chronic spasticity due to spinal cord disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5667G','3341','t',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5668H','3341','t',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5669J','3341','t',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5670K','3341','t',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5670K','3342','t',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5670K','3343','t',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5701C','3341','t',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3357','t',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3358','t',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3359','t',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3360','t',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3361','t',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3362','t',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3363','t',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3364','t',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3365','t',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3366','t',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3367','t',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3368','t',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3369','t',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3370','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3371','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3372','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3373','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3374','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3375','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3376','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3377','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5742F','3834','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3357','t',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3358','t',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3359','t',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3360','t',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3361','t',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3362','t',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3363','t',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3364','t',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3365','t',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3366','t',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3367','t',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3368','t',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3369','t',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3370','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3371','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3372','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3373','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3374','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3375','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3376','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3377','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5744H','3834','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5663C','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5663C','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5664D','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5664D','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5665E','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5665E','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5666F','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5666F','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5715T','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5716W','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5717X','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5637Q','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5638R','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5639T','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5640W','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5641X','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5642Y','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5651K','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5604Y','3981','t',$$<p>Initial treatment of HIV infection in a patient over 12 years of age, weighing 40&#160;kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5604Y','3982','t',$$<p>Continuing treatment of HIV infection where the patient over 12 years of age, weighing 40&#160;kg or more, has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9558C','3328','t',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5776B','3387','t',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (6 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3392','t',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for reinfusion into patients with non-myeloid malignancies who have had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3393','t',$$<p>Mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic transplantation to facilitate harvest of such cells in healthy donors</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3394','t',$$<p>Patients with non-myeloid malignancies receiving marrow-ablative chemotherapy and subsequent peripheral blood progenitor cell or bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3395','t',$$<p>Patients with breast cancer receiving standard dose adjuvant chemotherapy who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3396','t',$$<p>Patients receiving first-line chemotherapy for Hodgkin's disease who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3397','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3398','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Ewing's sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3399','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3400','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3401','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3402','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin's lymphoma (intermediate or high grade)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3403','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in osteosarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3404','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin's disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5787N','3405','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in rhabdomyosarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3392','t',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for reinfusion into patients with non-myeloid malignancies who have had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3393','t',$$<p>Mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic transplantation to facilitate harvest of such cells in healthy donors</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3394','t',$$<p>Patients with non-myeloid malignancies receiving marrow-ablative chemotherapy and subsequent peripheral blood progenitor cell or bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3395','t',$$<p>Patients with breast cancer receiving standard dose adjuvant chemotherapy who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3396','t',$$<p>Patients receiving first-line chemotherapy for Hodgkin's disease who have had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3397','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3398','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Ewing's sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3399','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3400','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3401','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3402','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin's lymphoma (intermediate or high grade)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3403','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in osteosarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3404','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin's disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5788P','3405','t',$$<p>Patients being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in rhabdomyosarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5718Y','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5789Q','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5789Q','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5634M','3328','t',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5634M','3329','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5634M','3330','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5634M','3331','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5634M','3332','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5635N','3328','t',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5635N','3329','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5635N','3330','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5635N','3331','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5635N','3332','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5636P','3328','t',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5636P','3329','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists or clinical immunologists of patients with severe atopic dermatitis for whom other systemic therapies are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5636P','3330','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by dermatologists of patients with severe psoriasis for whom other systemic therapies are ineffective or inappropriate and in whom the disease has caused significant interference with quality of life</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5636P','3331','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by nephrologists of patients with nephrotic syndrome in patients in whom steroids and cytostatic drugs have failed or are not tolerated or are considered inappropriate and in whom renal function is unimpaired</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5636P','3332','t',$$<p>Management (which includes initiation, stabilisation and review of therapy) by rheumatologists or clinical immunologists of patients with severe active rheumatoid arthritis for whom classical slow-acting anti-rheumatic agents (including methotrexate) are ineffective or inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5706H','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5706H','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9569P','3420','t',$$<p>Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9569P','3421','t',$$<p>Prophylaxis of cytomegalovirus infection and disease in solid organ transplant patients at risk of cytomegalovirus disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9563H','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9563H','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9563H','3969','t',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9563H','3970','t',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9563H','3973','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:<br/> (a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or<br/> (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9563H','3974','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3357','t',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3362','t',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3363','t',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3364','t',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3365','t',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3369','t',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3370','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3371','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3372','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3373','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3374','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3375','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3376','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3377','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9514R','3834','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9500B','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9500B','3356','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5643B','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5734T','3531','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).<br/><br/> Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:<br/> (a) who has severe active juvenile idiopathic arthritis; AND<br/> (b) whose parent or authorised guardian has signed a patient acknowledgement; AND<br/> (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND<br/> (d) who has demonstrated either:<br/> (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or<br/> (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:<br/> &#8212; oral or parenteral methotrexate at a dose of at least 20&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or<br/> &#8212; oral methotrexate at a dose of at least 10&#160;mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months.  (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)<br/><br/> Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/><br/> Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.<br/><br/> If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.<br/><br/> The following criteria indicate failure to achieve an adequateresponse and must be demonstrated in all patients at the time of the initial application:<br/> (a) an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (b) at least 4 active joints from the following list:<br/> (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with etanercept.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  Apatient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5734T','3800','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).<br/><br/> Initial PBS-subsidised treatment with etanercept by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with etanercept for this condition more than once in the current treatment cycle.<br/><br/> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for a patient who has received PBS-subsidised treatment with etanercept in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised etanercept treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with etanercept may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised etanercept treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised etanercept treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where a response assessment is not undertaken and submitted toMedicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5734T','3801','f',$$<p>Continuing treatment.<br/><br/> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.<br/><br/> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to aminimum of 12 weeks of treatment with an initial treatment course.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial etanercept after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9503E','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9504F','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9653C','3342','t',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9653C','3343','t',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9653C','4052','t',$$<p>Bone metastases from castration-resistant prostate cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9653C','3341','t',$$<p>Treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5707J','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5707J','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9524G','3413','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9524G','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9525H','3413','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9525H','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9526J','3413','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9526J','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9527K','3413','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9527K','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5757B','3710','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)<br/><br/> Initial PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.<br/><br/> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDstaken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.<br/><br/> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.<br/><br/> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage suchas joint destruction or bony overgrowth).<br/><br/> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.<br/><br/> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.<br/><br/> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.<br/><br/> A maximum of 22 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3&#160;mg per kg.  Up to a maximum of 3 repeats may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5757B','3814','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)<br/><br/> Initial course of PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for patients who have received PBS-subsidised treatment with infliximab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment, within the timeframes specified below.<br/><br/> A maximum of 22 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3&#160;mg per kg.  Up to a maximum of 3 repeats may be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/>Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5757B','3813','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with infliximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with infliximab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with infliximab.<br/><br/> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 3&#160;mg per kg.  Up to a maximum of 2 repeats may be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to completea maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.<br/><br/> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9529M','3949','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients weighing at least 27&#160;kg who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9529M','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9530N','3949','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients weighing at least 27&#160;kg who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9530N','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9531P','3413','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9531P','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9534T','3949','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients weighing at least 27&#160;kg who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9534T','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9536X','3413','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9536X','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9538B','3413','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9538B','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9539C','3413','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9539C','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5657R','3338','t',$$<p>Iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5657R','3339','t',$$<p>Iron overload in patients with thalassaemia major in whom desferrioxamine therapy has proven ineffective</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5626D','3326','t',$$<p>Schizophrenia in patients who are non-responsive to other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5626D','3327','t',$$<p>Schizophrenia in patients who are intolerant of other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5627E','3326','t',$$<p>Schizophrenia in patients who are non-responsive to other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5627E','3327','t',$$<p>Schizophrenia in patients who are intolerant of other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5777C','3388','t',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5777C','3389','t',$$<p>Functional carcinoid tumour causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120&#160;mg every 28 days.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5778D','3388','t',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5778D','3389','t',$$<p>Functional carcinoid tumour causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120&#160;mg every 28 days.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5779E','3388','t',$$<p>Active acromegaly in a patient with persistent elevation of mean growth hormone levels of greater than 2.5&#160;micrograms per litre AND<br/> (a) after failure of other therapy including dopamine agonists; or<br/> (b) as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; or<br/> (c) if the patient is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5779E','3389','t',$$<p>Functional carcinoid tumour causing intractable symptoms.  The patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents, and surgery or antineoplastic therapy must have failed or be inappropriate.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120&#160;mg every 28 days.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9511N','3409','t',$$<p>Acromegaly in a patient controlled on Sandostatin subcutaneous injections.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9511N','3410','t',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30&#160;mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9512P','3409','t',$$<p>Acromegaly in a patient controlled on Sandostatin subcutaneous injections.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9512P','3410','t',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30&#160;mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9513Q','3409','t',$$<p>Acromegaly in a patient controlled on Sandostatin subcutaneous injections.<br/> In a patient treated with radiotherapy, treatment must cease if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose). Octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission.<br/> Treatment must cease if IGF1 is not lower after 3 months of treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9513Q','3410','t',$$<p>Functional carcinoid tumour or vasoactive intestinal peptide secreting tumour (VIPoma) with symptom control on Sandostatin subcutaneous injections.<br/> Treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 30&#160;mg every 28 days and having allowed adequate rescue therapy with Sandostatin subcutaneous injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5618Q','4009','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.<br/><br/> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specificreason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5618Q','4010','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (c) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR<br/><br/> (e) WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authorityapplication [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5618Q','4011','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial treatment with bosentan monohydrate of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR<br/> (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than bosentan monohydrate.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for thesecond authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5618Q','3162','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with bosentan monohydrate of patients who have received approval for initial PBS-subsidised treatment with bosentan monohydrate and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of bosentan monohydrate treatment [see Note for definition of response].<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.<br/><br/> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5618Q','4012','f',$$<p>Cessation of treatment (all patients)<br/> Final PBS-subsidised supply for patients with WHO Functional Class III or IV primary pulmonary hypertension or WHO Functional Class III or IV pulmonary arterial hypertension secondary to connective tissue disease or WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who have not responded to bosentan monohydrate therapy [see Note for definition of response], to allow for gradual cessation of treatment.<br/><br/> Applications for authorisation under this criterion should be made on the telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday) [see Note on authority approval requirements].<br/><br/> Approval will only be granted for the 62.5&#160;mg tablet strength.  The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment.<br/><br/> Under no circumstances will telephone approvals be granted for treatment that would extend the final treatment period beyond 1 month</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5619R','4009','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.<br/><br/> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specificreason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5619R','4010','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with bosentan monohydrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (c) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR<br/><br/> (e) WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology).<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authorityapplication [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for the second authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5619R','4011','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial treatment with bosentan monohydrate of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease, or pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who wish to re-commence PBS-subsidised bosentan monohydrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with bosentan monohydrate; OR<br/> (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than bosentan monohydrate.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) two completed authority prescription forms [see Note for authority approval requirements]; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  No repeats will be authorised for the first authority prescription issued under this criterion [see Note for full details of authority approval requirements].  A maximum of 4 repeats will be authorised for thesecond authority prescription issued under this criterion.  Where fewer than 4 repeats are initially requested with the second authority prescription, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5619R','3162','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with bosentan monohydrate of patients who have received approval for initial PBS-subsidised treatment with bosentan monohydrate and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of bosentan monohydrate treatment [see Note for definition of response].<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.<br/><br/> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5619R','4012','f',$$<p>Cessation of treatment (all patients)<br/> Final PBS-subsidised supply for patients with WHO Functional Class III or IV primary pulmonary hypertension or WHO Functional Class III or IV pulmonary arterial hypertension secondary to connective tissue disease or WHO Functional Class III or IV pulmonary arterial hypertension associated with a congenital systemic-to-pulmonary shunt (including Eisenmenger's physiology), who have not responded to bosentan monohydrate therapy [see Note for definition of response], to allow for gradual cessation of treatment.<br/><br/> Applications for authorisation under this criterion should be made on the telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday) [see Note on authority approval requirements].<br/><br/> Approval will only be granted for the 62.5&#160;mg tablet strength.  The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment.<br/><br/> Under no circumstances will telephone approvals be granted for treatment that would extend the final treatment period beyond 1 month</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5713Q','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5774X','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5774X','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9549N','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9550P','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5644C','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9515T','3977','t',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy;<br/> (3) Has received no prior peginterferon alfa therapy for the treatment of hepatitis B</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9515T','3978','t',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.<br/><br/> Treatment is limited to 1 course of treatment for a duration of up to 48 weeks</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9515T','3412','t',$$<p>Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.<br/> The treatment course is limited to up to 48 weeks. <br/> Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5753T','3513','f',$$<p>Initial 1 (new patients)<br/> Initial PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with active ankylosing spondylitis who has radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis and who has not received any PBS-subsidised treatment with either adalimumab, etanercept, golimumab or infliximab in this treatment cycle; AND<br/> (a) who has at least 2 of the following:<br/> (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or<br/> (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) [for further information on the BASMI please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; or<br/> (iii) limitation of chest expansion relative to normal values for age and gender [for chest expansion normal values please refer to the Medicare Australia website at www.medicareaustralia.gov.au]; AND<br/> (b) who has failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months.<br/><br/> The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.<br/><br/> If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.<br/><br/> If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the MedicareAustralia website [www.medicareaustralia.gov.au].<br/><br/> For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Medicare Australia website at www.medicareaustralia.gov.au.<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:<br/> (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND<br/> (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 10&#160;mg per L.<br/><br/> The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.<br/><br/> Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.<br/><br/> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au] which must include the following:<br/> (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and<br/> (ii) a completed BASDAI Assessment Form [www.medicareaustralia.gov.au]; and<br/> (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and<br/> (iv) a signed patient acknowledgment form.<br/><br/> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.<br/><br/>A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.<br/><br/> At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 18 weeks of treatment may be requested by telephone.<br/><br/> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5753T','3803','f',$$<p>Initial 2 (change or re-commencement for all patients)<br/> Initial PBS-subsidised treatment with infliximab, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who, in this treatment cycle, has received prior PBS-subsidised TNF-alfa antagonist treatment for this condition and is eligible to receive further TNF-alfa antagonist therapy, and has not failed PBS-subsidised therapy with infliximab in the current treatment cycle.<br/><br/> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised TNF-alfa antagonist therapy or, under this restriction, for patients who have received previous PBS-subsidised TNF-alfa antagonist therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to Medicare Australia no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.<br/><br/> Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].<br/><br/> A maximum of 18 weeks of treatment with infliximab will be approved under this criterion.<br/><br/> At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 18 weeks of treatment may be requested bytelephone.<br/><br/> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5753T','3804','f',$$<p>Continuing treatment for all patients<br/> Continuing PBS-subsidised treatment, by a rheumatologist, of an adult with a documented history of active ankylosing spondylitis who:<br/> (a) has demonstrated an adequate response to treatment with infliximab; and<br/> (b) whose most recent course of PBS-subsidised therapy in this treatment cycle was with infliximab.<br/><br/> An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:<br/> (a) an ESR measurement no greater than 25&#160;mm per hour; or<br/> (b) a CRP measurement no greater than 10&#160;mg per L; or<br/> (c) an ESR or CRP measurement reduced by at least 20% from baseline.<br/><br/> Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.<br/><br/> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form [www.medicareaustralia.gov.au].<br/><br/> All measurements provided must be no more than 1 month old at the time of application.<br/><br/> A maximum of 24 weeks of treatment with infliximab will be authorised under this criterion.<br/><br/> At the time of the authority application, the doctor should request the appropriate number of vials, based on the weight of the patient, to provide for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone.<br/><br/> All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment following an initial treatment course it must be made following aminimum of 12 weeks of treatment with infliximab.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.<br/><br/> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised TNF-alfa antagonist was approved in this cycle and the date of the first application under a new cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9516W','3977','t',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy;<br/> (3) Has received no prior peginterferon alfa therapy for the treatment of hepatitis B</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9516W','3978','t',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.<br/><br/> Treatment is limited to 1 course of treatment for a duration of up to 48 weeks</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9516W','3412','t',$$<p>Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and have a contraindication to ribavirin, who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.<br/> The treatment course is limited to up to 48 weeks. <br/> Patients may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5606C','3973','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who has failed antihepadnaviral therapy and who satisfies all of the following criteria:<br/> (a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or<br/> (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5606C','3974','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has failed antihepadnaviral therapy and who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5613K','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5613K','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5614L','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5614L','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5746K','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5746K','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5745J','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5745J','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5710M','3597','t',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5751Q','4015','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with iloprost and who have been assessed by a physician from a designated hospital to have:<br/> WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.<br/><br/> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximumof 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5751Q','4016','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with iloprost trometamol of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III drug-induced pulmonary arterial hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (c) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease; OR<br/> (d) WHO Functional Class IV drug-induced pulmonary arterial hypertension.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time ofapplication, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5751Q','3170','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial PBS-subsidised treatment with iloprost trometamol of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised iloprost trometamol after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with iloprost trometamol; OR<br/> (b) WHO Functional Class IV primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have received prior treatment with a PBS-subsidised PAH agent other than iloprost trometamol; OR<br/> (c) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and who have failed to respond to a prior PBS-subsidised PAH agent.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent; and<br/> (5) for WHO Functional Class III patients, where this is the first application for iloprost trometamol, assessment details of the PBS-subsidised PAH agent they have failed to respond to.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficientsupply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5751Q','3171','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with iloprost trometamol of patients who have received approval for initial PBS-subsidised treatment with iloprost trometamol, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of iloprost trometamol treatment [see Note for definition of response].<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.<br/><br/> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9548M','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5603X','3592','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient over 12 years of age, weighing 40&#160;kg or more, with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5603X','3593','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient over 12 years of age, weighing 40&#160;kg or more, has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5738B','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5738B','3356','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5739C','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5739C','3356','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5740D','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5740D','3356','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9564J','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9564J','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9566L','3342','t',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5724G','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5725H','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5726J','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5727K','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5728L','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5729M','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5730N','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5645D','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5646E','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5647F','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5648G','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5649H','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5650J','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9542F','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9542F','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5791T','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5791T','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5756Y','3492','f',$$<p>Initial 1<br/> Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have severe active psoriatic arthritis; and<br/> (2) have received no prior PBS-subsidised biological treatment for this condition in this Treatment Cycle; and<br/> (3) have failed to achieve an adequate response to:<br/> (a) methotrexate at a dose of at least 20&#160;mg weekly for a minimum period of 3 months; and<br/> (b) sulfasalazine at a dose of at least 2&#160;g per day for a minimum period of 3 months; or<br/> (c) leflunomide at a dose of up to 20&#160;mg daily for a minimum period of 3 months.<br/><br/> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.<br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities, including severity, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).<br/><br/> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND either<br/> (i) an active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/>If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.<br/><br/> A maximum of 22 weeks treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats may be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).<br/><br/> The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.<br/><br/> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5756Y','3811','f',$$<p>Initial 2<br/> Initial PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults who:<br/> (1) have a documented history of severe active psoriatic arthritis; and<br/> (2) have received prior PBS-subsidised biological treatment for this condition in this Treatment Cycle and are eligible to receive further biological therapy; and<br/> (3) have not failed treatment with infliximab during the current Treatment Cycle.<br/><br/> Applications for patients who have received PBS-subsidised treatment with infliximab within this Treatment Cycle and who wish to re-commence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised infliximab treatment, within the timeframes specified below.<br/><br/> A maximum of 22 weeks treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats may be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised infliximab treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy), patients must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised infliximab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must besubmitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5756Y','3812','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with infliximab, by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis, of adults:<br/> (1) who have a documented history of severe active psoriatic arthritis; and<br/> (2) whose most recent course of PBS-subsidised biological agent for this condition in the current Treatment Cycle was with infliximab; and<br/> (3) who, at the time of application, demonstrate an adequate response to treatment with infliximab.<br/><br/> An adequate response to treatment with infliximab is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline; AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 2 repeats may be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of theapplication, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with infliximab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course.<br/><br/> Patients who fail to demonstrate a response to treatment with infliximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug, in this Treatment Cycle.  Patients may re-trial infliximab after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9545J','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9545J','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5654N','3828','t',$$<p>Chronic iron overload in patients with disorders of erythropoiesis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5655P','3828','t',$$<p>Chronic iron overload in patients with disorders of erythropoiesis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9507J','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9507J','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5792W','3599','t',$$<p>Treatment, in addition to optimised background therapy in combination with other antiretroviral agents, of an antiretroviral experienced patient infected with only CCR5-tropic HIV-1, who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.  A tropism assay to determine CCR5 only strain status is required prior to initiation.  Individuals with CXCR4 tropism demonstrated at any time point are not eligible.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5793X','3599','t',$$<p>Treatment, in addition to optimised background therapy in combination with other antiretroviral agents, of an antiretroviral experienced patient infected with only CCR5-tropic HIV-1, who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.  A tropism assay to determine CCR5 only strain status is required prior to initiation.  Individuals with CXCR4 tropism demonstrated at any time point are not eligible.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5794Y','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5795B','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5796C','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5797D','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5798E','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5799F','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5800G','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5653M','3595','t',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 100&#160;mg ritonavir twice daily in an antiretroviral experienced patient who, after at least one antiretroviral regimen, has experienced virological failure or clinical failure or genotypic resistance.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5737Y','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5737Y','3356','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of cardiac allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9589Q','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9591T','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9594Y','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9596C','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5656Q','3828','t',$$<p>Chronic iron overload in patients with disorders of erythropoiesis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5711N','3961','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented chronic hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5711N','3962','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5712P','3964','t',$$<p>Chronic hepatitis B in a patient without cirrhosis who has failed lamivudine and who satisfies all of the following criteria:<br/> (a) Repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration in conjunction with documented chronic hepatitis B infection; or<br/> (b) Repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months, whilst on previous antihepadnaviral therapy except in patients with evidence of poor compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5712P','3966','t',$$<p>Chronic hepatitis B in a patient with cirrhosis who has failed lamivudine and who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9547L','4017','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.<br/><br/> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particulartest/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9547L','4018','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with sildenafil citrate of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9547L','3174','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial PBS-subsidised treatment with sildenafil citrate of patients with one of the following:<br/> (a) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised sildenafil citrate after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with sildenafil citrate; OR<br/> (b) WHO Functional Class III primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with a PAH agent other than sildenafil citrate.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9547L','3175','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with sildenafil citrate of patients who have received approval for initial PBS-subsidised treatment with sildenafil citrate, and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of sildenafil citrate treatment [see Note for definition of response].<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.<br/><br/> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5609F','3314','t',$$<p>Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9567M','3601','t',$$<p>Treatment of HIV infection, in addition to optimised background therapy in combination with other antiretroviral agents, and co-administered with 200&#160;mg ritonavir twice daily in an antiretroviral experienced patient who, after each of at least three different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes, has experienced virological failure or clinical failure or genotypic resistance.<br/> Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9544H','3720','f',$$<p>Initial 1 (patient re-commencing after a break of more than 24 months)<br/><br/> Initial PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have failed to respond to at least 1 PBS-subsidised TNF-alfa antagonist; and<br/> (c) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (d) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.<br/><br/> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be usedin place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.<br/><br/> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.<br/><br/> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement andrestriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.<br/><br/> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.<br/><br/> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.<br/><br/> A maximum of two infusions will be authorised under this restriction.<br/><br/> Assessment of a patient's response to an initial course of treatment must be made at least 12 weeks after the first infusion so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date it was conducted</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9544H','3824','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)<br/><br/> Initial course of PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have failed to respond to at least 1 PBS-subsidised TNF-alfa antagonist; and<br/> (c) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for patients who have received PBS-subsidised treatment with rituximab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised rituximab treatment, within the timeframes specified below.<br/><br/> A maximum of two infusions will be authorised under this restriction.<br/><br/> Where the most recent course of PBS-subsidised rituximab treatment was approved under either of the initial 1 or 2 treatment restrictions patients must be assessed for response at least 12 weeks after the first infusion.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date of assessment.<br/><br/> A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.<br/><br/> A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for morethan 12 months, may apply for a further course of rituximab under the Continuing treatment restriction.<br/><br/> Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.<br/><br/> Patients who fail to demonstrate a response to rituximab treatment and who qualify to trial an alternate bDMARD according to the interchangeability arrangements for bDMARDs for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9544H','3823','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with rituximab, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with rituximab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with rituximab.<br/><br/> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of two infusions will be authorised under this restriction.<br/><br/> Patients may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The demonstration of response must be submitted to Medicare Australia within 4 weeks of assessment.<br/><br/>A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction.<br/><br/> Patients who fail to demonstrate a response to treatment with rituximab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5755X','3585','f',$$<p>Initial treatment of Crohn disease in a paediatric patient.<br/><br/> Initial PBS-subsidised treatment by a gastroenterologist, paediatrician or consultant physician as specified in the NOTE below, of a patient aged 6 to 17 years inclusive with moderate to severe refractory Crohn disease who satisfies the following criteria:<br/> (a)  has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b)  whose parent or authorised guardian has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (c) has failed to achieve an adequate response to 2 of the following 3 conventional prior therapies including:<br/> (i) a tapered course of steroids, starting at a dose of at least 1&#160;mg per kg or 40&#160;mg (whichever is the lesser) prednisolone (or equivalent), over a 6 week period;<br/> (ii) an 8 week course of enteral nutrition;<br/> (iii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 10&#160;mg per square metre weekly for 3 or more months.<br/><br/> NOTE: Prescribers must be gastoenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.<br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities includingseverity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).<br/><br/> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) severity of disease activity which results in a Paediatric Crohn Disease Activity Index (PCDAI) Score greater than or equal to 30 as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) The most recent PCDAI assessment must be no more than 1 month old at the time of application.<br/><br/> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet including the date of assessment of the patient's condition; and<br/> (ii) details of previous systemic drug therapy [dosage, date of commencement and duration of therapy], or dates of enteral nutrition; and<br/> (iii) the signed patient acknowledgement.<br/><br/> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatmentperiod.<br/><br/> A PCDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.<br/><br/> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.<br/><br/> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5755X','3810','f',$$<p>Continuing treatment of Crohn disease in a patient initiated on PBS-subsidised treatment as a paediatric patient.<br/><br/> Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of moderate to severe refractory Crohn disease; and<br/> (b) has demonstrated or sustained an adequate response to treatment with infliximab.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition.<br/><br/> The PCDAI assessment must be no more than 1 month old at the time of application.<br/><br/> If the application is the first application for continuing treatment with infliximab, a PCDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.<br/><br/> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.<br/><br/>Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.<br/><br/> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to receive PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5755X','3008','f',$$<p>Initial PBS-subsidised treatment of Crohn disease in a paediatric patient who has previously received non-PBS-subsidised therapy with infliximab.<br/><br/> Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient aged 6 to 17 years inclusive who:<br/> (a) has a documented history of moderate to severe refractory Crohn disease and was receiving treatment with infliximab prior to 4&#160;July 2007; and<br/> (b) had a Paediatric Crohn Disease Activity Index (PCDAI) Score of greater than 30 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss; and<br/> (c) whose parent or authorised guardian has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has demonstrated or sustained an adequate response to treatment with infliximab.  For advice please contact Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/>(i) the completed current and baseline Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition; and<br/> (ii) the signed patient acknowledgement.<br/><br/> The current PCDAI assessment must be no more than 1 month old at the time of application. The baseline PCDAI assessment must be from immediately prior to commencing treatment with infliximab.<br/><br/> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.<br/><br/> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5754W','2996','f',$$<p>Initial 1 (new patients)<br/> Initial treatment of Crohn disease in a patient assessed by CDAI.<br/><br/> Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (c) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application. <br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au). <br/><br/>The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have a severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as assessed.<br/><br/> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/><br/> The most recent CDAI assessment must be no more than 1 month old at the time of application.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient's condition; and<br/> (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (iii) the signed patient acknowledgement.<br/><br/> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.<br/><br/> A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.<br/><br/>This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.<br/><br/> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5754W','3805','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient assessed by CDAI.<br/><br/> Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.<br/><br/> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.<br/><br/> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of thepatient's condition; and<br/> (ii) details of prior TNF alfa antagonist treatment including details of date and duration of treatment.<br/><br/> A maximum quantity and number of repeats to provide for an initial course of infliximb consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.<br/><br/> A CDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab so that there is adequate time for a response to be demonstrated.<br/><br/> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.<br/><br/> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5754W','3806','f',$$<p>Continuing treatment of Crohn disease in a patient assessed by CDAI.<br/><br/> Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) has demonstrated or sustained an adequate response to treatment with infliximab.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition.<br/><br/> The CDAI assessment must be no more than 1 month old at the time of application.<br/><br/> If the application is the first application for continuing treatment with infliximab, a CDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.<br/><br/> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.<br/><br/> Where an assessment is not submitted to Medicare Australia withinthese timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.<br/><br/> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5754W','2999','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.<br/><br/> Initial PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below of a patient who satisfies the following criteria:<br/> (a) has confirmed Crohn disease defined by standard clinical, endoscopic and/or imaging features, including histological evidence with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy; and<br/> (c) has evidence of intestinal inflammation; and<br/> (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (e) has failed to achieve an adequate response to prior systemic drug therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40&#160;mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.<br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities includingseverity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).<br/><br/> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have evidence of intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (b) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (c) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.<br/><br/> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/><br/> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and<br/>(iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.<br/><br/> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.<br/><br/> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.<br/><br/> The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.<br/><br/> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.<br/><br/> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5754W','3807','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient or a patient with extensive small intestine disease.<br/><br/> Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with infliximab or adalimumab for this condition; and<br/> (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.<br/><br/> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.<br/><br/> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) reports and dates of the pathology or diagnostic imaging test(s)nominated as the response criteria, if relevant; and<br/> (ii). details of prior TNF alfa antagonist treatment including details of date and duration of treatment.<br/><br/> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.<br/><br/> The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of therapy so that there is adequate time for a response to be demonstrated.<br/><br/> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.<br/><br/> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5754W','3808','f',$$<p>Continuing treatment of Crohn disease in a patient with short gut syndrome or an ostomy patient.<br/><br/> Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease with intestinal inflammation and with short gut syndrome or with an ileostomy or colostomy; and<br/> (b) has demonstrated or sustained an adequate response to treatment with infliximab.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> An adequate response to infliximab treatment is defined as:<br/> (a) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (b) reversal of high faecal output state; or<br/> (c) avoidance of the need for surgery or total parenteral nutrition (TPN).<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy or the date of clinical assessment.<br/><br/> The patient's assessment must be no more than 1 month old at the time of application.<br/><br/> If the application is the first application for continuing treatmentwith infliximab, an assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.<br/><br/> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.<br/><br/> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5754W','3002','f',$$<p>Initial 1<br/> Initial treatment of Crohn disease in a patient with extensive small intestine disease.<br/><br/> Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with severe refractory Crohn disease who satisfies the following criteria:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b) has extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50&#160;cm of the small intestine; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has failed to achieve an adequate response to prior systemic therapy including:<br/> (i) a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; and<br/> (ii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 15&#160;mg weekly for 3 or more months.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.<br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity atthe time of application. Details of the accepted toxicities including severity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).<br/><br/> The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) have severity of disease activity which results in a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220;<br/> AND/OR<br/> (b) have evidence of active intestinal inflammation, including:<br/> (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour, or, a C-reactive protein (CRP) level greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: higher than normal lactoferrin or calprotectin level; AND/OR<br/> (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery;<br/> AND/OR<br/> (c) be assessed clinically as being in a high faecal output state;<br/> AND/OR<br/> (d) be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of infliximab.<br/><br/> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/><br/> Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS-subsidised therapy.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/>(i) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and<br/> (ii) (1) reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; or<br/> (2) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the dates of assessment of the patient's condition, if relevant; and<br/> (iii) date of the most recent clinical assessment; and<br/> (iv) the signed patient acknowledgement.<br/><br/> All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application.<br/><br/> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday). Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.<br/><br/> The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.<br/><br/> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.<br/><br/> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5754W','3809','f',$$<p>Continuing treatment of Crohn disease in a patient with extensive small intestine disease.<br/><br/> Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, or consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease with extensive intestinal inflammation affecting more than 50&#160;cm of the small intestine; and<br/> (b) has demonstrated or sustained an adequate response to treatment with infliximab.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> An adequate response to infliximab treatment is defined as:<br/> (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or<br/> (b) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (c) reversal of high faecal output state; or<br/> (d) avoidance of the need for surgery or total parenteral nutrition (TPN).<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; or<br/> (ii) the reports and dates of the pathology test or diagnosticimaging test(s) used to assess response to therapy; or<br/> (iii) the date of clinical assessment.<br/><br/> All assessments must be no more than 1 month old at the time of application.<br/><br/> If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.<br/><br/> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.<br/><br/> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5754W','3004','f',$$<p>Initial 3 (grandfather)<br/> Initial PBS-subsidised treatment of Crohn disease in a patient assessed by CDAI who has previously received non-PBS-subsidised therapy with infliximab.<br/><br/> Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7&#160;March 2007; and<br/> (b) had a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has demonstrated or sustained an adequate response to treatment with infliximab. For advice please contact Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> An adequate response to infliximab treatment is defined as a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition; and<br/>(ii) the signed patient acknowledgement.<br/><br/> The current CDAI assessment must be no more than 1 month old at the time of application.  The baseline CDAI assessment must be from immediately prior to commencing treatment with infliximab.<br/><br/> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.<br/><br/> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5754W','3005','f',$$<p>Initial 3<br/> Initial PBS-subsidised treatment of Crohn disease in a patient with short gut syndrome, an ostomy patient, or a patient with extensive small intestine disease, who has previously received non-PBS-subsidised therapy with infliximab.<br/><br/> Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of severe refractory Crohn disease and was receiving treatment with infliximab prior to 7&#160;March 2007; and<br/> (b) (1) has a history of extensive small intestinal disease with radiological evidence of intestinal inflammation affecting more than 50&#160;cm of the small intestine; or<br/> (2) has diagnostic imaging or surgical evidence of short gut syndrome or has an ileostomy or colostomy with a documented history of intestinal inflammation; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has demonstrated or sustained an adequate response to treatment with infliximab according to the criteria included in the relevant continuation restriction. For advice please contact Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> The same criteria used to determine an inadequate response to prior treatment at baseline must be used to determine response to treatment and eligibility for continuing therapy, according to the criteria included in the continuing treatment restriction.<br/><br/> An adequate response to infliximab treatment is defined as:<br/> (a) a reduction in Crohn Disease Activity Index (CDAI) Score to no greater than 150; or<br/> (b) improvement of intestinal inflammation as demonstrated by:<br/> (i) blood: normalisation of the platelet count, or an erythrocytesedimentation rate (ESR) level no greater than 25&#160;mm per hour, or a C-reactive protein (CRP) level no greater than 15&#160;mg per L; AND/OR<br/> (ii) faeces: normalisation of lactoferrin or calprotectin level; AND/OR<br/> (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or<br/> (c) reversal of high faecal output state; or<br/> (d) avoidance of the need for surgery or total parenteral nutrition (TPN).<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au) ] which includes the following:<br/> (i) (1) the completed current and baseline Crohn Disease Activity Index (CDAI) Score calculation sheet, where relevant, including the date of the assessment of the patient's condition; or<br/> (2) the reports and dates of the current and baseline pathology or diagnostic imaging test(s) in order to assess response to therapy; or<br/> (3) the date of clinical assessment(s); and<br/> (ii) the signed patient acknowledgement.<br/><br/> The patient's assessment must be no more than 1 month old at the time of application. The baseline CDAI assessments must be from immediately prior to commencing treatment with infliximab. Where a baseline assessment is not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.<br/><br/> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.<br/><br/> Patients are eligible to receive continuing infliximab treatment incourses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5612J','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5612J','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5733R','3802','f',$$<p>Continuing treatment.<br/><br/> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient 18 years or older:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.<br/><br/> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to aminimum of 12 weeks of treatment with an initial treatment course.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.<br/><br/> Where a patient with severe active juvenile idiopathic arthritis continues treatment with etanercept and is 18 years or older, etanercept 50&#160;mg may be prescribed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5758C','3259','f',$$<p>Initial treatment [Initial 1, Whole body (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.<br/><br/> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.<br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).<br/><br/> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/>(a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.<br/><br/> A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.<br/><br/>A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.<br/><br/> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5758C','3815','f',$$<p>Initial or re-Treatment [Initial 2, Whole body (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.<br/><br/> Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.<br/><br/> A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.<br/><br/>Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.<br/><br/> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.<br/><br/> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.<br/><br/> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5758C','3816','f',$$<p>Continuing treatment (Whole body)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and<br/> (c) who have demonstrated an adequate response to their most recent course of treatment with infliximab.<br/><br/> An adequate response to treatment is defined as:<br/> A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-biological treatment baseline value for this Treatment Cycle.<br/><br/> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet along with the date of the assessment of the patient's condition.<br/><br/> The most recent PASI assessment must be no more than 1 month old at the time of application.<br/><br/> Approval will be based on the PASI assessment of response to the most recent course of treatment with infliximab.<br/><br/> A maximum of 24 weeks of treatment with infliximab will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of5&#160;mg per kg.  Up to a maximum of 2 repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.<br/><br/> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.<br/><br/> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.<br/><br/> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5758C','3262','f',$$<p>Initial treatment [Initial 1, Face, hand, foot (New patients &#8212; No prior biological agent)]<br/> Initial treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and<br/> (b) have not received any prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot); and<br/> (d) have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments:<br/> (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or<br/> (ii) methotrexate at a dose of at least 10&#160;mg weekly for at least 6 weeks; and/or<br/> (iii) cyclosporin at a dose of at least 2&#160;mg per kg per day for at least 6 weeks; and/or<br/> (iv) acitretin at a dose of at least 0.4&#160;mg per kg per day for at least 6 weeks.<br/><br/> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, please provide details at the time of application.<br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity to necessitate permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application.  Details of acceptable toxicities including severity, associated with phototherapy, methotrexate, cyclosporin and acitretin, can be found on the Medicare Australia website (www.medicareaustralia.gov.au).<br/><br/> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at thetime of the application:<br/> (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where: <br/> (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or<br/> (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.<br/> (c) The most recent PASI assessment must be no more than 1 month old at the time of application.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and<br/> (iii) the signed patient and prescriber acknowledgements.<br/><br/> A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.<br/><br/>Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.<br/><br/> A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.<br/><br/> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.<br/><br/> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5758C','3817','f',$$<p>Initial or re-Treatment [Initial 2, Face, hand, foot (Received prior biological agent under PBS)]<br/> Treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over who:<br/> (a) have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle; and<br/> (c) have not failed PBS-subsidised therapy with infliximab for the treatment of this condition in the current Treatment Cycle.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (ii) details of prior biological treatment, including dosage, date and duration of treatment.<br/><br/> Applications for patients who have demonstrated a response to PBS-subsidised infliximab treatment within this Treatment Cycle and who wish to re-commence infliximab treatment within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised infliximab treatment has been submitted to Medicare Australia within 1 month of cessation of treatment.<br/><br/> A maximum of 22 weeks of treatment with infliximab will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 3 repeats will be authorised.<br/><br/>Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 22 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 22 weeks.<br/><br/> A PASI assessment of the patient's response to this course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab. In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.<br/><br/> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.<br/><br/> The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.<br/><br/> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5758C','3818','f',$$<p>Continuing treatment (Face, hand, foot)<br/> Continuing PBS-subsidised treatment as systemic monotherapy (other than methotrexate) by a dermatologist for adults 18 years and over:<br/> (a) who have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot; and<br/> (b) whose most recent course of PBS-subsidised biological treatment for this condition in this Treatment Cycle was with infliximab; and<br/> (c) who have demonstrated an adequate response to treatment with infliximab.<br/><br/> An adequate response to infliximab treatment is defined as the plaque or plaques assessed prior to biological treatment showing:<br/> (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or<br/> (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.<br/><br/> This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with infliximab, the assessment of response must be after a minimum of 12 weeks of treatment with an initial course.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> The most recent PASI assessment must be no more than 1 month old at the time of application.<br/><br/> A maximum of 24 weeks of treatment with infliximab will be authorisedunder this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 2 repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the treatment period beyond 24 weeks.<br/><br/> A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment.  This assessment, which will be used to determine eligibility for further continuing treatment must be submitted to Medicare Australia no later than 1 month from the date of completion of this course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.<br/><br/> It is recommended that an application is posted to Medicare Australia no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment.<br/><br/> The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.<br/><br/> Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy.  These patients may re-commence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5708K','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5708K','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5750P','3343','t',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9546K','3390','t',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9546K','3391','t',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5605B','3712','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)<br/><br/> Initial PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.<br/><br/> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDstaken continuously for at least 3 months each:<br/> &#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.<br/><br/> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.<br/><br/> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage suchas joint destruction or bony overgrowth).<br/><br/> The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.<br/><br/> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.<br/><br/> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5605B','3797','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)<br/><br/> Initial course of PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for patients who have received PBS-subsidised treatment with abatacept and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised abatacept treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 4 repeats may be authorised.<br/><br/> Where fewer than 4 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised abatacept treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/>Where the most recent course of PBS-subsidised abatacept treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5605B','3796','f',$$<p>Continuing treatment<br/> Continuing PBS-subsidised treatment with abatacept, in combination with methotrexate at a dose of at least 7.5&#160;mg weekly, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with abatacept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with abatacept.<br/><br/> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide sufficient for a single infusion. Up to a maximum of 5 repeats may be authorised.<br/><br/> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to completea maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with abatacept must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with abatacept, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.<br/><br/> Patients who fail to demonstrate a response to treatment with abatacept under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9505G','3425','t',$$<p>Treatment, as monotherapy, by a neurologist, of clinically definite relapsing-remitting multiple sclerosis in an ambulatory (without assistance or support) patient 18 years of age or older, who has experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years.<br/><br/> The diagnosis must be confirmed by magnetic resonance imaging of the brain and/or spinal cord and the date of the scan included in the patient's medical notes, unless written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient is included in the patient's medical notes.<br/><br/> Natalizumab must be ceased if there is continuing progression of disability while on treatment with natalizumab.  For continued treatment the patient must demonstrate compliance with, and an ability to tolerate, natalizumab</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5621W','3323','t',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50&#160;pmol per L, not responding to conventional therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5621W','3324','t',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15&#160;pmol per L and less than 50&#160;pmol per L AND an (adjusted) serum calcium concentration at least 2.6&#160;mmol per L, not responding to conventional treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5622X','3323','t',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50&#160;pmol per L, not responding to conventional therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5622X','3324','t',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15&#160;pmol per L and less than 50&#160;pmol per L AND an (adjusted) serum calcium concentration at least 2.6&#160;mmol per L, not responding to conventional treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5623Y','3323','t',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 50&#160;pmol per L, not responding to conventional therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5623Y','3324','t',$$<p>Management, including initiation and stabilisation, by a nephrologist, of a patient with chronic kidney disease on dialysis who has sustained secondary hyperparathyroidism with iPTH of at least 15&#160;pmol per L and less than 50&#160;pmol per L AND an (adjusted) serum calcium concentration at least 2.6&#160;mmol per L, not responding to conventional treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9523F','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9523F','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9562G','3969','t',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B without cirrhosis who is nucleoside analogue naive and satisfies all of the following criteria:<br/> (1) Elevated HBV DNA levels - greater than 20,000&#160;IU/mL (100,000 copies/mL) if HBeAg positive, or greater than 2,000&#160;IU/mL (10,000 copies/mL) if HBeAg negative - in conjunction with documented hepatitis B infection;<br/> (2) Evidence of chronic liver injury as determined by:<br/> (a) Confirmed elevated serum ALT; or<br/> (b) Liver biopsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9562G','3970','t',$$<p>Treatment, as sole PBS-subsidised therapy, in a patient with chronic hepatitis B with cirrhosis who is nucleoside analogue naive and who has detectable HBV DNA.<br/><br/> Persons with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30&#160;g per L, bilirubin greater than 30&#160;micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5630H','3326','t',$$<p>Schizophrenia in patients who are non-responsive to other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5630H','3327','t',$$<p>Schizophrenia in patients who are intolerant of other neuroleptic agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5790R','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5790R','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9540D','3413','t',$$<p>Patients naive to interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner). Male patients and their partners are using effective forms of contraception (one for each partner). Female partners of male patients are not pregnant.<br/> For patients with genotype 2 or 3 hepatitis C without hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 24 weeks. For hepatitis C patients with genotype 1, 4, 5 or 6 and those genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis, the treatment course is limited to 48 weeks.<br/> Patients with genotype 1, 4, 5 or 6 who are eligible for 48 weeks of treatment may only continue treatment after the first 12 weeks if the result of an HCV RNA quantitative assay (performed at the same laboratory using the same test) shows that the plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop. (An HCV RNA assay at week 12 is unnecessary for genotype 2 and 3 patients because of the high likelihood of early viral response by week 12).<br/> Patients with genotype 1, 4, 5 or 6 who are viral positive at week 12 but have attained at least a 2 log drop in viral load may only continue treatment after the first 24 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. Similarly, genotype 2 or 3 patients with hepatic cirrhosis or bridging fibrosis may only continue treatment after the first 24 weeks if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 24. An HCV RNA qualitative assay at week 24 is unnecessary for those patients with genotype 1, 4, 5 or 6 who became viral negative at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9540D','3414','t',$$<p>Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated)<br/><br/> Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior treatment with interferon alfa or peginterferon alfa for hepatitis C and who satisfy all of the following criteria:<br/> (1) Documented chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive);<br/> (2) Female patients of child-bearing age are not pregnant, not breast-feeding, and both patient and their partner are using effective forms of contraception (one for each partner).  Male patients and their partners are using effective forms of contraception (one for each partner).  Female partners of male patients are not pregnant.<br/> The treatment course is limited to 48 weeks.  Patients may only continue treatment after the first 12 weeks of treatment if plasma HCV RNA is not detectable by an HCV RNA qualitative assay at week 12</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5780F','3390','t',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5780F','3391','t',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5781G','3390','t',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5781G','3391','t',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5782H','3390','t',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where serum phosphate is greater than 1.6&#160;mmol per L at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5782H','3391','t',$$<p>Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on calcium and where the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.<br/> Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5658T','3338','t',$$<p>Iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5658T','3339','t',$$<p>Iron overload in patients with thalassaemia major in whom desferrioxamine therapy has proven ineffective</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5610G','3314','t',$$<p>Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5735W','3802','f',$$<p>Continuing treatment.<br/><br/> Continuing PBS-subsidised treatment with etanercept, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient 18 years or older:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with etanercept; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with etanercept.<br/><br/> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with etanercept must include a measurement of response to the prior course of therapy. This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with etanercept, it must be accompanied by an assessment of response to aminimum of 12 weeks of treatment with an initial treatment course.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.<br/><br/> Where a patient with severe active juvenile idiopathic arthritis continues treatment with etanercept and is 18 years or older, etanercept 50&#160;mg may be prescribed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5783J','3821','f',$$<p>Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100&#160;mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.<br/><br/> If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.<br/><br/> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).<br/><br/> Oligo-secretory and non-secretory patients are defined as having active disease with less than 10&#160;g per L serum M protein and less than 200&#160;mg per 24 hour Bence-Jones proteinuria.<br/><br/> Thalidomide treatment failure is defined as:<br/> (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or<br/> (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.<br/><br/> Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of dailyliving.<br/><br/> Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.<br/><br/> Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:<br/> (1) less than a 25% reduction in serum or urine M protein; or<br/> (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.<br/><br/> Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.<br/><br/> To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:<br/> (a) the level of serum monoclonal protein; or<br/> (b) Bence-Jones proteinuria &#8212; the results of 24-hour urinary light chain M protein excretion; or<br/> (c) the serum level of free kappa and lambda light chains; or<br/> (d) bone marrow aspirate or trephine; or<br/> (e) if present, the size and location of lytic bone lesions (not including compression fractures); or<br/> (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or<br/> (g) if present, the level of hypercalcaemia, correctedfor albumin concentration.<br/><br/> As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10&#160;g per L and urinary Bence-Jones protein undetectable or less than 200&#160;mg per 24 hours) must be provided; and<br/> (3) duration of thalidomide and daily dose prescribed; and<br/> (4) a signed patient acknowledgment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5783J','3205','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.<br/><br/> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).<br/><br/> Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5784K','3821','f',$$<p>Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100&#160;mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.<br/><br/> If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.<br/><br/> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).<br/><br/> Oligo-secretory and non-secretory patients are defined as having active disease with less than 10&#160;g per L serum M protein and less than 200&#160;mg per 24 hour Bence-Jones proteinuria.<br/><br/> Thalidomide treatment failure is defined as:<br/> (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or<br/> (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.<br/><br/> Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of dailyliving.<br/><br/> Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.<br/><br/> Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:<br/> (1) less than a 25% reduction in serum or urine M protein; or<br/> (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.<br/><br/> Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.<br/><br/> To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:<br/> (a) the level of serum monoclonal protein; or<br/> (b) Bence-Jones proteinuria &#8212; the results of 24-hour urinary light chain M protein excretion; or<br/> (c) the serum level of free kappa and lambda light chains; or<br/> (d) bone marrow aspirate or trephine; or<br/> (e) if present, the size and location of lytic bone lesions (not including compression fractures); or<br/> (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or<br/> (g) if present, the level of hypercalcaemia, correctedfor albumin concentration.<br/><br/> As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10&#160;g per L and urinary Bence-Jones protein undetectable or less than 200&#160;mg per 24 hours) must be provided; and<br/> (3) duration of thalidomide and daily dose prescribed; and<br/> (4) a signed patient acknowledgment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5784K','3205','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.<br/><br/> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).<br/><br/> Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5785L','3821','f',$$<p>Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100&#160;mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.<br/><br/> If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.<br/><br/> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).<br/><br/> Oligo-secretory and non-secretory patients are defined as having active disease with less than 10&#160;g per L serum M protein and less than 200&#160;mg per 24 hour Bence-Jones proteinuria.<br/><br/> Thalidomide treatment failure is defined as:<br/> (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or<br/> (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.<br/><br/> Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of dailyliving.<br/><br/> Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.<br/><br/> Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:<br/> (1) less than a 25% reduction in serum or urine M protein; or<br/> (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.<br/><br/> Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.<br/><br/> To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:<br/> (a) the level of serum monoclonal protein; or<br/> (b) Bence-Jones proteinuria &#8212; the results of 24-hour urinary light chain M protein excretion; or<br/> (c) the serum level of free kappa and lambda light chains; or<br/> (d) bone marrow aspirate or trephine; or<br/> (e) if present, the size and location of lytic bone lesions (not including compression fractures); or<br/> (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or<br/> (g) if present, the level of hypercalcaemia, correctedfor albumin concentration.<br/><br/> As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10&#160;g per L and urinary Bence-Jones protein undetectable or less than 200&#160;mg per 24 hours) must be provided; and<br/> (3) duration of thalidomide and daily dose prescribed; and<br/> (4) a signed patient acknowledgment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5785L','3205','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.<br/><br/> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).<br/><br/> Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5786M','3821','f',$$<p>Initial PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of a patient with a histological diagnosis of multiple myeloma who has progressive disease after at least 1 prior therapy and who has undergone or is ineligible for a primary stem cell transplant.  The patient must have experienced treatment failure after a trial of at least four (4) weeks of thalidomide at a dose of at least 100&#160;mg daily or have failed to achieve at least a minimal response after eight (8) or more weeks of thalidomide-based therapy for progressive disease.<br/><br/> If the dosing requirement for thalidomide cannot be met, the application must state the reasons why this criterion cannot be satisfied.<br/><br/> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).<br/><br/> Oligo-secretory and non-secretory patients are defined as having active disease with less than 10&#160;g per L serum M protein and less than 200&#160;mg per 24 hour Bence-Jones proteinuria.<br/><br/> Thalidomide treatment failure is defined as:<br/> (1) confirmed disease progression during thalidomide treatment or within 6 months of discontinuing thalidomide treatment; or<br/> (2) severe intolerance or toxicity unresponsive to clinically appropriate dose adjustment.<br/><br/> Severe intolerance due to thalidomide is defined as unacceptable somnolence or sedation interfering with activities of dailyliving.<br/><br/> Toxicity from thalidomide is defined as peripheral neuropathy (Grade 2 or greater, interfering with function), drug-related seizures, serious Grade 3 or 4 drug-related dermatological reactions, such as Stevens-Johnson Syndrome, or other Grade 3 or 4 toxicity.<br/><br/> Failure to achieve at least a minimal response after 8 or more weeks of thalidomide-based therapy for progressive disease is defined as:<br/> (1) less than a 25% reduction in serum or urine M protein; or<br/> (2) in oligo-secretory and non-secretory myeloma patients only, less than a 25% reduction in the difference between involved and uninvolved serum free light chain levels.<br/><br/> Lenalidomide will only be subsidised for patients with multiple myeloma who are not receiving concomitant PBS-subsidised bortezomib.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Multiple Myeloma Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of thalidomide treatment failure; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response.<br/><br/> To enable confirmation by Medicare Australia, current diagnostic reports of at least one of the following are required:<br/> (a) the level of serum monoclonal protein; or<br/> (b) Bence-Jones proteinuria &#8212; the results of 24-hour urinary light chain M protein excretion; or<br/> (c) the serum level of free kappa and lambda light chains; or<br/> (d) bone marrow aspirate or trephine; or<br/> (e) if present, the size and location of lytic bone lesions (not including compression fractures); or<br/> (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or<br/> (g) if present, the level of hypercalcaemia, correctedfor albumin concentration.<br/><br/> As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients.  Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (either previous or current serum M protein less than 10&#160;g per L and urinary Bence-Jones protein undetectable or less than 200&#160;mg per 24 hours) must be provided; and<br/> (3) duration of thalidomide and daily dose prescribed; and<br/> (4) a signed patient acknowledgment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5786M','3205','f',$$<p>Continuing PBS-subsidised treatment, as monotherapy or in combination with dexamethasone, of multiple myeloma in a patient who has previously been issued with an authority prescription for lenalidomide and who does not have progressive disease.<br/><br/> Progressive disease is defined as at least 1 of the following:<br/> (a) at least a 25% increase and an absolute increase of at least 5&#160;g per L in serum M protein (monoclonal protein); or<br/> (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200&#160;mg per 24 hours; or<br/> (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase of the difference between involved free light chain and uninvolved free light chain; or<br/> (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or<br/> (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or<br/> (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or<br/> (g) development of hypercalcaemia (corrected serum calcium greater than 2.65&#160;mmol per L not attributable to any other cause).<br/><br/> Authority applications for continuing treatment may be made by telephone to Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5615M','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5615M','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5611H','3314','t',$$<p>Parkinson's disease in patients severely disabled by motor fluctuations which do not respond to other therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5607D','4019','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.<br/><br/> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particulartest/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5607D','4020','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (c) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment maybe requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5607D','3214','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial treatment with ambrisentan of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised ambrisentan after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with ambrisentan; OR<br/> (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than ambrisentan.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5607D','3215','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with ambrisentan of patients who have received approval for initial PBS-subsidised treatment with ambrisentan and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of ambrisentan treatment [see Note for definition of response].<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.<br/><br/> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.  Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5608E','4019','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure of 8&#160;mmHg or less, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO.<br/><br/> Patients must have failed to respond [see Note for definition of response] to 6 or more weeks of appropriate vasodilator treatment unless intolerance or a contraindication to such treatment exists.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Details of prior vasodilator treatment, including the dose and duration of treatment, must be provided at the time of application. Where the patient has an adverse event to a vasodilator or where vasodilator treatment is contraindicated, details on the nature of the adverse event or contraindication according to the TGA-approved Product Information must also be provided with the application.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particulartest/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5608E','4020','f',$$<p>Initial (new patients)<br/> Application for initial PBS-subsidised treatment with ambrisentan of patients who have not received prior PBS-subsidised treatment with a PAH agent and who have been assessed by a physician from a designated hospital to have:<br/> (a) WHO Functional Class III primary pulmonary hypertension and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (b) WHO Functional Class III pulmonary arterial hypertension secondary to connective tissue disease and a mean right atrial pressure greater than 8&#160;mmHg, as measured by RHC, or, where a RHC cannot be performed on clinical grounds, right ventricular function as assessed by ECHO; OR<br/> (c) WHO Functional Class IV primary pulmonary hypertension; OR<br/> (d) WHO Functional Class IV pulmonary arterial hypertension secondary to connective tissue disease.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT; and<br/> (3) a signed patient acknowledgment form.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment maybe requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5608E','3214','f',$$<p>Initial (change or re-commencement for all patients)<br/> Application for initial treatment with ambrisentan of patients with one of the following:<br/> (a) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease who wish to re-commence PBS-subsidised ambrisentan after a break in therapy and who have demonstrated a response to their most recent course of PBS-subsidised treatment with ambrisentan; OR<br/> (b) primary pulmonary hypertension or pulmonary arterial hypertension secondary to connective tissue disease and whose most recent course of PBS-subsidised treatment was with an alternate PAH agent other than ambrisentan.<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes the results on which approval for the first application for PBS-subsidised PAH agent was granted; and<br/> (3) the date of the first application for PBS-subsidised treatment with a PAH agent; and<br/> (4) the results of the patient's response to treatment with their last course of PBS-subsidised PAH agent.<br/><br/> Where fewer than 3 tests (see requirement 2 above) are able to be performed on clinical grounds, a patient specific reason outlining why the particular test/s could not be conducted must be provided with the authority application [see Note for test requirements].<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats may be requested.  Where fewer than 5 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5608E','3215','f',$$<p>Continuing treatment (all patients)<br/> Continuing PBS-subsidised treatment with ambrisentan of patients who have received approval for initial PBS-subsidised treatment with ambrisentan and who have been assessed by a physician from a designated hospital to have achieved a response to their most recent course of ambrisentan treatment [see Note for definition of response].<br/><br/> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form [www.medicareaustralia.gov.au] which includes results from the 3 tests below, where available:<br/> (i) RHC composite assessment; and<br/> (ii) ECHO composite assessment; and<br/> (iii) 6MWT.<br/><br/> The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e. every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted.  In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application.<br/><br/> The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information.  A maximum of 5 repeats will be authorised.  Where fewer than 5 repeats are initially requested under this criterion, authority approvals for sufficient repeats to complete a maximum of 6 months of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9565K','3985','t',$$<p>Initial treatment of HIV infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9565K','3986','t',$$<p>Continuing treatment of HIV infection where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9657G','3716','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)<br/><br/> Initial PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.<br/><br/> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/>&#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.<br/><br/> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.<br/><br/> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/>The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.<br/><br/> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.<br/><br/> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.<br/><br/> Up to a maximum of 3 repeats of each strength may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9657G','3826','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)<br/><br/> Initial course of PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for patients who have received PBS-subsidised treatment with tocilizumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats of each strength may be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessmentmust be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9657G','3825','f',$$<p>Continuing treatment<br/><br/> Continuing PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with tocilizumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats of each strength may be authorised.<br/><br/>Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with tocilizumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with tocilizumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1476Q','4025','f',$$<p>Initial 1 (new and recommencing patients after a break of more than 12 months)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a)  has been diagnosed with systemic juvenile idiopathic arthritis; AND<br/> (b)  has polyarticular course disease and either:<br/> (i)  failure to achieve an adequate response to the following treatment regimen (see (1) below for definition of failure to achieve an adequate response):<br/> &#8212; oral or parenteral methotrexate at a dose of at least 15&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids for a minimum of 3 months; or<br/> (ii)  severe intolerance of, or toxicity due to, methotrexate (see (2) below for definition of severe intolerance and toxicity); OR<br/> (c)  has refractory systemic symptoms, demonstrated by:<br/> &#8212; an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5&#160;mg per kg per day following a minimum of 2 months of therapy; AND<br/> (d)  has not received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months.<br/><br/> (1)  The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy and must be demonstrated in all patients at the time of the initial application:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (ii)  at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); AND/OR<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with  refractory systemic symptoms:<br/> (i)  an active joint count of at least 2 active joints; AND<br/> (ii)  persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; AND/OR<br/>(iii)  a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN).<br/><br/> (2)  Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/> Toxicity to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonia, or serious sepsis.<br/> If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.<br/><br/> The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  the date of assessment of severe active systemic juvenile idiopathic arthritis;<br/> (ii) details of prior treatment including dose and duration of treatment;<br/> (iii) pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/>The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment in a treatment cycle they will not be eligible to receive further PBS-subsidised tocilizumab therapy in that treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1476Q','4026','f',$$<p>Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)<br/><br/> Initial PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months; AND<br/> (c)  has not failed PBS-subsidised therapy with tocilizumab for this condition more than once in the current treatment cycle.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate.<br/><br/> Applications for a patient who has received PBS-subsidised treatment with tocilizumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with tocilizumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior tothe date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria. Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that course of tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1476Q','4027','f',$$<p>Initial 3 ('grandfather' patients)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; and<br/> (b)  was receiving treatment with tocilizumab prior 1&#160;November 2011; and<br/> (c)  has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with tocilizumab; and<br/> (d)  is receiving treatment with tocilizumab at the time of application.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish the baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> The baseline systemic juvenile idiopathic arthritis assessment must be provided and must be from immediately prior to commencing treatment with tocilizumab.  (See NOTE (3) above for definition of baseline measurements to determine response.)<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/>Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient,  for two infusions (one months supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1476Q','4028','f',$$<p>Continuing treatment<br/><br/> Continuing treatment with tocilizumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has demonstrated an adequate response to treatment with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii)  a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with refractory systemic symptoms:<br/> (i)  absence of fever greater than 38 degrees Celsius in the preceding seven days; AND/OR<br/> (ii)  a reduction in the CRP level and platelet count by at least 30% from baseline; AND/OR<br/> (iii)  a reduction in the dose of corticosteroid by at least 30% from baseline.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  baseline and current pathology reports detailing CRP and platelet count where appropriate.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatmentwas approved under the Initial treatment restriction, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9658H','3716','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)<br/><br/> Initial PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.<br/><br/> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/>&#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.<br/><br/> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.<br/><br/> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/>The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.<br/><br/> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.<br/><br/> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.<br/><br/> Up to a maximum of 3 repeats of each strength may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9658H','3826','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)<br/><br/> Initial course of PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for patients who have received PBS-subsidised treatment with tocilizumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats of each strength may be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessmentmust be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9658H','3825','f',$$<p>Continuing treatment<br/><br/> Continuing PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with tocilizumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats of each strength may be authorised.<br/><br/>Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with tocilizumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with tocilizumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1481Y','4025','f',$$<p>Initial 1 (new and recommencing patients after a break of more than 12 months)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a)  has been diagnosed with systemic juvenile idiopathic arthritis; AND<br/> (b)  has polyarticular course disease and either:<br/> (i)  failure to achieve an adequate response to the following treatment regimen (see (1) below for definition of failure to achieve an adequate response):<br/> &#8212; oral or parenteral methotrexate at a dose of at least 15&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids for a minimum of 3 months; or<br/> (ii)  severe intolerance of, or toxicity due to, methotrexate (see (2) below for definition of severe intolerance and toxicity); OR<br/> (c)  has refractory systemic symptoms, demonstrated by:<br/> &#8212; an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5&#160;mg per kg per day following a minimum of 2 months of therapy; AND<br/> (d)  has not received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months.<br/><br/> (1)  The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy and must be demonstrated in all patients at the time of the initial application:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (ii)  at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); AND/OR<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with  refractory systemic symptoms:<br/> (i)  an active joint count of at least 2 active joints; AND<br/> (ii)  persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; AND/OR<br/>(iii)  a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN).<br/><br/> (2)  Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/> Toxicity to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonia, or serious sepsis.<br/> If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.<br/><br/> The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  the date of assessment of severe active systemic juvenile idiopathic arthritis;<br/> (ii) details of prior treatment including dose and duration of treatment;<br/> (iii) pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/>The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment in a treatment cycle they will not be eligible to receive further PBS-subsidised tocilizumab therapy in that treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1481Y','4026','f',$$<p>Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)<br/><br/> Initial PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months; AND<br/> (c)  has not failed PBS-subsidised therapy with tocilizumab for this condition more than once in the current treatment cycle.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate.<br/><br/> Applications for a patient who has received PBS-subsidised treatment with tocilizumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with tocilizumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior tothe date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria. Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that course of tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1481Y','4027','f',$$<p>Initial 3 ('grandfather' patients)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; and<br/> (b)  was receiving treatment with tocilizumab prior 1&#160;November 2011; and<br/> (c)  has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with tocilizumab; and<br/> (d)  is receiving treatment with tocilizumab at the time of application.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish the baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> The baseline systemic juvenile idiopathic arthritis assessment must be provided and must be from immediately prior to commencing treatment with tocilizumab.  (See NOTE (3) above for definition of baseline measurements to determine response.)<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/>Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient,  for two infusions (one months supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1481Y','4028','f',$$<p>Continuing treatment<br/><br/> Continuing treatment with tocilizumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has demonstrated an adequate response to treatment with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii)  a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with refractory systemic symptoms:<br/> (i)  absence of fever greater than 38 degrees Celsius in the preceding seven days; AND/OR<br/> (ii)  a reduction in the CRP level and platelet count by at least 30% from baseline; AND/OR<br/> (iii)  a reduction in the dose of corticosteroid by at least 30% from baseline.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  baseline and current pathology reports detailing CRP and platelet count where appropriate.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatmentwas approved under the Initial treatment restriction, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9659J','3716','f',$$<p>Initial 1 (new patient or patient re-commencing after a break of more than 24 months)<br/><br/> Initial PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have severe active rheumatoid arthritis; and<br/> (b) have received no PBS-subsidised treatment with a bDMARD for this condition in the previous 24 months; and<br/> (c) have failed, in the 24 months immediately prior to the date of application, to achieve an adequate response to at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20&#160;mg weekly and one of which must be:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20&#160;mg weekly dose, then the 6 months of intensive DMARD treatment must include at least 3 months continuous treatment with each of at least 2 of the DMARDs:<br/> &#8212; hydroxychloroquine at a dose of at least 200&#160;mg daily; and/or<br/> &#8212; leflunomide at a dose of at least 10&#160;mg daily; and/or<br/> &#8212; sulfasalazine at a dose of at least 2&#160;g daily.<br/><br/> The application must include details of the contraindication or intolerance to methotrexate.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20&#160;mg weekly dose can be found on the Medicare Australia website [www.medicareaustralia.gov.au].  The maximum tolerated dose of methotrexate must be documented in the application, if applicable.<br/><br/> If 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved product information or cannot be tolerated at the doses specified above, then one or more of the following DMARDs may be used in place of these agents in order to satisfy the requirement for a trial of 6 months of intensive DMARD therapy with at least 2 DMARDs taken continuously for at least 3 months each:<br/>&#8212; azathioprine at a dose of at least 1&#160;mg/kg per day; and/or<br/> &#8212; cyclosporin at a dose of at least 2&#160;mg/kg/day; and/or<br/> &#8212; sodium aurothiomalate at a dose of 50&#160;mg weekly.<br/><br/> The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances.  Details of the toxicities, including severity, which will be accepted as a reason for substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.<br/><br/> If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application.  Details of the toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:<br/> an elevated erythrocyte sedimentation rate (ESR) greater than 25&#160;mm per hour or a C-reactive protein (CRP) level greater than 15&#160;mg per L;<br/> AND either<br/> (i) a total active joint count of at least 20 active (swollen and tender) joints; or<br/> (ii) at least 4 active joints from the following list of major joints:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/>The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy.  All measures must be no more than one month old at the time of initial application.<br/><br/> If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.<br/><br/> Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) a signed patient acknowledgement.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.<br/><br/> Up to a maximum of 3 repeats of each strength may be authorised</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9659J','3826','f',$$<p>Initial 2 (change or re-commencement after break of less than 24 months)<br/><br/> Initial course of PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults who:<br/> (a) have a documented history of severe active rheumatoid arthritis; and<br/> (b) have received prior PBS-subsidised bDMARD treatment for this condition and are eligible to receive further bDMARD therapy.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for patients who have received PBS-subsidised treatment with tocilizumab and who wish to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats of each strength may be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under either of the initial 1 or 2 treatment restrictions, patients must have been assessed for response following a minimum of 12 weeks of therapy.  This assessmentmust be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, patients must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9659J','3825','f',$$<p>Continuing treatment<br/><br/> Continuing PBS-subsidised treatment with tocilizumab, by a rheumatologist or clinical immunologist with expertise in the management of rheumatoid arthritis, of adults:<br/> (a) who have a documented history of severe active rheumatoid arthritis; and<br/> (b) who have demonstrated an adequate response to treatment with tocilizumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment was with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> an ESR no greater than 25&#160;mm per hour or a CRP level no greater than 15&#160;mg per L or either marker reduced by at least 20% from baseline;<br/> AND either of the following:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form(s); and<br/> (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 8&#160;mg per kg.  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats of each strength may be authorised.<br/><br/>Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with tocilizumab must include a measurement of response to the prior course of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with tocilizumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.<br/><br/> Patients who fail to demonstrate a response to treatment with tocilizumab under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug for this condition</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1482B','4025','f',$$<p>Initial 1 (new and recommencing patients after a break of more than 12 months)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a)  has been diagnosed with systemic juvenile idiopathic arthritis; AND<br/> (b)  has polyarticular course disease and either:<br/> (i)  failure to achieve an adequate response to the following treatment regimen (see (1) below for definition of failure to achieve an adequate response):<br/> &#8212; oral or parenteral methotrexate at a dose of at least 15&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids for a minimum of 3 months; or<br/> (ii)  severe intolerance of, or toxicity due to, methotrexate (see (2) below for definition of severe intolerance and toxicity); OR<br/> (c)  has refractory systemic symptoms, demonstrated by:<br/> &#8212; an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5&#160;mg per kg per day following a minimum of 2 months of therapy; AND<br/> (d)  has not received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months.<br/><br/> (1)  The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy and must be demonstrated in all patients at the time of the initial application:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (ii)  at least 4 active joints from the following list:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); AND/OR<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with  refractory systemic symptoms:<br/> (i)  an active joint count of at least 2 active joints; AND<br/> (ii)  persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; AND/OR<br/>(iii)  a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN).<br/><br/> (2)  Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/> Toxicity to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonia, or serious sepsis.<br/> If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.<br/><br/> The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  the date of assessment of severe active systemic juvenile idiopathic arthritis;<br/> (ii) details of prior treatment including dose and duration of treatment;<br/> (iii) pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/>The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment in a treatment cycle they will not be eligible to receive further PBS-subsidised tocilizumab therapy in that treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1482B','4026','f',$$<p>Initial 2 (retrial or recommencement of treatment after a break of less than 12 months)<br/><br/> Initial PBS-subsidised treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has received PBS-subsidised treatment with tocilizumab for this condition in the previous 12 months; AND<br/> (c)  has not failed PBS-subsidised therapy with tocilizumab for this condition more than once in the current treatment cycle.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate.<br/><br/> Applications for a patient who has received PBS-subsidised treatment with tocilizumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised tocilizumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with tocilizumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior tothe date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria. Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that course of tocilizumab.<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1482B','4027','f',$$<p>Initial 3 ('grandfather' patients)<br/><br/> Initial treatment by a rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; and<br/> (b)  was receiving treatment with tocilizumab prior 1&#160;November 2011; and<br/> (c)  has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with tocilizumab; and<br/> (d)  is receiving treatment with tocilizumab at the time of application.<br/><br/> To ensure consistency in determining response, the same indices of disease severity used to establish the baseline must be provided for all subsequent continuing treatment applications.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Systemic Juvenile Idiopathic Arthritis  PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  pathology reports detailing CRP and platelet count where appropriate; and<br/> (3)  a signed patient or authorised guardian acknowledgement form.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> The baseline systemic juvenile idiopathic arthritis assessment must be provided and must be from immediately prior to commencing treatment with tocilizumab.  (See NOTE (3) above for definition of baseline measurements to determine response.)<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with tocilizumab.<br/><br/>Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient,  for two infusions (one months supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1482B','4028','f',$$<p>Continuing treatment<br/><br/> Continuing treatment with tocilizumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient who:<br/> (a)  has a documented history of systemic juvenile idiopathic arthritis; AND<br/> (b)  has demonstrated an adequate response to treatment with tocilizumab.<br/><br/> An adequate response to treatment is defined as:<br/> (a)  in a patient with polyarticular course disease:<br/> (i)  a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii)  a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/> (b)  in a patient with refractory systemic symptoms:<br/> (i)  absence of fever greater than 38 degrees Celsius in the preceding seven days; AND/OR<br/> (ii)  a reduction in the CRP level and platelet count by at least 30% from baseline; AND/OR<br/> (iii)  a reduction in the dose of corticosteroid by at least 30% from baseline.<br/><br/> The authority application must be made in writing and must include:<br/> (1)  completed authority prescription form(s); and<br/> (2)  a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i)  baseline and current pathology reports detailing CRP and platelet count where appropriate.<br/><br/> The most recent systemic juvenile idiopathic arthritis assessment must be no more than 1 month old at the time of application.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatmentwas approved under the Initial treatment restriction, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised tocilizumab treatment was approved under the continuing treatment criteria, the patient must have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Patients are eligible to receive continuing tocilizumab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month supply).  A separate authority prescription form must be completed for each strength requested.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are requested at the time of initial application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> If a patient fails to respond to 2 courses of treatment they will not be eligible to receive further PBS-subsidised tocilizumab therapy in this treatment cycle.  A patient may re-trial tocilizumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised treatment was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9654D','3691','f',$$<p>Initial 1<br/> Initial treatment of complex refractory FISTULISING CROHN DISEASE.<br/><br/> Initial PBS-subsidised treatment with infliximab by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician as specified in the NOTE below; and<br/> (b) has an externally draining enterocutaneous or rectovaginal fistula; and<br/> (c) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/> (ii) a signed patient acknowledgement.<br/><br/> The most recent fistula assessment must be no more than 1 month old at the time of application.<br/><br/> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6 will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 3 doses of infliximab may be requested by telephone by contactingMedicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.<br/><br/> An assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (up to 6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.<br/><br/> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.<br/><br/> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9654D','3819','f',$$<p>Initial 2<br/> Change or re-commencement of treatment of complex refractory FISTULISING CROHN DISEASE.<br/><br/> Initial PBS-subsidised treatment with infliximab of complex refractory fistulising Crohn disease by a gastroenterologist or a consultant physician as specified in the NOTE below, of a patient with complex refractory fistulising Crohn disease who:<br/> (a) has a documented history of complex refractory fistulising Crohn disease; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or infliximab for a draining enterocutaneous or rectovaginal fistula; and<br/> (c) has not failed PBS-subsidised therapy with infliximab for this condition more than once in the current treatment cycle.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of TNF-alfa antagonist therapy within the timeframes specified in the relevant restriction.<br/><br/> Where the most recent course of PBS-subsidised TNF-alfa antagonist treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> If the response assessment to the previous course of TNF-alfa antagonist treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of TNF-alfa antagonist.<br/><br/> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includesthe following:<br/> (i) a completed current Fistula Assessment Form including the date of assessment of the patient's condition; and<br/> (ii) details of prior TNF-alfa antagonist treatment including details of date and duration of treatment.<br/><br/> The most recent fistula assessment must be no more than 1 month old at the time of application.<br/><br/> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period.<br/><br/> An assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (up to 6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.<br/><br/> This assessment must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.<br/><br/> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9654D','3693','f',$$<p>Initial 3 (grandfather)<br/> Initial PBS-subsidised treatment of complex refractory FISTULISING CROHN DISEASE in a patient who has previously received non-PBS-subsidised therapy with infliximab.<br/><br/> Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below, or other consultant physician in consultation with a gastroenterologist of a patient who satisfies the following criteria:<br/> (a) has a documented history of complex refractory fistulising Crohn disease and was receiving treatment with infliximab prior to 1&#160;March 2010; and<br/> (b) had a draining enterocutaneous or rectovaginal fistula(e) prior to commencing treatment with infliximab; and<br/> (c) has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) is receiving treatment with infliximab at the time of application; and<br/> (e) has demonstrated or sustained an adequate response to treatment with infliximab.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> An adequate response to infliximab treatment is defined as:<br/> (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or<br/> (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/>(i) a completed current and baseline Fistula Assessment form including the date of assessment of the patient's condition; and<br/> (ii) a signed patient acknowledgement.<br/><br/> The current fistula assessment must be no more than 1 month old at the time of application.<br/><br/> The baseline fistula assessment must be from immediately prior to commencing treatment with infliximab.<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.<br/><br/> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 2 repeats will be authorised.  No applications for increased repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9654D','3820','f',$$<p>Continuing treatment of complex refractory FISTULISING CROHN DISEASE.<br/><br/> Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, a consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of complex refractory fistulising Crohn disease; and<br/> (b) has demonstrated or sustained an adequate response to treatment with infliximab.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> An adequate response is defined as:<br/> (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or<br/> (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient.<br/><br/> Authority applications must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Fistulising Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes a completed Fistula Assessment form including the date of the assessment of the patient's condition.<br/><br/> The fistula assessment must be no more than 1 month old at the time of application.<br/><br/> If the application is the first application for continuing treatment with infliximab, an assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.<br/><br/> An assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criteria.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond,or to have failed to sustain a response, to treatment with infliximab.<br/><br/> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg.  Up to a maximum of 2 repeats will be authorised.  No applications for increased repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5755X','3585','f',$$<p>Initial treatment of Crohn disease in a paediatric patient.<br/><br/> Initial PBS-subsidised treatment by a gastroenterologist, paediatrician or consultant physician as specified in the NOTE below, of a patient aged 6 to 17 years inclusive with moderate to severe refractory Crohn disease who satisfies the following criteria:<br/> (a)  has confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or consultant physician as specified in the NOTE below; and<br/> (b)  whose parent or authorised guardian has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (c) has failed to achieve an adequate response to 2 of the following 3 conventional prior therapies including:<br/> (i) a tapered course of steroids, starting at a dose of at least 1&#160;mg per kg or 40&#160;mg (whichever is the lesser) prednisolone (or equivalent), over a 6 week period;<br/> (ii) an 8 week course of enteral nutrition;<br/> (iii) immunosuppressive therapy including:<br/> &#8212; azathioprine at a dose of at least 2&#160;mg per kg daily for 3 or more months; or<br/> &#8212; 6-mercaptopurine at a dose of at least 1&#160;mg per kg daily for 3 or more months; or<br/> &#8212; methotrexate at a dose of at least 10&#160;mg per square metre weekly for 3 or more months.<br/><br/> NOTE: Prescribers must be gastoenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> If treatment with any of the above-mentioned drugs is contraindicated according to the relevant TGA-approved Product Information, please provide details at the time of application.<br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. Details of the accepted toxicities includingseverity can be found on the Medicare Australia website (www.medicareaustralia.gov.au).<br/><br/> The following initiation criterion indicates failure to achieve an adequate response and must be demonstrated in all patients at the time of the application:<br/> (a) severity of disease activity which results in a Paediatric Crohn Disease Activity Index (PCDAI) Score greater than or equal to 30 as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/> (b) The most recent PCDAI assessment must be no more than 1 month old at the time of application.<br/><br/> All tests and assessments should be performed preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed current Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet including the date of assessment of the patient's condition; and<br/> (ii) details of previous systemic drug therapy [dosage, date of commencement and duration of therapy], or dates of enteral nutrition; and<br/> (iii) the signed patient acknowledgement.<br/><br/> A maximum quantity and number of repeats to provide for an initial course of infliximab consisting of 3 doses at 5&#160;mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of infliximab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatmentperiod.<br/><br/> A PCDAI assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated.<br/><br/> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to treatment with infliximab.<br/><br/> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 12 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised infliximab treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5755X','3810','f',$$<p>Continuing treatment of Crohn disease in a patient initiated on PBS-subsidised treatment as a paediatric patient.<br/><br/> Continuing PBS-subsidised treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient who:<br/> (a) has a documented history of moderate to severe refractory Crohn disease; and<br/> (b) has demonstrated or sustained an adequate response to treatment with infliximab.<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/> (i) the completed Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition.<br/><br/> The PCDAI assessment must be no more than 1 month old at the time of application.<br/><br/> If the application is the first application for continuing treatment with infliximab, a PCDAI assessment of the patient's response must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated.<br/><br/> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.<br/><br/>Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.<br/><br/> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to receive PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5755X','3008','f',$$<p>Initial PBS-subsidised treatment of Crohn disease in a paediatric patient who has previously received non-PBS-subsidised therapy with infliximab.<br/><br/> Initial PBS-subsidised supply for continuing treatment with infliximab by a gastroenterologist, paediatrician, consultant physician as specified in the NOTE below or other consultant physician in consultation with a gastroenterologist, of a patient aged 6 to 17 years inclusive who:<br/> (a) has a documented history of moderate to severe refractory Crohn disease and was receiving treatment with infliximab prior to 4&#160;July 2007; and<br/> (b) had a Paediatric Crohn Disease Activity Index (PCDAI) Score of greater than 30 prior to commencing treatment with infliximab. Where a baseline CDAI assessment is not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss; and<br/> (c) whose parent or authorised guardian has signed a patient acknowledgement indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/> (d) has demonstrated or sustained an adequate response to treatment with infliximab.  For advice please contact Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> NOTE: Prescribers must be gastroenterologists (code 87), consultant physicians [internal medicine specialising in gastroenterology (code 81)] or consultant physicians [general medicine specialising in gastroenterology (code 82)].<br/><br/> An adequate response to infliximab treatment is defined as a reduction in Paediatric Crohn Disease Activity Index (PCDAI) Score by at least 15 points as compared to baseline AND a total PCDAI score of 30 points or less.<br/><br/> Applications for authorisation must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which includes the following:<br/>(i) the completed current and baseline Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient's condition; and<br/> (ii) the signed patient acknowledgement.<br/><br/> The current PCDAI assessment must be no more than 1 month old at the time of application. The baseline PCDAI assessment must be from immediately prior to commencing treatment with infliximab.<br/><br/> The assessment of the patient's response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to Medicare Australia no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion.<br/><br/> Where an assessment is not submitted to Medicare Australia within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with infliximab.<br/><br/> Patients are eligible to receive continuing infliximab treatment in courses of up to 24 weeks providing they continue to sustain the response.<br/><br/> Patients who fail to demonstrate or sustain a response to treatment with infliximab for Crohn disease as specified in the criteria for continuing treatment with infliximab, will not be eligible to recommence PBS-subsidised treatment with this drug within 12 months of the date on which treatment was ceased.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5&#160;mg per kg. Up to a maximum of 2 repeats will be authorised. No applications for increased repeats will be authorised.<br/><br/> Where fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9655E','3420','t',$$<p>Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9655E','3421','t',$$<p>Prophylaxis of cytomegalovirus infection and disease in solid organ transplant patients at risk of cytomegalovirus disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9660K','3588','t',$$<p>Initial treatment of HIV infection in combination with other antiretroviral agents in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9660K','3589','t',$$<p>Continuing treatment of HIV infection in combination with other antiretroviral agents where the patient has previously received PBS-subsidised therapy for HIV infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9661L','3527','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).<br/><br/> Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:<br/> (a) who has severe active juvenile idiopathic arthritis; AND<br/> (b) whose parent or authorised guardian has signed a patient acknowledgement; AND<br/> (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND<br/> (d) who has demonstrated either:<br/> (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or<br/> (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:<br/> &#8212; oral or parenteral methotrexate at a dose of at least 20&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or<br/> &#8212; oral methotrexate at a dose of at least 10&#160;mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months.  (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)<br/><br/> Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/><br/> Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.<br/><br/> If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.<br/><br/> The following criteria indicate failure to achieve an adequateresponse and must be demonstrated in all patients at the time of the initial application:<br/> (a) an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (b) at least 4 active joints from the following list:<br/> (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to havefailed to respond to treatment with adalimumab.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9661L','3798','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).<br/><br/> Initial PBS-subsidised treatment with adalimumab by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.<br/><br/> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for a patient who has received PBS-subsidised treatment with adalimumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, the patientmust have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9661L','3529','f',$$<p>Initial 3 ('grandfather' patients).<br/><br/> Initial PBS-subsidised supply for continuing treatment with adalimumab, by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) was receiving treatment with adalimumab prior to 1&#160;March 2010; and<br/> (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab; and<br/> (d) is receiving treatment with adalimumab at the time of application.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.<br/><br/> A maximum of 24 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> The assessment of the patient's response to this initial course of PBS-subsidised therapy must be made within the 4 weeks prior to completion of the course in order to ensure continuity of treatment.<br/><br/> A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/>If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.<br/><br/> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9661L','3799','f',$$<p>Continuing treatment.<br/><br/> Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with adalimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with adalimumab.<br/><br/> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy.This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9662M','3527','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).<br/><br/> Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:<br/> (a) who has severe active juvenile idiopathic arthritis; AND<br/> (b) whose parent or authorised guardian has signed a patient acknowledgement; AND<br/> (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND<br/> (d) who has demonstrated either:<br/> (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or<br/> (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:<br/> &#8212; oral or parenteral methotrexate at a dose of at least 20&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or<br/> &#8212; oral methotrexate at a dose of at least 10&#160;mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months.  (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)<br/><br/> Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/><br/> Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.<br/><br/> If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.<br/><br/> The following criteria indicate failure to achieve an adequateresponse and must be demonstrated in all patients at the time of the initial application:<br/> (a) an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (b) at least 4 active joints from the following list:<br/> (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to havefailed to respond to treatment with adalimumab.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9662M','3798','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).<br/><br/> Initial PBS-subsidised treatment with adalimumab by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.<br/><br/> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for a patient who has received PBS-subsidised treatment with adalimumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, the patientmust have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9662M','3529','f',$$<p>Initial 3 ('grandfather' patients).<br/><br/> Initial PBS-subsidised supply for continuing treatment with adalimumab, by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) was receiving treatment with adalimumab prior to 1&#160;March 2010; and<br/> (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab; and<br/> (d) is receiving treatment with adalimumab at the time of application.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.<br/><br/> A maximum of 24 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> The assessment of the patient's response to this initial course of PBS-subsidised therapy must be made within the 4 weeks prior to completion of the course in order to ensure continuity of treatment.<br/><br/> A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/>If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.<br/><br/> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9662M','3799','f',$$<p>Continuing treatment.<br/><br/> Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with adalimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with adalimumab.<br/><br/> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy.This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9663N','3527','f',$$<p>Initial 1 (new patient or patient recommencing after a break of more than 12 months).<br/><br/> Initial treatment by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years:<br/> (a) who has severe active juvenile idiopathic arthritis; AND<br/> (b) whose parent or authorised guardian has signed a patient acknowledgement; AND<br/> (c) who has not received PBS-subsidised treatment with adalimumab or etanercept for this condition in the previous 12 months; AND<br/> (d) who has demonstrated either:<br/> (i) severe intolerance of, or toxicity due to, methotrexate (see below for definition of severe intolerance and toxicity); or<br/> (ii) failure to achieve an adequate response to 1 or more of the following treatment regimens:<br/> &#8212; oral or parenteral methotrexate at a dose of at least 20&#160;mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or<br/> &#8212; oral methotrexate at a dose of at least 10&#160;mg per square metre weekly together with at least 1 other DMARD, alone or in combination with corticosteroids, for a minimum of 3 months.  (Note: use of alternative DMARDs in children is dependent on approval by the Therapeutic Goods Administration as age restrictions may apply.)<br/><br/> Severe intolerance is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant NSAIDs on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours.<br/><br/> Toxicity is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis.<br/><br/> If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, please provide details at time of application.<br/><br/> If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of this toxicity at the time of application.<br/><br/> The following criteria indicate failure to achieve an adequateresponse and must be demonstrated in all patients at the time of the initial application:<br/> (a) an active joint count of at least 20 active (swollen and tender) joints; OR<br/> (b) at least 4 active joints from the following list:<br/> (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The joint count assessment should be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the initial application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated.  This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia no later than 4 weeks from the date of completion of this initial course of treatment.  Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to havefailed to respond to treatment with adalimumab.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9663N','3798','f',$$<p>Initial 2 (change or re-commencement after break of less than 12 months).<br/><br/> Initial PBS-subsidised treatment with adalimumab by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) in this treatment cycle, has received prior PBS-subsidised treatment with adalimumab or etanercept for this condition; and<br/> (c) has not failed PBS-subsidised therapy with adalimumab for this condition more than once in the current treatment cycle.<br/><br/> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> Applications for a patient who has received PBS-subsidised treatment with adalimumab in this treatment cycle and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised adalimumab treatment, within the timeframes specified below.<br/><br/> A maximum of 16 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 3 repeats will be authorised.<br/><br/> Where fewer than 3 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 16 weeks of treatment with adalimumab may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> Where the most recent course of PBS-subsidised adalimumab treatment was approved under either of the Initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where the most recent course of PBS-subsidised adalimumab treatment was approved under the continuing treatment criteria, the patientmust have been assessed for response, and the assessment must be submitted to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/> Where a response assessment is not undertaken and submitted to Medicare Australia within these timeframes, the patient will be deemed to have failed to respond to that particular course of bDMARD.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9663N','3529','f',$$<p>Initial 3 ('grandfather' patients).<br/><br/> Initial PBS-subsidised supply for continuing treatment with adalimumab, by a paediatric rheumatologist, or under the supervision of a paediatric rheumatology treatment centre, of a patient under 18 years who:<br/> (a) has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) was receiving treatment with adalimumab prior to 1&#160;March 2010; and<br/> (c) has demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with adalimumab; and<br/> (d) is receiving treatment with adalimumab at the time of application.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)]; and<br/> (3) an acknowledgement signed by a parent or authorised guardian.<br/><br/> A maximum of 24 weeks of treatment will be authorised under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> The assessment of the patient's response to this initial course of PBS-subsidised therapy must be made within the 4 weeks prior to completion of the course in order to ensure continuity of treatment.<br/><br/> A patient ceasing treatment or swapping to an alternate agent and wishing to demonstrate a response to treatment, must be assessed no earlier than 12 weeks from the commencement of PBS-subsidised treatment.  This assessment must be provided to Medicare Australia no later than 4 weeks from the date that course was ceased.<br/><br/>If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.<br/><br/> A patient may only qualify for PBS-subsidised treatment under this restriction once</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9663N','3799','f',$$<p>Continuing treatment.<br/><br/> Continuing PBS-subsidised treatment with adalimumab, by a rheumatologist or under the supervision of a paediatric rheumatology treatment centre, of a patient:<br/> (a) who has a documented history of severe active juvenile idiopathic arthritis; and<br/> (b) who has demonstrated an adequate response to treatment with adalimumab; and<br/> (c) whose most recent course of PBS-subsidised bDMARD treatment in this treatment cycle was with adalimumab.<br/><br/> An adequate response to treatment is defined as:<br/> (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or<br/> (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%:<br/> &#8212; elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or<br/> &#8212; shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)].<br/><br/> A maximum of 24 weeks of treatment will be approved under this restriction.<br/><br/> At the time of authority application, medical practitioners should request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses.  Up to a maximum of 5 repeats will be authorised.<br/><br/> Where fewer than 5 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> All applications for continuing treatment with adalimumab must include a measurement of response to the prior course of therapy.This assessment must be provided to Medicare Australia no later than 4 weeks from the cessation of that treatment course.  If the application is the first application for continuing treatment with adalimumab, it must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course.<br/><br/> If a patient fails to respond to treatment 3 times (twice with one agent and once with the other) they will not be eligible to receive further PBS-subsidised bDMARD therapy in this treatment cycle.  A patient may re-trial adalimumab after a minimum of 12 months have elapsed between the date the last PBS-subsidised bDMARD was stopped and the date of the first application under a new treatment cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9664P','3328','t',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9665Q','3328','t',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9666R','3328','t',$$<p>Management of rejection in patients following organ or tissue transplantation, under the supervision and direction of a transplant unit. Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9667T','3342','t',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9668W','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9669X','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9670Y','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9587N','3334','t',$$<p>Treatment of anaemia requiring transfusion, defined as a haemoglobin level of less than 100&#160;g per L, where intrinsic renal disease, as assessed by a nephrologist, is the primary cause of the anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3357','t',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3358','t',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3359','t',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3360','t',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3361','t',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3362','t',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3363','t',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3364','t',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3365','t',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3366','t',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3367','t',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3368','t',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3369','t',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3370','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3371','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3372','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3373','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3374','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3375','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3376','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3377','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9692D','3834','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3357','t',$$<p>For use in a patient undergoing induction and consolidation therapy for acute myeloid leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3358','t',$$<p>Mobilisation of peripheral blood progenitor cells to facilitate harvest of such cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3359','t',$$<p>Mobilisation of peripheral blood progenitor cells, in a normal volunteer, for use in allogeneic transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3360','t',$$<p>A patient receiving marrow-ablative chemotherapy and subsequent bone marrow transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3361','t',$$<p>A patient with a non-myeloid malignancy receiving marrow-ablative chemotherapy and subsequent autologous peripheral blood progenitor cell transplantation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3362','t',$$<p>A patient with breast cancer receiving standard dose adjuvant chemotherapy who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3363','t',$$<p>A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia with fludarabine and cyclophosphamide who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3364','t',$$<p>A patient receiving first-line chemotherapy for Hodgkin disease who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3365','t',$$<p>A patient receiving chemotherapy for myeloma who has had a prior episode of febrile neutropenia, and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3366','t',$$<p>A patient with severe congenital neutropenia (absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, and in whom a bone marrow examination has shown evidence of maturational arrest of the neutrophil lineage)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3367','t',$$<p>A patient with severe chronic neutropenia (absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart, or evidence of neutrophil dysfunction, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3368','t',$$<p>A patient with chronic cyclic neutropenia (absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles, and, either having experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics, or having recurrent clinically significant infections (a minimum of 3 in the previous 12 months))</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3369','t',$$<p>A patient with inoperable Stage III, IVa or IVb squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx receiving neoadjuvant treatment with docetaxel in combination with cisplatin and fluorouracil who has had a prior episode of febrile neutropenia or prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre), and for whom there is clinical justification for wishing to continue therapy with the same drug combination, dosage and treatment schedule, and for whom a good response to treatment is anticipated providing chemotherapy can be delivered as planned</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3370','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3371','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in breast cancer (adjuvant chemotherapy with docetaxel in combination with an anthracycline and cyclophosphamide)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3372','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3373','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in infants and children with CNS tumours</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3374','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3375','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin lymphoma (aggressive grades; or low grade receiving an anthracycline-containing regimen)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3376','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3377','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in sarcoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9694F','3834','t',$$<p>A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9696H','3851','f',$$<p>Initial (new patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:<br/> (1) Splenectomised and:<br/> (a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and<br/> (b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;<br/> OR<br/> (2) Not splenectomised and:<br/> (a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2&#160;mg/kg/day of prednisone for at least 4-6 weeks; and<br/> (b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and<br/> (c) in whom splenectomy is contraindicated for medical reasons.<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:<br/> (a) a platelet count of less than or equal to 20,000&#160;million per L;<br/> OR<br/> (b) a platelet count of 20-30,000&#160;million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],<br/> (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and<br/> (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.<br/><br/>The full blood count must be no more than 1 month old at the time of application.<br/><br/> At the time of the written authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1&#160;microgram/kg.  Up to 1 repeat may be requested with the initial written application.<br/><br/> Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  The dose (microgram/kg/week) must be provided at the time of application.<br/><br/> Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.<br/><br/> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9696H','3852','f',$$<p>Initial (grandfather patients)<br/> Initial PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with romiplostim prior to 1&#160;April&#160;2011 and in whom the criteria for initial treatment can be demonstrated to have been met at the time romiplostim was commenced.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.<br/><br/> For patients whose dose of romiplostim had been stable for at least 4 weeks at the time of the initial application for PBS-subsidy, the medical practitioner should request sufficient number of vials based on the weight of the patient and dose (microgram/kg/week) to provide up to 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.<br/><br/> Where the patient is in the titration phase of treatment with romiplostim, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1&#160;microgram/kg.  Up to 1 repeat may be requested with the initial written application.<br/><br/> Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  The dose (microgram/kg/week) must be provided at the time of application.<br/><br/> Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, aslong as the total period of treatment authorised under this restriction does not exceed 24 weeks.<br/><br/> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9696H','3853','f',$$<p>Continuing therapy or re-initiation after a break in therapy<br/> First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with romiplostim during the initial period of PBS-subsidised treatment.<br/><br/> For the purposes of this restriction, a sustained platelet response is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised romiplostim,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L on at least four (4) occasions, each at least one week apart;<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.<br/><br/> Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:<br/> (1) a completed authority prescription form, and<br/> (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).<br/><br/> The most recent platelet count must be no more than one month old at the time of application.<br/><br/> The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone.<br/><br/> Authority approval will not be given for doses of higher than10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9696H','3854','f',$$<p>Second and subsequent applications for continuing therapy<br/> Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with romiplostim and who continues to display a response to treatment with romiplostim.<br/><br/> For the purposes of this restriction, a continuing response to treatment with romiplostim is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with romiplostim,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline platelet count.<br/><br/> Platelet counts must be no more than 1 month old at the time of application.<br/><br/> Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.<br/><br/> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9698K','3851','f',$$<p>Initial (new patients)<br/> Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who is:<br/> (1) Splenectomised and:<br/> (a) has had an inadequate response to, or is intolerant to, corticosteroid therapy post splenectomy; and<br/> (b) has had an inadequate response to, or is intolerant to, immunoglobulin therapy post splenectomy;<br/> OR<br/> (2) Not splenectomised and:<br/> (a) has had an inadequate response, or is intolerant to, corticosteroid therapy at a dose equivalent to 0.5-2&#160;mg/kg/day of prednisone for at least 4-6 weeks; and<br/> (b) has had an inadequate response, or is intolerant to, immunoglobulin therapy; and<br/> (c) in whom splenectomy is contraindicated for medical reasons.<br/><br/> The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of initial application:<br/> (a) a platelet count of less than or equal to 20,000&#160;million per L;<br/> OR<br/> (b) a platelet count of 20-30,000&#160;million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)],<br/> (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and<br/> (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.<br/><br/>The full blood count must be no more than 1 month old at the time of application.<br/><br/> At the time of the written authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1&#160;microgram/kg.  Up to 1 repeat may be requested with the initial written application.<br/><br/> Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  The dose (microgram/kg/week) must be provided at the time of application.<br/><br/> Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.<br/><br/> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9698K','3852','f',$$<p>Initial (grandfather patients)<br/> Initial PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with romiplostim prior to 1&#160;April&#160;2011 and in whom the criteria for initial treatment can be demonstrated to have been met at the time romiplostim was commenced.<br/><br/> The authority application must be made in writing and must include:<br/> (1) a completed authority prescription form,<br/> (2) a signed patient acknowledgement,<br/> (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (4) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.<br/><br/> For patients whose dose of romiplostim had been stable for at least 4 weeks at the time of the initial application for PBS-subsidy, the medical practitioner should request sufficient number of vials based on the weight of the patient and dose (microgram/kg/week) to provide up to 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.<br/><br/> Where the patient is in the titration phase of treatment with romiplostim, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1&#160;microgram/kg.  Up to 1 repeat may be requested with the initial written application.<br/><br/> Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  The dose (microgram/kg/week) must be provided at the time of application.<br/><br/> Once a patient's dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, aslong as the total period of treatment authorised under this restriction does not exceed 24 weeks.<br/><br/> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9698K','3853','f',$$<p>Continuing therapy or re-initiation after a break in therapy<br/> First period of PBS-subsidised continuing treatment or re-initiation of interrupted PBS-subsidised treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with romiplostim during the initial period of PBS-subsidised treatment.<br/><br/> For the purposes of this restriction, a sustained platelet response is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS-subsidised romiplostim,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L on at least four (4) occasions, each at least one week apart;<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline (pre-treatment) platelet count on at least four (4) occasions, each at least one week apart.<br/><br/> Applications for the first period of continuing PBS-subsidised treatment or re-initiation of interrupted treatment must be made in writing and must include:<br/> (1) a completed authority prescription form, and<br/> (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application - Supporting Information Form [may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)], and<br/> (3) copies of the platelet count pathology reports (unless previously provided for patients re-initiating therapy).<br/><br/> The most recent platelet count must be no more than one month old at the time of application.<br/><br/> The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.<br/><br/> Where fewer than 5 repeats are initially requested with the authority prescription, authority approvals for sufficient repeats to complete a maximum of 24 weeks of treatment may be made by telephone.<br/><br/> Authority approval will not be given for doses of higher than10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9698K','3854','f',$$<p>Second and subsequent applications for continuing therapy<br/> Continuing treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has previously received PBS-subsidised therapy with romiplostim and who continues to display a response to treatment with romiplostim.<br/><br/> For the purposes of this restriction, a continuing response to treatment with romiplostim is defined as:<br/> (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS-subsidised treatment with romiplostim,<br/> AND either of the following:<br/> (b) a platelet count greater than or equal to 50,000&#160;million per L<br/> OR<br/> (c) a platelet count greater than 30,000&#160;million per L and which is double the baseline platelet count.<br/><br/> Platelet counts must be no more than 1 month old at the time of application.<br/><br/> Authority applications for second and subsequent periods of continuing therapy may be made by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.<br/><br/> Authority approval will not be given for doses of higher than 10&#160;micrograms/kg/week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9743T','3704','t',$$<p>Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy.<br/><br/> Treatment must be commenced in a hospital-based movement disorder clinic</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9745X','3740','f',$$<p>Initial treatment of uncontrolled severe allergic asthma<br/><br/> Initial PBS-subsidised treatment with omalizumab by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient aged 12 years or older with uncontrolled severe allergic asthma who has been under the care of this physician for at least 12 months, and satisfies the following criteria:<br/><br/> (a) has a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by standard clinical features, including:<br/> (i)  forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200&#160;mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or<br/> (ii)  airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or<br/> (iii)  peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; and<br/><br/> (b) duration of asthma of at least 1 year; and<br/><br/> (c) FEV1 less than or equal to 80% predicted, documented on 3 or more occasions in the previous 12 months; and<br/><br/> (d) past or current evidence of atopy, documented by skin prick testing or RAST; and<br/><br/> (e) total serum human immunoglobulin E (IgE) greater than or equal to 76&#160;IU/mL; and<br/><br/> (f) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and<br/><br/> (g) has failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented (see NOTE).  Optimised asthma therapy includes:<br/> (i)  adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (budesonide 1600&#160;micrograms per day or fluticasone propionate 1000&#160;micrograms per day or equivalent), pluslong-acting beta-2 agonist therapy (at least salmeterol 50&#160;micrograms bd or eformoterol 12&#160;micrograms bd) for at least 12 months, unless contraindicated or not tolerated, AND<br/> (ii)  oral corticosteroids (at least 10&#160;mg per day prednisolone (or equivalent)) for at least 6 weeks, unless contraindicated or not tolerated.<br/><br/> If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the authority application.  Details of the accepted toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement of treatment with optimised asthma therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The initial IgE assessment must be no more than 12 months old at the time of application.  A re-assessment of free IgE can only be made at least 12 months after the last dose of omalizumab.  For patients re-commencing omalizumab within 12 months of the last dose the previous pre-omalizumab IgE level should be used.<br/><br/> The IgE pathology report must be provided with the authority application.<br/><br/> The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application:<br/> (a) an Asthma Control Questionnaire (ACQ-5) score of at least 2.0, as assessed in the previous month, AND<br/> (b) while on oral corticosteroids and in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician.<br/><br/> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes the following:<br/>(i)  details of prior optimised asthma drug therapy (dosage, date of commencement and duration of therapy); and<br/> (ii)  details of severe exacerbation/s experienced while on oral corticosteroids (date and treatment); and<br/> (iii)  the signed patient acknowledgement; and<br/> (c) a completed Asthma Control Questionnaire (ACQ-5) calculation sheet including the date of assessment of the patient's symptoms. (For copies of the ACQ please contact Novartis Medical Information on 1800&#160;671&#160;203 or medinfo.phauno@novartis.com)<br/><br/> At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information) to be administered every 2 or 4 weeks.<br/><br/> Where fewer than the required number of repeats to complete 28 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 28 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 28 weeks.<br/><br/> The Asthma Control Questionnaire (5 item version) assessment of the patient's response to this initial course of treatment, and the assessment of oral corticosteroid dose, must be made at around 24 to 26 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.<br/><br/> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply.  Where a response assessment is not undertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9745X','3822','f',$$<p>Continuing treatment<br/><br/> Continuing PBS-subsidised treatment with omalizumab, by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient who:<br/> (a) has a documented history of severe allergic asthma; and<br/> (b) has demonstrated or sustained an adequate response to treatment with omalizumab.<br/><br/> An adequate response to omalizumab treatment is defined as:<br/> (a) a reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 0.5 from baseline, OR<br/> (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ-5 score from baseline.<br/><br/> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes details of maintenance oral corticosteroid dose; and<br/> (c) a completed Asthma Control Questionnaire (ACQ-5) calculation sheet including the date of assessment of the patient's symptoms. (For copies of the ACQ please contact Novartis Medical Information on 1800&#160;671&#160;203 or medinfo.phauno@novartis.com)<br/><br/> All applications for continuing treatment with omalizumab must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient's response to the prior course of treatment, and the assessment of oral corticosteroid dose, must be made at around 20 to 22 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.<br/><br/> The first assessment should, where possible, be completed by the same physician who initiated treatment with omalizumab.  If the same physician cannot assess the patient please call Medicare Australia on 1800&#160;700&#160;270.<br/><br/> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply.  Where a response assessment is notundertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab.<br/><br/> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 20 to 22 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised omalizumab treatment.<br/><br/> Patients are eligible to receive continuing courses of omalizumab treatment of up to 24 weeks providing they continue to demonstrate an adequate response to treatment.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for a continuing course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information), sufficient for 24 weeks of therapy.<br/><br/> Where fewer than the required number of repeats to complete 24 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).<br/><br/> A patient who fails to respond to a course of PBS-subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS-subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9745X','3742','f',$$<p>Initial PBS-subsidised treatment of severe allergic asthma in a patient who has previously received non-PBS-subsidised therapy with omalizumab (grandfather patients)<br/><br/> Initial PBS-subsidised supply for continuing treatment with omalizumab by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, of a patient aged 12 years or older with severe allergic asthma who satisfies the following criteria:<br/><br/> (a) has a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by standard clinical features, including:<br/> (i)  forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200&#160;mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or<br/> (ii)  airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or<br/> (iii)  peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; and<br/><br/> (b) duration of asthma of at least 1 year; and<br/><br/> (c) past or current evidence of atopy, documented by skin prick testing or RAST; and<br/><br/> (d) has signed a patient acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criteria for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment for grandfathered patients; and<br/><br/> (e) prior to omalizumab therapy had failed to achieve adequate control with optimised asthma therapy. Optimised asthma therapy includes:<br/> (i)  adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (budesonide 1600&#160;micrograms per day or fluticasone propionate 1000&#160;micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50&#160;micrograms bd or eformoterol 12&#160;micrograms bd) for at least 12 months, and<br/> (ii)  may have included maintenance dose oral corticosteroids; and<br/><br/>(f) has demonstrated an adequate response to treatment with omalizumab.<br/><br/> A review of the patient's records should be conducted to extract pre- and post-omalizumab data on symptoms, quality of life, medication doses, exacerbations and hospitalisations.  Examples of parameters to establish response include:<br/> (i)  a reduction in Asthma Control Questionnaire (ACQ-5) score of at least 0.5;<br/> (ii)  an improvement of at least 0.5 in the Asthma Quality of Life Questionnaire (AQLQ or mini-AQLQ);<br/> (iii)  maintenance oral corticosteroid dose reduced by at least 25% from baseline; and/or<br/> (iv)  a reduction in the number of hospitalisations or severe exacerbations requiring use of systemic corticosteroids, compared to the 12 months prior to commencement of omalizumab.<br/><br/> Where baseline assessments are not available, please call Medicare Australia on 1800&#160;700&#160;270 to discuss.<br/><br/> If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the authority application.  Details of the accepted contraindications and toxicities, including severity, which will be accepted for the purposes of exempting a patient from the requirement of treatment with optimised asthma therapy can be found on the Medicare Australia website [www.medicareaustralia.gov.au].<br/><br/> The authority application must be made in writing and must include:<br/> (a) a completed authority prescription form; and<br/> (b) a completed Severe Allergic Asthma PBS Authority Application - Supporting Information Form (may be downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)) which includes the following:<br/> (i)  details of prior optimised asthma drug therapy (dosage, date of commencement and duration of therapy); and<br/> (ii)  details of pre- and post-omalizumab data on symptoms, quality of life, medication doses, exacerbations and hospitalisations; and<br/> (iii)  the signed patient acknowledgement.<br/><br/> At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeatsto provide for an initial course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA-approved Product Information) to be administered every 2 or 4 weeks.<br/><br/> Where fewer than the required number of repeats to complete 24 weeks of treatment are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks of omalizumab therapy may be requested by telephone by contacting Medicare Australia on 1800&#160;700&#160;270 (hours of operation 8&#160;a.m. to 5&#160;p.m. EST Monday to Friday).  Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period beyond 24 weeks.<br/><br/> An assessment of the patient's continued response to this course of PBS-subsidised treatment must be made at around 20 to 22 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed.  The same parameters used to establish response to non-PBS-subsidised therapy with omalizumab should be used for the assessment.<br/><br/> This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to Medicare Australia within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply.  Where a response assessment is not undertaken and submitted to Medicare Australia within this timeframe, the patient will be deemed to have failed to respond to treatment with omalizumab.<br/><br/> It is recommended that an application for continuing treatment is posted to Medicare Australia at the time of the 20 to 22 week assessment, to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised omalizumab treatment.<br/><br/> Patients are eligible to receive continuing courses of omalizumab treatment of up to 24 weeks providing they continue to demonstrate an adequate response to treatment.<br/><br/> Patients may qualify for PBS-subsidised treatment under this restriction once only</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9747B','3355','t',$$<p>Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis of renal allograft rejection.  Management includes initiation, stabilisation and review of therapy as required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8266C','3280','f',$$<p>Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8298R','3280','f',$$<p>Migraine attack in a patient where attacks in the past have usually failed to respond to analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9714G','2423','f',$$<p>Treatment of infections suspected or proven to be due to a susceptible organism in patients who require a liquid formulation and in whom the syrup formulations are unsuitable</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9734H','3281','f',$$<p>adverse events have occurred with other suitable PBS-listed drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9734H','3282','f',$$<p>drug interactions have occurred with other suitable PBS-listed drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9734H','3283','f',$$<p>drug interactions are expected to occur with other suitable PBS-listed drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9734H','3284','f',$$<p>transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9734H','3285','f',$$<p>transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9736K','3281','f',$$<p>adverse events have occurred with other suitable PBS-listed drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9736K','3282','f',$$<p>drug interactions have occurred with other suitable PBS-listed drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9736K','3283','f',$$<p>drug interactions are expected to occur with other suitable PBS-listed drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9736K','3284','f',$$<p>transfer to another suitable PBS-listed drug would cause patient confusion resulting in problems with compliance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9736K','3285','f',$$<p>transfer to another suitable PBS-listed drug is likely to result in adverse clinical consequences</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5888X','3619','t',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy, in combination with a 5HT3 antagonist and dexamethasone, where any 1 of the following chemotherapy agents are to be administered:<br/> (a) altretamine;<br/> (b) carmustine;<br/> (c) cisplatin when a single dose constitutes a cycle of chemotherapy;<br/> (d) cyclophosphamide at a dose of 1500&#160;mg per square metre per day or greater;<br/> (e) dacarbazine;<br/> (f) procarbazine when a single dose constitutes a cycle of chemotherapy;<br/> (g) streptozocin.<br/> No more than 1 pack containing 1 x 125&#160;mg capsule and 2 x 80&#160;mg capsules will be authorised per cycle of cytotoxic chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5888X','3620','t',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat breast cancer, in combination with a 5HT3 antagonist and dexamethasone, where cyclophosphamide and an anthracycline are to be co-administered.<br/> No more than 1 pack containing 1 x 125&#160;mg capsule and 2 x 80&#160;mg capsules will be authorised per cycle of cytotoxic chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5888X','3621','t',$$<p>Management of nausea and vomiting associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy, in combination with a 5HT3 antagonist and dexamethasone on day 1, where the patient has had a prior episode of chemotherapy induced nausea or vomiting where any 1 of the following intravenous chemotherapy agents is to be administered:<br/> (a) arsenic trioxide;<br/> (b) azacitidine;<br/> (c) carboplatin;<br/> (d) cyclophosphamide at a dose of less than 1500&#160;mg per square metre per day;<br/> (e) cytarabine at a dose of greater than 1&#160;g per square metre per day;<br/> (f) dactinomycin;<br/> (g) daunorubicin;<br/> (h) doxorubicin;<br/> (i) epirubicin;<br/> (j) fotemustine;<br/> (k) idarubicin;<br/> (l) ifosfamide;<br/> (m) irinotecan;<br/> (n) melphalan;<br/> (o) methotrexate at a dose of 250&#160;mg to 1&#160;g per square metre;<br/> (p) oxaliplatin;<br/> (q) raltitrexed.<br/> No more than one pack containing 1 x 125&#160;mg capsule and 2 x 80&#160;mg capsules will be authorised per cycle of cytotoxic chemotherapy. Concomitant use of a 5HT3 antagonist should not occur with aprepitant on days 2 and 3 of any chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5893E','3180','t',$$<p>Hairy cell leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5945X','3180','t',$$<p>Hairy cell leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5945X','3899','t',$$<p>Myeloproliferative disease with excessive thrombocytosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5946Y','3895','t',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5947B','3895','t',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5948C','3895','t',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5949D','3895','t',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5953H','3898','t',$$<p>Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5953H','3895','t',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5956L','3898','t',$$<p>Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5956L','3895','t',$$<p>Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5996N','3899','t',$$<p>Myeloproliferative disease with excessive thrombocytosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5997P','3899','t',$$<p>Myeloproliferative disease with excessive thrombocytosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5998Q','3899','t',$$<p>Myeloproliferative disease with excessive thrombocytosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4011D','1244','f',$$<p>Onychomycosis due to dermatophyte infection proven by microscopy or culture and confirmed by an approved pathology provider</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4046Y','3227','f',$$<p>For the management of actinic keratoses in patients where other standard treatments are inappropriate, and topical drug therapy is required as field treatment for clinically visible and subclinical lesions</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4070F','1417','f',$$<p>Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4134N','3073','f',$$<p>Treatment of solar keratosis on the face and scalp in patients where other standard treatments are inappropriate and topical drug therapy is required as field treatment for clinically visible and subclinical lesions</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4144D','1109','f',$$<p>For the short-term treatment of anxiety</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4145E','1109','f',$$<p>For the short-term treatment of anxiety</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4150K','1278','f',$$<p>Patients with terminal disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4150K','1277','f',$$<p>Patients with refractory phobic or anxiety states</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4151L','1278','f',$$<p>Patients with terminal disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4151L','1277','f',$$<p>Patients with refractory phobic or anxiety states</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4179Y','1606','f',$$<p>For use in patients pre- and post-angioplasty</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4190M','1265','f',$$<p>Patients requiring an NSAID in whom a risk of upper gastrointestinal complications is high or with a history of peptic ulcer disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4216X','1278','f',$$<p>Patients with terminal disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4216X','1277','f',$$<p>Patients with refractory phobic or anxiety states</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4233T','1417','f',$$<p>Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4252T','2853','f',$$<p>For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4255Y','2853','f',$$<p>For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4258D','2853','f',$$<p>For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4259E','2853','f',$$<p>For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4263J','2853','f',$$<p>For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4266M','2853','f',$$<p>For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4270R','2853','f',$$<p>For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4277D','1417','f',$$<p>Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4284L','1676','f',$$<p>Initial treatment, in combination with methotrexate, of specific accepted war-caused or service-related disability of refractory rheumatoid arthritis. Initial treatment may be prescribed by rheumatologists or consultant physicians for the reduction of signs and symptoms and prevention of structural joint damage in adult patients with active rheumatoid arthritis who satisfy all of the following criteria:<br/> (1) (a) Proven raised erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP); and<br/> (1) (b) Proven erosive rheumatoid arthritis without end-stage disease;<br/> (2) Failure of an adequate trial of methotrexate and 2 other disease modifying anti-rheumatic drugs (such as sulfasalazine, hydroxychloroquine, leflunomide or cyclosporin) &#8212; unless these drugs were contraindicated or intolerance had developed;<br/> (3) No history of active tuberculosis requiring treatment in the last 3 years;<br/> (4) No history of opportunistic infection in the last 2 months;<br/> (5) Female patients of child-bearing age are not pregnant, not breast-feeding, and are using an effective form of contraception.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Infliximab (Remicade) RPBS Authority Application - Supporting Information form (contact the VAPAC on 1800 552 580 for a copy of the form)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4284L','1677','f',$$<p>Continuing treatment, in combination with methotrexate, of specific accepted war-caused or service-related disability of refractory rheumatoid arthritis. Continuing treatment may be prescribed by rheumatologists or consultant physicians, following initial therapy of 3 doses, in patients who satisfy the following criteria:<br/> (1) There is improvement in ESR and/or CRP; and<br/> (2) An ACR20 (American College of Rheumatology) response is achieved by 14 weeks after the commencement of therapy.</p><p> Applications for authorisation must be in writing and must include:<br/> (1) a completed authority prescription form; and<br/> (2) a completed Infliximab (Remicade) RPBS Authority Application - Supporting Information form (contact the VAPAC on 1800 552 580 for a copy of the form)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4290T','1792','f',$$<p>Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.</p><p> Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4302K','1792','f',$$<p>Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.</p><p> Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4303L','1417','f',$$<p>Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4320J','2821','f',$$<p>For the treatment of refractory neuropathic pain not controlled by other drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4322L','2821','f',$$<p>For the treatment of refractory neuropathic pain not controlled by other drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4323M','2821','f',$$<p>For the treatment of refractory neuropathic pain not controlled by other drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4324N','2821','f',$$<p>For the treatment of refractory neuropathic pain not controlled by other drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4380M','3131','f',$$<p>For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5&#160;mg of prednisone or equivalent per day. <br/> Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density T-score of less than -1.0)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4390C','1113','f',$$<p>For the treatment of ano-genital warts</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4396J','1417','f',$$<p>Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4397K','1417','f',$$<p>Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4398L','1417','f',$$<p>Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4399M','1417','f',$$<p>Treatment of benign prostatic hyperplasia where surgery is inappropriate, or where other drug treatment has failed or is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4443W','1793','f',$$<p>For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5&#160;mg of prednisone or equivalent per day. Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density t-score of less than -1.0)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4444X','1793','f',$$<p>For preservation of bone mineral density in patients on long-term glucocorticoid therapy where patients are undergoing continuous treatment with a dose equal to or greater than 7.5&#160;mg of prednisone or equivalent per day. Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic (bone mineral density t-score of less than -1.0)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4559Y','2279','f',$$<p>Primary treatment of histopathologically confirmed superficial basal cell carcinoma where other standard treatments are inappropriate and topical drug therapy is required</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4566H','1113','f',$$<p>For the treatment of ano-genital warts</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4570M','2208','f',$$<p>For the treatment of obese patients.<br/> Total treatment will not exceed 12 months from initial application.<br/> Patients are eligible for 1 continuous treatment in a lifetime.<br/> The patient must be receiving, or enrolled to receive, professional dietetic and weight management advice (where this is available).</p><p> Initial treatment for patients who meet the following criteria to qualify:<br/> (a) Body Mass Index (BMI) greater than or equal to 35 with no known co-morbidities; or<br/> (b) BMI greater than or equal to 30 with 1 or more of the following co-morbidities:<br/> (i) diabetes;<br/> (ii) ischaemic heart disease;<br/> (iii) psychiatric conditions;<br/> (iv) hypertension.<br/> The prescriber must provide the following:<br/> (a) initial body weight; and<br/> (b) BMI.</p><p> Continuing treatment for patients who have previously been issued with an authority prescription for orlistat.  After 3 months and up to 6 months following commencement of orlistat treatment, patient's initial body weight must have been reduced by 2.5&#160;kg or 2.5% (whichever is the lesser).</p><p> Continuing treatment for patients who have previously been issued with an authority prescription for orlistat. After 6 months and up to 12 months following commencement of orlistat treatment, patient's initial body weight must have been reduced by 5&#160;kg or 5% (whichever is the lesser)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4571N','1270','f',$$<p>Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4572P','1270','f',$$<p>Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4573Q','1270','f',$$<p>Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4576W','1270','f',$$<p>Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4577X','1270','f',$$<p>Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4578Y','1270','f',$$<p>Patients who have indicated that they are ready to cease smoking and who have entered a support and counselling program</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4579B','1792','f',$$<p>Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.</p><p> Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4580C','1792','f',$$<p>Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.</p><p> Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4584G','1792','f',$$<p>Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.</p><p> Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4585H','1792','f',$$<p>Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.</p><p> Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4586J','1792','f',$$<p>Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.</p><p> Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4591P','1604','f',$$<p>To be approved for the treatment of refractory neuropathic pain not controlled by other drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4592Q','1604','f',$$<p>To be approved for the treatment of refractory neuropathic pain not controlled by other drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4593R','1604','f',$$<p>To be approved for the treatment of refractory neuropathic pain not controlled by other drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4594T','1604','f',$$<p>To be approved for the treatment of refractory neuropathic pain not controlled by other drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4595W','1604','f',$$<p>To be approved for the treatment of refractory neuropathic pain not controlled by other drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4596X','1792','f',$$<p>Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.</p><p> Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4597Y','1792','f',$$<p>Specific accepted war-caused or service-related disabilities for males with vasculogenic, psychogenic or neurogenic erectile dysfunction.</p><p> Authorisation will not be given for any additional prescriptions within 6 months or for any increased quantities or repeats</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4646M','2853','f',$$<p>For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4647N','2853','f',$$<p>For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4648P','2853','f',$$<p>For wounds where there is evidence of critical colonisation and for well-assessed chronic wounds that have not responded to conventional dressings</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2090B','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5502N','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5504Q','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5505R','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5506T','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5509Y','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5510B','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5521N','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5532E','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5545W','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5560P','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5561Q','2802','f',$$<p>Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5564W','3830','f',$$<p>Bacterial keratitis under the supervision and direction of an ophthalmologist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5567B','3830','f',$$<p>Bacterial keratitis under the supervision and direction of an ophthalmologist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5301B','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5302C','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5303D','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5304E','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5305F','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5306G','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5307H','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5308J','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5311M','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5312N','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5313P','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5314Q','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5315R','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5316T','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5317W','3638','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where colicky pain is a symptom</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5318X','3639','t',$$<p>Continuing supply for a palliative care patient where colicky pain is a symptom</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5319Y','3649','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient for analgesia or fever where alternative therapy cannot be tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5320B','3650','t',$$<p>Continuing supply for a palliative care patient for analgesia or fever where alternative therapy cannot be tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5322D','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5324F','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5331N','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5332P','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5333Q','3636','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where dry mouth is a symptom</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5334R','3636','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where dry mouth is a symptom</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5335T','3637','t',$$<p>Continuing supply for a palliative care patient where dry mouth is a symptom</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5336W','3637','t',$$<p>Continuing supply for a palliative care patient where dry mouth is a symptom</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5337X','3657','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient for the prevention of epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5338Y','3657','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient for the prevention of epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5339B','3657','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient for the prevention of epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5340C','3658','f',$$<p>Continuing supply for a palliative care patient for the prevention of epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5341D','3658','f',$$<p>Continuing supply for a palliative care patient for the prevention of epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5342E','3658','f',$$<p>Continuing supply for a palliative care patient for the prevention of epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5343F','3649','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient for analgesia or fever where alternative therapy cannot be tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5344G','3650','t',$$<p>Continuing supply for a palliative care patient for analgesia or fever where alternative therapy cannot be tolerated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5345H','3645','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5346J','3645','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5347K','3645','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5348L','3645','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5349M','3646','t',$$<p>Continuing supply for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5350N','3646','t',$$<p>Continuing supply for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5351P','3646','t',$$<p>Continuing supply for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5352Q','3646','t',$$<p>Continuing supply for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5353R','3645','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5354T','3646','t',$$<p>Continuing supply for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5355W','3655','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient where anxiety is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5356X','3655','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient where anxiety is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5357Y','3656','f',$$<p>Continuing supply for a palliative care patient where anxiety is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5358B','3656','f',$$<p>Continuing supply for a palliative care patient where anxiety is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5359C','3653','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient where insomnia is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5360D','3654','f',$$<p>Continuing supply for a palliative care patient where insomnia is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5361E','3645','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5362F','3645','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5363G','3665','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5364H','3646','t',$$<p>Continuing supply for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5365J','3646','t',$$<p>Continuing supply for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5366K','3666','f',$$<p>Continuing supply for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5368M','3665','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5370P','3666','f',$$<p>Continuing supply for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5371Q','3655','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient where anxiety is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5372R','3655','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient where anxiety is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5373T','3656','f',$$<p>Continuing supply for a palliative care patient where anxiety is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5374W','3656','f',$$<p>Continuing supply for a palliative care patient where anxiety is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5375X','3653','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient where insomnia is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5376Y','3654','f',$$<p>Continuing supply for a palliative care patient where insomnia is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5377B','3645','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5378C','3665','f',$$<p>Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5379D','3646','t',$$<p>Continuing supply for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5380E','3666','f',$$<p>Continuing supply for a palliative care patient where severe pain is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5385K','3634','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where a painful mouth is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5386L','3635','t',$$<p>Continuing supply for a palliative care patient where a painful mouth is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5387M','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5388N','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5389P','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5390Q','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5391R','3659','f',$$<p>Initial supply, for up to 3 months, for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5392T','3660','f',$$<p>Continuing supply for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5393W','3661','f',$$<p>Initial supply, for up to 3 months, for a palliative care patient with severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5394X','3661','f',$$<p>Initial supply, for up to 3 months, for a palliative care patient with severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5395Y','3662','f',$$<p>Continuing supply for a palliative care patient with severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5396B','3662','f',$$<p>Continuing supply for a palliative care patient with severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5399E','3659','f',$$<p>Initial supply, for up to 3 months, for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5400F','3660','f',$$<p>Continuing supply for a palliative care patient with chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5401G','3663','f',$$<p>Initial supply for dose titration for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5402H','3663','f',$$<p>Initial supply for dose titration for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5403J','3663','f',$$<p>Initial supply for dose titration for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5404K','3663','f',$$<p>Initial supply for dose titration for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5405L','3663','f',$$<p>Initial supply for dose titration for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5406M','3663','f',$$<p>Initial supply for dose titration for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5407N','3664','f',$$<p>Continuing supply for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5408P','3664','f',$$<p>Continuing supply for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5409Q','3664','f',$$<p>Continuing supply for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5410R','3664','f',$$<p>Continuing supply for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5411T','3664','f',$$<p>Continuing supply for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5412W','3664','f',$$<p>Continuing supply for breakthrough pain in a palliative care patient with cancer who is receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5421H','3636','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where dry mouth is a symptom</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5422J','3637','t',$$<p>Continuing supply for a palliative care patient where dry mouth is a symptom</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5423K','3235','f',$$<p>Initial supply, in combination with oral laxatives, for a palliative care patient with opioid-induced constipation who has failed to respond to laxatives</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5424L','3238','f',$$<p>Continuing supply, in combination with oral laxatives, for a palliative care patient with opioid-induced constipation who has demonstrated a response to methylnaltrexone</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5426N','3642','t',$$<p>Initial supply, for up to 4 months, for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5427P','3643','t',$$<p>Continuing supply for a palliative care patient where constipation is a problem</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1002R','1715','f',$$<p>Herpes simplex keratitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1085D','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1085D','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1085D','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1086E','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1086E','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1086E','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1088G','1731','f',$$<p>Serious supra-ventricular cardiac arrhythmias</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1088G','1732','f',$$<p>Serious ventricular cardiac arrhythmias where treatment is initiated in a hospital (in-patient or out-patient)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1090J','1731','f',$$<p>Serious supra-ventricular cardiac arrhythmias</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1090J','1732','f',$$<p>Serious ventricular cardiac arrhythmias where treatment is initiated in a hospital (in-patient or out-patient)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1104D','1254','f',$$<p>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1104D','1268','f',$$<p>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1104D','1122','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1104D','1263','f',$$<p>Patients receiving palliative care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1104D','1400','f',$$<p>Terminal malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1104D','1025','f',$$<p>Anorectal congenital abnormalities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1104D','1221','f',$$<p>Megacolon</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1115Q','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1119X','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1121B','1669','f',$$<p>Radiation induced mucositis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1127H','1466','f',$$<p>Vernal kerato-conjunctivitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1131M','1290','f',$$<p>Primary and relapsing superficial urothelial carcinoma of the bladder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1140B','1419','f',$$<p>Treatment of carcinoma in situ of the urinary bladder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1166J','1285','f',$$<p>Phaeochromocytoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1166J','1239','f',$$<p>Neurogenic urinary retention</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1211R','1026','f',$$<p>Anovulatory infertility</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1211R','1267','f',$$<p>Patients undergoing in-vitro fertilisation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1229Q','1148','f',$$<p>Haemodialysis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1256D','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1256D','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1256D','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1257E','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1257E','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1257E','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1258F','1254','f',$$<p>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1258F','1268','f',$$<p>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1258F','1122','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1258F','1263','f',$$<p>Patients receiving palliative care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1258F','1400','f',$$<p>Terminal malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1258F','1025','f',$$<p>Anorectal congenital abnormalities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1258F','1221','f',$$<p>Megacolon</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1259G','1254','f',$$<p>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1259G','1268','f',$$<p>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1259G','1122','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1259G','1263','f',$$<p>Patients receiving palliative care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1259G','1400','f',$$<p>Terminal malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1259G','1025','f',$$<p>Anorectal congenital abnormalities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1259G','1221','f',$$<p>Megacolon</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1260H','1254','f',$$<p>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1260H','1268','f',$$<p>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1260H','1122','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1260H','1263','f',$$<p>Patients receiving palliative care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1260H','1400','f',$$<p>Terminal malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1260H','1025','f',$$<p>Anorectal congenital abnormalities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1260H','1221','f',$$<p>Megacolon</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1263L','1254','f',$$<p>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1263L','1268','f',$$<p>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1263L','1122','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1263L','1263','f',$$<p>Patients receiving palliative care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1263L','1400','f',$$<p>Terminal malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1263L','1025','f',$$<p>Anorectal congenital abnormalities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1263L','1221','f',$$<p>Megacolon</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1296F','1148','f',$$<p>Haemodialysis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1299J','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1299J','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1300K','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1300K','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1326T','1177','f',$$<p>Initial treatment of peptic ulcer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1327W','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1327W','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1327W','1476','f',$$<p>Zollinger-Ellison syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1356J','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1356J','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1356J','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1411G','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1434L','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1434L','1241','f',$$<p>Obsessive-compulsive disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1441W','1188','f',$$<p>Invasive ocular infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1441W','1714','f',$$<p>Perioperative use in ophthalmic surgery</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1441W','1391','f',$$<p>Suspected pseudomonal eye infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1443Y','1001','f',$$<p>Acromegaly</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1443Y','1255','f',$$<p>Parkinson's disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1443Y','1841','f',$$<p>Pathological hyperprolactinaemia where surgery is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1443Y','1842','f',$$<p>Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1443Y','1843','f',$$<p>Pathological hyperprolactinaemia where radiotherapy is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1443Y','1844','f',$$<p>Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1444B','1289','f',$$<p>Prevention of the onset of lactation in the puerperium for medical reasons</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1445C','1001','f',$$<p>Acromegaly</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1445C','1255','f',$$<p>Parkinson's disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1445C','1841','f',$$<p>Pathological hyperprolactinaemia where surgery is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1445C','1842','f',$$<p>Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1445C','1843','f',$$<p>Pathological hyperprolactinaemia where radiotherapy is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1445C','1844','f',$$<p>Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1446D','1001','f',$$<p>Acromegaly</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1446D','1255','f',$$<p>Parkinson's disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1446D','1841','f',$$<p>Pathological hyperprolactinaemia where surgery is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1446D','1842','f',$$<p>Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1446D','1843','f',$$<p>Pathological hyperprolactinaemia where radiotherapy is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1446D','1844','f',$$<p>Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1453L','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1502C','1294','f',$$<p>Proctitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1502C','1454','f',$$<p>Ulcerative colitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1509K','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1510L','1128','f',$$<p>For use in a hospital</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1511M','1128','f',$$<p>For use in a hospital</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1518X','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1520B','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1526H','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1527J','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1542E','1754','f',$$<p>Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1542E','1755','f',$$<p>Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1546J','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1547K','1453','f',$$<p>Tyrosinaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1548L','1314','f',$$<p>Pyridoxine non-responsive homocystinuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1559C','1001','f',$$<p>Acromegaly</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1559C','1255','f',$$<p>Parkinson's disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1559C','1841','f',$$<p>Pathological hyperprolactinaemia where surgery is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1559C','1842','f',$$<p>Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1559C','1843','f',$$<p>Pathological hyperprolactinaemia where radiotherapy is not indicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1559C','1844','f',$$<p>Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1561E','1041','f',$$<p>Cataplexy associated with narcolepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1561E','1241','f',$$<p>Obsessive-compulsive disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1561E','1287','f',$$<p>Phobic disorders in adults</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1581F','1878','f',$$<p>Anovulatory infertility</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1581F','1118','f',$$<p>For the treatment of infertility in males due to hypogonadotrophic hypogonadism</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1581F','1117','f',$$<p>For the treatment of infertility in males associated with isolated luteinising hormone deficiency</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1581F','1120','f',$$<p>For the treatment of males who have combined deficiency of human growth hormone and gonadotrophins and in whom the absence of secondary sexual characteristics indicates a lag in maturation</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1581F','1116','f',$$<p>For the treatment of boys over the age of 16 years who show clinical evidence of hypogonadism or delayed puberty. Treatment must not extend beyond 6 months</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1590Q','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1606M','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1609Q','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1614Y','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1614Y','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1615B','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1615B','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1616C','1347','f',$$<p>Severe acne not responding to other tetracyclines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1621H','1416','f',$$<p>Treatment of anaerobic infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1623K','2884','f',$$<p>For patients requiring doses greater than 20&#160;mg per week</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1627P','1355','f',$$<p>Severe depression</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1628Q','1355','f',$$<p>Severe depression</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1638F','1300','f',$$<p>Prophylaxis in large bowel surgery</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1638F','1448','f',$$<p>Treatment, in a hospital, of acute anaerobic sepsis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1646P','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1653B','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1654C','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1655D','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1656E','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1659H','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1659H','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1674D','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1674D','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1703P','1304','f',$$<p>Prophylaxis of recurrent streptococcal infections (including rheumatic fever)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1705R','1304','f',$$<p>Prophylaxis of recurrent streptococcal infections (including rheumatic fever)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1758M','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1758M','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1758M','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1759N','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1759N','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1759N','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1779P','1421','f',$$<p>Treatment of chronic spasticity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1780Q','1421','f',$$<p>Treatment of chronic spasticity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1783W','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1783W','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1783W','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1784X','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1784X','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1784X','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1785Y','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1785Y','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1785Y','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1788D','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1788D','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1788D','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1795L','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1795L','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1797N','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1797N','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1797N','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1798P','1288','f',$$<p>Prevention of migraine</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1799Q','3132','f',$$<p>Cellulitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1800R','1459','f',$$<p>Urethritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1807D','1093','f',$$<p>Epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1821W','1300','f',$$<p>Prophylaxis in large bowel surgery</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1821W','1448','f',$$<p>Treatment, in a hospital, of acute anaerobic sepsis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1824B','1087','f',$$<p>Dysmenorrhoea</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1824B','1222','f',$$<p>Menorrhagia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1850J','1093','f',$$<p>Epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1862B','1285','f',$$<p>Phaeochromocytoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1862B','1239','f',$$<p>Neurogenic urinary retention</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1880Y','1749','f',$$<p>Treatment of hormone-dependent breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1891M','1836','f',$$<p>Infections where resistance to amoxycillin is suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1891M','1837','f',$$<p>Infections where resistance to amoxycillin is proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1892N','1836','f',$$<p>Infections where resistance to amoxycillin is suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1892N','1837','f',$$<p>Infections where resistance to amoxycillin is proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1895R','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1896T','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1897W','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1898X','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1900B','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1903E','1385','f',$$<p>Splenectomised persons over 2 years of age</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1903E','1284','f',$$<p>Persons with Hodgkin's disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1903E','1282','f',$$<p>Persons at high risk of pneumococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1909L','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1913Q','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1914R','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1915T','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1923F','1225','f',$$<p>Methylmalonic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1923F','1307','f',$$<p>Propionic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1928L','1102','f',$$<p>For local intra-articular or peri-articular infiltration</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1938B','1670','f',$$<p>Chylous ascites</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1938B','1068','f',$$<p>Chylothorax</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1938B','1671','f',$$<p>Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1938B','1513','f',$$<p>Hyperlipoproteinaemia type 1</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1938B','1511','f',$$<p>Long chain fatty acid oxidation disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1953T','1081','f',$$<p>Detrusor overactivity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1973W','1864','f',$$<p>Late stage Parkinson's disease as adjunctive therapy in patients being treated with levodopa&#8212;decarboxylase inhibitor combinations</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1981G','1303','f',$$<p>Prophylaxis of meningococcal disease in close contacts and carriers</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1981G','1297','f',$$<p>Prophylactic treatment of contacts of patients with Haemophilus influenzae type B</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1984K','1303','f',$$<p>Prophylaxis of meningococcal disease in close contacts and carriers</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1984K','1297','f',$$<p>Prophylactic treatment of contacts of patients with Haemophilus influenzae type B</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2000G','1754','f',$$<p>Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2000G','1755','f',$$<p>Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2001H','1754','f',$$<p>Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2001H','1755','f',$$<p>Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2003K','1754','f',$$<p>Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2003K','1755','f',$$<p>Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2011W','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2012X','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2013Y','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2027Q','1147','f',$$<p>Gyrate atrophy of the choroid and retina</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2027Q','1458','f',$$<p>Urea cycle disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2041K','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2043M','1350','f',$$<p>Severe cardiac arrhythmias</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2044N','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2080L','1066','f',$$<p>Chronic stable plaque type psoriasis vulgaris</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2091C','1254','f',$$<p>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2091C','1268','f',$$<p>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2091C','1122','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2091C','1263','f',$$<p>Patients receiving palliative care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2091C','1400','f',$$<p>Terminal malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2091C','1025','f',$$<p>Anorectal congenital abnormalities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2091C','1221','f',$$<p>Megacolon</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2103Q','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2109B','1749','f',$$<p>Treatment of hormone-dependent breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2110C','1749','f',$$<p>Treatment of hormone-dependent breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2117K','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2118L','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2122Q','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2123R','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2124T','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2136K','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2138M','1093','f',$$<p>Epilepsy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2161R','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2166B','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2170F','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2179Q','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2179Q','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2179Q','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2236Q','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2237R','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2240X','1177','f',$$<p>Initial treatment of peptic ulcer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2241Y','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2241Y','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2242B','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2242B','1241','f',$$<p>Obsessive-compulsive disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2242B','1862','f',$$<p>Panic disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2269K','1302','f',$$<p>Prophylaxis of endocarditis in patients hypersensitive to penicillin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2270L','1091','f',$$<p>Endophthalmitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2270L','1464','f',$$<p>Use initiated in a hospital for infections where vancomycin is an appropriate antibiotic</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2308L','1028','f',$$<p>Antidote to folic acid antagonists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2312Q','1130','f',$$<p>For use in combination with another antibiotic in the treatment of proven serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2316X','1542','f',$$<p>Hormone-dependent breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2316X','1088','f',$$<p>Endometrial cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2328M','1188','f',$$<p>Invasive ocular infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2328M','1714','f',$$<p>Perioperative use in ophthalmic surgery</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2328M','1391','f',$$<p>Suspected pseudomonal eye infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2329N','1188','f',$$<p>Invasive ocular infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2329N','1714','f',$$<p>Perioperative use in ophthalmic surgery</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2329N','1391','f',$$<p>Suspected pseudomonal eye infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2343H','1350','f',$$<p>Severe cardiac arrhythmias</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2344J','1350','f',$$<p>Severe cardiac arrhythmias</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2347M','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2375B','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2380G','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2382J','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2446R','1006','f',$$<p>Acute myelogenous leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2448W','1006','f',$$<p>Acute myelogenous leukaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2454E','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2454E','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2474F','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2481N','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2522R','1860','f',$$<p>Major depression where other antidepressant therapy has failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2522R','1861','f',$$<p>Major depression where other antidepressant therapy is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2523T','1860','f',$$<p>Major depression where other antidepressant therapy has failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2523T','1861','f',$$<p>Major depression where other antidepressant therapy is contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2527B','1537','f',$$<p>For pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2554K','1294','f',$$<p>Proctitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2554K','1454','f',$$<p>Ulcerative colitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2555L','1254','f',$$<p>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2555L','1268','f',$$<p>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2555L','1122','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2555L','1263','f',$$<p>Patients receiving palliative care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2555L','1400','f',$$<p>Terminal malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2555L','1025','f',$$<p>Anorectal congenital abnormalities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2555L','1221','f',$$<p>Megacolon</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2556M','1254','f',$$<p>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2556M','1268','f',$$<p>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2556M','1122','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2556M','1263','f',$$<p>Patients receiving palliative care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2556M','1400','f',$$<p>Terminal malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2556M','1025','f',$$<p>Anorectal congenital abnormalities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2556M','1221','f',$$<p>Megacolon</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2557N','1254','f',$$<p>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2557N','1268','f',$$<p>Patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2557N','1122','f',$$<p>For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2557N','1263','f',$$<p>Patients receiving palliative care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2557N','1400','f',$$<p>Terminal malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2557N','1025','f',$$<p>Anorectal congenital abnormalities</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2557N','1221','f',$$<p>Megacolon</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2622B','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2626F','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2629J','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2646G','3550','f',$$<p>A child aged less than 9 years with proven glutaric aciduria type 1</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2650L','2612','f',$$<p>An infant or young child with proven glutaric aciduria type 1</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2681D','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2682E','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2694T','1020','f',$$<p>Alopecia areata</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2694T','1102','f',$$<p>For local intra-articular or peri-articular infiltration</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2694T','1146','f',$$<p>Granulomata, dermal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2694T','1189','f',$$<p>Keloid</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2694T','1191','f',$$<p>Lichen planus hypertrophic</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2694T','1192','f',$$<p>Lichen simplex chronicus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2694T','1197','f',$$<p>Lupus erythematosus, chronic discoid</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2694T','1237','f',$$<p>Necrobiosis lipoidica</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2694T','1465','f',$$<p>Uveitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2702F','1279','f',$$<p>Pelvic inflammatory disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2703G','1279','f',$$<p>Pelvic inflammatory disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2707L','1851','f',$$<p>Bronchiectasis in patients aged 8 years or older</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2707L','1852','f',$$<p>Chronic bronchitis in patients aged 8 years or older</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2707L','1346','f',$$<p>Severe acne</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2711Q','1851','f',$$<p>Bronchiectasis in patients aged 8 years or older</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2711Q','1852','f',$$<p>Chronic bronchitis in patients aged 8 years or older</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2711Q','1346','f',$$<p>Severe acne</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2714W','1459','f',$$<p>Urethritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2715X','1459','f',$$<p>Urethritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2722G','1089','f',$$<p>Endometriosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2725K','1542','f',$$<p>Hormone-dependent breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2725K','1088','f',$$<p>Endometrial cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2727M','1542','f',$$<p>Hormone-dependent breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2727M','1088','f',$$<p>Endometrial cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2728N','1543','f',$$<p>Hormone-dependent advanced breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2734X','1543','f',$$<p>Hormone-dependent advanced breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2738D','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2739E','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2745L','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2746M','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2808T','1863','f',$$<p>Parkinson's disease as adjunctive therapy in patients being treated with levodopa&#8212;decarboxylase inhibitor combinations</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2809W','1863','f',$$<p>Parkinson's disease as adjunctive therapy in patients being treated with levodopa&#8212;decarboxylase inhibitor combinations</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2810X','1863','f',$$<p>Parkinson's disease as adjunctive therapy in patients being treated with levodopa&#8212;decarboxylase inhibitor combinations</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2812B','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2813C','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2815E','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2820K','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2833D','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2834E','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2839K','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2840L','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2841M','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2845R','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2856H','1609','f',$$<p>Depression where all other anti-depressant therapy has failed or is inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2857J','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2863Q','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2881P','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2882Q','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2887Y','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2888B','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2956N','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2990J','1020','f',$$<p>Alopecia areata</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2990J','1102','f',$$<p>For local intra-articular or peri-articular infiltration</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2990J','1146','f',$$<p>Granulomata, dermal</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2990J','1189','f',$$<p>Keloid</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2990J','1191','f',$$<p>Lichen planus hypertrophic</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2990J','1192','f',$$<p>Lichen simplex chronicus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2990J','1197','f',$$<p>Lupus erythematosus, chronic discoid</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2990J','1237','f',$$<p>Necrobiosis lipoidica</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2990J','1313','f',$$<p>Psoriasis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3016R','1258','f',$$<p>Parkinson's disease which is not drug induced</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3064G','1150','f',$$<p>Hepatic coma or precoma (chronic porto-systemic encephalopathy)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3064G','1613','f',$$<p>Constipation in patients with malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3078B','1453','f',$$<p>Tyrosinaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3112T','1077','f',$$<p>Corneal grafts</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3112T','1465','f',$$<p>Uveitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3130R','1302','f',$$<p>Prophylaxis of endocarditis in patients hypersensitive to penicillin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3131T','1091','f',$$<p>Endophthalmitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3131T','1464','f',$$<p>Use initiated in a hospital for infections where vancomycin is an appropriate antibiotic</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3136C','1276','f',$$<p>Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3138E','1145','f',$$<p>Gram-positive coccal infections where these cannot be safely and effectively treated with a penicillin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3190X','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3190X','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3402C','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3403D','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3404E','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3405F','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3407H','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3412N','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3416T','1613','f',$$<p>Constipation in patients with malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3416T','2823','f',$$<p>Chronic constipation or faecal impaction not adequately controlled with first line interventions such as bulk-forming agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3416T','2693','f',$$<p>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function not responding to other oral therapies</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3416T','1263','f',$$<p>Patients receiving palliative care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3417W','1314','f',$$<p>Pyridoxine non-responsive homocystinuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3418X','3216','f',$$<p>Parkinson disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3419Y','3216','f',$$<p>Parkinson disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3420B','3216','f',$$<p>Parkinson disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3421C','3216','f',$$<p>Parkinson disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3422D','3216','f',$$<p>Parkinson disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3438Y','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3438Y','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3442E','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3443F','1225','f',$$<p>Methylmalonic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3443F','1307','f',$$<p>Propionic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3444G','1225','f',$$<p>Methylmalonic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3444G','1307','f',$$<p>Propionic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5053Y','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5134F','3883','f',$$<p>Chronic obstructive pulmonary disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5137J','3883','f',$$<p>Chronic obstructive pulmonary disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5143Q','3216','f',$$<p>Parkinson disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5145T','3216','f',$$<p>Parkinson disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5265D','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5268G','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5269H','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5276Q','3827','f',$$<p>Chronic stable plaque type psoriasis vulgaris of the scalp in a patient who is not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5277R','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5278T','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5279W','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5280X','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5285E','3539','f',$$<p>Hypertension in a patient who is not adequately controlled with any two of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5286F','3539','f',$$<p>Hypertension in a patient who is not adequately controlled with any two of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5287G','3539','f',$$<p>Hypertension in a patient who is not adequately controlled with any two of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5288H','3539','f',$$<p>Hypertension in a patient who is not adequately controlled with any two of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5289J','3539','f',$$<p>Hypertension in a patient who is not adequately controlled with any two of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5292M','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5293N','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5294P','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5295Q','3545','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5434B','1148','f',$$<p>Haemodialysis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5435C','1148','f',$$<p>Haemodialysis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5437E','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5438F','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5439G','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5440H','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5441J','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5454C','3046','f',$$<p>For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5459H','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5460J','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5461K','1978','f',$$<p>Acute episode of mild to moderate ulcerative proctitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5470X','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5471Y','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5477G','3132','f',$$<p>Cellulitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5478H','3132','f',$$<p>Cellulitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5479J','3132','f',$$<p>Cellulitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5481L','3679','f',$$<p>Urea cycle disorders in order to prevent low plasma arginine or citrulline levels</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5482M','1458','f',$$<p>Urea cycle disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5483N','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5484P','3678','f',$$<p>A patient aged 3 years or older with proven glutaric aciduria type 1</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8000C','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8003F','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8007K','1177','f',$$<p>Initial treatment of peptic ulcer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8008L','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8008L','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8008L','1476','f',$$<p>Zollinger-Ellison syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8023G','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8024H','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8025J','1303','f',$$<p>Prophylaxis of meningococcal disease in close contacts and carriers</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8025J','1297','f',$$<p>Prophylactic treatment of contacts of patients with Haemophilus influenzae type B</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8035X','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8039D','1081','f',$$<p>Detrusor overactivity</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8043H','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8054X','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8055Y','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8057C','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8058D','1225','f',$$<p>Methylmalonic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8058D','1307','f',$$<p>Propionic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8059E','1225','f',$$<p>Methylmalonic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8059E','1307','f',$$<p>Propionic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8061G','1225','f',$$<p>Methylmalonic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8061G','1307','f',$$<p>Propionic acidaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8078E','1618','f',$$<p>Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8079F','1618','f',$$<p>Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8083K','1374','f',$$<p>Short-term reduction of intra-ocular pressure in patients already on maximally tolerated anti-glaucoma therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8115D','1289','f',$$<p>Prevention of the onset of lactation in the puerperium for medical reasons</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8121K','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8122L','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8128T','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8132B','1205','f',$$<p>Maintenance treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8132B','1233','f',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8132B','1035','f',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8136F','1752','f',$$<p>Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8136F','1753','f',$$<p>Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8141L','1752','f',$$<p>Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8141L','1753','f',$$<p>Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8146R','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8173E','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8174F','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8174F','1241','f',$$<p>Obsessive-compulsive disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8179L','2213','f',$$<p>Treatment of hormone-dependent breast cancer in post-menopausal women</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8197K','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8198L','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8198L','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8200N','1838','f',$$<p>Uncomplicated urethritis due to Chlamydia trachomatis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8200N','1839','f',$$<p>Uncomplicated cervicitis due to Chlamydia trachomatis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8201P','1405','f',$$<p>Trachoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8213G','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8214H','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8215J','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8216K','1750','f',$$<p>Treatment of hormone-dependent metastatic breast cancer in post-menopausal patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8220P','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8224W','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8225X','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8226Y','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8227B','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8238N','1754','f',$$<p>Asthma in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8238N','1755','f',$$<p>Chronic obstructive pulmonary disease in patients unable to use this drug delivered from an oral pressurised inhalation device via a spacer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8239P','1752','f',$$<p>Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8239P','1753','f',$$<p>Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8240Q','1752','f',$$<p>Patients with frequent episodes of asthma who are currently receiving treatment with oral corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8240Q','1753','f',$$<p>Patients with frequent episodes of asthma who are currently receiving treatment with optimal doses of inhaled corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8245Y','1608','f',$$<p>Treatment of hormone-dependent advanced breast cancer in post-menopausal women</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8245Y','2691','f',$$<p>Treatment of hormone-dependent early breast cancer in post-menopausal women</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8245Y','2692','f',$$<p>Extended adjuvant treatment of hormone-dependent early breast cancer in post-menopausal women commencing within 6 months of ceasing treatment with tamoxifen citrate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8253J','1480','f',$$<p>Treatment of acute myocardial infarction within 6 hours of onset of attack</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8254K','1836','f',$$<p>Infections where resistance to amoxycillin is suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8254K','1837','f',$$<p>Infections where resistance to amoxycillin is proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8260R','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8265B','1205','f',$$<p>Maintenance treatment of hypercalcaemia of malignancy refractory to anti-neoplastic therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8265B','1233','f',$$<p>Multiple myeloma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8265B','1035','f',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8270G','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8270G','1241','f',$$<p>Obsessive-compulsive disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8272J','1096','f',$$<p>Eradication of Helicobacter pylori associated with peptic ulcer disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8287E','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8301X','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8302Y','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8305D','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8306E','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8310J','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8313M','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8319W','1836','f',$$<p>Infections where resistance to amoxycillin is suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8319W','1837','f',$$<p>Infections where resistance to amoxycillin is proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8328H','1314','f',$$<p>Pyridoxine non-responsive homocystinuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8331L','1177','f',$$<p>Initial treatment of peptic ulcer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8332M','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8332M','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8332M','1476','f',$$<p>Zollinger-Ellison syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8333N','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8333N','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8333N','1476','f',$$<p>Zollinger-Ellison syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8335Q','1725','f',$$<p>as adjunctive therapy with low-dose aspirin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8335Q','1726','f',$$<p>where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8335Q','1727','f',$$<p>where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8336R','1405','f',$$<p>Trachoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8349K','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8354Q','1266','f',$$<p>Patients unable to achieve co-ordinated use of other metered dose inhalers containing this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8369L','1276','f',$$<p>Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8382E','1728','f',$$<p>Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8384G','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8385H','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8386J','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8387K','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8388L','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8393R','1255','f',$$<p>Parkinson's disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8394T','1255','f',$$<p>Parkinson's disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8398B','1350','f',$$<p>Severe cardiac arrhythmias</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8399C','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8399C','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8399C','1476','f',$$<p>Zollinger-Ellison syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8400D','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8401E','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8404H','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8405J','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8408M','1266','f',$$<p>Patients unable to achieve co-ordinated use of other metered dose inhalers containing this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8409N','1266','f',$$<p>Patients unable to achieve co-ordinated use of other metered dose inhalers containing this drug</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8410P','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8411Q','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8416Y','1314','f',$$<p>Pyridoxine non-responsive homocystinuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8417B','1484','f',$$<p>For infants and very young children with pyridoxine non-responsive homocystinuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8424J','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8430Q','1758','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8430Q','1759','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8431R','1758','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8431R','1759','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8432T','1758','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8432T','1759','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8432T','2680','f',$$<p>Symptomatic treatment of chronic obstructive pulmonary disease (COPD), where the FEV1 is less than 50% predicted normal and there is a history of repeated exacerbations with significant symptoms despite regular beta-2 agonist bronchodilator therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8439E','1547','f',$$<p>Symptomatic treatment of osteoarthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8439E','1848','f',$$<p>Symptomatic treatment of rheumatoid arthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8440F','1547','f',$$<p>Symptomatic treatment of osteoarthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8440F','1848','f',$$<p>Symptomatic treatment of rheumatoid arthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8445L','1453','f',$$<p>Tyrosinaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8446M','1453','f',$$<p>Tyrosinaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8449Q','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8455B','1497','f',$$<p>For acute pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8464L','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8477E','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8478F','1670','f',$$<p>Chylous ascites</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8478F','1068','f',$$<p>Chylothorax</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8478F','1671','f',$$<p>Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8478F','1513','f',$$<p>Hyperlipoproteinaemia type 1</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8478F','1511','f',$$<p>Long chain fatty acid oxidation disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8479G','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8489T','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8490W','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8491X','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8492Y','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8493B','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8494C','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8501K','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8502L','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8504N','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8506Q','1541','f',$$<p>Treatment of hormone-dependent advanced breast cancer in post-menopausal women with disease progression following treatment with tamoxifen citrate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8506Q','2457','f',$$<p>Treatment of hormone-dependent early breast cancer in post-menopausal women following a minimum of 2 years' treatment with tamoxifen citrate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8507R','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8507R','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8508T','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8508T','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8509W','1177','f',$$<p>Initial treatment of peptic ulcer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8512B','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8512B','1241','f',$$<p>Obsessive-compulsive disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8513C','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8517G','1758','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8517G','1759','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8518H','1758','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8518H','1759','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8519J','1758','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8519J','1759','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled salmeterol xinafoate and fluticasone propionate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8519J','2680','f',$$<p>Symptomatic treatment of chronic obstructive pulmonary disease (COPD), where the FEV1 is less than 50% predicted normal and there is a history of repeated exacerbations with significant symptoms despite regular beta-2 agonist bronchodilator therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8521L','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8523N','1537','f',$$<p>For pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8524P','1537','f',$$<p>For pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8525Q','1537','f',$$<p>For pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8526R','1481','f',$$<p>Treatment of acute myocardial infarction within 12 hours of onset of attack</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8527T','1481','f',$$<p>Treatment of acute myocardial infarction within 12 hours of onset of attack</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8541M','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8542N','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8543P','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8545R','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8548X','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8554F','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8555G','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8561N','1547','f',$$<p>Symptomatic treatment of osteoarthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8561N','1848','f',$$<p>Symptomatic treatment of rheumatoid arthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8562P','1547','f',$$<p>Symptomatic treatment of osteoarthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8562P','1848','f',$$<p>Symptomatic treatment of rheumatoid arthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8564R','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8565T','1878','f',$$<p>Anovulatory infertility</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8565T','1119','f',$$<p>For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8566W','1878','f',$$<p>Anovulatory infertility</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8566W','1119','f',$$<p>For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8567X','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8567X','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8577K','1578','f',$$<p>Patients with intractable seizures requiring treatment with a ketogenic diet</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8577K','1579','f',$$<p>Glucose transport protein defects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8577K','1580','f',$$<p>Pyruvate dehydrogenase deficiency</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8577K','1581','f',$$<p>Infants and young children with glucose-galactose intolerance and multiple monosaccharide intolerance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8581P','1582','f',$$<p>Acute exacerbations of chronic bronchitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8582Q','1378','f',$$<p>Short-term treatment of acute pain</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8583R','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8589C','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8590D','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8591E','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8592F','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8593G','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8600P','1629','f',$$<p>Maintenance of healed gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8600P','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8600P','3429','f',$$<p>Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8601Q','1628','f',$$<p>Healing of gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8611F','1615','f',$$<p>For dosage titration in chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8612G','1613','f',$$<p>Constipation in patients with malignant neoplasia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8612G','2823','f',$$<p>Chronic constipation or faecal impaction not adequately controlled with first line interventions such as bulk-forming agents</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8612G','2693','f',$$<p>Paraplegic and quadriplegic patients and others with severe neurogenic impairment of bowel function not responding to other oral therapies</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8612G','1263','f',$$<p>Patients receiving palliative care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8613H','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8618N','1622','f',$$<p>Eczema</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8622T','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8623W','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8624X','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8625Y','1756','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8625Y','1757','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8625Y','2671','f',$$<p>For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with oral corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8625Y','2672','f',$$<p>For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with inhaled corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8625Y','2673','f',$$<p>For maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with a combination of an inhaled corticosteroid and a long-acting beta-2 agonist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8626B','3883','f',$$<p>Chronic obstructive pulmonary disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8629E','1670','f',$$<p>Chylous ascites</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8629E','1068','f',$$<p>Chylothorax</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8629E','1671','f',$$<p>Fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8630F','1578','f',$$<p>Patients with intractable seizures requiring treatment with a ketogenic diet</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8630F','1579','f',$$<p>Glucose transport protein defects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8630F','1580','f',$$<p>Pyruvate dehydrogenase deficiency</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8630F','1581','f',$$<p>Infants and young children with glucose-galactose intolerance and multiple monosaccharide intolerance</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8631G','1453','f',$$<p>Tyrosinaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8632H','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8633J','1643','f',$$<p>Contraception</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8633J','2689','f',$$<p>Idiopathic menorrhagia where oral treatments are ineffective</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8633J','2690','f',$$<p>Idiopathic menorrhagia where oral treatments are contraindicated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8639Q','1148','f',$$<p>Haemodialysis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8640R','1148','f',$$<p>Haemodialysis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8641T','1148','f',$$<p>Haemodialysis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8642W','1148','f',$$<p>Haemodialysis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8643X','1148','f',$$<p>Haemodialysis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8644Y','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8667E','1453','f',$$<p>Tyrosinaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8669G','1789','f',$$<p>Severe disabling pain due to cancer not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8670H','1789','f',$$<p>Severe disabling pain due to cancer not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8676P','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8677Q','1314','f',$$<p>Pyridoxine non-responsive homocystinuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8678R','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8681X','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8700X','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8701Y','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8702B','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8703C','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8713N','1878','f',$$<p>Anovulatory infertility</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8713N','1119','f',$$<p>For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8714P','1878','f',$$<p>Anovulatory infertility</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8714P','1119','f',$$<p>For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8715Q','1878','f',$$<p>Anovulatory infertility</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8715Q','1119','f',$$<p>For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8716R','1148','f',$$<p>Haemodialysis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8727H','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8728J','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8729K','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8738X','1096','f',$$<p>Eradication of Helicobacter pylori associated with peptic ulcer disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8744F','1314','f',$$<p>Pyridoxine non-responsive homocystinuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8745G','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8746H','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8748K','1261','f',$$<p>Patients hypersensitive to other oral diuretics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8750M','1756','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8750M','1757','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8750M','2680','f',$$<p>Symptomatic treatment of chronic obstructive pulmonary disease (COPD), where the FEV1 is less than 50% predicted normal and there is a history of repeated exacerbations with significant symptoms despite regular beta-2 agonist bronchodilator therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8752P','1978','f',$$<p>Acute episode of mild to moderate ulcerative proctitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8760C','1998','f',$$<p>For patients unable to take a solid dose form of an ACE inhibitor</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8784H','2046','f',$$<p>Chronic arthropathies</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8796Y','1756','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with oral corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8796Y','1757','f',$$<p>Patients who previously had frequent episodes of asthma while receiving treatment with optimal doses of inhaled corticosteroids and who have been stabilised on concomitant inhaled eformoterol fumarate dihydrate and budesonide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8796Y','2671','f',$$<p>For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with oral corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8796Y','2672','f',$$<p>For single maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with inhaled corticosteroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8796Y','2673','f',$$<p>For maintenance and reliever therapy in a patient who experiences frequent asthma symptoms while receiving treatment with a combination of an inhaled corticosteroid and a long-acting beta-2 agonist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8804J','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8814X','2094','f',$$<p>Relief of persistent pain associated with osteoarthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8826M','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8826M','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8829Q','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8831T','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8832W','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8836C','1241','f',$$<p>Obsessive-compulsive disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8836C','1975','f',$$<p>Panic disorder where other treatments have failed or are inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8837D','1241','f',$$<p>Obsessive-compulsive disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8837D','1975','f',$$<p>Panic disorder where other treatments have failed or are inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8843K','1537','f',$$<p>For pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8846N','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8849R','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8849R','2964','f',$$<p>for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8849R','2965','f',$$<p>who has been assessed by a psychiatrist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8849R','3092','f',$$<p>Continuing PBS-subsidised treatment, for moderate to severe generalised anxiety disorder (GAD), of a patient commenced on escitalopram prior to 1&#160;November 2008</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8849R','2967','f',$$<p>for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8849R','2968','f',$$<p>who has been assessed by a psychiatrist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8849R','3093','f',$$<p>Continuing PBS-subsidised treatment, for moderate to severe social anxiety disorder (social phobia, SAD), of a patient commenced on escitalopram prior to 1&#160;November 2008</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8855C','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8856D','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8857E','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8865N','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8866P','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8867Q','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8868R','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8871X','1878','f',$$<p>Anovulatory infertility</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8871X','1119','f',$$<p>For the treatment of infertility in males due to hypogonadotrophic hypogonadism, following failure of 6 months' treatment with human chorionic gonadotrophin to achieve adequate spermatogenesis. Combined treatment with HCG must be given</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8872Y','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8872Y','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8872Y','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8878G','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8883M','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8886Q','2273','f',$$<p>Initial treatment of gastric ulcer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8887R','1547','f',$$<p>Symptomatic treatment of osteoarthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8887R','1848','f',$$<p>Symptomatic treatment of rheumatoid arthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8888T','1547','f',$$<p>Symptomatic treatment of osteoarthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8888T','1848','f',$$<p>Symptomatic treatment of rheumatoid arthritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8891Y','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8892B','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8893C','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8894D','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8895E','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8895E','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8898H','2462','f',$$<p>Glioblastoma multiforme, suspected or confirmed, at the time of initial surgery</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8934F','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8935G','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8936H','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8954G','3689','f',$$<p>Acute treatment, in combination with an oral antibiotic, of severe acne vulgaris</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8955H','3690','f',$$<p>Maintenance treatment of severe acne vulgaris</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8956J','3688','f',$$<p>Management of symptomatic venous thromboembolism in a patient with a solid tumour(s)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8957K','3688','f',$$<p>Management of symptomatic venous thromboembolism in a patient with a solid tumour(s)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8958L','3688','f',$$<p>Management of symptomatic venous thromboembolism in a patient with a solid tumour(s)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8959M','3688','f',$$<p>Management of symptomatic venous thromboembolism in a patient with a solid tumour(s)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8960N','3688','f',$$<p>Management of symptomatic venous thromboembolism in a patient with a solid tumour(s)</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8978M','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8979N','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8980P','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('8981Q','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9019Q','2385','f',$$<p>Hypertension in patients receiving concurrent antihypertensive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9020R','2385','f',$$<p>Hypertension in patients receiving concurrent antihypertensive therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9021T','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9022W','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9023X','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9040T','2418','f',$$<p>Type 1 diabetes</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9042X','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9043Y','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9044B','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9045C','1540','f',$$<p>For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9048F','1281','f',$$<p>Pernicious anaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9048F','1250','f',$$<p>Other proven vitamin B</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9048F','1298','f',$$<p>Prophylaxis after gastrectomy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9049G','2449','f',$$<p>who are currently receiving treatment with a dihydropyridine calcium channel blocker</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9049G','2450','f',$$<p>whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9049G','2451','f',$$<p>who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9050H','2449','f',$$<p>who are currently receiving treatment with a dihydropyridine calcium channel blocker</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9050H','2450','f',$$<p>whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9050H','2451','f',$$<p>who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9051J','2449','f',$$<p>who are currently receiving treatment with a dihydropyridine calcium channel blocker</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9051J','2450','f',$$<p>whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9051J','2451','f',$$<p>who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9052K','2449','f',$$<p>who are currently receiving treatment with a dihydropyridine calcium channel blocker</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9052K','2450','f',$$<p>whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9052K','2451','f',$$<p>who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9053L','2449','f',$$<p>who are currently receiving treatment with a dihydropyridine calcium channel blocker</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9053L','2450','f',$$<p>whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9053L','2451','f',$$<p>who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9054M','2449','f',$$<p>who are currently receiving treatment with a dihydropyridine calcium channel blocker</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9054M','2450','f',$$<p>whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9054M','2451','f',$$<p>who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9055N','2449','f',$$<p>who are currently receiving treatment with a dihydropyridine calcium channel blocker</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9055N','2450','f',$$<p>whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9055N','2451','f',$$<p>who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9056P','2449','f',$$<p>who are currently receiving treatment with a dihydropyridine calcium channel blocker</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9056P','2450','f',$$<p>whose blood pressure and/or angina is inadequately controlled with other classes of antihypertensive and/or anti-anginal agent, and in whom adjunctive therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9056P','2451','f',$$<p>who are intolerant of the side effects of other classes of antihypertensive and/or anti-anginal agent, and in whom replacement therapy with a dihydropyridine calcium channel blocker would be appropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9057Q','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9057Q','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9058R','1143','f',$$<p>Gonorrhoea</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9106G','1851','f',$$<p>Bronchiectasis in patients aged 8 years or older</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9106G','1852','f',$$<p>Chronic bronchitis in patients aged 8 years or older</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9106G','1346','f',$$<p>Severe acne</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9107H','1279','f',$$<p>Pelvic inflammatory disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9108J','1459','f',$$<p>Urethritis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9109K','1177','f',$$<p>Initial treatment of peptic ulcer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9110L','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9110L','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9110L','1476','f',$$<p>Zollinger-Ellison syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9132P','1453','f',$$<p>Tyrosinaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9133Q','1314','f',$$<p>Pyridoxine non-responsive homocystinuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9134R','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9135T','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9144G','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9145H','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9149M','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9150N','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9151P','3216','f',$$<p>Parkinson disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9152Q','3216','f',$$<p>Parkinson disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9153R','3216','f',$$<p>Parkinson disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9155W','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9156X','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9164H','1314','f',$$<p>Pyridoxine non-responsive homocystinuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9165J','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9192T','3016','f',$$<p>Bordetella pertussis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9192T','3017','f',$$<p>Atypical mycobacterial infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9196B','1148','f',$$<p>Haemodialysis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9197C','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9197C','1241','f',$$<p>Obsessive-compulsive disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9197C','1862','f',$$<p>Panic disorder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9199E','1537','f',$$<p>For pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9200F','1537','f',$$<p>For pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9201G','1537','f',$$<p>For pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9208P','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9209Q','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9210R','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9211T','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9212W','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9213X','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9214Y','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9215B','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9216C','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9217D','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9218E','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9219F','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9220G','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9221H','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9222J','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9223K','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9226N','3046','f',$$<p>For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9227P','3046','f',$$<p>For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9229R','3046','f',$$<p>For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9230T','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9231W','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9232X','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9233Y','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9234B','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9235C','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9236D','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9237E','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9238F','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9239G','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9240H','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9241J','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9242K','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9243L','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9244M','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9245N','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9246P','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9247Q','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9248R','3047','f',$$<p>For use in patients who meet the criteria set out in the General Statement for Lipid-Lowering Drugs, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9249T','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9250W','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9253B','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9254C','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9255D','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9257F','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9261K','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9263M','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9265P','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9267R','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9268T','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9269W','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9270X','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9273C','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9274D','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9275E','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9276F','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9277G','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9278H','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9279J','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9281L','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9286R','1285','f',$$<p>Phaeochromocytoma</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9286R','1239','f',$$<p>Neurogenic urinary retention</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9297H','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9299K','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9300L','3552','f',$$<p>For use in patients on insulin therapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9301M','3553','f',$$<p>For use in patients on insulin therapy who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9308X','1276','f',$$<p>Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9309Y','1276','f',$$<p>Patients with proven inborn errors of protein metabolism who are unable to meet their energy requirements with permitted food and formulae</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9314F','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9315G','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9326W','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9326W','1846','f',$$<p>Septicaemia, suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9326W','1847','f',$$<p>Septicaemia, proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9329B','1147','f',$$<p>Gyrate atrophy of the choroid and retina</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9329B','1458','f',$$<p>Urea cycle disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9330C','1453','f',$$<p>Tyrosinaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9331D','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9331D','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9346X','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9346X','3308','f',$$<p>Stable coronary heart disease in a patient who is stabilised on treatment with perindopril and amlodipine at the same doses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9347Y','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9347Y','3308','f',$$<p>Stable coronary heart disease in a patient who is stabilised on treatment with perindopril and amlodipine at the same doses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9348B','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9348B','3308','f',$$<p>Stable coronary heart disease in a patient who is stabilised on treatment with perindopril and amlodipine at the same doses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9349C','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9349C','3308','f',$$<p>Stable coronary heart disease in a patient who is stabilised on treatment with perindopril and amlodipine at the same doses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9355J','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9356K','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9357L','1035','f',$$<p>Bone metastases from breast cancer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9365X','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9366Y','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9367B','1211','f',$$<p>Major depressive disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9372G','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9373H','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9374J','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9375K','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9376L','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9377M','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9381R','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9384X','1453','f',$$<p>Tyrosinaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9385Y','1147','f',$$<p>Gyrate atrophy of the choroid and retina</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9385Y','1458','f',$$<p>Urea cycle disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9386B','3081','f',$$<p>Glycogen storage disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9387C','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9393J','3088','f',$$<p>Treatment of severe primary Restless Legs Syndrome in a patient who manifests all 4 diagnostic criteria below and whose baseline International Restless Legs Syndrome Rating Scale (IRLSRS) score is greater than or equal to 21 points prior to initiation of pramipexole.</p><p> The date and IRLSRS score must be documented in the patient's medical records at the time pramipexole treatment is initiated.</p><p> The diagnostic criteria for Restless Legs Syndrome are:<br/> (a) An urge to move the legs usually accompanied or caused by unpleasant sensations in the legs; and<br/> (b) The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting; and<br/> (c) The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues; and<br/> (d) The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur during the evening or night.</p><p> Pramipexole is not PBS-subsidised for Restless Legs Syndrome secondary to other causes</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9394K','3088','f',$$<p>Treatment of severe primary Restless Legs Syndrome in a patient who manifests all 4 diagnostic criteria below and whose baseline International Restless Legs Syndrome Rating Scale (IRLSRS) score is greater than or equal to 21 points prior to initiation of pramipexole.</p><p> The date and IRLSRS score must be documented in the patient's medical records at the time pramipexole treatment is initiated.</p><p> The diagnostic criteria for Restless Legs Syndrome are:<br/> (a) An urge to move the legs usually accompanied or caused by unpleasant sensations in the legs; and<br/> (b) The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting; and<br/> (c) The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues; and<br/> (d) The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur during the evening or night.</p><p> Pramipexole is not PBS-subsidised for Restless Legs Syndrome secondary to other causes</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9395L','1453','f',$$<p>Tyrosinaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9396M','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9397N','1286','f',$$<p>Phenylketonuria</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9399Q','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9400R','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9406C','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9407D','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9408E','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9409F','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9413K','3046','f',$$<p>For use in patients with cystic fibrosis, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9423Y','1177','f',$$<p>Initial treatment of peptic ulcer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9424B','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9424B','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9424B','1476','f',$$<p>Zollinger-Ellison syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9432K','2964','f',$$<p>for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9432K','2965','f',$$<p>who has been assessed by a psychiatrist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9432K','2966','f',$$<p>Continuing PBS-subsidised treatment, for moderate to severe generalised anxiety disorder (GAD), of a patient commenced on escitalopram prior to 1&#160;March 2008</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9432K','2967','f',$$<p>for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9432K','2968','f',$$<p>who has been assessed by a psychiatrist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9432K','2969','f',$$<p>Continuing PBS-subsidised treatment, for moderate to severe social anxiety disorder (social phobia, SAD), of a patient commenced on escitalopram prior to 1&#160;March 2008</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9433L','2964','f',$$<p>for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9433L','2965','f',$$<p>who has been assessed by a psychiatrist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9433L','2966','f',$$<p>Continuing PBS-subsidised treatment, for moderate to severe generalised anxiety disorder (GAD), of a patient commenced on escitalopram prior to 1&#160;March 2008</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9433L','2967','f',$$<p>for whom a GP Mental Health Care Plan, as described under item 2710 of the Medicare Benefits Schedule, has been prepared</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9433L','2968','f',$$<p>who has been assessed by a psychiatrist</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9433L','2969','f',$$<p>Continuing PBS-subsidised treatment, for moderate to severe social anxiety disorder (social phobia, SAD), of a patient commenced on escitalopram prior to 1&#160;March 2008</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9434M','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9436P','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9437Q','1458','f',$$<p>Urea cycle disorders</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9438R','3134','f',$$<p>A child aged from 6 months up to 10 years with proven glutaric aciduria type 1</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9441X','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9446E','1578','f',$$<p>Patients with intractable seizures requiring treatment with a ketogenic diet</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9446E','1579','f',$$<p>Glucose transport protein defects</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9446E','1580','f',$$<p>Pyruvate dehydrogenase deficiency</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9454N','3152','f',$$<p>Detrusor overactivity in a patient who cannot tolerate oral oxybutynin, or who cannot swallow oral oxybutynin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9464D','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9464D','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9472M','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9477T','1177','f',$$<p>Initial treatment of peptic ulcer</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9478W','1533','f',$$<p>Gastro-oesophageal reflux disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9478W','1337','f',$$<p>Scleroderma oesophagus</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9479X','1865','f',$$<p>Prevention and treatment of infection in partial or full skin thickness loss due to burns</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9479X','1866','f',$$<p>Prevention and treatment of infection in partial or full skin thickness loss due to epidermolysis bullosa</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9479X','1386','f',$$<p>Stasis ulcers</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9480Y','3190','f',$$<p>Systemic treatment of Pseudomonas aeruginosa infection in a patient with cystic fibrosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9481B','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9482C','3307','f',$$<p>Hypertension in a patient who is not adequately controlled with either of the drugs in the combination</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9486G','3035','f',$$<p>For use in patients who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9491M','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9492N','3036','f',$$<p>For use in patients who have severe dry eye syndrome, including Sjogren's syndrome, and who are receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9494Q','3209','f',$$<p>Chronic stable plaque type psoriasis vulgaris in a patient who is not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9499Y','1220','f',$$<p>Maple syrup urine disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1152P','3043','f',$$<p>Treatment of dynamic equinus foot deformity due to spasticity in an ambulant paediatric cerebral palsy patient aged from 2 to 17 years inclusive</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1152P','3045','f',$$<p>Continuing PBS-subsidised treatment of dynamic equinus foot deformity due to spasticity in an ambulant cerebral palsy patient 18 years of age or older who was commenced on PBS-subsidised treatment with clostridium botulinum type A toxin-haemagglutinin complex as a paediatric patient</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1152P','1524','f',$$<p>Treatment of spasmodic torticollis, either as monotherapy or as adjunctive therapy to current standard care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1152P','3988','f',$$<p>Treatment of blepharospasm or hemifacial spasm in an adult</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1152P','3141','f',$$<p>Treatment of moderate to severe spasticity [defined as MAS greater than or equal to 3 using modified Ashworth scale] of the upper limb in adults following a stroke, as second line therapy when standard management has failed (e.g. physiotherapy and/or oral spasticity agents) or as an adjunct to physical therapy.<br/> Maximum number of treatments to be authorised is 4 (total Botox and Dysport) per upper limb per lifetime.  Treatment should not be initiated until 3 months post-stroke in patients who do not have established severe contracture.  Treatment should be discontinued if the patient does not respond (decrease of MAS greater than 1 in at least one joint) after two treatments.<br/> The date of the stroke must be provided.<br/> Contraindications to treatment include established severe contracture and known sensitivity to botulinum toxin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6103F','3989','f',$$<p>Treatment of blepharospasm or hemifacial spasm in a patient 12 years or older</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6103F','3043','f',$$<p>Treatment of dynamic equinus foot deformity due to spasticity in an ambulant paediatric cerebral palsy patient aged from 2 to 17 years inclusive</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6103F','3044','f',$$<p>Continuing PBS-subsidised treatment of dynamic equinus foot deformity due to spasticity in an ambulant cerebral palsy patient 18 years of age or older who was commenced on PBS-subsidised treatment with botulinum toxin type A purified neurotoxin complex as a paediatric patient</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6103F','1524','f',$$<p>Treatment of spasmodic torticollis, either as monotherapy or as adjunctive therapy to current standard care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6103F','3139','f',$$<p>Treatment of moderate to severe spasticity of the upper limb in a cerebral palsy patient aged from 2 to 17 years inclusive</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6103F','3140','f',$$<p>Continuing PBS-subsidised treatment of moderate to severe spasticity of the upper limb in a cerebral palsy patient 18 years of age or older who was commenced on PBS-subsidised treatment with botulinum toxin type A purified neurotoxin complex as a paediatric patient</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6103F','3141','f',$$<p>Treatment of moderate to severe spasticity [defined as MAS greater than or equal to 3 using modified Ashworth scale] of the upper limb in adults following a stroke, as second line therapy when standard management has failed (e.g. physiotherapy and/or oral spasticity agents) or as an adjunct to physical therapy.<br/> Maximum number of treatments to be authorised is 4 (total Botox and Dysport) per upper limb per lifetime.  Treatment should not be initiated until 3 months post-stroke in patients who do not have established severe contracture.  Treatment should be discontinued if the patient does not respond (decrease of MAS greater than 1 in at least one joint) after two treatments.<br/> The date of the stroke must be provided.<br/> Contraindications to treatment include established severe contracture and known sensitivity to botulinum toxin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6103F','3950','f',$$<p>Treatment of severe primary axillary hyperhidrosis in a patient 12 years or older who has failed or is intolerant to topical aluminium chloride hexahydrate after one to two months of treatment. </p><p> Maximum number of treatments per year is 3, with no less than 4 months to elapse between treatments</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6293F','3043','f',$$<p>Treatment of dynamic equinus foot deformity due to spasticity in an ambulant paediatric cerebral palsy patient aged from 2 to 17 years inclusive</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6293F','3045','f',$$<p>Continuing PBS-subsidised treatment of dynamic equinus foot deformity due to spasticity in an ambulant cerebral palsy patient 18 years of age or older who was commenced on PBS-subsidised treatment with clostridium botulinum type A toxin-haemagglutinin complex as a paediatric patient</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6293F','1524','f',$$<p>Treatment of spasmodic torticollis, either as monotherapy or as adjunctive therapy to current standard care</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6293F','3988','f',$$<p>Treatment of blepharospasm or hemifacial spasm in an adult</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6293F','3141','f',$$<p>Treatment of moderate to severe spasticity [defined as MAS greater than or equal to 3 using modified Ashworth scale] of the upper limb in adults following a stroke, as second line therapy when standard management has failed (e.g. physiotherapy and/or oral spasticity agents) or as an adjunct to physical therapy.<br/> Maximum number of treatments to be authorised is 4 (total Botox and Dysport) per upper limb per lifetime.  Treatment should not be initiated until 3 months post-stroke in patients who do not have established severe contracture.  Treatment should be discontinued if the patient does not respond (decrease of MAS greater than 1 in at least one joint) after two treatments.<br/> The date of the stroke must be provided.<br/> Contraindications to treatment include established severe contracture and known sensitivity to botulinum toxin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1768C','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1769D','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('1832K','1448','f',$$<p>Treatment, in a hospital, of acute anaerobic sepsis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3323X','1302','f',$$<p>Prophylaxis of endocarditis in patients hypersensitive to penicillin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5006L','1836','f',$$<p>Infections where resistance to amoxycillin is suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5006L','1837','f',$$<p>Infections where resistance to amoxycillin is proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5008N','1836','f',$$<p>Infections where resistance to amoxycillin is suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5008N','1837','f',$$<p>Infections where resistance to amoxycillin is proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5009P','1836','f',$$<p>Infections where resistance to amoxycillin is suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5009P','1837','f',$$<p>Infections where resistance to amoxycillin is proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5011R','1836','f',$$<p>Infections where resistance to amoxycillin is suspected</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5011R','1837','f',$$<p>Infections where resistance to amoxycillin is proven</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5032W','1669','f',$$<p>Radiation induced mucositis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5034Y','1102','f',$$<p>For local intra-articular or peri-articular infiltration</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5034Y','1189','f',$$<p>Keloid</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5034Y','1191','f',$$<p>Lichen planus hypertrophic</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5048Q','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5049R','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5057E','1145','f',$$<p>Gram-positive coccal infections where these cannot be safely and effectively treated with a penicillin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5076E','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5076E','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5077F','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5077F','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5083M','1302','f',$$<p>Prophylaxis of endocarditis in patients hypersensitive to penicillin</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5090X','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5091Y','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5096F','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5097G','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5111B','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5112C','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5113D','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5114E','1422','f',$$<p>Treatment of corticosteroid-responsive dermatoses</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5115F','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5116G','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5117H','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5118J','1128','f',$$<p>For use in a hospital</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5119K','1128','f',$$<p>For use in a hospital</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5123P','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5123P','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5126T','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5126T','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5132D','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5136H','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5148Y','1102','f',$$<p>For local intra-articular or peri-articular infiltration</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5150C','1537','f',$$<p>For pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5154G','1448','f',$$<p>Treatment, in a hospital, of acute anaerobic sepsis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5155H','1416','f',$$<p>Treatment of anaerobic infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5163R','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5176K','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5176K','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5177L','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5177L','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5178M','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5178M','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5179N','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5179N','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5186Y','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5186Y','1036','f',$$<p>Bone pain due to malignant disease</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5190E','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5191F','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5194J','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5195K','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5197M','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5201R','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5202T','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5203W','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5204X','1054','f',$$<p>Chronic arthropathies (including osteoarthritis) with an inflammatory component</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5224Y','2046','f',$$<p>Chronic arthropathies</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5230G','1169','f',$$<p>Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5231H','1378','f',$$<p>Short-term treatment of acute pain</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5232J','1497','f',$$<p>For acute pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5232J','1615','f',$$<p>For dosage titration in chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5233K','1102','f',$$<p>For local intra-articular or peri-articular infiltration</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5233K','1189','f',$$<p>Keloid</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5233K','1191','f',$$<p>Lichen planus hypertrophic</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5237P','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5238Q','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5239R','1358','f',$$<p>Severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5257Q','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5258R','1345','f',$$<p>Serious staphylococcal infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5848T','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5853C','3545','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5857G','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5858H','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5898K','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5899L','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5901N','1419','f',$$<p>Treatment of carcinoma in situ of the urinary bladder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5902P','1290','f',$$<p>Primary and relapsing superficial urothelial carcinoma of the bladder</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5904R','1028','f',$$<p>Antidote to folic acid antagonists</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5960Q','1618','f',$$<p>Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5961R','1618','f',$$<p>Adjunctive therapy for use with ifosfamide or high dose cyclophosphamide</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5967C','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5968D','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5969E','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5970F','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5971G','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5972H','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5986C','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5987D','3050','f',$$<p>Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.</p><p> Increased maximum quantities will be limited to a maximum of 7 days per chemotherapy cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4007X','1371','f',$$<p>Severe seborrhoeic dermatitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4008Y','1371','f',$$<p>Severe seborrhoeic dermatitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4010C','1243','f',$$<p>Onychomycosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4049D','1105','f',$$<p>For relief of urinary symptoms when antibiotic or other therapy alone is inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4050E','1972','f',$$<p>Initial treatment of venous ulcers</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4050E','1973','f',$$<p>Continuation of treatment of venous ulcers where patient's ability to tolerate dressing has been demonstrated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4082W','1164','f',$$<p>Hypocalcaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4082W','1247','f',$$<p>Osteoporosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4082W','1845','f',$$<p>Proven calcium malabsorption</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4089F','1368','f',$$<p>Severe intractable rhinorrhoea, associated with perennial rhinitis, unresponsive to insufflated nasal steroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4090G','1368','f',$$<p>Severe intractable rhinorrhoea, associated with perennial rhinitis, unresponsive to insufflated nasal steroids</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4092J','1367','f',$$<p>Severe intractable rhinitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4094L','1162','f',$$<p>Hyperphosphataemia in chronic renal failure</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4106D','1371','f',$$<p>Severe seborrhoeic dermatitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4115N','1457','f',$$<p>Upper and lower respiratory tract infections</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4142B','1162','f',$$<p>Hyperphosphataemia in chronic renal failure</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4246L','1379','f',$$<p>Short-term use when oral laxative therapy has failed or is inappropriate</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4321K','1272','f',$$<p>Patients with documented hypomagnesaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4333C','1164','f',$$<p>Hypocalcaemia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4333C','1247','f',$$<p>Osteoporosis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4333C','1845','f',$$<p>Proven calcium malabsorption</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4348W','1111','f',$$<p>For the topical treatment of secondarily infected traumatic skin lesions</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4349X','1062','f',$$<p>Chronic severe disabling pain not responding to non-narcotic analgesics</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4350Y','1111','f',$$<p>For the topical treatment of secondarily infected traumatic skin lesions</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4463X','1402','f',$$<p>Tinea pedis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4473K','1402','f',$$<p>Tinea pedis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4522B','1110','f',$$<p>For the short-term treatment of insomnia</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4551M','1101','f',$$<p>For colostomy and ileostomy use</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4551M','1125','f',$$<p>For use by paraplegic and quadriplegic patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4551M','1134','f',$$<p>For use with surgical appliances</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4556T','1101','f',$$<p>For colostomy and ileostomy use</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4556T','1125','f',$$<p>For use by paraplegic and quadriplegic patients</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4556T','1134','f',$$<p>For use with surgical appliances</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4938X','1972','f',$$<p>Initial treatment of venous ulcers</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4939Y','1972','f',$$<p>Initial treatment of venous ulcers</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4940B','1972','f',$$<p>Initial treatment of venous ulcers</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4941C','1973','f',$$<p>Continuation of treatment of venous ulcers where patient's ability to tolerate dressing has been demonstrated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4942D','1973','f',$$<p>Continuation of treatment of venous ulcers where patient's ability to tolerate dressing has been demonstrated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('4943E','1973','f',$$<p>Continuation of treatment of venous ulcers where patient's ability to tolerate dressing has been demonstrated</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2036E','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2038G','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5815C','3499','f',$$<p>For the prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5816D','3934','f',$$<p>A patient who is receiving treatment as described in items 13200, 13201 or 13202 of the Medicare Benefits Schedule and who:<br/> (i)  Has an antral follicle count of 20 or less; and<br/> (ii)  Weighs 90&#160;kg or less; and<br/> (iii)  Is undergoing a gonadotrophin releasing hormone antagonist cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5817E','3934','f',$$<p>A patient who is receiving treatment as described in items 13200, 13201 or 13202 of the Medicare Benefits Schedule and who:<br/> (i)  Has an antral follicle count of 20 or less; and<br/> (ii)  Weighs 90&#160;kg or less; and<br/> (iii)  Is undergoing a gonadotrophin releasing hormone antagonist cycle</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6178E','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6181H','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6182J','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6335K','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6336L','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6366C','3294','f',$$<p>For luteal phase support in patients who are receiving medical treatment as described in items 13200 or 13201 of the Medicare Benefits Schedule. The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6431L','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6432M','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6433N','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6464F','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9583J','3499','f',$$<p>For the prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9584K','3499','f',$$<p>For the prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9599F','3499','f',$$<p>For the prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9608Q','3294','f',$$<p>For luteal phase support in patients who are receiving medical treatment as described in items 13200 or 13201 of the Medicare Benefits Schedule. The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9609R','3294','f',$$<p>For luteal phase support in patients who are receiving medical treatment as described in items 13200 or 13201 of the Medicare Benefits Schedule. The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9631X','3293','f',$$<p>Patients who are receiving medical treatment as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('2082N','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5501M','1715','f',$$<p>Herpes simplex keratitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5503P','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5507W','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5508X','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5517J','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5518K','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5519L','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5520M','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5524R','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5525T','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5526W','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5527X','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5528Y','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5529B','1466','f',$$<p>Vernal kerato-conjunctivitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5535H','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5535H','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5542Q','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5542Q','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5553G','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5553G','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5555J','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5555J','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5556K','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5558M','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5558M','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5559N','1362','f',$$<p>Severe dry eye syndrome, including Sjogren's syndrome</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5562R','3426','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with open-angle glaucoma that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5562R','3427','f',$$<p>Reduction of elevated intra-ocular pressure in a patient with ocular hypertension that is not adequately controlled with monotherapy</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5566Y','1714','f',$$<p>Perioperative use in ophthalmic surgery</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5566Y','1391','f',$$<p>Suspected pseudomonal eye infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5568C','1465','f',$$<p>Uveitis</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5569D','1714','f',$$<p>Perioperative use in ophthalmic surgery</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5569D','1391','f',$$<p>Suspected pseudomonal eye infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5570E','1714','f',$$<p>Perioperative use in ophthalmic surgery</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5570E','1391','f',$$<p>Suspected pseudomonal eye infection</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('3388H','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5818F','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5819G','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5820H','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5822K','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('5824M','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6169Q','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6170R','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6266T','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6295H','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6296J','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6297K','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6310D','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6311E','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6312F','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6313G','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6314H','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6315J','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6316K','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6317L','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6318M','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6319N','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6329D','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6330E','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6345Y','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6465G','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6466H','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6467J','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6476W','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9585L','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9586M','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9604L','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9628R','3862','f',$$<p>Short stature in accordance with the 'Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. The program also aims to correct neonatal hypoglycaemia due to biochemical growth hormone deficiency and improve body composition for children with Prader-Willi Syndrome.</p><p> The Guidelines specify the eligibility criteria for the conditions that are eligible for treatment through the program which include:</p><p> (i) short stature and slow growth;<br/> (ii) short stature associated with biochemical growth hormone deficiency;<br/> (iii) growth retardation secondary to intracranial lesion or cranial irradiation;<br/> (iv) neonates/infants at risk of hypoglycaemia secondary to growth hormone deficiency;<br/> (v) short stature associated with Turner Syndrome;<br/> (vi) short stature due to short stature homeobox (SHOX) gene disorders;<br/> (vii) short stature associated with chronic renal insufficiency;<br/> (viii) biochemical growth hormone deficiency and precocious puberty;<br/> (ix) Prader-Willi syndrome.</p><p> Genotropin branded products are available for the treatment of Prader-Willi Syndrome in accordance with the Guidelines</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6171T','1569','f',$$<p>Treatment of opiate dependence in accordance with the law of the relevant State or Territory</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6172W','1569','f',$$<p>Treatment of opiate dependence in accordance with the law of the relevant State or Territory</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6307Y','1538','f',$$<p>Treatment of opiate dependence, including maintenance and detoxification (withdrawal), within a framework of medical, social and psychological treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6308B','1538','f',$$<p>Treatment of opiate dependence, including maintenance and detoxification (withdrawal), within a framework of medical, social and psychological treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6309C','1538','f',$$<p>Treatment of opiate dependence, including maintenance and detoxification (withdrawal), within a framework of medical, social and psychological treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6470M','2295','f',$$<p>Treatment of opiate dependence within a framework of medical, social and psychological treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('6471N','2295','f',$$<p>Treatment of opiate dependence within a framework of medical, social and psychological treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9749D','2295','f',$$<p>Treatment of opiate dependence within a framework of medical, social and psychological treatment</p>$$);
insert into drugs.restriction (pbscode, code, streamlined, restriction) values ('9750E','2295','f',$$<p>Treatment of opiate dependence within a framework of medical, social and psychological treatment</p>$$);




truncate db.lu_version;
insert into db.lu_version (lu_major,lu_minor) values (0, 250);
